0001144204-15-030158.txt : 20150513 0001144204-15-030158.hdr.sgml : 20150513 20150513161614 ACCESSION NUMBER: 0001144204-15-030158 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150331 FILED AS OF DATE: 20150513 DATE AS OF CHANGE: 20150513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 15858635 BUSINESS ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 BUSINESS PHONE: 2153450919 MAIL ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 10-Q 1 v409474_10q.htm FORM 10-Q

FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission file number 0-21617

ProPhase Labs, Inc.
(Exact name of registrant as specified in its charter)

Nevada		23-2577138
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

621 N. Shady Retreat Road, Doylestown, Pennsylvania 18901

(Address of principal executive office) (Zip Code)

(215) 345-0919

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or shorter period that the registration was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company (See definition of “large accelerated filer”, "accelerated filer”, “non-accelerated filer" and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at May 13, 2015
Common Stock, $0.0005 par value		15,892,296

ProPhase Labs, Inc. and Subsidiaries

TABLE OF CONTENTS

		PAGE
*PART I.*	*FINANCIAL INFORMATION*

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets as of March 31, 2015 (unaudited) and December 31, 2014	3

	Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2015 and 2014 (unaudited)	4

	Condensed Consolidated Statement of Stockholders’ Equity for the Three Months Ended March 31, 2015 (unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2015 and 2014 (unaudited)	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30

Item 4.	Controls and Procedures	30

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	31
Item 1A.	Risk Factors	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31
Item 3.	Defaults Upon Senior Securities	31
Item 4.	Mine Safety Disclosures	31
Item 5.	Other Information	31
Item 6.	Exhibits	31

Signatures		32

Certifications

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	March 31, 2015			December 31, 2014
	(unaudited)
ASSETS
Cash and cash equivalents (Note 2)	$	5,021		$	2,926
Accounts receivable, net		3,468			5,836
Inventory (Note 2)		3,277			3,292
Prepaid expenses and other current assets		670			1,404
Total current assets		12,436			13,458

Property, plant and equipment, net of accumulated depreciation of $4,424 and $4,341, respectively (Note 2)		2,558			2,599
Total assets	$	14,994		$	16,057

LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES:
Accounts payable	$	1,231		$	667
Accrued advertising and other allowances		3,232			3,685
Other current liabilities		1,061			889
Total current liabilities		5,524			5,241

Other long term obligations (Note 5)		100			100

Commitments and contingencies (Note 5)		-			-

STOCKHOLDERS' EQUITY:
Common Stock, $.0005 par value; authorized 50,000,000; issued: 25,125,113 shares (Note 3)		13			13
Additional paid-in-capital		54,698			54,664
Accumulated deficit		(14,599	)		(13,219	)
Treasury stock, at cost 9,232,817 shares		(30,742	)		(30,742	)
Total stockholders' equity		9,370			10,716
Total liabilities and stockholders' equity	$	14,994		$	16,057

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

	Three Months Ended
	March 31, 2015			March 31, 2014

Net sales (Note 2)	$	5,860		$	6,171

Cost of sales (Note 2)		2,198			2,191

Gross profit		3,662			3,980

Operating expenses:
Sales and marketing		2,812			2,997
Administration		2,021			1,507
Research and development		208			278
		5,041			4,782

Loss from operations		(1,379	)		(802	)

Interest expense, net		(1	)		(2	)

Loss before income tax		(1,380	)		(804	)

Income tax (Note 4)		-			-

Net loss	$	(1,380	)	$	(804	)

Basic and diluted loss per share:
Net loss	$	(0.09	)	$	(0.05	)

Weighted average common shares outstanding:
Basic and diluted		15,892			16,469

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statement of

Stockholders’ Equity

(in thousands, except share data)

(unaudited)

	Common Stock Shares				Additional
	Outstanding, Net of		Par		Paid-In		Accumulated			Treasury
	Shares of Treasury Stock		Value		Capital		Deficit			Stock			Total

Balance at December 31, 2014		15,892,296	$	13	$	54,664	$	(13,219	)	$	(30,742	)	$	10,716

Net loss		-		-		-		(1,380	)		-			(1,380	)

Share-based compensation expense (Note 3)		-		-		34		-			-			34

Balance at March 31, 2015		15,892,296	$	13	$	54,698	$	(14,599	)	$	(30,742	)	$	9,370

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

	Three Months Ended
	March 31, 2015			March 31, 2014

Cash flows from operating activities:
Net loss	$	(1,380	)	$	(804	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization		83			64
Share-based compensation expense		34			64
Gain on sale of equipment		(5	)		-
Changes in operating assets and liabilities:
Accounts receivable		2,368			2,463
Inventory		15			309
Accounts payable		564			(19	)
Accrued advertising and other allowances		(453	)		35
Other operating assets and liabilities, net		906			839
Net cash provided by operating activities		2,132			2,951

Cash flows from investing activities:
Capital expenditures		(42	)		(17	)
Proceeds from the sale of equipment		5			-
Net cash used in investing activities		(37	)		(17	)

Cash flows from financing activities:
Proceeds from issuance of common stock		-			947
Net cash provided by financing activities		-			947

Net increase in cash and cash equivalents		2,095			3,881

Cash and cash equivalents at beginning of period		2,926			1,638

Cash and cash equivalents at end of period	$	5,021		$	5,519

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 1 – Organization and Business

ProPhase Labs, Inc. (“we”, “us” or the “Company”), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along with supplement, personal care and cosmeceutical products.

Our primary business is the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE^ÒCold Remedy and our principal product is Cold-EEZE^Ò Cold Remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration of the common cold. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute non-lozenge forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE^® Cold Remedy QuickMelts^® and (ii) Cold-EEZE^® Cold Remedy Oral Spray. Cold-EEZE^® Cold Remedy Oral Spray is a liquid form of our zinc gluconate formulation that is sprayed in the mouth. Cold-EEZE^® Cold Remedy QuickMelts^® are fast dissolving tablets that are taken orally. Cold-EEZE^Ò Cold Remedy is an established product in the health care and cold remedy market. For the three months ended March 31, 2015 and 2014, we operated in one reporting segment and our revenues have come principally from our OTC cold remedy products.

We use a December 31 year-end for financial reporting purposes. References herein to Fiscal 2015 shall mean the fiscal year ended December 31, 2015 and references to other “Fiscal” years shall mean the year, which ended on December 31 of the year indicated. The term “we”, “us” or the “Company” as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2014. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of operating results that may be achieved over the course of the full year.

Seasonality of the Business

Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Use of Estimates

The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Our primary product, Cold-EEZE^ÒCold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE^® Cold Remedy QuickMelts^® and a Cold-EEZE^®Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Cold Remedy Oral Spray and QuickMelts^® products, and Organix^® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

Cash Equivalents

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.

Inventory Valuation

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At March 31, 2015 and December 31, 2014, the financial statements include adjustments to reduce inventory for excess or obsolete inventory of $505,000 and $797,000, respectively. The components of inventory are as follows (in thousands):

	March 31,		December 31,
	2015		2014

Raw materials	$	816	$	798
Work in process		207		418
Finished goods		2,254		2,076
	$	3,277	$	3,292

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures – five years.

Concentration of Risks

Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedyproducts are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.

We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2015, our cash balance was $5.0 million and our bank balance was $5.3 million. Of the total bank balance, $582,000 was covered by federal depository insurance and $4.7 million was uninsured at March 31, 2015.

Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at March 31, 2015 and December 31, 2014.

Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately 93% and 95% of total revenues for each of the three months ended March 31, 2015 and 2014, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three months ended March 31, 2015 and 2014, our net sales were principally related to domestic markets.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Long-lived Assets

We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.

Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Fair Value of Financial Instruments

Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments.

Revenue Recognition

Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

As of March 31, 2015 and December 31, 2014, we included a provision for sales allowances of $55,000 and $129,000, respectively, which are reported as a reduction to sales and account receivables. Additionally, accrued advertising and other allowances as of March 31, 2015 included (i) $1.5 million for estimated future sales returns and (ii) $1.6 million for cooperative incentive promotion costs. As of December 31, 2014, accrued advertising and other allowances included (i) $1.5 million for estimated future sales returns and (ii) $2.1 million for cooperative incentive promotion costs.

Advertising and Incentive Promotions

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2015 and 2014 were $3.1 million and $3.4 million, respectively. Included in prepaid expenses and other current assets was $172,000 and $885,000 at March 31, 2015 and December 31, 2014, respectively, relating to prepaid advertising and promotion expenses.

Shipping and Handling

Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.

Stock Based Compensation

We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.

Stock and stock options for the purchase of our common stock, $0.0005 par value, (“Common Stock”) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 3). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended March 31, 2015 and 2014, we charged to operations $34,000 and $64,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.

Variable Interest Entity

On March 22, 2010, we, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM™ technology (“TPM”). The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010 (see Note 6).

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Research and Development

Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended March 31, 2015 and 2014 were $208,000 and $278,000, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.

Income Taxes

We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 4).

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.

As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits.

Recently Issued Accounting Standards

In May 2014, the FASB issued new accounting guidance ASU No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. There is no option for early adoption. This ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016. On April 29, 2015 the FASB issued an exposure draft to extend the effective date of ASU 2014-09 until December 15, 2017. We are currently assessing the impact of this update, and believe that its adoption will not have a material impact on our consolidated financial statements.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

In June 2014, the FASB issued new accounting guidance ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this update require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. Companies should apply existing guidance in ASC 718, “Compensation - Stock Compensation”, as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in this update will be effective as of January 1, 2016. Earlier adoption is permitted. We may apply the amendments in this update either: (1) prospectively to all awards granted or modified after the effective date; or (2) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If a retrospective transition is adopted, the cumulative effect of applying this update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. In addition, if a retrospective transition is adopted, we may use hindsight in measuring and recognizing the compensation cost. We are currently assessing the impact of this update, and believe that its adoption on January 1, 2016 will not have a material impact on our consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The amendments in this update state that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our consolidated financial statements.

In February 2015, the FASB issued guidance that changes the evaluation criteria for consolidation and related disclosure requirements. This guidance introduces evaluation criteria specific to limited partnerships and other similar entities, as well as amends the criteria for evaluating variable interest entities with which the reporting entity is involved and certain investment funds. The guidance will become effective for us at the beginning of our first quarter of Fiscal 2017. We do not expect the adoption of this guidance will have a material impact on our consolidated financial statements.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 3 – Transactions Affecting Stockholders’ Equity

Stockholder Rights Plan

On September 8, 1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a “Right” and collectively, the “Rights”) payable to the stockholders of record on September 25, 1998, thereby creating a Stockholder Rights Plan (the “Rights Agreement”). The Plan was subsequently amended effective each of (i) May 23, 2008, (ii) August 18, 2009 and (iii) June 18, 2014. The Rights Agreement, as amended and restated, provides that each Right entitles the stockholder of record to purchase from the Company that number of common shares having a combined market value equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding common shares, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the ownership of 15% or more of the outstanding common shares. The Rights Agreement allows for an exemption for Ted Karkus, the Company’s Chairman and Chief Executive Officer, to acquire up to 20% of our Common Stock without our Board of Directors declaring a dividend distribution. The dividend has the effect of giving the stockholder a 50% discount on the share’s current market value for exercising such right. In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is June 18, 2024.

2012 Equity Line of Credit

On November 21, 2012, we entered into the equity line of credit agreement (such arrangement, the “2012 Equity Line”) with Dutchess Opportunity Fund II, LP (“Dutchess”) whereby Dutchess committed to purchase, subject to certain restrictions and conditions, up to 2,500,000 shares of our Common Stock, over a period of 36 months from the first trading day following the effectiveness of the registration statement registering the resale of shares purchased by Dutchess pursuant to the 2012 Equity Line. On November 26, 2012, we filed a registration statement with Securities and Exchange Commission (“SEC”) to register for sale for up to 2,500,000 shares of our Common Stock and the registration statement was deemed effective by the SEC on December 12, 2012. We amended this registration statement effective May 29, 2014 to withdraw and remove from registration all unissued and unsold shares. We also agreed with Dutchess to terminate the 2012 Equity Line as of May 28, 2014.

During the period January 1, 2014 through May 23, 2014, we sold an aggregate of 698,207 shares of Common Stock to Dutchess under and pursuant to the 2012 Equity Line and we derived net proceeds of $1.2 million. The sales of the shares under the 2012 Equity Line were deemed to be exempt from registration under the Securities Act of 1933, as amended in reliance upon Section 4(2) (or Regulation D promulgated thereunder).

2014 Equity Line of Credit

The Company and Dutchess executed a new equity line of credit agreement (such arrangement, the “2014 Equity Line”) dated May 28, 2014 whereby Dutchess committed to purchase, subject to certain restrictions and conditions, up to 3,000,000 shares of the Company’s Common Stock, over a period of 36 months from the effectiveness of the registration statement registering the resale of shares purchased by Dutchess pursuant to the 2014 Equity Line. On May 29, 2014, we filed a registration statement with the SEC to register for sale up to 3,000,000 shares of our Common Stock and the registration statement was declared effective by the SEC on June 4, 2014.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 3 – Transactions Affecting Stockholders’ Equity – continued

We may in our discretion draw on the facility from time to time, as and when we determine appropriate in accordance with the terms and conditions of the 2014 Equity Line. The maximum number of shares that the Company is entitled to put to Dutchess in any one draw down notice shall not exceed shares with a purchase price of $500,000, calculated in accordance with the 2014 Equity Line. We may deliver a notice for a subsequent put from time to time, following the one day pricing period for the prior put.

The purchase price shall be set at ninety-five percent (95%) of the VWAP of the Company’s Common Stock during the one trading day immediately following our put notice. The Company has the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales for a specific put, Dutchess must remit such excess proceeds to the Company; however, in the event Dutchess receives less than a five percent (5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on the applicable closing date so Dutchess’s return will equal five percent (5%).

There are put restrictions applied on days between the draw down notice date and the closing date with respect to that particular put. During such time, the Company shall not be entitled to deliver another draw down notice. In addition, Dutchess will not be obligated to purchase shares if Dutchess’s total number of shares beneficially held at that time would exceed 4.99% of the number of shares of our Common Stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, we are not permitted to draw on the facility unless there is an effective registration statement to cover the resale of the shares.

During the period June 13, 2014 through December 31, 2014, we sold an aggregate of 2,561,520 shares of our Common Stock to Dutchess under and pursuant to the 2014 Equity Line and we derived net proceeds of $3.7 million. The sales of the shares under the 2014 Equity Line were deemed to be exempt from registration under the Securities Act of 1933, as amended in reliance upon Section 4(2) (or Regulation D promulgated thereunder). At March 31, 2015, we have 438,480 shares of our Common Stock available for sale, at our discretion, under the terms of the 2014 Equity Line and covered pursuant to a registration statement.

The 1997 Option Plan

On December 2, 1997, our Board of Directors approved a Stock Option Plan (the “1997 Plan”), which was amended in 2005, the 1997 Plan provided for the granting of up to 4.5 million shares of Common Stock. Under the 1997 Plan, we were permitted to grant options to employees, officers or directors of the Company at variable percentages of the market value of stock at the date of grant. No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998. No options were granted under this Plan for the three months ended March 31, 2015 or 2014.

We are precluded from issuing any additional options or grants in the future under the 1997 Plan pursuant to the terms of the plan document. Options previously granted continue to be available for exercise at any time prior to such options’ respective expiration dates, but in no event later than ten years from the date granted. At March 31, 2015, there were 26,500 options outstanding under the 1997 Plan with an expiration date of December 2015.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 3 – Transactions Affecting Stockholders’ Equity – continued

The 2010 Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by shareholders on April 24, 2011 and further amended and approved by shareholders on May 6, 2013 (the “2010 Plan”). The 2010 Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Plan is equal to 1.6 million shares plus up to 900,000 shares that are authorized for issuance but unissued under the 1997 Plan for an aggregate of 2.5 million shares. The 1997 Plan expired on December 2, 2007 and no additional awards may be made. As of March 31, 2015, 1,481,750 of the options issued under the 1997 Plan prior to December 2007 expired unexercised or were terminated. As a consequence, these shares are deemed and remain unissued which up to a maximum of 900,000 shares became available for issuance under the 2010 Plan and the remaining 581,750 options are deemed cancelled. No options were granted under the 2010 Plan for the three months ended March 31, 2015 or 2014. At March 31, 2015, there were 19,659 shares of Common Stock that may be issued pursuant to the terms of the 2010 Equity Compensation Plan.

There were no stock options exercised for the three months ended March 31, 2015 or 2014.

The 2010 Directors’ Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Directors’ Equity Compensation Plan which was subsequently amended and approved by shareholders on May 6, 2013. A primary purpose of the 2010 Directors’ Equity Compensation Plan is to provide us with the ability to pay all or a portion of the fees of directors in restricted stock instead of cash. The 2010 Directors’ Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Directors’ Equity Compensation Plan is equal to 425,000. For the three months ended March 31, 2015 or 2014, no shares were granted to directors. At March 31, 2015, there were 147,808 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors’ Equity Compensation Plan.

Note 4 – Income Taxes

As of December 31, 2014, we have net operating loss carry-forwards of approximately $38.6 million for federal purposes that will expire beginning in Fiscal 2020 through Fiscal 2033. Additionally, there are net operating loss carry-forwards of approximately $20.1 million for state purposes that will expire beginning in Fiscal 2018 through Fiscal 2033. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock are assured, a valuation allowance equaling the total deferred tax asset is being provided. Management believes that this allowance is required due to the uncertainty of realizing these tax benefits in the future.

Note 5 – Commitments and Contingencies

Godfrey Settlement Agreement

In November 2004, we commenced an action against John C. Godfrey, Nancy Jane Godfrey, and Godfrey Science and Design, Inc. (together the “Godfreys”) for injunctive relief regarding the ownership of the Cold-EEZE^® trademark. The Godfreys subsequently asserted against us counterclaims and sought monetary damages and injunctive and declaratory relief relative to the Cold-EEZE^® trademark and other intellectual property.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 5 – Commitments and Contingencies – continued

On December 20, 2012, we and the Godfreys, including the Estate of Nancy Jane Godfrey, entered into a Settlement Agreement and Mutual General Release (the “Godfrey Settlement Agreement”), pursuant to which we resolved all disputes, including claims asserted by us and counterclaims asserted against us in the action. Pursuant to the terms of the Godfrey Settlement Agreement, we paid the Godfreys $2.1 million in December 2012 and we agreed to make four additional annual payments of $100,000 due in December of each of the next four years. Each annual payment in the amount of $100,000 will accrue interest at the per annum rate of 3.25%. The second annual installment of $100,000 plus accrued interest of $10,000 was paid in December 2014. Under the Godfrey Settlement Agreement, the Godfreys assigned, transferred and conveyed to us all of their right, title, and interest in U.S. Trademark Registration No. 1,838,542 for the trademark Cold-EEZE^®, among other intellectual property associated with such trademark. At each of March 31, 2015 and December 31, 2014, other current liabilities and other long term obligations include $100,000 and $100,000, respectively, for the two remaining annual installment payments.

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2015, as follows (in thousands):

Fiscal Year	Employment Contracts		Godfrey Settlement Agreement		Total
2015		769		100		869
2016		1,025		100		1,125
2017		1,025		-		1,025
2018		-		-		-
2019		-		-		-
Total	$	2,819	$	200	$	3,019

Note 6 – Investment in a Joint Venture

On March 22, 2010, we, PSI Parent, PSI and the Joint Venture entered into the LLC Agreement of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM.

In connection with the LLC Agreement, PSI Parent granted to us, pursuant to the terms of a License Agreement, dated March 22, 2010 (the “Original License Agreement”), (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit OTC drugs and certain other products that embody certain of PSI Parent’s TPM-related patents and related know-how (collectively, the “PSI Technology”) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug.

Pursuant to the Original License Agreement, we issued 1,440,000 shares of our Common Stock having an aggregate value of approximately $2.6 million to PSI Parent (such shares, the “PSI Shares”) and made a one-time payment to PSI Parent of $1.0 million in March 2010. We recorded an intangible asset valued at $3.6 million in March 2010 for the acquisition of the PSI Technology license.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 6 – Investment in a Joint Venture - continued

As previously announced in September 2014, we are implementing a series of new product development and pre-commercialization initiatives principally in the dietary supplement category. While several of our product development initiatives have advanced, including those specific to the dietary supplement category, our Phusion product development initiatives have not progressed to management’s satisfaction. At this time, management believes that any products embodying the licensed technology to be developed by Phusion will not be available until Fiscal 2016 or 2017 at the earliest, and may be more limited than previously forecasted and may encompass fewer products or have limited retail distribution.

During the third quarter of Fiscal 2014, our evaluation of the Company’s progress in its new product development pipeline and delays in Phusion product development caused management to reassess projections (including income projections) relied upon in December 2013. Accordingly, management performed an impairment analysis for the period ended September 30, 2014 for the licensed technology. As a consequence of our impairment assessment, we determined that a full impairment occurred of the intangible asset, licensed technology. As a consequence, we charged to operations a $3.6 million impairment charge during the third quarter of Fiscal 2014.

On October 17, 2014, we initiated a demand for arbitration with the American Arbitration Association, case number 01-14-0001-7373. This demand for arbitration pertains to our Phusion joint venture and the matter is against Phosphagenics, Inc. and Phosphagenics LTD (collectively known as the “Phosphagenics Entities”). We have raised certain claims based upon the alleged Phosphagenics Entities’ breach of a certain amended and restated licenses agreement for the exploitation of certain intellectual property and, separately, breach of the Phusion joint venture operating agreement as between the Company and the Phosphagenics Entities. The Phosphagenics Entities have made counter claims of breaches against the Company and Phusion. This matter is at its preliminary stage and at this time, no prediction as to the outcome of this action can be made.

Note 7 – Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of our Common Stock outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that shared in the earnings of the entity. Diluted earnings per share also utilize the treasury stock method which prescribes a theoretical buy-back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Options and warrants outstanding to acquire shares of our Common Stock at March 31, 2015 and 2014 were 1,739,500 and 1,637,500, respectively.

For the three months ended March 31, 2015 and 2014 dilutive earnings per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the three months ended March 31, 2015 and 2014, there were 358,411 and 586,215 Common Stock Equivalents, respectively, which were in the money, that were excluded from the earnings per share computation.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 7 – Earnings (Loss) Per Share – continued

A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):

	Three Months Ended								Three Months Ended
	March 31, 2015								March 31, 2014
	Loss			Shares		EPS			Loss			Shares		EPS
Basic earnings (loss) per share	$	(1,380	)		15,892	$	(0.09	)	$	(804	)		16,469	$	(0.05	)

Dilutives:
Options		-			-		-			-			-		-

Diluted income (loss) per share	$	(1,380	)		15,892	$	(0.09	)	$	(804	)		16,469	$	(0.05	)

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.

General

ProPhase Labs, Inc. (“we”, “us”, “ProPhase” or the “Company”), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along with supplements, personal care and cosmeceutical products.

Our primary business is the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE^ÒCold Remedy and our principal product is Cold-EEZE^Ò Cold Remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute non-lozenge forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE^® Cold Remedy QuickMelts^® and (ii) Cold-EEZE^® Cold Remedy Oral Spray. In Fiscal 2014, we expanded our Cold-EEZE^® Cold Remedy QuickMelts^®product line and began shipments to retailers in July 2014, Cold-EEZE^® Cold Remedy Plus Multi-Symptom QuickMelts^® for cold and flu. Each of our Cold-EEZE^® Cold Remedy QuickMelts^®products are based on our proprietary zinc gluconate formulation in combination with certain natural (i) immune system support, (ii) energy, (iii) sleep and relaxation, and/or (iv) cold and flu symptom relieving active ingredients. For the three ended March 31, 2015 and 2014, our revenues from operations have come principally from our OTC cold remedy products.

Product Development

Our flagship Cold-EEZE^® Cold Remedy brand has generally performed well within the cough-cold category over the past several years. However, some retailers are reallocating shelf space away from the cough-cold category to other product categories. With cough-cold shelf space at a premium, opportunities in the future to introduce new Cold-EEZE^® branded products in the cough-cold category may be limited. Therefore, to continue to grow our Company, we are in the process of implementing a series of new product development and pre-commercialization initiatives in the dietary supplement category. While management anticipates the growth potential in this category may be better, the risks associated with introducing new products that do not leverage the Cold-EEZE^® brand name may be higher. Therefore, no assurance can be made that our new product efforts will be successful. We currently expect that at least one product in this new category will begin shipping in late Fiscal 2015 or early Fiscal 2016.

Seasonality of the Business

Our sales are derived principally from our OTC cold remedy products. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for our OTC cold remedy products with a corresponding increase in marketing and advertising expenditures designed to promote our products during the Cold Season. In addition, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which is dependent upon the timing, length and severity of each cold season. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Results from Operations for the Three Months Ended March 31, 2015

as Compared to the Three Months Ended March 31, 2014

For the three months ended March 31, 2015, net sales were $5.9 million as compared to $6.2 million for the three months ended March 31, 2014. For the three months ended March 31, 2015, net sales of OTC cold remedy products were $5.3 million as compared to net sales of $5.8 million for three months ended March 31, 2014. The decline in net sales for the three months ended March 31, 2015 as compared to the three months ended March 31, 2014 was due principally to the timing of customer purchases and consumer demand as a consequence of the incidence and severity of upper respiratory illnesses, respectively. For the three months ended March 31, 2015 and 2014, our contract manufacturing operations generated net sales to third party customers of $530,000 and $404,000, respectively.

Cost of sales for the three months ended March 31, 2015 were $ 2.2 million as compared to $2.2 million for the three months ended March 31, 2014. For the three months ended March 31, 2015 and 2014, we realized a gross margin of 62.5% and 64.5%, respectively. The decrease of 2.0% in gross margin from the prior period is principally due to, (i) a reduction in the absorption of fixed production costs as a consequence of a decline in net sales and (ii) fluctuations in our product mix shipped from period to period Gross margins are principally influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs, if any, retail cooperative incentive promotion and the timing of shipments to customers which are factors of the seasonality of our sales activities and products.

Sales and marketing expense for the three months ended March 31, 2015 was $2.8 million as compared to $3.0 million for the three months ended March 31, 2014. The decrease in sales and marketing expense for the three months ended March 31, 2015 as compared to the three months ended March 31, 2014 was principally due to a decrease in our marketing expenditures.

General and administration (“G&A”) expenses for the three months ended March 31, 2015 was $2.0 million as compared to $1.5 million for the three months ended March 31, 2014. The increase of $514,000 in administration expense for the three months ended March 31, 2015 as compared to the three months ended March 31, 2014 was principally due to an increase in professional and legal fees related to certain, now resolved, litigation matters.

Research and development costs during the three months ended March 31, 2015 was $208,000, as compared to $278,000 for the three months ended March 31, 2014. The decrease in research and development costs for the three months ended March 31, 2015 as compared to the three months ended March 31, 2014 was due principally to a decrease in the amount and timing of our product development expenditures.

As a consequence of the effects of the above, the net loss for the three months ended March 31, 2015, was $1.4 million, or ($0.09) per share, as compared to a net loss of $804,000, or ($0.05) per share, for the three months ended March 31, 2014.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Liquidity and Capital Resources

Our aggregate cash and cash equivalents as of March 31, 2015 were $5.0 million compared to $2.9 million at December 31, 2014. The increase of $2.1 million in our cash balance for the three months ended March 31, 2015 was principally due to the net effect of (i) cash provided in operations of $2.1 million principally as a consequence of the net effect of (a) a decrease of accounts receivable of $2.4 million, (b) an increase of $906,000 to other operating assets and liabilities, offset by (c) our net loss of $1.4 million and, (ii) capital expenditures of $42,000. Our working capital was $6.9 million and $8.2 million as of March 31, 2015 and December 31, 2014, respectively.

2012 Equity Line of Credit

2014 Equity Line of Credit

The purchase price shall be set at ninety-five percent (95%) of the volume weighted average price (VWAP) of the Company’s Common Stock during the one trading day immediately following our put notice. The Company has the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales for a specific put, Dutchess must remit such excess proceeds to the Company; however, in the event Dutchess receives less than a five percent (5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on the applicable closing date so Dutchess’s return will equal five percent (5%).

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

General

Management believes that its strategy to maintain Cold-EEZE^Ò as a recognized brand name, its broader range of products, its adequate manufacturing capacity, together with its current working capital and its available 2014 Equity Line, if exercised, should provide a source of capital to fund normal business operations. Our operations support the current research and development expenditures related to new products. In addition to the funding from operations, it is likely that we will in the short and long term raise additional capital through the issuance of securities or secure other financing sources to support such product development research, new product acquisitions or a venture investment or acquisition. Such funding through the issuance of equity securities would result in the dilution of current stockholders’ ownership in the Company. Should our product development initiatives progress on certain formulations, additional development expenditures may require substantial financial support and may necessitate the consideration of alternative approaches such as licensing, joint venture, or partnership arrangements that we determine will meet our long term goals and objectives. Ultimately, should internal working capital be insufficient and external funding methods or other business arrangements become unattainable, it would likely result in the deferral or abandonment of future development relative to current and prospective product development initiatives and formulations.

Management is not aware of any other trends, events or uncertainties that have or are reasonably likely to have a material negative impact upon our (i) short-term or long-term liquidity, or (ii) net sales or income from continuing operations. Any challenge to our patent rights could have a material adverse effect on our future; however, we are not aware of any condition that would make such an event probable. Our business is subject to seasonal variations thereby impacting liquidity and working capital during the course of our fiscal year.

Management believes that cash generated from operations, along with our current cash balances, will be sufficient to finance working capital and capital expenditure requirements to fund normal business operations for at least the next twelve months. However, we will likely require additional capital to support, among other items, (i) new product introductions, (ii) expansion of our product marketing and promotion activities, (iii) additional research development activities, (iv) further investment in our Joint Venture, (v) venture investments or acquisitions, and/or (vi) support current operations.

To the extent that we do not generate sufficient cash from operations, we may need to incur indebtedness to finance plans for growth. Volatility in the credit markets and the liquidity of major financial institutions may have an adverse effect on our ability to fund our business strategy through borrowings, under either existing or newly created instruments in the public or private markets on terms that we believe to be reasonable, if at all.

Capital Expenditures

Capital expenditures during the remainder of Fiscal 2015 are not expected to be material.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Off-Balance Sheet Arrangements

It is not our usual business practice to enter into off-balance sheet arrangements such as guarantees on loans and financial commitments and retained interests in assets transferred to an unconsolidated entity for securitization purposes. We have no off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Certain Risk Factors

Our business is regulated by various agencies of the states and localities where our products are sold. Governmental regulations in foreign countries where we plan to commence or expand sales may prevent or delay entry into a market or prevent or delay the introduction, or require the reformulation of certain of our products. In addition, no prediction can be made as to whether new domestic or foreign legislation regulating our activities will be enacted. Any new legislation could have a material adverse effect on our business, financial condition and operations. Non-compliance with any applicable requirements may subject us or the manufacturers of our products to agency action, including warning letters, fines, product recalls, seizures and injunctions.

The manufacturing, processing, formulation, packaging, labeling and advertising of our cold remedy products are subject to regulation by several federal agencies, including (i) the Food and Drug Administration (“FDA”), (ii) the Federal Trade Commission (“FTC”), (iii) the Consumer Product Safety Commission, (iv) the United States Department of Agriculture, (v) the United States Postal Service, (vi) the United States Environmental Protection Agency and (vii) the United States Occupational Safety and Health Administration.

In addition to OTC and prescription drug products, the FDA regulates the safety, manufacturing, labeling and distribution of dietary supplements, including vitamins, minerals and herbs, food additives, food supplements and cosmetics. The FTC also has overlapping jurisdiction with the FDA to regulate the promotion and advertising of vitamins, OTC drugs, cosmetics and foods. In addition, certain of our OTC cold remedy products are homeopathic remedies which are subject to standards established by the Homeopathic Pharmacopoeia of the United States (“HPUS”). HPUS sets the standards for source, composition and preparation of homeopathic remedies which are officially recognized under the Federal Food, Drug and Cosmetics Act, as amended.

Preclinical development, clinical trials, product manufacturing, labeling, distribution and marketing of potential new products are also subject to federal and state regulation in the United States and other countries. Clinical trials and product marketing and manufacturing are subject to the rigorous review and approval processes of the FDA and foreign regulatory authorities. To obtain approval of a new drug product, a company must demonstrate through adequate and well-controlled clinical trials that the drug product is safe and effective for its intended use. Obtaining FDA and other required regulatory approvals is lengthy and expensive. Typically, obtaining regulatory approval for pharmaceutical products requires substantial resources and takes several years. The length of this process depends on the type, complexity and novelty of the product and the nature of the disease or other indication to be treated. Preclinical studies must comply with FDA regulations. Clinical trials must also comply with FDA regulations to ensure safety of the human subjects in the trial and may require large numbers of test subjects, complex protocols and possibly lengthy follow-up periods. Consequently, satisfaction of government

regulations may take several years, may cause delays in introducing potential new products for considerable periods of time and may require imposing costly procedures upon our activities. If regulatory approval of new products is not obtained in a timely manner or not at all, we could be materially adversely affected. Even if regulatory approval of new products is obtained, such approval may impose limitations on the indicated uses for which the products may be marketed which could also materially adversely affect our business, financial condition and future operations.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

We face significant technological risks inherent in developing new products. We may be subject to delays and/or ultimately unable to successfully implement our business plan and strategy to develop and commercialize one or more non-prescription remedies and/or dietary supplements. The commercialization and ultimate product market acceptance is subject to, among other influences, consumer purchasing trends, demand for our product, health and wellness trends, regulatory factors, retail acceptance and overall economic and market conditions. As a consequence, we may suspend or abandon some or all of our proposed new products before they become commercially viable. Even if we develop and obtain approval of a new product, if we cannot successfully commercialize it in a timely manner, our business and financial condition may be materially adversely affected.

We have aligned our operations to focus principally in the research, development, manufacture, marketing and sale of OTC cold remedy and consumer products, natural based health products and other supplement and cosmeceutical products. In addition, we may seek to acquire from third parties or enter into other arrangements with respect to new formulations, ingredients, applications and other products developed by third parties who may be seeking our commercialization, marketing and distribution expertise. There can be no assurance that we will be able to effectuate our business plan successfully or that our revenue growth will continue. In addition, we may not be successful in acquiring or otherwise entering into any new lines of business and, if we are successful in doing so, there can be no assurance that such new business will achieve profitability.

Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capability and the requirements associated with the development of potential OTC drug and other medicinal products in order to continue to compete on a national and international level. Our business development is dependent on continued conformity with government regulations, a reliable information technology system capable of supporting continued growth and continued reliable sources for product and materials to satisfy consumer demand. Many of our competitors have substantially greater capital resources, technical staffs, facilities, marketing resources, product development, distribution and experience than we do. As a consequence, our competitors may have certain advantages, including the ability to allocate greater resources for new product development, marketing and other purposes.

Readers should carefully review the risk factors described in other sections of this filing, our Annual Report on Form 10-K for the year ended December 31, 2014 as well as in other documents we file from time to time with the SEC.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Our significant accounting policies are described in Note 2 of Notes to Condensed Consolidated Financial Statements included under Item 1 of this Part I. However, certain accounting policies are deemed “critical”, as they require management’s highest degree of judgment, estimates and assumptions. These accounting estimates and disclosures have been discussed with Audit Committee of our Board of Directors. A discussion of our critical accounting policies, the judgments and uncertainties affecting their application and the likelihood that materially different amounts would be reported under different conditions or using different assumptions are as follows:

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Revenue Recognition – Sales Allowances

When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Our primary product, Cold-EEZE^ÒCold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® Cold Remedy lozenges we market and distribute two additional forms of our proprietary zinc formulation, Cold-EEZE^® Cold Remedy QuickMelts^® and Cold-EEZE^® Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Cold Remedy Oral Spray and QuickMelts^® products, and Organix^® products carry shelf-life expiration dates for which we aggregate such product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity fall within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such item that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

We classify product returns into principally three categories, (i) non-routine returns, (ii) obsolete product and (iii) product mix realignment by certain of our customers. “Non-routine” returns are defined as product returned to us as a consequence of unanticipated circumstances principally due to (i) retail store closings or (ii) unexpected poor retail sell through to consumers causing us to discontinue the product. “Obsolete” returns are defined as product returned to us as a consequence of product shelf-life “use by” expiration date. “Product mix realignment” returns are defined as product returned to us due to initiatives by the trade to discontinue purchasing certain of our products. Product mix realignment returns are generally nominal and are frequently related to discontinued or soon to be discontinued products.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

As of March 31, 2015, accrued advertising and other allowances included (i) $1.5 million for estimated future sales returns and (ii) $1.6 million for cooperative incentive promotion costs. As of December 31, 2014, accrued advertising and other allowances included (i) $1.5 million for estimated future sales returns and (ii) $2.1 million for cooperative incentive promotion costs. Additionally, as of March 31, 2015 and December 31, 2014, we included a provision for sales allowances of $55,000 and $129,000, respectively, which are reported as a reduction to sales and account receivables.

Income Taxes

Recently Issued Accounting Standards

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward looking statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. Many of these factors are beyond our ability to predict. Given the risks and uncertainties surrounding forward-looking statements, you should not place undue reliance on these statements. Forward-looking statements typically are identified by use of terms such as “anticipate”, “believe”, “plan”, “expect”, “intend”, “may”, “will”, “should”, “estimate”, “predict”, “potential”, “continue” and similar words although some forward-looking statements are expressed differently. This Report may contain forward-looking statements attributed to third parties relating to their estimates regarding the growth of our markets. You are cautioned that such forward looking statements are not guarantees of future performance and that all forward-looking statements address matters that involve risk and uncertainties, and there are many important risks, uncertainties and other factors that could cause our actual results, levels of activity, performance, achievements and prospects, as well as those of the markets we serve, to differ materially from the forward-looking statements contained in this Report.

Such risks and uncertainties include, but are not limited to:

The ability of our management to successfully implement our business plan and strategy;

Our ability to fund our operations including the cost and availability of capital and credit;

Our ability to compete effectively, including our ability to maintain and increase our markets and/or market share in the markets in which we do business;

Our dependence on sales from our principal product, Cold-EEZE^Ò Cold Remedy, and our ability to successfully develop and commercialize our new products within the cough-cold category or other categories such as dietary supplements;

Changes in our retail and distribution customers strategic business plans including, but not limited to, (i) expansions, mergers, and/or consolidations, (ii) retail shelf space allocations for products within each outlet and in particular the cough/cold category in which we compete, (iii) changes in their private label assortment and (iv) product selections, distribution allocation, merchandising programs and retail pricing of our products as well as competitive products;

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

The general financial and economic uncertainty, fluctuations in consumer confidence and the strength of an economic recovery, if any, and their impacts on our business including demand for our products;

Our ability to protect our proprietary rights;

Our continued ability to comply with regulations relating to our current products and any new products we develop, including our ability to effectively respond to changes in laws and regulations or the interpretation thereof including changing market rules and evolving federal, state and regional laws and regulations;

Potential disruptions in our ability to manufacture our products or our access to raw materials;

Seasonal fluctuations in demand for our products;

Our ability to attract, retain and motivate our key employees; and

Other risks identified in this Report.

You should also consider carefully the statements under other sections of this Report and our Annual Report on Form 10-K for the year ended December 31, 2014, which address additional risks that could cause our actual results to differ from those set forth in any forward-looking statements. Our forward-looking statements speak only as the date of this Report. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Like virtually all commercial enterprises, we can be exposed to the risk (“market risk”) that the cash flows to be received or paid relating to certain financial instruments could change as a result of changes in interest rate, exchange rates, commodity prices, equity prices and other market changes.

Our operations are not subject to risks of material foreign currency fluctuations, nor do we use derivative financial instruments in our investment practices. We place our marketable investments in instruments that meet high credit quality standards. We do not expect material losses with respect to our investment portfolio or exposure to market risks associated with interest rates. The impact on our results of one percentage point change in short-term interest rates would not have a material impact on our future earnings, fair value, or cash flows related to investments in cash equivalents or interest-earning marketable securities.

Current economic conditions may cause a decline in business and consumer spending which could adversely affect our business and financial performance including the collection of accounts receivables, realization of inventory and recoverability of assets. In addition, our business and financial performance may be adversely affected by current and future economic conditions, including due to a reduction in the availability of credit, financial market volatility and recession.

Item 4. Controls and Procedures.

The management of the Company, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of March 31, 2015. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of that date, the Company’s disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. During the quarter ended March 31, 2015, there were no changes in our internal control over financial reporting that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurances that the objectives of the control system will be met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. However, our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives.

Part II. Other Information

Item 1. Legal Proceedings.

PROPHASE LABS, INC. PROPHASE LABS, INC. FOR THE BENEFIT OF PHUSION LABORATORIES, LLC vs. Phosphagenics, Inc., Phosphagenics, LTD and Phusion Laboratories, LLC as a nominal defendant

On October 17, 2014, we initiated a demand for arbitration with the American Arbitration Association, case number 01-14-0001-7373. This demand for arbitration pertains to our Phusion Labs, LLC (“Phusion”) joint venture and the matter is against Phosphagenics, Inc. and Phosphagenics LTD (collectively known as the “Phosphagenics Entities”). We have raised certain claims based upon the alleged Phosphagenics Entities’ breach of a certain amended and restated licenses agreement for the exploitation of certain intellectual property and, separately, breach of the Phusion joint venture operating agreement as between the Company and the Phosphagenics Entities. This matter is at its preliminary stage and at this time, no prediction as to the outcome of this action can be made.

Item 1A. Risk Factors.

Not applicable

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not applicable

Item 5. Other Information.

None

Item 6. Exhibits

(1)

Exhibit 31.1 Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

(2)

Exhibit 31.2 Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

(3)

Exhibit 32.1 Certification by the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(4)

Exhibit 32.2 Certification by the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(5) 101 INS — XBRL Instance Document

(6) 101 SCH — XBRL Taxonomy Extension Schema Document

(7) 101 CAL — XBRL Taxonomy Extension Calculation Linkbase Document

(8) 101 DEF — XBRL Taxonomy Extension Definition Linkbase Document

(9) 101 LAB — XBRL Taxonomy Extension Label Linkbase Document

(10) 101 PRE — XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ProPhase Labs, Inc.

	By:	/s/ Ted Karkus
		Ted Karkus
		Chairman of the Board and Chief Executive Officer
		(Principal Executive Officer)

Date: May 13, 2015

	By:	/s/ Robert V. Cuddihy, Jr.
		Robert V. Cuddihy, Jr.
		Chief Operating Officer and Chief Financial Officer
		(Principal Accounting and Financial Officer)

Date: May 13, 2015

EX-31.1 2 v409474_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Ted Karkus, certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;

Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;

Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2015
	By:	/s/ Ted Karkus
		Ted Karkus
		Chairman of the Board and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 v409474_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Robert V. Cuddihy, Jr., certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2015
	By:	/s/ Robert V. Cuddihy, Jr.
		Robert V. Cuddihy, Jr.
		Chief Operating Officer and Chief Financial Officer (Principal Accounting and Financial Officer)

EX-32.1 4 v409474_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Ted Karkus, Chief Executive Officer of ProPhase Labs, Inc., a Nevada corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended March 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

	/s/ Ted Karkus
	Ted Karkus
	Chairman of the Board and Chief Executive Officer
	(Principal Executive Officer)
	May 13, 2015

EX-32.2 5 v409474_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert V. Cuddihy, Jr., Chief Financial Officer of ProPhase Labs, Inc., a Nevada corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended March 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

	/s/ Robert V. Cuddihy, Jr.
	Robert V. Cuddihy, Jr.
	Chief Operating Officer and Chief Financial Officer
	(Principal Accounting and Financial Officer)
	May 13, 2015

EX-101.INS 6 prph-20150331.xml XBRL INSTANCE DOCUMENT 0000868278 2012-01-01 2012-12-31 0000868278 2014-01-01 2014-03-31 0000868278 2014-01-01 2014-12-31 0000868278 2015-01-01 2015-03-31 0000868278 2014-03-31 0000868278 2015-03-31 0000868278 2015-05-13 0000868278 2012-12-01 2012-12-20 0000868278 2014-12-31 0000868278 2013-12-31 0000868278 us-gaap:SalesRevenueGoodsNetMember 2014-01-01 2014-03-31 0000868278 us-gaap:SalesRevenueGoodsNetMember 2015-01-01 2015-03-31 0000868278 prph:EstimatedFutureSalesReturnMember 2015-03-31 0000868278 prph:CooperativeIncentiveMember 2015-03-31 0000868278 prph:EstimatedFutureSalesReturnMember 2014-12-31 0000868278 prph:CooperativeIncentiveMember 2014-12-31 0000868278 prph:AdvertisingAndIncentivePromotionCostsMember 2015-03-31 0000868278 prph:AdvertisingAndIncentivePromotionCostsMember 2014-12-31 0000868278 us-gaap:EmploymentContractsMember 2015-03-31 0000868278 prph:GodfreySettlementAgreementMember 2015-03-31 0000868278 prph:TwoThousandFourteenEquityLineOfCreditMember 2014-05-01 2014-05-28 0000868278 prph:TwoThousandTwelveEquityLineOfCreditMember 2012-11-01 2012-11-21 0000868278 prph:TwoThousandFourteenEquityLineOfCreditMember 2015-01-01 2015-03-31 0000868278 us-gaap:CommonStockMember prph:DutchessMember prph:TwoThousandTwelveEquityLineOfCreditMember 2015-01-01 2015-03-31 0000868278 prph:TwoThousandFourteenEquityLineOfCreditMember 2014-05-28 0000868278 prph:Plan1997Member 2015-03-31 0000868278 prph:DirectorsPlan2010Member 2015-03-31 0000868278 prph:Plan2010Member 2015-03-31 0000868278 prph:AmendedOptionPlan1997Member 2015-01-01 2015-03-31 0000868278 prph:TwoThousandFourteenEquityLineOfCreditMember 2014-12-31 0000868278 prph:TwoThousandFourteenEquityLineOfCreditMember 2014-06-13 2014-12-31 0000868278 prph:PsiParentMember 2010-03-01 2010-03-31 0000868278 us-gaap:DomesticCountryMember 2014-12-31 0000868278 us-gaap:DomesticCountryMember 2014-01-01 2014-12-31 0000868278 us-gaap:StateAndLocalJurisdictionMember 2014-01-01 2014-12-31 0000868278 us-gaap:StateAndLocalJurisdictionMember 2014-12-31 0000868278 us-gaap:TreasuryStockMember 2014-12-31 0000868278 us-gaap:RetainedEarningsMember 2014-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000868278 us-gaap:CommonStockMember 2014-12-31 0000868278 us-gaap:RetainedEarningsMember 2015-01-01 2015-03-31 0000868278 us-gaap:TreasuryStockMember 2015-01-01 2015-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-03-31 0000868278 us-gaap:CommonStockMember 2015-01-01 2015-03-31 0000868278 us-gaap:CommonStockMember 2015-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2015-03-31 0000868278 us-gaap:RetainedEarningsMember 2015-03-31 0000868278 us-gaap:TreasuryStockMember 2015-03-31 0000868278 prph:TwoThousandFourteenEquityLineOfCreditMember 2015-03-31 0000868278 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2015-01-01 2015-03-31 0000868278 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MaximumMember 2015-01-01 2015-03-31 0000868278 us-gaap:MachineryAndEquipmentMember us-gaap:MinimumMember 2015-01-01 2015-03-31 0000868278 us-gaap:MachineryAndEquipmentMember us-gaap:MaximumMember 2015-01-01 2015-03-31 0000868278 us-gaap:ComputerSoftwareIntangibleAssetMember 2015-01-01 2015-03-31 0000868278 us-gaap:FurnitureAndFixturesMember 2015-01-01 2015-03-31 0000868278 prph:Plan1997Member 2015-01-01 2015-03-31 0000868278 prph:CommonStockEquivalentsMember 2014-01-01 2014-03-31 0000868278 prph:CommonStockEquivalentsMember 2015-01-01 2015-03-31 0000868278 us-gaap:ChiefExecutiveOfficerMember 2015-03-31 0000868278 prph:PsiTechnologyLicenseMember 2010-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2015-03-31 2015 Q1 ProPhase Labs, Inc. 0000868278 --12-31 Smaller Reporting Company PRPH 15892296

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Basis of Presentation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2014. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of operating results that may be achieved over the course of the full year.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Seasonality of the Business</i></strong> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold italic 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Use of Estimates</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our primary product, Cold-EEZE<font style="FONT-FAMILY:Symbol"><sup style="font-style:normal">Ò</sup></font> <sup style="font-style:normal"></sup>Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy QuickMelts<sup style="font-style:normal">®</sup> and a Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix<sup style="font-style:normal">®</sup>”). Each of the Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray and QuickMelts<sup style="font-style:normal">®</sup> products, and Organix<sup style="font-style:normal">®</sup> products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold italic 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Cash Equivalents</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Concentration of Risks</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy <sup style="font-style:normal"> </sup>products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2015, our cash balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million and our bank balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.3</font> million. Of the total bank balance, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">582,000</font> was covered by federal depository insurance and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.7</font> million was uninsured at March 31, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at March 31, 2015 and December 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 93</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 95</font>% of total revenues for each of the three months ended March 31, 2015 and 2014, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three months ended March 31, 2015 and 2014, our net sales were principally related to domestic markets.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i>Revenue Recognition</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As of March 31, 2015 and December 31, 2014, we included a provision for sales allowances of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">129,000</font>, respectively, which are reported as a reduction to sales and account receivables. Additionally, accrued advertising and other allowances as of March 31, 2015 included (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million for estimated future sales returns and (ii) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.6</font> million for cooperative incentive promotion costs. As of December 31, 2014, accrued advertising and other allowances included (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million for estimated future sales returns and (ii) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million for cooperative incentive promotion costs.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i>Stock Based Compensation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Stock and stock options for the purchase of our common stock, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0005</font> par value, (“Common Stock”) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 3). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended March 31, 2015 and 2014, we charged to operations $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">64,000</font>, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i>Advertising and Incentive Promotions</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2015 and 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.1</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.4</font> million, respectively. Included in prepaid expenses and other current assets was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">172,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">885,000</font> at March 31, 2015 and December 31, 2014, respectively, relating to prepaid advertising and promotion expenses.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Research and Development</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended March 31, 2015 and 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">208,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">278,000</font>, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i>Income Taxes</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 4).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits.  </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Fair Value of Financial Instruments </i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Recently Issued Accounting Standards</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May 2014, the FASB issued new accounting guidance ASU No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition.  The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts.  Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard.  There is no option for early adoption.  This ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016. On April 29, 2015 the FASB issued an exposure draft to extend the effective date of ASU 2014-09 until December 15, 2017.  We are currently assessing the impact of this update, and believe that its adoption will not have a material impact on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In June 2014, the FASB issued new accounting guidance ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this update require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. Companies should apply existing guidance in ASC 718, “Compensation - Stock Compensation”, as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in this update will be effective as of January 1, 2016. Earlier adoption is permitted. We may apply the amendments in this update either: (1) prospectively to all awards granted or modified after the effective date; or (2) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If a retrospective transition is adopted, the cumulative effect of applying this update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. In addition, if a retrospective transition is adopted, we may use hindsight in measuring and recognizing the compensation cost. We are currently assessing the impact of this update, and believe that its adoption on January 1, 2016 will not have a material impact on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The amendments in this update state that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In February 2015, the FASB issued guidance that changes the evaluation criteria for consolidation and related disclosure requirements. This guidance introduces evaluation criteria specific to limited partnerships and other similar entities, as well as amends the criteria for evaluating variable interest entities with which the reporting entity is involved and certain investment funds. The guidance will become effective for us at the beginning of our first quarter of Fiscal 2017. We do not expect the adoption of this guidance will have a material impact on our consolidated financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

5021000

2926000

3468000

5836000

3277000

3292000

670000

1404000

12436000

13458000

2558000

2599000

14994000

16057000

1231000

667000

3232000

3685000

1061000

889000

5524000

5241000

100000

13000

54698000

54664000

-14599000

-13219000

30742000

9370000

10716000

14994000

16057000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.3in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="7"> <div>Three Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="7"> <div>Three Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="7"> <div>March 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="7"> <div>March 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Loss</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>EPS</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Loss</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>EPS</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Basic earnings (loss) per share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>(1,380)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>15,892</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>(0.09)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>(804)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>16,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>(0.05)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Dilutives:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Diluted income (loss) per share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(1,380)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>15,892</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(0.09)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(804)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>16,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(0.05)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

505000

797000

582000

4700000

5300000

0.95

0.93

129000

55000

1500000

1600000

1500000

2100000

3400000

3100000

172000

885000

4424000

4341000

0.0005

50000000

25125113

9232817

869000

769000

100000

1125000

1025000

100000

1025000

3019000

2819000

200000

2100000

10000 0.0325 100000 100000 100000 100000 3000000 2500000 0.05 0.0499 698207 1200000

3000000

26500

425000

1600000

581750

4500000

2500000 0.15 0.95

147808

900000

19659

2561520

3700000

1440000

2600000

1000000

6171000

5860000

2191000

2198000

3980000

3662000

2997000

2812000

1507000

2021000

278000

208000

4782000

5041000

-802000

-1379000

2000

1000

-804000

-1380000

-804000

-1380000

-0.05

-0.09

38600000

Fiscal 2020 through Fiscal 2033 Fiscal 2018 through Fiscal 2033

20100000

-804000

-1380000

16469000

15892000

-0.05

-0.09

0 0 0 0 0 0

-804000

-1380000

-0.05

-0.09

16469000

15892000

-30742000

-13219000

54664000

13000

15892296

-1380000

34000

13000

54698000

-14599000

-30742000

15892296

64000

83000

5000

64000

34000

-2463000

-2368000

-309000

-15000

-19000

564000

35000 -453000

-839000

-906000

2951000

2132000

17000

42000

5000

-17000

-37000

947000

3881000

2095000

1638000

5519000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Note 1  Organization and Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">ProPhase Labs, Inc. (“we”, “us” or the “Company”), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along with supplement, personal care and cosmeceutical products.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our primary business is the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE<font style="FONT-FAMILY:Symbol"><sup style="font-style:normal">Ò</sup></font> <sup style="font-style:normal"></sup>Cold Remedy and our principal product is Cold-EEZE<font style="FONT-FAMILY:Symbol"><sup style="font-style:normal">Ò</sup></font> Cold Remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration of the common cold. In addition to Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy lozenges, we market and distribute non-lozenge forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy QuickMelts<sup style="font-style:normal">®</sup> and (ii) Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray. Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray is a liquid form of our zinc gluconate formulation that is sprayed in the mouth. Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy QuickMelts<sup style="font-style:normal">®</sup> are fast dissolving tablets that are taken orally. Cold-EEZE<font style="FONT-FAMILY:Symbol"><sup style="font-style:normal">Ò</sup></font> Cold Remedy is an established product in the health care and cold remedy market. For the three months ended March 31, 2015 and 2014, we operated in one reporting segment and our revenues have come principally from our OTC cold remedy products.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We use a December 31 year-end for financial reporting purposes. References herein to Fiscal 2015 shall mean the fiscal year ended December 31, 2015 and references to other “Fiscal” years shall mean the year, which ended on December 31 of the year indicated. The term “we”, “us” or the “Company” as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>Note 2  Summary of Significant Accounting Policies</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2014. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of operating results that may be achieved over the course of the full year.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Seasonality of the Business</i></strong> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold italic 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our primary product, Cold-EEZE<font style="FONT-FAMILY:Symbol"><sup style="font-style:normal">Ò</sup></font> <sup style="font-style:normal"></sup>Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy QuickMelts<sup style="font-style:normal">®</sup> and a Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix<sup style="font-style:normal">®</sup>”). Each of the Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray and QuickMelts<sup style="font-style:normal">®</sup> products, and Organix<sup style="font-style:normal">®</sup> products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold italic 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash Equivalents</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventory Valuation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At March 31, 2015 and December 31, 2014, the financial statements include adjustments to reduce inventory for excess or obsolete inventory of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">505,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">797,000</font>, respectively. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The components of inventory are as follows (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1in; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div style="CLEAR:both;CLEAR: both">Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">816</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">798</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div style="CLEAR:both;CLEAR: both">Work in process</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div style="CLEAR:both;CLEAR: both">Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,254</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,076</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,277</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,292</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property, Plant and Equipment</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures  five years.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Concentration of Risks</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy <sup style="font-style:normal"> </sup>products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2015, our cash balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million and our bank balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.3</font> million. Of the total bank balance, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">582,000</font> was covered by federal depository insurance and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.7</font> million was uninsured at March 31, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at March 31, 2015 and December 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 93</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 95</font>% of total revenues for each of the three months ended March 31, 2015 and 2014, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three months ended March 31, 2015 and 2014, our net sales were principally related to domestic markets.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Long-lived Assets</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i> </i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments </i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As of March 31, 2015 and December 31, 2014, we included a provision for sales allowances of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">129,000</font>, respectively, which are reported as a reduction to sales and account receivables. Additionally, accrued advertising and other allowances as of March 31, 2015 included (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million for estimated future sales returns and (ii) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.6</font> million for cooperative incentive promotion costs. As of December 31, 2014, accrued advertising and other allowances included (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million for estimated future sales returns and (ii) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million for cooperative incentive promotion costs.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Advertising and Incentive Promotions</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2015 and 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.1</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.4</font> million, respectively. Included in prepaid expenses and other current assets was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">172,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">885,000</font> at March 31, 2015 and December 31, 2014, respectively, relating to prepaid advertising and promotion expenses.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Shipping and Handling</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock Based Compensation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Stock and stock options for the purchase of our common stock, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0005</font> par value, (“Common Stock”) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 3). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended March 31, 2015 and 2014, we charged to operations $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">64,000</font>, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Variable Interest Entity</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On March 22, 2010, we, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM technology (“TPM”). The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010 (see Note 6).</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended March 31, 2015 and 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">208,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">278,000</font>, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 4).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits.  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recently Issued Accounting Standards</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May 2014, the FASB issued new accounting guidance ASU No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition.  The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts.  Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard.  There is no option for early adoption.  This ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016. On April 29, 2015 the FASB issued an exposure draft to extend the effective date of ASU 2014-09 until December 15, 2017.  We are currently assessing the impact of this update, and believe that its adoption will not have a material impact on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In June 2014, the FASB issued new accounting guidance ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this update require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. Companies should apply existing guidance in ASC 718, “Compensation - Stock Compensation”, as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in this update will be effective as of January 1, 2016. Earlier adoption is permitted. We may apply the amendments in this update either: (1) prospectively to all awards granted or modified after the effective date; or (2) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If a retrospective transition is adopted, the cumulative effect of applying this update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. In addition, if a retrospective transition is adopted, we may use hindsight in measuring and recognizing the compensation cost. We are currently assessing the impact of this update, and believe that its adoption on January 1, 2016 will not have a material impact on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The amendments in this update state that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In February 2015, the FASB issued guidance that changes the evaluation criteria for consolidation and related disclosure requirements. This guidance introduces evaluation criteria specific to limited partnerships and other similar entities, as well as amends the criteria for evaluating variable interest entities with which the reporting entity is involved and certain investment funds. The guidance will become effective for us at the beginning of our first quarter of Fiscal 2017. We do not expect the adoption of this guidance will have a material impact on our consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

64000

34000

3600000

816000

798000

207000

418000

2254000

2076000

P36M 500000

438480

In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998

16469000

15892000

P10Y

P39Y

P3Y

P7Y

P3Y

P5Y

0.5

1481750

1637500

1739500

586215

358411

0.2

3600000

EX-101.SCH 7 prph-20150331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statement of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Organization and Business link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Transactions Affecting Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Investment in a Joint Venture link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Transactions Affecting Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Investment in a Joint Venture (Details Textual) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Earnings (Loss) Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Earnings (Loss) Per Share (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 prph-20150331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 prph-20150331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 prph-20150331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Stockholders Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] Transactions Affecting Stock Holders Equity [Text Block] Investments in and Advances to Affiliates, Schedule of Investments [Abstract] Investments In and Advances To Affiliates, Schedule Of Investments [Text Block] Investments in and Advances to Affiliates, Schedule of Investments [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Text Block] Earnings Per Share [Text Block] Accounting Policies [Abstract] Organization, Consolidation, Basis Of Presentation, Business Description and Accounting Policies [Text Block] Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Policy Text Block] Nature Of Operations [Policy Text Block] Nature Of Operations [Policy Text Block] Disclosure of accounting policy for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Use Of Estimates, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration Risk Disclosure [Policy Text Block] Impairment Or Disposal Of Long-Lived Assets, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Fair Value Of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Advertising Costs, Policy [Policy Text Block] Advertising and Incentive Promotions [Policy Text Block] Shipping and Handling Cost, Policy [Policy Text Block] Shipping and Handling Cost, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Consolidation, Variable Interest Entity, Policy [Policy Text Block] Consolidation, Variable Interest Entity, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Statement Of Financial Position [Abstract] Statement [Table] Legal Entity [Axis] Entity [Domain] Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents (Note 2) Cash and Cash Equivalents, At Carrying Value Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accounts Receivable, Net, Current, Total Accounts receivable, net Inventory, Net, Total Inventory (Note 2) Inventory, Net Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Property, plant and equipment, net of accumulated depreciation of $4,424 and $4,341, respectively (Note 2) Property, Plant and Equipment, Net Assets, Total Total assets Liabilities [Abstract] LIABILITIES: Accounts Payable, Current Accounts payable Accrued Marketing Costs, Current Accrued advertising and other allowances Other Liabilities, Current Other current liabilities Liabilities, Current, Total Total current liabilities Liabilities, Other than Long-term Debt, Noncurrent, Total Other long term obligations (Note 5) Commitments and Contingencies Commitments and contingencies (Note 5) Stockholders Equity Attributable To Parent [Abstract] STOCKHOLDERS' EQUITY: Common Stock, Value, Issued Common Stock, $.0005 par value; authorized 50,000,000; issued: 25,125,113 shares (Note 3) Additional Paid In Capital, Common Stock Additional paid-in-capital Retained Earnings (Accumulated Deficit), Total Accumulated deficit Treasury Stock, Value Treasury stock, at cost 9,232,817 shares Stockholders Equity Attributable to Parent, Total Total stockholders' equity Balance Balance Liabilities and Equity, Total Total liabilities and stockholders' equity Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule Of Future Contingency Obligation [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block] Accounting Policies [Table] Other Operating Cost And Expense General Component [Axis] Information by component of other operating costs and expenses not included in the cost of sales. Other Operating Cost And Expense General Component [Domain] Name of each detailed component of other operating costs and expenses that are applicable to general sales and revenues, but not included in the cost of sales in the Income Statement. Advertising and Incentive Promotion Costs [Member] Advertising And Incentive Promotion Costs. Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Building and Building Improvements [Member] Machinery and Equipment [Member] Computer Software, Intangible Asset [Member] Computer Software [Member] Furniture and Fixtures [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Sales Revenue, Goods, Net [Member] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 3 [Member] Accrued Advertising and Other Allowances [Axis] Accrued Advertising And Other Allowances. Accrued Advertising and Other Allowances [Domain] Accrued Advertising And Other Allowances. Estimated Future Sales Return [Member] Estimated Future Sales Return. Cooperative Incentive [Member] Cooperative Incentive. Other Advertising and Marketing Promotions [Member] Other Advertising And Marketing Promotions. Award Type [Axis] Equity Award [Domain] Employee Stock Option [Member] Customer [Axis] Customer [Domain] Five Customer [Member] Two Customer [Member] Three Customer [Member] Three Customer [Member] Four Customer [Member] Limited Liability Company Agreement [Member] Range [Axis] Range [Domain] Maximum [Member] Minimum [Member] Accounting Policies [Line Items] Inventory Adjustments, Total Inventory Adjustments Cash, FDIC Insured Amount Cash, FDIC Insured Amount Cash, Uninsured Amount Cash, Uninsured Amount Due From Banks Due from Banks Concentration Risk, Percentage Concentration Risk, Percentage Concentration Risk, Percentage Sales Allowances, Goods Provision of Sales Allowance Accrued Liabilities Accrued Liabilities Marketing and Advertising Expense, Total Marketing and Advertising Expense Research and Development Expense, Total Research and development Research and development Common Stock, Par or Stated Value Per Share Common Stock, par value (in dollars per share) Balance Sheets Parenthetical [Abstract] Balance Sheets Parenthetical. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation Accumulated depreciation (in dollars) Common Stock, Shares Authorized Common Stock, shares authorized Common Stock, Shares, Issued Common Stock, shares issued Treasury Stock, Shares Treasury stock, shares (in shares) Commitments And Contingencies [Table] Estimated Future Obligation [Axis] Estimated Future Obligation. Estimated Future Obligation [Domain] Estimated Future Obligation Domain. Employment Contracts [Member] Godfrey Settlement Agreement [Member] Commitments And Contingencies [Line Items] Contractual Obligation, Due In Next Twelve Months 2015 Contractual Obligation, Due In Second Year 2016 Contractual Obligation, Due In Third Year 2017 Contractual Obligation, Due In Fourth Year 2018 Contractual Obligation, Due In Fifth Year 2019 Contractual Obligation, Due After Fifth Year Total Related Party [Axis] Related Party [Domain] Mr Karkus [Member] Mr karkus. Mr Cuddihy [Member] Mr Cuddihy. Employee Agreements [Axis] Employee Agreements [Domain] Employment Agreements Dated November 8, 2011 [Member] Reprensents employee agreemens plan Employment Agreements Dated August 19, 2009 [Member] reprents empoloyee agreements plan. Employment Agreements Dated August 19, 2009 Amendment 1 April 2011 [Member] Reprents employee agreements plan Title of Individual [Axis] Relationship to Entity [Domain] Chief Operating Officer [Member] Chief Executive Officer [Member] Ted Karkus [Member] Chief Operating Officer and Chief Financial Officer [Member] Payments For Legal Settlements Payments for Legal Settlements Settlement Benefit Settlement benefit (Note 3) Settlement benefit (Note 5) Reduction of payment obligation, settlement benefit Represents the amount of realized benefit as a consequence of a reduction of the previously recorded accrued royalties and commission obligation. Additional Royalties And Commissions Accrual Interest Percentage Additional Royalties and Commissions, Accrual Interest Percentage Represents the interest rate percentage computed on royalty installment amount due. Additional Royalties And Commissions Payable Installment Amount Additional Royalties and Commissions Payable, Installment Amount Represents additional royalties and commissions installment amount. Additional Annual Installment Includes In Other Current Liability Additional Annual Installment Includes In Other Current Liability It defines the portion of additional annual installment includes in other current Liability. Additional Annual Installment Includes In Other Long Term Obligation Additional Annual Installment Includes In Other Long Term Obligation It defines the portion of additional annual installment includes In other long term obligation. Stockholders' Equity [Table] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Plan Name [Axis] Plan Name [Domain] Plan 1997 [Member] Plan 2010 [Member] Directors Plan 2010 [Member] Directors Plan 2010 Fiscal 2010 Bonus [Member] fiscal year director plan Directors Plan 2010 Fiscal 2011 Bonus [Member] 2011 fiscal year director plan Directors Plan 2010 Deferred and Unpaid Cash Compensation [Member] Unpaid cash compensation Amended Option Plan 1997 [Member] Amended option Plan 1997. Equity Compensation Plan 2010 [Member] 2010 Equity Compensation Plan [member] Restricted Stock [Member] Dutchess [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Option Indexed to Issuers Equity [Axis] Option Indexed to Issuers Equity, Type [Domain] Agreement Type [Axis] Maximum Number Of Common Stock Authorized For Issuance Over 36 Months Maximum Number Of Common Stock Authorized For Issuance Over 36 Months Maximum number of common stock authorized for issuance over thirty six months. Investor Right To Use Excess Proceeds Maximum Percentage Investor Right To Use Excess Proceeds, Maximum Percentage The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations before deduction of valuation allowance. Share Purchase Put Restrictions Maximum Percentage Of Ownership Held By Investor To Purchase Shares In Equity Line Of Credit Share Purchase Put Restrictions Maximum Percentage Of Ownership Held By Investor To Purchase Shares In Equity Line Of Credit Share purchase put restrictions maximum percentage of ownership held by investor to purchase shares in equity line of credit. Stock Issued During Period Shares Under Specific Agreement Stock Issued During Period Shares Under Specific Agreement Stock issued during period shares under specific agreements. Stock Issued During Period Value Specific Agreement Stock Issued During Period Value Specific Agreement It defines the aggregate value of stock issued during a period . Common Stock, Capital Shares Reserved For Future Issuance Common Stock, Capital Shares Reserved for Future Issuance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Options outstanding - beginning of year (in shares) Options outstanding - end of year (in shares) Options outstanding - Shares Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share Based Compensation Arrangement By Share Based Payment Award, Options, Deemed Cancelled Share Based Compensation Arrangement By Share Based Payment Award, Options, Deemed Cancelled Share-based compensation arrangement by share-based payment award, options, deemed cancelled. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Common Stock Shares Unissued Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Common Stock Shares Unissued Share based compensation arrangement by share based payment award options grants in period common stock shares unissued. Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement Equity method investment ownership percentage required for rights exercisable under right agreement. Equity Method Investment, Ownership Percentage Equity Line, Purchase Price Percentage Equity Line, Purchase Price Percentage It represents the lowest daily volume weighted average price of our Common Stock during the five consecutive trading day period. Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Available for grant, Shares (in shares) Available for grant, Shares (in shares) EX-101.PRE 11 prph-20150331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!S7WC=T0$``&D2```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-%NVC`4AN\G[1TBWT[$ MV-LZ-A&X8-UEA[3N`3S[0"("T-XU;5NSO_:_!B!4I*V>4]0XJMH/$II./'\;WNP"I MP&J7*E;G''YPGG0-K4JE#^!P9N%CJS+>QB4/2J_4$K@<#F^X]BZ#RX/<]6"3 M\4]8J+7-Q>T6'^])(MC$BME^8:=5,16";;3*2,HWSKQ2&3PIE%C9KTEU$](G MQ&#\J$(W\W^!I[K?N#6Q,5#,5DF1RC]8M%H,%ZO M6]R!,H4(RJ0:(+>V[,>R58U[YCZAWR].O!_$E4&Z]^L;7\@AB7!\)L+QA0C' M5R(<-T0XOA'A&!'A^$Z$0PRI@%!Q5$'%4@453Q543%50<55!Q58%%5\55(Q5 M4'%62<59)15GE52<55)Q5DG%62459Y7OY:P9#]+`^^O;OY>^S9F37,H["^G* M?U_[IN>4:Q7!_,D1(X>K`[SL?89#*ZMG-9Z]K[P)A[ZG]#$0F$,X^NNI!P$80]=J M>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L M)MI<3_3_MCAQ(DN) MT$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04 M``8`"````"$`FBV37+@!```J$0``&@`(`7AL+U]R96QS+W=OS;O$R:&ED&N;?H"P%=O$EHVD/O+W%2:U&PC;B]F+ M02N\&F9W1V-O=M]U%7UJZ\K&)`(FL8BT29NL-'DBW@\O#RL1.:],IJK&Z$2< MM1.[[?W=YE57RH>77%&V+@I9C$M$X7W[**5+"UTK-VE:;<+.L;&U\F%I<]FJ M]*1R+3&.%]+^S2&V5SFC?98(N\_"^8=S&T[^/W=S/):I?F[2CUH;?^,(^=78 MDRNT]B&ILKGVB>A#3G8[JTE`+.1M,#!E1@-3$@XW.4"R@PMF=G!!L<-=*[)4 M"-S<`,7-DAG-D@(#R(P&D(3#30Z0[."?/5?C:&)2F6U.M`MSZ"Z3^ MPJCZVT_-P$@?N@P2K"EVN,>:G&IN:DAF@)L:(+E!=H]%FBPAWA.35'X[M#P```/__`P!02P,$%``&``@` M```A`)I%DNKZ`@``%0D```\```!X;"]W;W)K8F]O:RYX;6R45EUOFS`4?9^T M_X#\OO+9]$--JGY-RS1ME9*UCY8+)E@U-K)-D^S7[T(6>@,K:I_@XG`X]]QS M[%Q<;DKIO7!CA593$AX%Q.,JU9E0JRGYO?SZY91XUC&5,:D5GY(MM^1R]OG3 MQ5J;YR>MGST`4'9*"N>J<]^W:<%+9H]TQ16LY-J4S$%I5KZM#&>9+3AWI?2C M()CX)1.*[!#.S7LP=)Z+E-_JM"ZYFKJYK(6'U+`YBXL^Z)N^-E_&,\E4RA%*=()@HH_!`(..303NZNBT MBK^#SL(!JQ+321!*\DXV_U`.V)PAG../X42HJPF":2* M7M=6*&XM`HC!*ITL)WTBB[HLF=E2G=.%6"D!B6#*T:LTU;5R&`8/^[0/LS1, M69:VR:%7><[A5JWHPNGTN<"6B:&WCLU9'V8.NT7)Z9)M8&=XG6P*;AP*GC(\$>BW%RPH%9QX&PR6(3"K!G@T_:%HP2[CAO66@G%58(IS0:6'H5JR MFF[M=\KM+[O??]M<6/O"3Y0*"QAJOK5/0C1KQ^'9B58IG[.&UA`YL+9*!5RV M1XSC8X5!D](EEYXK6`DE:6J8"]/-3T?`K M6Y7=0U>E[.](;:O*UM^.-6O3?0EYOY%5FEVYNXL)?55D M+>/L(.9`YZ#0:MC:7\DZ(9'M[#:=03\*>N&CWQ8_ MLJ"MD:X$CZUOV_%+DX;>VE/_<" M=TD`;NTI%\^%I+2M[,P%JWXBB"@J)%DHDB6H5_'%O20."NKR>TI%NMNT[&)! MT\"2O$EE"Y(U$%\30QE]JKO%4\A"1R13A.?U$$TC6#?6 M^+DV"88.&%GA^3UM9VB,D`BM#'U7#R?CL$^"P4E-U.H141)LB`KT56.$!)VH M!8E"/9P8X1NBH-_O=TJ"#5'&JC%"4-32]\T2:N$H'(S4G/(?$27!6QNR[3O9 MBW0K8H3@))`;)!G=T!8.'EE8@G4WS,:($:)*%!+3#2T<14.!-5'RK36:"9\W MLP0;HH;*8S,C1(ER%T8X&8>)Y]X0%3TB2H(-4885,4(\;&;7Z*I$BP9#5/.) MP!2ZWZ@.;8B:#$G)N+71*L]=F58I#HRO@G!(2A=F3/7/*TAP\([GD6_.2H7! MA6=D&1@=GR@`^CD+W5O*C&'^"V4X@#5EPP#&YB*(40M/#-.BMT3)<7IWPQ,< MOIHHIV;NW#7D)8IEA!@VAR[.F.CRE/?K(Q3!P0P]T;_H`J-C M8H49.X1/=7=T$0]-<#C-FXTS.N:HQD$,[C+BA=&POU4_:P!_-2HP2L,#/QZ( M*]H>:4++DEL9.\O#/`'G^[OXH1'+#XWN4Z$/P#F_28_T>]H>BYI;)3W`H^X\ M@*9M\4L!+P1KN@/IG@DXX7<_3_!%1^%XX,X!?&!,7"_D$;C_1MS]#P``__\# M`%!+`P04``8`"````"$`]NWR710#``#R"0``&0```'AL+W=O!Z#C!A1[4U$$N1 M97HV2V#JTC;=88E7"\X.'LP]4"XZK&9R-`=FY4\"+O_;'S!&C;E5@_100`MH MZN,J22>+X!$:D?>8]1@39Y&+V8PQ2?B""4#B22=X=[E.-6BH<^IJ6(\Q<>Q" M-F-(DJ8GC",3++1EOFZC`B_1!'F6C=F)5UN]-A@S-97W&RO@9`::\S,K,#3: MR7P]R&PP46CZZ[\4K(5MS&LMS-$!R^)\'0H\U#$;Z#`8RP$KX&1.+\FLP&]Y M;S!69BO@9,[79)9@5^JP4&8V6V`DYFF*=.T>?U0(\:5C]8_NL>9(GH(YE> M&M%D$L+OU#E7UOOV5[,Q.NLS2TX93%,B`[)E'2-J=L3_FQUPW+['*;,)NI)& M>[X!V9),9&:<.E5@/#*GMCF..KPCWS#?T59X-2EA1PS]#%8Z-V>V>9"LT]OY MEDDX:_5M!=]6!/;%T`=PR9@\/JBO@M/7VNHO````__\#`%!+`P04``8`"``` M`"$`-AZ*=F@#``"?"@``&0```'AL+W=OSCF^!B]OGIK:><2,$]K&;N"-7`>W.2U(NXW=W[_NKF:NPP5J"U33 M%L?N,^;NS>KSI^6>L@=>82P<8&AY[%9"=`O?YWF%&\0]VN$6_E-2UB`!EVSK M\XYA5*BFIO;#T6CB-XBTKF98L$LX:%F2'*K]AU5SEM.J#8D)J(9T7J.DV^N-^VE*%-#;Z?@FN4]]SJXHR^(3FCG);" M`SI?"SWW//?G/C"ME@4!!S)VA^$R=F^#139W_=52Y?.'X#T?_'9X1?=?&"F^ MD19#V+!,<@$VE#Y(Z'TA2]#LGW7?J07XP9P"EVA7BY]T_Q63;25@M2,P)'TM MBN<4\QP"!1HOC"133FL0`)].0^1D0"#H27WO22&JV!U/O&@Z&@<`=S:8BSLB M*5TGWW%!F[\:%!RH-$EX(('O`TD0>==A-)V]AV5\8+D^L81>.(N":/(.+:!: M&8+O7DMXJ2%?AZ.R3I%`JR6C>P?F%^SS#LG=$"R`N`]91W*,_7^I0]R2Y%:R MQ"YL/`B4PZ0\KL91M/0?87GS`R;1&/@\84:!B5F?\X13"Y/V&+GB\N993RR' M"5P=K<&:#:V]/#>]`PF6#GK61!<,N='$DGN."4,3DIY#QM'4Q&3GF!.+X0CF M:.A(+M88]M7KSF13[,+HG7*/3OPJPD1C]"Z2F:[M0FH7LD'!T`@W&FI\79L$ M@P=#V\Q,)]&8@3:[D.K"7,U=&(SDG\F1#5H,L3#QEXN58%OLW+Q1HC$#L;HP M5=J4-+,AM1NR0<&0.C&E7K;VLLF2/+&R231F(/E0B/0^AH>K2K3_"+(K:WI2 MFR$;%`P/TX]XD$VV!^N9D&C,(&7+Y/HM0*H!IQ2R0<'P($\7U@/S[3THFVP/ M5HJ)QIP4K.U":AG._FR#V$JC]7C.>0VE`]NJ[X.%O"RD&^%XS_@ M?-"A+?Z.V):TW*EQ"90C;PJ;CND3AKX0M%.OQ@T5<#)0/RLX"&)X-(X\`)>4 MBOY"WN!XM%S]`P``__\#`%!+`P04``8`"````"$`66P;#<,#``"H#@``&0`` M`'AL+W=OUJVTJM5%6]/#O@)-8"1K:SV?W[CCV$$*OY2%]\RD MXJ)*?3(*?8]5F!"K;LI*JD:A9!9:UD"75\"@W@:HEH[E=5!9!%(;CH*2\\M'# M7-[B0ZS7/&,/(MN5K-+H1+*":HA?;7FM#M[*[!9W)95/N_I=)LH:7*QXP?6K M=>I[93;_LJF$I*L"\GXA=S0[^+8/9^Y+GDFAQ%J/P%V`@9[G/`MF`7A:+G(. M&9BR>Y*M4_\#F=]'B1\L%[9`OSG;J\YO3VW%_I/D^5=>,:@V],ET8"7$DX%^ MRCE;TUVA?XC]9\8W6PWM3B`CD]@\?WU@*H.*@IL1AI&) M`@*`3Z_D9FM`1>B+_=[S7&]3/QZ/DDD8$X![*Z;T(S_&"8EN=1)@0#:_!ZKI\3877B2(*SJ)MA?6@.&%MBB1B%)VIHA!YIG MUCP=SUKK"2%LJ=L)#;A#.&Y=(B&:)Y:0P&YMS2>,XR&,!MQAG+0ND1'-#6-X MB7$RA-&`.XQ3AQ'-BNMD0.@,V=$>E M3>[:+)`2(5C3."3'B$Z2)"#\V[.TZ%/>.(D=X@9T+@KR?X,'ITJ_#JWKU/\' MIS-J^KM(<(!-'7*8.SW*;#!8W&AZ M49K.`+KQ/7V81,<`XL2=#>0PC\P!J/NB),X4NI$39\T5B2+H7*+1H!%DT9V6 M'M].V-+&CBTEX879'CFCJ%^B%MWA="7:V*]Q#AI%D3.*7(4V]MZM&PT:1!;= MR=*59V/O9QPTA2*#[C"Z\FSL_8R#1I`Y>E][<388/'#!I:M]O:%2\,*`!^J2 MR0W[R(I">9G8F5.[-1<4>25L#W!-JNF'?J-SP2GD%6\/2<#2! MZ"3>-/!!B]J>>%="PPW!_MS"C9#!@3P<`7@MA#X\&"FW=\SE7P```/__`P!0 M2P,$%``&``@````A``Z^,:2E`@``U`<``!D```!X;"]W;W)K&ULG%7);MLP$+T7Z#\0O$>4Y-VP'"0(T@9H@:#H M3#$REM8YK53-,[SG!M\N/W]:;)5^,27G%@%#;3)<6MO,"3&LY)*:2#6\AB>% MTI):N-5K8AK-:>Z#9$72.!X3246-`\-<7\.ABD(P_J#81O+:!A+-*VHA?U.* MQAS9)+N&3E+]LFENF)(-4*Q$)>S>DV(DV?QI72M-5Q7XWB5#RH[<_J9'+P73 MRJC"1D!'0J)]SS,R(\"T7.0"'+BR(\V+#-\E\_LDQF2Y\`7Z+?C67%PC4ZKM M%RWR;Z+F4&WHD^O`2JD7!WW*W5\03'K1C[X#SQKEO*";ROY0VZ]BMR6&1Z,H]$D'B0`1RMN M[*-PE!BQC;%*_@F@Y$`52-(#"9P/)"G,U_O!)"3B?3U02Y<+K;8(A@6D3$/= MZ"5S('S;"#APV#L']B&0HX'JORX'PV1!7J%B[("Y[V/2R1E#0/:D#7K7:SMP M5SOM:/=*0#QO>\)33\B)`#9QB.%T+#CE#`](5@ M?BZ+Z29S`//]?D-=4-?9J",8,/!6^7Y/H_'I>\.W-6>GGB#=L#TB^WV^=5OC0/_JZL!TQ>:M86NZZH+ZCKK M5C5@VE6=G=RW.@NM;[F]+@D?U_[MX(>SGLKX:N M^7>JUZ(VJ.(%#$<<3<"/#ELYW%C5^)VQ4A:VJ;\LX>O)89G%$8`+I>SQQNW] MT_=X^1<``/__`P!02P,$%``&``@````A`/K^U7BP"```C2H``!D```!X;"]W M;W)K&ULG%K;CMLX$GU?8/_!\'MLZ^9+H]U!))*[ M`\P"B\',[+/;5G<+L2W#4J>3OU]215EU46PY>4BZCP]+=3V7B4'[?EKCB^KL=__6D^+<>CJMX<=YM]>IA.J^U;?MA4D_*4'^TG+^7YL*GMK^?7:74Z MYYM=,^BPGX:SV7QZV!3',41X.`^)4;Z\%-M%1*7FU70UM9&>'G>%5>"F?73.7];C+\CZ=-C M,T%_%_E'A7X>56_EQ[_.Q>[WXIC;V;;KY%;@N2R_.NIO.P?9P5,QVC0K\-_S M:)>_;-[W]1_EQ[_SXO6MMLN=6$5.V,/NA\JKK9U1&V82)B[2MMS;!.S?HT/A M2L/.R.;[>AS:!Q>[^FT]CN:39#&+`DL?/>=5;0H7?@?D`(?"H)$ M/DA\"1*$=P>QCVLRL?_Z3`*;\S()DOD=J9: M;>K-T^.Y_!C9`K;RJ]/&;8?@P49N)QFFY#+M/YMU.]TNR!<793VV.\].:&5+ MY=M3-)L]3K_9Y=UZ3BHY`65D+<.MI0NK6@"'98-TRVD'&0#LWRB7\/*DJ=5] M$6]+`XOOKZQ6HR,[C>V#4@#P@[K'-/EGDI$DETQ`HJ1$LXAR-'#"9E[C8+%< MT,^-C!%VF1#!MIR'"W;D]=A6/IK(F#XZ!0YL/[=D&0<4!S0'#`)(LO;).%E7 MFO%/]W^[2FZ0W>DD:3;G*7"2I)G0V21@GV?^\\M**PYH#A@$$`TV7ZSA>H4Y M,L]]SB8<.(LF]3"Q.S\(6+ED0.G61'%`<\!+" M6!&GP%G!FE#1&?YL%2]FO+Q:_H<8.XGB7-.04.Z(EYA<&' M7;Z*`YH#!@%$@#ONL`8^O[D@;A`7L&("@&,KH]O^`>OI6Z+B@.:`00#1 ML9(Z@O"F$#>*"0F80Z3`H4*Z_@B=NN5@/N%Y[457XF$"40+1"# M$9JS,\/A.8-UVN[=%?E,Y`PDG#-'5,`1+1"#$9JS<.PSI$>4[K*;:[\OZJ11B#$2K&62$2,[CEC:(!4C?-F7MWL;VJ0Y1`M$`,1FC.SM%0S@.+!GR0SK6VC7PN.P0B5X@R.2;EMR`'8(I7"CQ2>Y-M_/%FM]"=N9"T'J4&.Z]5PQ.!1 M5(US.:9FP,*`-U(U_'P1``GJ)8Z6\9*?+CP#[QADNEX+CO*3JD.#B#AWO,#B MKK>JALT<.F0IIYYT<>@5K[:6T*V/0+1`#$:HA+LL.NRQZ!GOMI[4S7HF$"40 M+1#CD=96YD&"9HN*<.9Y=Y&%8+FDR&9\]WL2%L.=6@F.%HCQB&]N[@T$>205 M8Q/"8FX4E6/SHN('V!!(6`1'E.#H"X+.-NA[@6;[F`O)'GRIC+ML/.RQ\9"? M7CT)YC"A4]ADDWE&)U0)1`O$8(1J8+8^[&75?24GEH2?"3WI2O/R#*R%'P`T MB=+?O'`8*LX9,-HT-^H,[-J637?0#5EO2D/NZ9E`E$"T0`Q&:,[,YF_D##9\ M_9P5,6`:]**$>T56:O?PAQ1(4>T0`Q&2,YNIH?GW+!O?F7I0N)S>.:'H7D6 MB!:(P0C-^2Y/CGH\.>0G/T_R7CJWS9-^69-Y`I8`<3M$"X[!")70X\BW#[%1 MCR.'_-CG25Y*KPUX2I>Z$H@6B,$(%>/,0;6 M`($[1`N.P0C5P.S86=F`!>FQY8B?+B(@@98@7@:+A,G-/*5+70E$"\1@A(IA MOGS=!J(>/XY8JTP]J>\.X,ZL_*!.L!:(P0@5T^/#M_\[*.KQX8@? MYCP)Q"2]&X#[KO)CL!;.,9A#M3A+'-Z1P$#I@K`MFD9`\@NRFB>L[V:>T"6L M!*(%8C!"),1W&7/#9J\Y$3]^>E*78280)1`M$(,1FO-=QAR#@5[?PYZ$<^:^ MJP1'"\1@A.;*([V%/@I*Q%PGP*RTP+UE"YU)1`M$(,1*N:7C#CN,V)6WJDG=9EF`E$"T0(Q&*&Y,]^] M?EB+P01O%`]WRLP/ZU0H@6B!&(S0G)F_#OOB)^[S66:CJ2=!\!'<4['^VNS_LO=)3NM250+1` MW+7`RRLVB(%;?G#S[)"?7_,LW^^KT;9\=S?X(GOKXX)>;A=^"=V7Y`Q/@X>L MN:+'TZ4L;F.,S9RZ,9W7W4E?.,V:=/JP-E3[S$6#C`T/#$+85HE[[/LQ+7B'NTQ0U8"LIJ M)."1[7S>,HQR=:BN_'$03/T:D<;5#$MV"PCC-8M4&Q)1<2K(G6=.EM^VS64H6T%<;^$$Y0=N=7#!7U- M,D8Y+80'=+X6>AGSPE_XP+1>Y00BD&EW&"X2]SY<;L+(]=OB*R:X4 M4.X8(I*!+?/7!\PSR"C0>.-8,F6T`@'PUZF);`W("'I1_P\D%V7B1E,OG@51 M"'!GB[EX))+2=;(]%[3^IT%A1Z5)QAU)!.H[^_A6$E\+4O$](('6*T8/#C0- MN.0MDBT8+H'X&)B6T8O*/DN0A4U(\,?VEEY"QB=A<(N)36(9&R-VY MQK>U27#B3LY2$)Y9GC5FHG+)JR(*^OEV6!-NRYJ;;5&-F2E88SQ=VK0S[=#)=].<-7=./Z))@ M6]>)5_5^JC%AH/,5>($%V%P`!EIH]A%E$FRVT#BR,Z8Q9RUT]L+(B;RFSH;` MV\TKP59.[!9)-296*;';Y[K-T+/XB!X)MO58DR75F.MZKML,/5!<(T%R2KX_ M@=0I6YG5M6D'TE^;G:H!HZG-FN!O%R_4,]88`/.H_U)T1W>@X0E@`@9'0&@- M[G>DZ6%K2CL-ETZ:!@U/`>4S<3O`\!B`;<$HZ3O:)-HNY>DS[K1I$!1-7H"C M*Y-`.85+Z80X<>BBZ@U$W]`U9CN\P57%G8SNY781`G/_5F\^J=Q\U.[2&V#Q M:-$._T!L1QKN5+B`HX$W@P')].JB'P1MU06YI0)6#O6SA!43PV43>``N*!7' M!WDE]TOK^C\```#__P,`4$L#!!0`!@`(````(0`1C@.)OP(``%0'```9```` M>&PO=V]R:W-H965T01"&K M359I5VJEJNKEV3$&K,48V4ZR^_<=XP0!Z25]2;`Y/G/.S'A8/;R*&AV9TEPV M&0Z]`"/64)GSILSP]V^[NSE&VI`F)[5L6(;?F,8/Z_?O5B>I7G3%F$'`T.@, M5\:T2]_7M&*":$^VK($WA52"&%BJTM>M8B3O#HG:CX)@Y@O"&^P8ENH6#ED4 MG+(G20^"-<:1*%83`_IUQ5M]81/T%CI!U,NAO:-2M$"QYS4W;QTI1H(NG\M& M*K*OP?=K>$_HA;M;7-$+3I74LC`>T/E.Z+7GA;_P@6F]RCDXL&E'BA49?@R7 MVQ3[ZU67GQ^E*GCXHGG_B#8-D0YEL`?92OECH"+ M0CDKR*$V7^7I(^-E9:#:"1BROI;YVQ/3%!(*-%Z46"8J:Q``OTAPVQF0$/+: M_9]X;JH,QS,O28,X!#C:,VUVW%)B1`_:2/'3@<(SE2.)SB0QJ#^_CVXE\9V@ MSM\3,62]4O*$H&<@I&Z)[;U&,#[4^/ND7Z18L)5BBV"U;=P&(69P.$2-MT,*W:[/@J;;Y./+&8099&6R,(L_^)[(% M_ZL>#C.(/-@814['D>V]B6&L_+TW[:&I]\7$N\.XNL3)_#Z[(2*H.+];C\\'R-[82;[&QBJW0CR^Q"@52;BRZA9%M-UOVTL`XZQXK^'HQ:/'``W`AI;DL['7OOX?K M7P```/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9 MEEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B M;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV% M;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT` M;Q)__/QY.1`R:"'1 MBR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/ M*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2 MAAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF) M$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[ M#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H M8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#? M7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-5 M8,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1 MVVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[ M8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T M74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY M;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G> M:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL M_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%] M\88MW7YYHMBS.A<3?F`-1+:\K?,. M'MN=)PXMRS?]I+KRJ._'7IV7C8L9YNV8''R[+0OVR(N7FC4=)FE9E7?`7^S+ M@SAEJXLQZ>J\?7XY/!2\/D"*=5F5W7N?U'7J8OYMU_`V7U>P[S<2YL4I=_]P MD;XNBY8+ONTFD,Y#HI=[3KS$@TRKQ::$'4C9G99ME^Y7,L]HZ'JK12_0CY(= MA?:_(_;\^$=;;OXJ&P9J0YUD!=:Q>RGO@)_M\Z&;?.7JON' M'_]DY6[?0;DCV)'GV M2S>()]'4#PC`G343W5,I4[I.\2(Z7O]$$%&I,`E52>!3)2'T[B2!2@*?0Q(Z MBT@4?T[%PVWU*CWF7;Y:M/SH0.L!<7'(92.3.626\@0@\L?R@"YRSE+UJ--6H%5JU1A3L5*DJ%: M2,P$Q'XT]())S3+RVX(1-%\X[V=[#BPS2!5&;U8TJ&`X0 M'C^"F%,[V>0R%5='(+XFBO15K?'5E4S%4?A9K-KC2Y-=SPOM&B#U[!A55##QB-J M\<[D.QF<8>0-X8&W*=A=/D\NC=[VI51A4!#B6P.ZF#=2J/N(DQB=YE^P1-V[")H6,40<3H-J&-F(O_DKF32W;7J[UK*HC,*HE@[CQ*Z;#8B'0V%2N\O;*7J[?AI#VUX5 M!JD]D##2OO&PIRQ$0,E0>)/<7=Y/+[T_M,J5*HPB%_A3FWYV"V&2`Q7&^QB5 M:*NH0TE441&#Y)+@XN5+Y<`X\:=D>+$TF5G./^ZK"6[*%PQMIU48?,DGX>4K MA0GXX)4"+]-X3:Q9NV,9JRKA%/Q%7I0IO':>1_$2GY)Y2N4URAK/Y.5>CGOG M`-RM#_F.?<_;7=D(IV);2.E/IF#_+=[.\:'CA_[VMN8=W*K[?_?P*PJ#:YH_ M`?"6\^[T(!,@]#W64)GSIESZOW_=73]C!-"7[F[Q1MZP:F26A8F`#KDA+[->8[F")A6BYQ#!M9V M3[%BZ=_@;#/UT6K1^?.'L[T^^>WI2NZ_*IX_\(:!V5`F6X"ME(\6>I_;+0A& M;Z+ON@+\4%[."K*KS4^Y_\9X61FH=@H)V;RR_.66:0J&`DT0I9:)RAH$P+.6TO?H3ALI_CH0/E`YDNA``L\# M"8XN)HD/)/`\DD2S%*>3_TM!+JW.I5MBR&JAY-Z#-P^$ZY;8]QAGP&SMB<'D M]^T!7VS,C0WJ0@&MH:1/JV2R0$]0!GJ`K!T$FJB'1$/$YAW$$8)`7J\1;+M< MHPT::9P.%:P=9-:5RN:U.=D8"`!C3@5\;(X%@XDGF2>ST1\[R-PYET3)\'@S M.(X3W!\/1"5#4>=5S@:-Q,U[^JZX:P?!8:+F41S-\*A58$);DO<13IJ;P&ZV"*9*MF%UK3TJ=W:Z M1E"5?M<-_C7.H`-AXH[V-W`A=/NH/X"!W)*2?2>JY(WV:E8`91A,H9S*C72W M,++M6GXK#8SB[F<%-R^#W@X#`!=2FM>%O33ZNWSU#P``__\#`%!+`P04``8` M"````"$``Z0-DU91``"O!`$`%````'AL+W-H87)E9%-T&UL[)W; M;AQ7EJ;O!YAW"`@JE`20-$E1EN6#&C0EV:R2+99(V^@I]$4P,TB&G:>*R)1$ M7]5%/\'T50,]@-$/T`^A>9-ZDOG^M?:.V!&12.;BWDU MS9?\65U^4"^J(A_75T6QG$X^V-_=_?"#:5[.;F6C^6JV_.S6A_/YZ/5M)@ML\/9.'LR6Y;+Z^QXYN.S[$\_6#[Z M]`,]ZH_?R[Z:SY97-8^.BW'_VZ_R:B>[M[>5[>_NW>]_V;T%:T8[&P8Z@HL5ZSV&,Z^SWQ?7_>>.5E4E3J?[VD2$L+BG MY:2HLB.H=#FO!@.>3O.)OG]1+.;5$JG.CN;313X;/'A6Y1+Z[/1Z>CZ?]-=U M\N+DR_YG87[&F\YGV>ER/OIA*SN]RJNBSIZOEJ8UC-A_[6C.YF=U,68ELWH^ M*<%*/RHAQ*_>-BU$C]07_0P]/3)V>G_4^/\OHJ8YYLI'\4?UJ5+_,) MO&%M7\^71;8_6-SAR-2YSJIB5/#T^:38RF;%LC_R\>PEX\"LC2.=5,4B+\=9 M\1I;4D-/K<.VF8V"A.1U#9WZ0Y_-EXC7S<\@KHNB6EYO90M(OK2QM;V%U-(6 MG,TOLGR$T5E-C#?C`OLU*O,EUD;?W3[8.M@_L!?YY[T#K`E,A_;+\F4QV;PM M7]WZE3\[/OS\^-GQV?&3TX_[NVH(N\BO1=4UWU3\M+H%L7F_D!L MI$#E4L1W/H^PWNP`-\1*@H@,WWKSTYN?^G0X/7M^]/LOGS][_.3%Z6^S)W_X MYOCLGP?$[.KK[9W=W=W[V0+[B7BOBD^R?+6\FE?EC]#S_NX6W^K_/\G*NH;$ M'V?[][?V]/][][+:==W5X=Y@7X?C,<2Y8L2`>VO&_XFLG91 MCLJ!SISA0.L5*E.[GS<(5KT?%8NE6-<-0YC_'Z'7) MFJCPG7*6C>>325[5`ZYUQ:.1BRQY)\-\.+G?\G80D%:B^C3O3A8>=TGK/]H7 M@"A\;,7_N68M:QW-Z1*;YMJ&*7O.7J)^OHO+"0PAC/@KF9+&7P-/]'6QS&J\ M3%3[H8\YDM"S[IN?^J*:XQ<7U?QBJ$EAQUBHZ%T&)N+4EB`+.LVK'Q#8H1<_ M'$_+F05%4O$^LUX4-1'9R/WGN,`IS,V[])]S[90[@@?MBOJ//=-N+JHY]K1A M5_^9XQD&MX`X85=K/:\-=%X0.A=929@_+;)E_GHX5/PF6-^#@6R)41-6U7_U M\[PN1V8XQN5DI;A&3[4*,R#U=T5Y>:7GF-N_\-4X[,_?E5,SXMJD%4DGN/$ M/0?QK7F.C:^\*)8D5-#Q25[-$"4TZ'%AGN3NQG<:DV)$V/A8C$QQ.3>&D?$Y M6^+"GDB56\&;(DF+Q`92?SC^ M?E6':&DY)^XD7!J1`BG0=F7C4_W;PG9,X,N2+#@[1ZI7(F(YNQNMR,T3/4Z# M7MG"?*H,ZD&I!KF(_WAFU2D_X4'LJUE]J"]/^5:(RN9'A`_&:GA;7_.OCR4Y$FU^84; MY"$:!M,'`LX53J`_,!G/J"C&P8<0@KV=[LTF@M#`@.%B^O/T-W!1SL@[Y-AN MV$!W<0I^+`]&**(K4,3;GZI97RKAZ^9;]R(61^&T?*!S2N)M+$O2W/Z+MKEU M#\K(G8.0S&1W) M+[//)[!W,-?7@ACVLK_\^=^R=-H;MX\D]7&H[,Y?_OP?KXJ__/G_;#'6?ZQJ M_I7-JTPZP-]XXP58$!_>W>)C(S,VBWG`T-:!=!DH&E$.WQ\110V7^3+ MJQ`X717Y9'FEX'6\&I$2+Z^0+YP@SUX0X8TS[+N60X),Q$1NN2+'!MWYKK"G M\DD]!\*])):2L;='Q?9UX:BF7T!H\FT&FK.X;4;>-A2'/8AVS\^.1)UL7*TN ML78Y^^11^>.LOU`AQ)?9JY+%UZO%8F))!B`+.:75]JJY^ZC*WR5`)Y+^WO+039X=&V;07HA2*7P:Z+D M'%KO`/]5V07X;GU5+K)S6`TK:A1R,MY^\N1_/7&]98?ZOQ/^!\HO#T%*9@(A M/KL%^5C*J"H7RUL?`&O_Z!_O[>HOMN`"/`6.W],GU5,0$W_DK)SB++\N7F4O MYA!(WU[DTQ),R@:VQS^P*9>/_N__'JSC;S.3Z@0?UXM\Q((7DL7J97'KD9$C M>^&\$(7FSFPC!%1['TVJ],@-_\UZ]' M@%O*OY)I$FK0]0$$Z//9=G@L4_'*'(L+_1PCAP7!RO48JN<$0IM9NU/>?<^" MS3;D#ZMR],-7Q216!?[1]O4?+9ZRJ7?*]S)SD]]YKFCF=%'EUSOO56NS:K5D M\J!W0J6>\IRLDV)(&;'-A@LW0P1+_$,70'[=1J53P+VK]V2_(2IZ;]&Z(JD$ MXB('XR:SJN>3EXKPERJ(IFG2,O^!P&>.8D]^?4K]:XJYE;[.,A`F*%C2FS-N M8VY/&T."E^1M;?+D(>*),V%00^WG@#FL%H0*A40&*KC45#]-P<;&5$ M2`Z'N2V@KXC\*;9GU,6EMC);$;9>42%0=%JP3*)>)0FD-0Z<8G\V M979V34Y\K:`&,Q:%J`DO$.[M,6J6LSI1M@A M:U$JKI(Z67!5*,V>QYX5]14)_YY,LFD!@1547WB;CF8@-Q=QDHF]%S>,H`N-@"'MCJX/H2H``GT:-CIX3S*!3+168=.7LS'9`!67'3I) M2`%4I6>*=\%(LKP6V<9QSP8UV)(U.W3(\@5Y!^QA_"V11+,&C$5_7Q9\4#E$ M4**S]>J\+L=E3O#+R-[,HE?(9I:"AHP`UMA2"9A3:NT1?]OL=;J:&CK`%D_) MGVE^&:FG(W1,R$"N0'[>LO@;\>R]@W+^NN7JVJ790PGRJ`# MB-??DSBZFN7D>3!89`R=1H(WFDZC5K11_5@*-NTZ+["<9.A4O5TUFO(B%"M]%:0T]." M!AZK?IA2/'D-!".P#$F:8OC)A0R:.GWBT!1"!X?E!B1R;YU5(N@5T#&%DCF1 MR6PT68T17C06QQ+0R0"\356>Y#%Z&65NSF6J3!3[9B+9VTT47$^N-70-A/EF M9JP\%:>,0#005NS6*/#%X>&)T#E790UM<*:D_A>3`@I'`$F@B6:5Q3+"-IID M$#'C3LW?N`4C3&Z((\+V_6I&E0,^F=0H/'RK!`*G&A_,IR/&<(8-&[.6\RU9 M%JR;VP+`-/31?`(_P.K+7 M[I/Y$(8\*;7-DM?(6)@Z,('U8HB2H[IU`Z1CJ9MB@T>1&@_B'A4XD!YQF""+0:9 M78+QVY(8#TMMS"G@-,*-+:#8`-=VLB^\0J&]Y>DWR@7'-">H78&00BMT8=;* M3N56U!6A?7H(26SA890HBT<#N0Q+PN"I]]9FK6B`A16JR4AWL-*=)]V%8#Q> M%=1:&%[K]PA+Y9MY15A'6-A:8A54"4PT6[#%>*N*%1O=5A4D^-,JK_!QV15. M@O\8=4V7$]%HBR):%]W-]0*W[(:LK4)Z.*U/-7S:QYG6=:%:39`#V:`-/)NJ M2-;A'VBN!A%).ZQX$:-H#5\5((H,TDZJ5D(7XW;_Y.P,@Y6C04%]16%W@1:U M^@[,12*[BBA1NMJQQL4(%%J1,R16EX5DXG*F7Q#^,HZ^"PT M3;%6*ZSX9K'3AF.#6%.-D7N88ZA5-DF((&.NHPCC%5,BKBI<>[=Q:]]MBG;[ MC'Y9Y0"RC#=?2,Y_M"#4=T/8;^HT##Z_<3/VA"*]U&L08IY)LBV<:B#VM<&7 M-BR6=3QXSP%"=^B+W:97]MK]ZA>X?Q6F/#1.W)?V,24-5G+G*W.QHK8^97NP MB>E45:2BB$'Q#$?*""2C+ERT:WV_@[.FB9'T((M2BP(DWOB."9*Z-QN]W4B% M=4MI,D"1*;3]8$!:29=.L0^Y(W]?*A#635B!$8_1 MF3X4",4>:_ZSX0A/B65+!:M.8D8E:"LK"Z^@Y\]\MVGB4X$O>@1;=\+LJ/!2 ME]&HWRJ.4LK`&DG,,,7@(,GFNH2Q\*BAB@4G"IQ=>#3Y:!ZB&5@"V1$.,8<9 ML%@BNML;U9=/S8$>-D3V4OPKJ$-43YI!(%M*Z(UX,C#4U"5K4U))#LAHJ4BZ M&#Z"XNHJ@JR-E.OKH`-Z!,ZCL;91\1YSA(;RR68UD2?TYC-6?<7<=(:/L$&M M-829JNWY>]78T-=D%X(&*VZ\AUE MG3NDTT0;@D(\6H73N/EQJ88$1V!@1DK'=;'<\Y7B#*_EPP(U-ZA'Y7U)'&ZN M*XFW%44:)29X)'@OV86&;RL5!BR(&)"\#-66\Y78PE`)OZ(I=0XV->`ZAG'2 MW;0@G,97]36^8SY%&IYZO"33#WQ#-FUI7U?/4BBH:SQZ5C7D,X2$02@:.TV" M>0ZT=DD1ZZX;`D*ZYBG++">X:DM/BRVW`%SR':!O,F)U[ M>%^+#VTK[]!,TFH.?L2C/*-OTX\%/W&7TB/+7'YE1N@?73<6.):EI_FOS6K\F@6DKQ=Z1J&Y$0I_8(AE[\P;ZJ(J=VB]'6#ZUWXUQ=.XI MLF\Y,@?RD!TE;87>FVAOA.,K"1($)O'W[Z;[NS'AD2.^3P2W!!CDO0'K*&EJ MP%IY-&EZ;\^Z%?40889K`K"U(?ZT)<15"JF+:)_Y.PU`=,_[R@[U?U9Z2=)A M2Q-=ACP-Y=D`CFIU[7DV8<$*RCP^;E+GY(@D*0O1;UA7XRX(ARDX&7)E2YH1 MN"D@S^8:C"PI`0`5)D`>U6*VB?[T1 MP&C+RZAACD,VVZT`V'&0)V`[X"Y*S#_MW4+RG2.(RH^LF"2,F$PD=$[Y:1K/ MZ"V3T4$"0*>FT)%T4[`JH"92A`0>$%`447[V`(I@*(RPIK`>&JOZ]S9$`,P> M%9[AI`0(AAW0SQ<%I7"V?%2H\F>-K%0"Q@Z6N#(H.7*LT-.\UP%D%/&L,!;> M$R2E#F.CL[ZD6%@MMX',I[WM"H5):-+##Y:/CAL0]]L(<_4)WCY"CF8S-_(N M!-N.8`AWXK!`H158^<'@CHNRJI?;:O+W?ZG`:1*=W7EZ_/2Y'0T)I%`:%N%D M,D\@8ZN5`$M?Z\(`6-$,;B"7*99VWJ&(T7V!/'JK1`O==4J.&AFUB]TYJ)$= M9<2F='IJDD8/ZR0YH--"?%@''D4)2"N;+10@!CA2;K@91^^1.J3/P4X,6OL` M\G?[_NY]78U@6[S]X.$#NRL!U8I@K#3_C)4H%4>:`K#O,36^\S/A)@[9?6#I!_6 M://]KY^""UBCU.5\/AY\>Q)0WZWLI+E71`;"P-_^4.W#:RXA,:'2RTITPF M%32!'3Z@VP2ABFDWB(F9<4\3VH$F@[\16C,(+%T'-1T7_Y@#/.7$\&6)/Z"W MD"BW@-OX%\.DA(`LK[=!7[QZ7W\"\R@@<]+)3]NT8#KO6,L9XBOX:N:M49_$ M!>-&YQ?+5Y*Q^*2*S`RHV2^`]^VHI/]5OL;T8@!UVNQ";L$>'1BA(T[:(L;M M>8D79?W#0`R>KC08>L"BZ%M3P9_BFGDRS@B&2(O-1<):+WTLXK?S/<:V`$ M:(`1P^9Y*]X#8]^*S40T.H:@.WM"O2F@T?1AZF(@1=N+CFA@I+F)\^/E3RJ&=4#K`:BW=.N<_X,CF*R$E*>IY&\\6\ M*/.8:':ZD084QSSJN"^$1:K=8$PM/\=*V<'-7C:/VY@X;]3S<\_4*^M^^ MO[.;<3IO(KW3O)*A\WSV`__CMX&%I^[%IQ`L[^52E)@E<^X+:MNTMP]V'L09,KU,T4T/\#K.I[N5`0'/-I&Z M/5HZ8'I@:X_?ULNKZM?VDZYY=<2,OZ[Q,4[#9MFER9` M?CF?((NP1;?VE(N%]"5T"/!IVZ(6D@XB782"_E.:$;*P4@15O(EY"4D*_34< M%":P@8(9];M0?(V:$I_\RY__'4UN%(,=>QYC=`^#>R+E#J[MF2!-&GN#8K"X ML)0KB]AG/G'[E$C;E$)%(8D<>JK3+3WE#NO"BM)C*(RV$!:;2&N*L.@-?9LJ8K58C MH^8VHTOPT$Y6PWDVA$0U11LDW!M$S8VH+V4^+4=JC&A\%C.X^VGH'^Q2LGA9 M4)<6FJ:79+-?U)O,P9A#!,1?"IA#-=W,7FPE0UO"/SUYVM1S5B>=:@V]C,BF M[KA)AY'<]C4AS";*_W4'.42-%CXAQU9YMG7.2=O)F,@")SF")`H\AZU4S[@[ M@&1&'92':V]VQ"0[M.2&6)BNW"()9Y!.-NO89DZZ%!1[UJ*GAC MM2U`@46)_1B5U6@U)>0R2"DVU[I%DHDP-%`S!P"$J?5QF$_V1.I(&*_\3;:0 M5A\G^+-U)XXMI]<\1).,K2SICH`BI MF!)I&,.8G/,LRUTQ^OFGE:KZ0<0DB0(%62FN24E=$#U?K>=*NJ`4]L.8@HR7 MUM*E&9R\1'E(%5V%;"!Y*'J77(\_T4O$^FK'9<(A\1,F$4#E^&BD+VZ#-Z`3 MKCDVU:/SR`MI#[&,PC*>;8*2QMC(>3HY@C0H9NS2@@B4/A')9C(_1K%`++3. M1#H"$,01G"3\;KN`<)UYY;EZVS2DV8*MA6J-&9-??@;BC+JL&TNW$#@+I#>/`X"66JA$<8K,@VU2X1VC_G, M,_P01V4Q'#"WT1"S#0.0=:!.VJ810S`2[VP9.+JGZO8?"IRD/(B993FOVJ,0 MN@`7DL-:D4(*98IH@J.;;?F"'&567S!KCF&*<8;$5;50$E3\G3TB\877Y\7R ME9IYG-:ZL11[2AJD_`8ATUHX;Z:HW4)BE1.L::3)J^&YWWK$[KV-;N0QIXB7 M8ZAT^:M2@U2_DB$)27*F`9DF.#=B-42AQ;\2/J?^HI(6.:X)0_6TI'(&'A6. MC;'G,%PR@\FT4"V&:"+7C[-G&.=)QL6Z2:,X."17A]A!GS!LL"=1\S>I_"=A MN/W.<&$,Y[S9Q6!`-@W#AJ3->+D0PXZ1Q-$2/KD-:?YJUNFRZ'NYUYE\-1ON M1O&+FT\8L52HA'L5Y&,@/`S-41X\!8R0M/HA)D\.7-WAM6CXFT6?]QF\?$41'OP[DC5A76Y,E(R3+OMR>;S<(VQD9)M M*,Y&5Q`\2GUMIEG0H.,0,@N6^\C*NGT\\Z5V-5(O$6YYA" M0:AL4U.]I1S18!@#BKUP<"][X1Y1^MD'>$^)=5%,A`49B6XSZ*GEMG`%B=<% M0?BP:`N4H[ON;@E0%*6>&,TO:D6J6CC!/=AZ"-@R$1C&,EH[P83V_:Q$!2/$72KJ$*QQ2QN&@' MIU9DG\5/)XA47VV.QB-'@ZU@:>AH:&FTRZ7HY21QUOV>VAS7>W@_HZ.H9I_L M)">&7D<@9$$\SI)<6=3G1TB8W'KIT^Y%(^\XG(FD9(.>T'#J'!`!U):LN`0] M=2V+7`VIN>]%0G&(QY-=0AY5WVEPT6:[4[RV8AZ@0!HXM1:8OHK/%MNFORBT M!SS"Y\S#MU4D91Z1=I&N5?&QT1#@Q&!U"*V[H^-CC?$.^?LXGQ*`-52&/&@G M*K::;4O0S\:+A-8MV%)"6FD:WF8)4[Y-_,+GB_ M++Y"N9N03-U11YK%YR,=`P#?EM#SZ0L@A*7N^VOGL35NF"CAA3R1_*;B4WP1 M(L*!)60%&9Q=E)>*T#'X-BQIBVXSDVYE5:0($!WP)"IF<*-%8S**@<+)-I"< MJ[GS7`#(OU:5=Q.'X)8KP9:CLG5 M!--SOC-W:0NV0%EWZ/J:&^9J^\GD46F4J'")@0T&$HO[T;%?';AVG8V8&`5V M,S8L$+6VOZ0[0?!P/^9S$Y%K]4Y,P52K49#97I%`0RQ4";MEIMN6/7:S9-(G M3#--6R)AXPO!-5P/;#%H'4-_-;R68H!T62X>V_G?E,#D#2TP43(;WUE43*"^[$7/^R\^$Z'?V*= M9`WIWWE3O]#Z]W?V_HKU]^.]P]YO;QQ;*4NXPTD3H;WM'3:D")YW$+C.42D) M34B<._,GC6X"Q$&#SL68,ZXM[!UD_0*_F`-4N<+>"G-'ALRKJ`(!="0S;IK@-D3V["TH!DLT MJ]4NH<$B/?3SZ.A"K50,)VL:1\'-;QQ$"$:S'RD2S]%4A:%LR M?G<(FK8XMG;[7B*,4C$^.(C2J9)&VER#B.GB"C.SL.3=?C''ZGNW]QYXI="F M^.BC8+OZM3ZS)6LT-%V&%C5Q0!OK%9>1B(L-TLISA'\&UODTEN:TIB_Y'P%( M?8TY"4[4A-\G(,>&>NC=P;HBG`5]."X:P62U?\]0M39KD%;M" MUM_EJ8(9?A'*D^#VTOO^<\1/37)I:ZF3V_)#;=0H4'`"=GY=*"&%1AZ(V5DI MIX6B*[0M=&A9*&7GH$F1T"1O`AIUO;M#8%S\L;2!:Z`A*U&3@>K,72 MS"=U9C/3E>"DJ(^=!A![DKS]\PD!V?;IB-]M8$LZL6T6`SB,C9!:%2%Q:((= M?6\D-Y:TZ;CH$4U,>T&%02H4RHG?".Z0A30+8B4Y;44T4+A!6G%?N0[6C>;0 MDF[/4'/0BN.%Z6ZDAP)O7!9#NC204=/K461EC!3U6=K(V7:]1K%_M_?+11A9 MHMXCOQ'A5`]9KX>%3'8*T#CLLGE.@)!UA4*WD[:?6$")0$3U44AK[(H]$#E- MSA&$Z>T@4T<;_7PU=O=KW5!PCPMJ;$%1J(S-Q>NB&@&TZRCTF,Y76->DFXD( M$!.ND$)NT9;>`(=Y%H/)(7H/@LO:,3EE MA/!J]AC_88UZR7NV5=`!OQ[,4H)V3O?N)U=<"(Y>\Z.#FHRL26;XV;.C[(ZT MAU7^#I5<9M^R2D#QP6SQ[&B+O8M/5L92;",OSNNF@&BOUM-9C&TOWJR<"RR1/!/RQ_$<"@E6P*`8A@F8KFD*.L=R.3JJ M?BLK^KC[]]7D0R*P.J`>D`1_BVZ1J1WB^0#;MM7(^J?F#W M1.N^=:Y/2UC][SA,:UKV`\ATW7@4>';RU5_^]3]1Q-'5C-O)+_FM$PGBF;X-#^V]AMR3=W\XJ!H$-DMU<,Y@ZL&=5R1']PTH59Z M;D+-(H3%:,YOCY\XHQE6/E<4;,#$>)$\Y5_],HX2:M&%1\U(DF6W?- M3SPTG8ZQ:.\H02>QW$WLWX=W!YKY@@#:\E`MX#$F;<,/1'6>2QLK/=S0%M>; MJ>"=F_S`B``T]Y8!HU7ZV7'K_NY'K5G%6"C=,7F6OQ[>Y_)=DU>98'E%3_.V M-L202_6@>'006KE)@* M6[7^!(8Q?YC"A^;LF[C0L@-18&V@IE"#,4-2;_7"D/=+]S?,*N^0M)]H05I<4V8H9!4T/$UD]TJL+Z^7;I7):#-Y`$)[JX/5.]@W*S=WUJPNI M+)JN1X+Z&Z.0CM#[9.\3PN`-T.S0RN675#BQ:!*TG^.PU_4>VN$%?:-[G)^, M*@)OPS?$//9/^XFB(_'>/;'U&"",$D3D&';B<]1E:V5CFR7IOE)9P>KC-J=U M,5'G[$F#P&B_``&CZZ!L&U,=#&U*(IW4:5_-MPD4.$.[X&T))!N.0A$]B%=C M]=<*:?+K4\0![\V#K8Z_VZD8]LEH+(EQ0KNCF]?T!9/7,(N).=%;C.4T#7TB MVO$K^]$W^8#\I?6L$Z)P>PEE/V+MV'(31!J\D4GYZ2FU[_R@RQPLZ)L!&3<0 M=5ROX_[GJBN0C#0'?%:`EC'MTRIP&G2$1C6,9@9"%:"0$CW]"*K_:JG\G4Z" M6+.U-;DX2<+U5PE-8F4[2M&Y>1E$Q'4_=F6%KB&W#G%CMJ.+\@(GAD@*`XI[ MA40N`A1T=`=(:#EM>EPQ&A2*I4T@%00DC4]D%W2T\"LEDLBX15BW@=$-Y<0\ M/W7B^#>T`@T!&U[;Q-&S\#U;NOY@Y:&<.,.R!TF`9S96\A)OS`#P0W`B>'3, M[9JP2&36'"7C1]OKUSRN9D&6 M[6P7BA&86A/3O/DIZVWWT0N`VIG:`8[1?EAUZ`"NMD7-FI]0KX:'AHX5>E^' M)D3)SM/#T\^1>!M`;B_@5!KDDCO7K6?[\/0;,JL=>VM[]Z']M%$L$EMQY<@* M!CI88;'*$>I@UXP0&Q%Z*<9S6")L3V1A2]9LI3E1'ENMI%]JZ7XH!W7GM*F. MEKTLW+A8KBV+@,ZE50&K__D4>`?R@F8IL>"`$+`X:XV1?'),"I%`RB*/UKDK M*UGY;T<%XV`E*<1<.0[X``TD)N)C_J4MF+&A$(,IQA*'7K6DQ[=1!A0/48Q4 MT9M6,?=..M,>DTT5IIV2\L*^+='-TP%I6BA01$Q"JZ'T$=I%)/9+?IDT7E;6 MF&;TBYY#';`1]EOXK6SM&;V.#:=MT!7>-AMQI(N3N6I5A_VQ-B[.+PC( MB6;#E=I[]RV9_)!F==)#(KM)1EU$0GO?UIY*.EDCD8,WC(\K!C(WXRWXTHIV MF9;:PRRM7ZV[R#]&33%"?^('(@I.T8)D[PP0(61;++/1N+%Q77X):O@I;,\O MS_V6+KY075BQ62"AVTH9#NTKZZ*O05:`,?C= MBJ-OWI+\D*H9SB*R`PL.!6RI M7B&EQQJP\3P[*2I&H5T1WWPF3'6)O.O^K\\++%RXW-59K_%>2)<-/#L-X!D# MT,2!Z7'727_);.SQGTE20_9H!ISBA@4U$_/;.)K8>.&-_YSQQ35)+5W162NE M`Y8E4S1YN`T.CF61NK/"0;='^I4*9?Q2\7#ALSI M\/0H>[#WD9EEO==`I]L!!DL_-)/,S#KE9"B`V3"#&(/U1O<:.C0K"@8PG'./ MI,#>!']AZNSM<6)JB.0VT]XL*;1H%8TUH6:_X^X6A=-TXB%CZ/(3S(FZ_QIM M@'^LT-LXK%:K=A"GCN1A\Y1N%>G9V+,KN:)9A*K:!BXD$"'BEH@R_B;@\&9J M-'Z[8%D&Z\R]LW^W:VD'0YI73.GJ\A6)6H%)T+4H%V("9I309*VM@S0VNU%# M<8??B<"8:EA:X,P(!9`I$_$-I[%-<'VK\KJ=_1G3-`6RJ;U:"!2+TL MD(4+QA'E'%K8T)^P8N.*>;+6V$GJPV9^V=T%/4&FDB!**@8:U5RL+59KN:1B MUN.!@_2X':^E#]3=[2?AT&_3?G'9\M08*W@_=Y?AWD\WI`P1I:13/IDVIC%= M!%SN#HO:1$@\B>MU2D'+5(<%,9B8_^)NA;BLIVU_4T]SN+HDF-G@:QKO*B>. M2WGKY[;C?"SP*X;$><#D,S,>P](E*RT\WB??8%F.RE/B/?G,DG M.#JXV4J@A6#Y[H0%+<^XB-PDWG5894^K':QSL&8$U0D7U5/QR:[43"EKXZ>+J?^[2H/1N]F MNXAA(%8S41,/O.U*2`?`H,C?(#Y\6IQ7*SEDO#&J*3*E<723(IK"1'!-3R5' M5('Z+6`U]4"N0I1*=F`$BFB!NK7"+_6&!,VB-O$2;]/,A#Y949[0:-T<>+P8#C;Z4I(J`4;VQS1A,>X11M:LOXX)WIL!^V4"C8H M"#X8)\#*S%@XZ")BM")E3X";".W@K)S.;$A(4#6[9:$]5P[TT%R"T^P]1$TX MB+[\KMB8/%8O9G`@ENPTGO*3[WWJ61<9>S-;@ZENB8D,F>)2G<%O[2< MG2FN\&,G)(J6CLI.GJHD2^X\JX)EMA3A2%UL_M$PZK^\E??$)-<(29N?7$?S6EV`9#4.U7@4^ M6GFZLWVLC&^--ZH"0%>GB,QOYJE$Q(6>$*XUU=!`ODY!U'V!/::K!N0;21G1 M0UE>Y890J?4%MFV6IA9%`\KN*1&AV*3>][M4G2V(4;+%IP^-"-[V98FT?[YW MX'/V5V/V)4[I@9]%&X30#?!E=M0686^[;5+728]^"?DP=$WKAE]I`*F5\JEB M;./-5O8#%VP+RR&>UTK1#3V2GNG*@^FYP=?A[(^?;8%,!!`,#[AO[?B^BK"M MT$]A-312=0:_?7"_LW%Y6<$6:>?%"@O)F*RP(XZ*)>3&]9-B,3740T0SB'E=8C?V19IQUEH7@B*>3*`#L\804JUD!Y!@41;"T>A;RN/<3#=#]GS1W& M-/KA):(`MPH2HYQEBU1S:9\1(S!A7U86*$8)"Z`!1X6.0W9 M;4L3;5Z@:#8CF16N:P>APQN-=+EZRPKHC4`F?MHE%4I[$0V>V3*]&&#WW73$ M0.\'WF!A.OM3\MFTJ2N$]UFU`_V52G64^C#2>GE)+5BL<&%'T+^F83WMY')] MWL!47YL$KNVC:H9I,()@;!*)198^3&)!<^YHT>/4AG5A?AG;(-H+3U, M%:?NTZO'L=H!7_=3^\,;-H@)]V/L\TRWHK&C(^*(P[6D&T=,';#D4T9_\%HL;MJW[N[O6D+)9!'$;M'9+61RT@[3W M.,E`[GV%!8YWEGCQ&Z1M+(:/46"_L%!_2;::4,5^P2@(7$6OD-KAS'9;3&'. MT3]FMO`N&Z$G2SP-JXS;MAL"&LJD*JPI^VRP`DO+?-)?/6',Q^7">N&&:Q=D MO/N9/[>(;L9].,BL+4CYWYWRKL'L9-.R,+ICM9>FD2#^6YOG5Q\5H+8YO[(A\M!9R0AT\BW5VCUY$H) M-'T@%L/Y,G28R7KYPK5X#2N9!6T,I\/6\3+`L1;J6E!+\-I7]<>K1H*"Z'9Q M0S83^J;;B'GOP.3!5JHPH;FD&.'[D,1E?_=!%$(^Z00#K+E9/QHME6'7;Q-* M/?3F)^P/+Y"/8,2IW^!/_-(/YN#`T7X\V>`FU)OZ^4J$"1KA$ZZEE!V8"&+" M&G$"'B^MX5D[2B+LAR.+"?8>WKN76F6Y$B`0&EEQ`G86A7=,D0]46!!N]L)O MEE)4^5A[HG1+NPA[9)U589,-VW/0R8-W,^5G;#^X?2-U0WWV1TAG"JV"P7_+ MD'?68A99,;]^M1EL*4B><#Q+^9H5*$+YQ8ST/3LDIRMD6R,M3H>]>V";A*7O M9K`;_?Z[&N0..DQ+N!)!J"*46*"T"T+8/&;$AP!S;H.Z^D"#UF;D7LE&ZD$&9`^:\& MXCH5OU/$O:G]KI5GKJYP+-*08K,2;A>)[A9H%-T"2*-44?7,_J6S>K3O^6/` MU5>ST!E!W8?[(+@PJUU MK/9E(E3%C`R)=U"XZJ?NHV";GU7"''Z8TTX8:<5=",9VQ'#:7&*4()OT6!B)A_S+Z@Q MD(4S?=O=FA,"DZQ+Z0!"J>5Q7^JV7:[+N-;B=H=;W.Y&MGW[W>%)_/2X$6_/@T@B+>=A?L2=/$=G4B/?Q#;O&(Y3-0!\LQ1$ARAB8J@#Q:86#0)]D5!\D1;%')OK#*6CM!O@'1URE>A<'D_S5O-RU2\0U;PBK(621`?GN4=C,P6U8YC"XCR(>OT@P7 M`ZME35;09=ZNGL)8N3E@'Q:/&DMU2T@'GDILHB*TQ+`V9@OE),X8+*M;Y7_S M4R27`Y(RL@PX/^?W7\UJLKK&"`733KMQ?,EH[)?F#CQ`"^1@._C--Q*FH,5^ MYXFU%06#?K#S\.%OHJ$:C(04#%VQ7&UP;FMM^XL5"=3>O?'VWIWO&WN8Q*E/ MPD4(^A5&S4S`BE<6+N793I=.2ODE$:(/&MM&:VL=\VH6=( MLBFH_>O-7(8_-&%\,&MX<.^CK8./;J1ZVQ00(U>D%DYWA%/ MBT,"+QU87TL+U`96Q4`*YC:E]Q`DT#O3H*\=L)Y7#7UU$XL6*,SG0UO$#J5B M"*/H4`&'/QA:F9OFS@#<6^33QBB4;&+;T!B,A'1B`GB#HCL"*Q.3)J$S;<2JLQ:G_[03[H(IT;J`W)A4461%E^ M78(E$,*]8K0:._!RHF53+1,36U%SH"L<(8O+2R2]H\P#,[!`=>B5HHT182"? M#N,OZ-'7CR/@J./._Q][Y[H;QW'E\5<9&`Y``T.*%U&7Q48`Q8NC@)((DEIC M8^0#R2%C6A2'X)!K,]@7R3<]01Y"3Y;?_YRZ=77W7&@[V"`+!`XUW5UUJLZU MSJUP_K+9=#^"Z2BO!AD`.@S%X@F;SJ)=NK0A03LBOA;(=&=V7%2T4G$XI%H3(@Y M&RH)L`V8<,TT.M>Y0$!H]^#^G36$%N5>\HTDL`WZ*+!=JZ>?=$*13%84$T(R M8K6BO2X#L!3#_K[.Z%!FV4@G"_N;I7;8(H_&4SK&'P MB$V+WEVB>\UE#DQ1;?)6YZF3OO$#6^407F_I%]^0_)6QAQ\O,LT)([B1M?N4 MH!32(21RAWWX1"!OI>>:C#6,B[7A\TVX(03]`^.W-B_#DM@Y0R(P(HA8FC]S M`^@G0G97%C`>E"A41IW M:H@@`QZI);IL0_%>$&5K+X?/-E]&MQ?;,(L;2HO.^,I<>P'YMAF['JYL":LN M\1;!@/Q*XP'N2B3PRQ7C<12C*;U+NJ,/S`Y+4TL5K(1'A" MWC[L-OQ??D-89$?#R'SP(-.05T%RDG+O.9C"<9'I3$*:E7H@LG"/9E^;7KM0 MOR(H(=N=,%YT5VU%([OG`_`U%^WP`E++_*=EVQ$,6:5D3 MS+>A1&Y0%PVV!P=I`T'L5$-D[>GSX8O5%W&<7X5]Y]J$%B_G+@PD4:8TY/X< MTI[WC[G%9_":6[,^_KGFPW?J3/34LD7SQ^V6#UM&@DFS-!P3=B"6ZS,T$D!$ MVU4)UI9L&4'C13QLHS&>]Z/&G2D^ZF,T%C-%5+7EZ$[APR0;3M%:WF/+R^D?HP-PF2EX@_Q/O+6GHLAOU M34>&XM5H>7?W3[N^4E:H_QWP'R(N=UMXU:_5:.'W7TWN\75X>ZBOGKSZS\E? M_>>U5?WKC'9/YF7ZQ+WB:_KE=@^2\5>.B05,!N_(5#@?V)1WK[[\O07';S739\4-,>-O/[JQ$/>R")@"HNK$O45OZ"R!!6-9J9PE MKDXN0_QYHO:$=TH:\Y98WE1O&HY= M7!@8L)X9)Y1HRR/VRU"L?M]U-8?R[N):G%*<>4)2)740'1+$8'[+O4S`^2W- M8&B.-S@\I[$\,CEVJ$N,W_&].X[+\U%P(NM(2$S$/-#X%?&I$_VS!C76V%0< M'RDTTC!N%,A72ZY(.+X0119O85]H_2[+5@8'5;2DX:R?!K]YFZTG;;G-@Z_+ M=LO,E4PK8<9`5`!+R:C@1Y>??%1V(9[XTI\0BJUC,P.0]/5:<(Q(,9;#\BS6 MD`@.G`$*DS.>^8%5SY[+0T/+U+0%UC%$)XLTNIEDA-[INLU;HH$)CD5W"4&) MP(]+R*][XK.-E?7-W[F0F5!:P_:'>D0=6M#K\FTVAC='CP]OM.7C.P"6S:K$ M'=O3&V`[K2GL!7!]6CEASE+'0?)%ZJJXU:\,7!)$VGZZ;[TG@)('\;RL` M7[&-*)%X#U6GD)-*:ERV[`'WN-%VN(ND_G:N)OQ]I'I)X=2?ZDX] M\Y?%4+O2K,&W!04R8^B#R"7-KE#>E]+03-E2]F9UL$+@OW@[8"G,[UX1C[`# M%QP7;A4=G!&<"W&G(Y0J:V$T3R.:>3-] M^.R_J8UJ6HUWKW8MDB8VKY_(L+:V2/6#P+SUSUG#U$]2*4;]8+G^X4VZ)%D2 M[J39DK3_95,)PB^MT'4.,;\.5:%>S45DA$;,I,5X(GN>8S*8=EQ7QQ+MR^,' MGW4@>!;.]G&F.=:,L>",4_7!32U0:6?+W]H+T5:SI6O#)-#C1BO8(#RK;S12 MH=?,'-11(M9B>"68!BO\NA^%;J5 M]H\^3.;'R6"?C$M:8>8S&Q>L602IB<-D;+U';5%%=-7^T$TME9ARB"/1AW`+ M$@,Q-GZ@@QYIBU@CF#-JK;MLW7,ID3G5Y8^R4&)5BA6W6\7'A("_E/0R80$Z M(!B0O$A`XFI,ZIM:D8ZXH3T89-BOBBBXM,6@+:YRHIIG3/Y@G`$1)?+SC;*$ M)EKL+D>BN6'M=A<@-!5_^W@]_FF9++K!$@IR#QV#)U&%.C5QD`63\//@,1(]?X6.3TT M8;;%!;41W4^*9C6'8!?!L*>SBIBD$[5N"#?7='BY,,NO_([KA=L1@LS$%&J^ MW'_LZ7LX&?3\R*I:$FDH=H?F8)?]@O9H,3='8V:J._+5]FQQX$G"R%8A0U)! M:#-I);KT@+U4XP8=NLUYH/:)[#>W7^1@:&.49#M:I69H@L2\'1036+"%%%R[ M-SF=(%8QRY8M"OME6QM.Y#Y-O?=LQW4[@&PE9E4U1J3%LC^QN(DYELU+%%IU M>U%8V;F86$MJ>LSD6L+HTOT).%]BNS\:DG`%[>T#^_<#55W,CJ,&:<;T.LYT M35].8K83UW)(@X^:9I!Z^:6,73`Y`P#/`XCMU^>:]UK)B+K11:U4P[DN^CQ- MD'$AU>6$<@$QDQFR5L&E;(TA1\#X*G[,TCUJ&=-18+K$$&($?L`Y4R7Q)EE] MJH"I-=L&"@[%<1%VK!.0O)!#M/?FFLY6X3.)"PB"$#>2GUF\&EY7-PO1,;SM MK6IQHVJERI\NJ`Q77;R--WZ"QT^]`"&7'F(P]/!I5O-CE]RB2NT\I?:K#!> M?*HL=.@A],1ESM*7L`$96>D(WTKE%9-Q4`IO^R?6*S[LBHY82V8)G!)F**-&'/Z_!VM\4' MXS,[K%FT4P3(.;$A.H==A-\&Q68[0[+K_D.VOFR$7*=IB@UDH:&Z MW:*0SFW.%2P*1!PVYT)OWX!_&YS" M44"L@5L M.6<`/%!801Q8C$A.Y+]D^+7R*=C2OS@=F0Z!(%W)$;WGM9%7M1L]N!ZFFX*) M/1/0O!U"3&("=)6E4M4G]]W8.G%IGT;:WZB!JYMQO2^F-Z8OIP%#RUJZ1.&4O7.CTL*IM.S"/#-,!6[L1=R=IORMO8BT@P*P0?M@(*V M$'S=N)_OE!MM*2,Q>1']+T1Z,_KST?*)["F0TY74)Y$`QE-^-?HS]P=5_$TC M`2GJ8H6P)=WE@;%_)>'2:^?Z&S(1X'-,N9$^1([);$#@6MV)B7PUSL>#?*^; MU65QXJYB0FLQ[%XD27$[-32AM$R0G/O$=R@DQ?>`#A95<\9R3;'!C3VU):4, M->BO\:Y!:&@Q@UG+3\LU6@VU/IBKK>W(&+5;/UFR6MO;?&K%2Y!=?$+2!GTY MZ4.C(E'U(8(_%(8\%2/J94PIBB[9MM/[A^53;@23*#.0T."Q?4/Y'J9#JCXW M?W;,HT-.DZJ!`QQF+1$[8L.#01EQ&Q.1)=L[OV%38X^=``M0M<@']':X:*44 M/4&1',B-EY85K(G6AL\VGEM'"RR>F*)\U;[@="\0XNRD;XUJLSG)X1Y-V,O8 MD7`"KQ-+7%0GU@9[YO="+H+\)WK?3#:[FJDBFE3')^O+D&5(CMF*C2VM[S*S M_#K.M7"*:4-,&&,//]:@0>&@Y;R8T&C(#U,F$3*X;))Y.(`5E6XL@O1M4+>2 M^<)D2=7EG4^,OOA^-_*^-S:II0DIS)LOG@W7:8S>!T;M4X^Q0%80CHR*0:-2 MC3$#WY>)^\),!X[/3*":_FZ9;%M0&_)"-=Q)P6N8X/C0@1U9J3M4U.).Z!N= M7X^MN85^"&(@2&:S)M!H]_P+WWY?-;)OEA\N7SKJS]^AUC MUB^?2?_Z\AF^V9SQ_&G]7)JX_NW(7"OUK[L'1_5/,_1B_;K)6QQ]D]9*@_#J M_,`V'FH@.%WIW?KUH_M/GV3*@-\C@H=J[@GWE;=='.BF>RFJI?C7-_4@[V__ M0COUOQI=#:'ZH@GI4#=?@EO&/X`(()'PUFO=2*83(KDQZ;HRD9T.>O?+_+10:,=8@,A,JUV$6VN[XW^(UM&DO3_0I^MS,1LMF; M==1U+2X,(Z_3(C@K2GT.E77$%FN0A;:D8M.^ZR47`>P0!N^Z"(_VA:I-POTW M_R+98LFOXY.?%_G*_#2N;,35,M4*??,O=!]1+6*5>%=*QMMQ[M.Y$-H7$?C' MJLN$&J1S\MP^#]]Z&0&>WV6O932=-<+%ZEF;N]Q:4&'N8640 M2I9&_.LC@2*'^]#VD,]Z!2[8.L.G-_>/LB\,?76]>UPL+?S9ENZ M#M)$>UKJ6O>+'W"O3'MK!Z5GY^?7=+EL6:UHK__A?A\GOB,.9'0(CQGJ]7Q8 MS1\YHP.W66DC>1[XEG\'Z5Y_8"3*67[6Q>?1]!I%7G1`#L]A3#CPK;7!;)$9 MB"-O;T3\WRN0L%!K`+;'X8"!GLX:NV_`.*L9"D-22<O[RZM1W+[T#\PG<'`NLPT+(JQU\+\X%+SX,/Y4CS;#`,2JY78] M-N>B!JD=,(`F]Z1^]\.'J5^>B/O@H3+8V24C/R4"-WQQ1U^(NR8-SE68[9M@K]>[QXT3&-J*376 MNW?YL_[.F*Y?W^R&8`[[TPW`7CB.E1'J_N99MP`,EH(BF"UXI\K=YU.?4GW! MG8>AMVV]#4=%+_MX.<%4I2-"HDGM6W>/":$B#A M0GX'WCOPM/+8+@95%=LL="[YW?^W+)%3,-?C8W>&5`-^>U%C)&L[T3*'?W/= MZ(K(%HG5G^)XZVF&W2O#HD[$2E;DF1E+[N'Z".(+MW:OKO@ZSGQ.\Y$VY>^%P\1+Y;'`\'LB)1&"DFC3P\-.Q51:S7JDV.\UV=6 MQ8A5&=CB(LI.Y[-3U^/$Y19FSB@UZOG6HVF0$@A4$DU)+)%&.(ETZKZM1@\? MRPB.ZI+03;PNI778-.@[3@^DBV1A?QJ$?7@O"GN#GBWWD""GJ?'M!1=4FN5E M9F?2`I[=9(OJ1`92:K47V;\"B$&4(7,@L-F3'^[%ORPI1HY%Z MKE3G[_VGINX">3R64N6[[1],I>%?8=L29@-E0D9.F7Y@8SL+E->+:Q!O9#3. M':F[8/';([24&83!#F1,"SH'M@DX=O/R*+953:*O!G3*2.X9GSU$]J(J@#.O M70^CO[V\NL(OP`DX=)6T'`6[H"-DEW90#0Y;PBAGRV;@AE!"B/+@?Y'=SIPK:27(+H'<"*/6<75])J=EGJ/!D'>Z<4(59 MQJ;JD5("9G?;AOKU(V5?V1EP?WR&8OTCA#&)&4)].Y3FZ.ZW4,_QB'VJP*I' M%*M,<:_.H[E/?C[65*H=;9['\B%2QZ_,+2D^6WJGKR49+ M<^9^(93JJ^9%F^U+!)O4B!I;F_^,.?%DG..1N"O.QS6D\PRH@Y;.SG*-D!T0 MRF&[/9?%>%M>_%M^@UA0BT*S7-]S&"%7*P06HJOO80J`*4@IPU&O<-?GHY.YD$>F*_S6YL5=K:.N03*S'F\9C[K@JXK?; MF)&T^JS'5N7(<)T:C4=#^Y_FTM9=K7IE*G?9P8EE.6W8;4+!G,!-.:-D5NZJ3)1$>] ML8WTJ6DY[(A`/=,0B\F/$B;W9+`,-YY9&H@%IVK,EB\&VV2*15Z^K<'UZHA\ MG1/2@VX`;*)32`NGP51[$GQ8$V`2+#4H':_-AJCCH_D!L\P:3G1S[%/SU=EP M-=^?'Z2$[%XZ@1'Q(!,+J_=OBJ_P?]OON7-Y2=FT+IXKR M:\,!)JXX[$TQ91$GR[,_F4SN7OU#`````/__`P!02P,$%``&``@````A`'XG M,;JM"P``2&@```T```!X;"]S='EL97,N>&ULY%W[;^/&$?Z]0/\'@M<6"5"? M)(JR),=R<);-]H"K&^1L2(I+D=+>H1%R MEBCMS#??//;!)7GY_8OG*I_L,'("?Z&.W@Y5Q?:M8.7XCPOU;_?&V4Q5HMCT M5Z8;^/9"?;4C]?NKW_[F,HI?7?OCDVW'"HCPHX7Z%,>;B\$@LIYLSXS>!AO; MAV_60>B9,7P,'P?1)K3-582-/'>@#8?G`\]T?#61<.%9(D(\,WS>;LZLP-N8 ML?/@N$[\RF2IBF==O'_T@]!\<`'JRT@WK4PV^U`2[SE6&$3!.GX+X@;!>NU8 M=AGE?#`?@*2K2W_K&5X<*5:P]>.%JN6'E.2;]ZN%>JXJBWW_WS1WOUKY^^*7_WT[?J(%-#9((/]LM\.]PK%KY.)`]2 M"ZXNUX%/#-&!)F3KXMD//OL&?@?!`.;ASZXNHU^43Z8+1T8(SPK<(%1B\#+8 MQX[XIFDY[FMR6,,#+##2WWD.N`D/#A(-I]7S@&@RFV8( M@[-IC$>H31Z89.+!_3:9/U?8Q.F:-.OJPA^GBUFQWZ[>=)7CHL1A%UVYKXB> M\/%AH1H&U)#1<(BT4H<=2=E\.01])U-V/CF996-C;$Q[M8R+Q;+?4.'8Z)/* M!H7&N^G-R>CL7UF==6D9/E4&8,+URZ(#J;LGOZ<&ODX1)R?NT([C,2:5*_HL M]8K:>.]X=J3_62@$&TW,!:U M0F<3([0\,/I7C'9QL=>_BB.+KR(G[Q7+:=K"\RP`(H@,QW7ST>YX@N-!.')U M"0/OV`Y]`SXHZ?O[UPV,!GV8(Z#?!LGO&G[]&)JO(XV-B<0:1('KK!#%XY*- M05-KE^>WQO*6Z27(1%'4"#6,Y?0(0F^OY\O^D2[G\[Z%:@:\>A;Z;H*OGH4: M\-^R-T[37D#O"V0N3XD=G#,.WT[G\_EL=#Z;S>;Z>*3KC.2'-*(=?V6_V#B- M[(VF,H()()B/9_-S#8`,]1E3=5($8P`PG4QFD]%)0@D>;6WP6=:@>?2O4H02/(J07!JKZ;3*AQ8&VSI MI3PRZVU\G$WAEK>W[76Q62/,4Q^"<`7+!MEYF1'.5)-C5Y>NO8YA1AHZCT_X M-PXV\.]#$,=PPN?J_0()\(J(J09!VI3Y;&Q2P6ACF[:V0GTI MY<:UAB\V.JZPM*%%V0&KGJR>6= M3$]'$3`HL6S7_8C#A'^L\Y$)+/9=7;ZLR=8.V&^#>Q]PYPB^A17U]&TR"DD^ M@.?K&FFUC11SLW%?[[;>@QT:;!,.4\&.XLI]\>F:#9^*S^Q\C&>SY4HU$?-# M&,2V%;--0NQ$21V><0V>42I(!$\7_;"3I9)$X$F8CR[Z83FL4C_P(E4_!)>P M_C[C`;=#I4$-+J!!O0]/GPA@T2-#`$Z0@0"W;Z4<0'C*0`"3R0P!!&B!`.#L MB8HN>3`BU0QBH%`)^H^E$FI,9B6G\HA6UI5?T+_'2H,KOYUH)O46`KV@&3[L M`=!)95V)E55BB-LATPH*X,,>"@SH=?OI\F"Y(8\[X*``((T04G0Y0%`&]C'2 M7U22F@LZ11FY[G$<0H("2Y%L"`!'"@3BB)&D_G=$,4CJ@6DT2.J"*02N#]Y? M)7K-">H)KH>4A`'P2,F*HEZ/N![CA#00"+(J)(D&35:)I!ADU5DW+J2.ZB9-X/>L>3)[2F:.X`LVER)3:;Q@ MSL2][+AVJCP%H?,+3#+QPCD+#MBABA=:QHY%CWP.S1LV,MZ9ZV7 MS2[3%6)QC/PR:X;UM,B!N.:E[1UN:]DLF(.3%:K22!M1+LZ:(#\=L""L="D0 MWG*EG0^R6B(:+:&8X9`3\F--40;EPLM:F98?"!%OPY5F.L_",]O'N!(BOBSSO M!ENRS+JW6EZJLO70L.#QP17Q.U5L'\!L,>>T@'=G=B6=BPD\J?)ED]X`]VLDO56@RQ@4M`)X4"8>THUU'U^V MZC3_;\?Q4H?2>`HC&TJ#P_>L,/"%M39-6OF\OMI_;>/D$PSL!7M33-OFWO3X M_(KVFW6]/]<1E2ID^WZH-F+I;$\4M!#))=!\"AUS,EI'*C<"+.'[&D@MCP/W ML7I09]DU"+C(/<&(KR->"(/N99\FT2&##;JDPP%J\O=!'CX$(:"J["C+`$\& MJ9:T4F;S.2)4"LO=C8)W&\%=D,E],4JGGI"AJIZ'SP?X=.09D+!WA:IDN6=O M7R8/BHB.:;VS\-@0$GQG=!#>^";X7.NE5'=6WW M5S5W91M,8$L)N4"/OSPOWX"BX%T3X2[/P]\K9\H["WNA?)8UP@U)6\>%FX_@ MSA+<'&1M([CN_3HYF&[GV"5^U7##&,$%$_*VLO(D'(.U M1!9I4?V<97PA>8+(*+RBK\ M",P1OM#DMK(*/X+CJ"PPN:VLPH^`D,C204E;684?P0M4%H1;6UFY'W5P')$U M$>3^O-*/?*SB+C417%16X4<^5L>"L4IE%7[D8Q5-;HNK\"-()7SI\$5;684? M^3JA"]8):F/A1Y[[B2#WNQ65CWA-,.(3*87OX!WA"+L_$8X2*877^"@?"T9Y M(J7P%Q_?NF!\)U(*3X$\8I$.7XA;E/MHS+.K"[)[;:ZRJLL'#/8S(C#@>0#6 MUH7G-`3XE`>V"Q/G7\0@7+`6DO1D6\_*$BZJSP7Q^8#=J(B@VY>-:_IF'(2O M"NZ\S,7Q3I\(BOM3$.0<\1(T^"@"Z,_P3`QXW(8"O"0,\3&,VQ?;B,ES@:<' M+\-J(P9:)VCX^,,EBC9BH'4BAB^J.'X2$?/>WVQS#_&U%+MN$1$?'/_97O&1 MPS.L`4@127?V-@[-//[XE-($B;G#6S'D,O@2D=R".KMO1#K^O(,[+V0DXMY. MDCLXAA8!_M=M3&C$5D0(GJX2$7+OQ'`?GRR).1$(2TA$`+NAS,WUL3\[FD^N;LXF^O+ZY,>9#;;C\+U"&C]BY@&>T='B$#7O4 M#NPN'^D7D0L/N@E38U/P'XMC"Y5\2."S^PT!;%@!RHP81/DC@*[^!P``__\# M`%!+`P04``8`"````"$`ES-ZX90#``!S"P``&````'AL+W=O):DVK+:MU$I5OTN?'3")M8"I M[6QV_WUG&*#!J53RD@`^/G,\QQ[/YL-KD7LO0ANIRJW/QJ'OB3)1J2R/6_^_ M?Y]&2]\SEI%3)N1"E)1(M M0T-LUKX)5`$R[32IA!9AV3XMLZS^P=A4G` M!H@UCF;(FJ@<*.#7*R3N)T@C?R5U,K6GK3^9CV>+<,(`[AV$L4\2*7TO.1NK MBA\$8@T5D40-"?Q?:#R:C]DTG-_!,6DXX+_A8"!Y.6.S`2P!K:I.V".W?+?1 MZN+!=@7=IN*X^=D:F/^<%4@'8A\0O/7A.,&"#5CSL@LWP0LD/VD0>T+`;X=@ M?43<(M`_T-`)@=0,%X)@%()VH;(]?;B.&SEQ"1'5JJ<1FRRZ\9X,R,%P&0C> M^M.KU4XZ5M)%"-I7*#2^^M"+"R3#XR(8]N%5W*D3EQ"P03L?9GU$W")<'V#. M<"$([@N9]\/L"4%"#G_:,G&+<(7,[Q&"X+Z0W_Z2$X28-_Z'*R=C,8W73O6, M6=PC`\%]&4LG'X28U3*BD+FNM,-N,O`*&WQ,$=Q7L7)4$()H>)0CN*V%./=@3I"?%/;HMQ)7"X`89GI4:[8AQCVN#(7N6\V6T1E6'9'S'$T[L`WNNXJK(S*9$^7 MLT?W#:9GF7/LXPYS(P<+X/`T(=KQS#W8C#`].3>NM9@;.4[=Q>Y@`MOJ+_?@ M;0%V#=E#(X32KTI_\V51GWTV6ZZB:/4[;U1TJ*6A&[H0^BABD>?&2]096Q0& M4[NO7<_5-$/=`'0O%3^*KUP?96F\7&0P-1PO($.:^A]ZL:JJ[_^#LM"WU(\G M:&X%7%/A&,"94K9]P;QU[?+N%P```/__`P!02P,$%``&``@````A`$L&ULG%I=C^)&$'R/ ME/^`>#_`-E]>+1L=GKDD4B)%43Z>O6!VK0.,;._MW;]/MWN,NWL(F'M9EJ*F MJ9ZI<0W@QY^^'O:#+UE9Y<5Q-0Q&D^$@.VZ*;7Y\60W__NO3A^5P4-7I<9ON MBV.V&G[+JN%/3S_^\/A>E)^KURRK!U#A6*V&KW5]>AB/J\UK=DBK47'*CO#* MKB@/:0U/RY=Q=2JS=-L,.NS'X60R'Q_2_#BD"@]EGQK%;I=O,E-LW@[9L:8B M9;9/:]!?O>:GJJUVV/0I=TC+SV^G#YOB<((2S_D^K[\U18>#P^;AUY=C4:;/ M>^C[:S!--VWMYHE7_I!ORJ(J=O4(RHU)J-]S/(['4.GI<9M#!SCM@S+;K88? M@P<[G0['3X_-!/V39^\5^W]0O1;O/Y?Y]K?\F,%LPSKA"CP7Q6>D_KI%"`:/ MO=&?FA7XHQQLLUWZMJ__+-Y_R?*7UQJ6>P8=86,/VV\FJS8PHU!F%,ZPTJ;8 M@P#X.SCD:`V8D?1K\_B>;^O7U3":CV:+210`??"<5?6G'$L.!YNWJBX._Q(I M<*6H2.B*1*#>O1[>763JBL!C6V0^FH:SQ?(>*2"ZZ0<>VRKA*%S.@MG\=D-C MFIQFKDU:IT^/9?$^``-#^]4IQ>T0/$#E=I)I2L[3_G^S#M.-13YBE=40=AY, M:`56^?(4+B:/XR^PO!O'6?N<0#*2EH%KB64-`?"7E56#;,M!*T%/Y\9@Y7AC MEUW3ZD4V`>&#<%P;.8B M^=YKXM#6P>E.-&`T8!D@M,$;]=>&9-B,0MM4:2-.W%AI-IE-)LI-"1$Z\8:/ M6,0+;X1E(X1V<#W7CCL@@HO5=PG!',HR5GB#[GLL_K_2%9]S=7:T0QT26QQ&!B-6`9 M(,3&]XA%LA8;*['$<6(O;%1ZG4GE`X+0][QE(X3T`'9E_XENV$K\4CET[4BD M/L(=ZOE"4J87*,91NAXM1V0/&%?,+/VN-@&%G+QDJG5P'&IEWEA<,A+'Z&0: M,2:83K`[. M0S:*R<<:O;%2E)-\I<*E.G2M`R*Y?>/;)A&$N4\PCM!U;#DB]6/$,?T]%XJ" M4?;A68Y(G8H$/V'`^G:(\1#+$:D4\XPIO3'3E'XPE5<.:0&+2+<)-&(\CN6( M5(@AUE\A19Z<0WV,#(A$7@@P`?1%)'$4/JDW!UD^2/:`V=:_!TI"V8/:?^N` MQ:6;98T8CV,Y(A5BA/572(%WPP"%#E_K([DB=P,1#C(=8CDB%=V5D M2!EYW0>.Q!72L`XQ'L=R1"J$?='?J2&RM0_TQP)'FLV:])N,8F64Q".H53`M MX?QQW')$ZL<@8CNM7S:$.$KWH3\R.%(WKXF'&`^Q')%*58K=<"O%T`TOZ*Q* M\(L@F5X>8CDB%:KTZCF7%$?R^JH_T81M9K&H6ZIC4W(FM=_"&`^Q')'B5;#U M%'\AX&)U!%Z'1.)&T(CQ.)8C4NE=\152#MTP@@ZKQ`WK-!L/L1R1"C%'[M]4 ME#XWC-!&%#-"K$Z72=B2.B-HQ'*.$(_?W=POOAFEK@BQ/BTZ4C>IB8<8#[$< MD4KORJ^(\NNZ$1R)*Z1A'6(\CN6(5*CRJ]^FBBB0KAO!D>!ZU1U^O:0XD\Y& M\!#+$2D>P^IN%T(AQD,L1Z1"%5X]C4#Y M=,,(;8BQ=F+/""VI,X)&;,00*1Y3A+GXQO12Y@C1L3XD1CJ8$@\Q'F(Y(A1. M57A=5]BP;UT)'(E9U$.,AUB.2(4JM/H98$HI).9RJ0^)C@0;N_-SK$C)F70V M@(=8CDCQWY5GTPMY%JO#Z]J1^#33L`XQ'L=R1"J%J>IOU2FR;QJ!2)V>Q`WK M$.,AEB-2(>8)VTP]C4`I)(R@]Q3<5(#=T(]_P>+"#TN.P87S,4"_AA^R\B5+LOV^&FR*-[RK((2/KV?T?,?#QQ`_E"I\'3PDS6T# MX_,+<"/"*7W)?D_+E_Q8#?;9#DI.1@LP=TFW,M"3NC@UO\$_%S7<@M#\^PJW MG&3P<^QD!.1=4=3M$WCC\?DFEJ?_````__\#`%!+`P04``8`"````"$`'5@$ M,\X'``!%(@``&0```'AL+W=O#/K, M>5^2G),08C_^\?U\JGP+XB2,+OVJ46M4*\%E%^W#RVN_^N=7YTNO6DE2_[+W M3]$EZ%=_!$GUCZ???WO\B.*WY!@$:04<+DF_>DS3JU6O)[MCSJO*&TSP_UASHX/3WN0^@!&_9*'!SZU6?# MVAKM:OWI,1N@O\+@(RE\KB3'Z&,Z>(1#7B=K) M,K"**_O@X+^?TDWT,0G"UV,*Z6Y#CUC'K/T/.TAV,*)@4S.S9NRB$S0`_JV< M0U8:,"+^]^SZ$>[38[_:[-3:W4;3@/#*2Y"D3L@LJY7=>Y)&Y[]YD,$:E9N8 MP@2N:&+6>NUVJ]/K@DN)LBF4[VLO:6"*$=64?A M*H3=FM%J=%@W2V0=(8/K?0WL"@%#.$3"@ MN'BN697Q/!9R7=)&(Z\2^'!?*UD:^[,.=#<7" M8+-&2,HS9F!-L`]WW@2KPI!E<>]H8($8LD+NS!I6BB%+Y?;LJO-%(5MC;#_U MGQ[CZ*,""S>D.[GZ[#%@6,P%5Q=>*_EZ\[/E!I8(YO+,;/I5:#^L)`FLD=^> MS$[[L?X-UK6=B!G0&$.-&&($6WF8K:V#D0X<'8QU,-&!JX.I#F8Z\'0PU\%" M!TL=K'2PUL%&!]L"J$.^\J3!A/L_DL9L6-)PN`<("EG4,H01*+%U,-*!HX.Q M#B8Z<'4PU<%,!YX.YCI8Z&"I@Y4.UCK8Z&!;`$J&8%U3,G3[88VSAT7WJ["@ MR=ECZK.'QY@/>;:&A-B$C`AQ"!D3,B'$)61*R(P0CY`Y(0M"EH2L"%D3LB%D M6R1*4]+$ M>1Z$35P0LB1D1,;O!I[:TN/X>YM$,$@P[IUXPG5 MA(T0,2$30EQ"IH3,."GF,8\I MYK&I-G&>!V$3%X0L"5D1LB9D0\B6DQMYA%'\[WED)FH>!2GDD1";D[;R!&RV MU$$:Y4$X2(XPZN2K[IB3%M1J86)K&YT)D;FY=5&F/8&G>1#>?R:,9-<\$0// MF<+]M8[,\R`T6@@CV9$E)^4=61'96EBK`ZEU9),'X?VWPBCKB#*WX7U-J8D; M*,^'KW^,Y5WUY#JZ0% ML5UR(@;%Z+0Z6DM61+(6-RD=[(T(DCW4)M6VZ*N4$#LR^D0-9>%J$0ED9J>8 MV>-BB$ANN&Q$,FJ$R,P7"`>1%(X1R:@)(AGE(I+V4T12.$,DA1XB*9PCDL(% M(BE<(I)1*T0R:HU(VF\02>$64294T\..`(KG,^53G!WC:7,^H,&&)4 M898CZN;I&2&2+Z$.(BD<(Y)1$T0RRD4D[:>(I'"&2`H]1%(X1R2%"T12N$0D MHU:(9-0:D;3?()+"+:),J&:,'0D4,_9+&RYVBJTW MB*3]5A&JZ6'G$\7T_-K,YJ<<8Y2PIELRZKQ$#1^> M6YLR*EJCJ+0Y&XR2/=7W98JU6FWL"*:LVKY&5YC6-U_<"YM^>),DBP1'V33@ MM^2_/?/?ARB=_:[,E@\/>8X_]'[.=O`:'S`?@QGE:USTX*S M\AN\:<$Y+>7/+>N9OP3K1BT+S@FI8-"VX-"*&ULE%5=;YLP%'V?M/^`_%[,1P()"JD:JFZ5 M-FF:]O'L@`&K@)'M-.V_W[6=#Z#=EKP`]CT^/O=<^[*Z?6D;YYD*R7B7(M_U MD$.[G!>LJU+T\\?#S0(Y4I&N(`WO:(I>J42WZX\?5GLNGF1-J7*`H9,IJI7J M$XQE7M.62)?WM(-(R45+%`Q%A64O*"G,HK;!@>=%N"6L0Y8A$9=P\+)D.;WG M^:ZEG;(D@C9$@7Y9LUX>V=K\$KJ6B*==?Y/SM@>*+6N8>C6DR&GSY+'JN"#; M!O)^\68F!:KPH&&6C;'4'+%-WY218C MO%X9?WXQNI>#;T?6?/])L.(+ZRB8#672!=AR_J2ACX6>@L7XS>H'4X!OPBEH M27:-^L[WGRFK:@75GD-".J^D>+VG,@=#@<8-YIHIYPT(@*?3,GTRP!#R8MY[ M5J@Z16'DSF,O]`'N;*E4#TQ3(B??2<7;WQ;D'Z@L27`@@?>!Q`^N)@D/)/`^ MDP2+N3^/_B\%V[2,2_=$D?5*\+T#)P^$RY[H<^PGP*SM"<'D]^T!7_2:.[W( M+`6TA)(^KX,H7N%GJ$-^P&PL!F[1&3-&9.\@@A,$@[Z32/#M>I%ZT42D?Z(W M>6PL9&%JI1/+!A,C`>#,4,"_W='@%,V&F4>+R:X.!?KDF#IYK.9;9UL)BY/4G>Y"1E MP^C,_XNFZ!I-&CS5%(Z=V%A,;#4%\]DXG(W"7GSV<>14?(TJ#1ZK"J+E>-N- MQ=CJA4$\M6H<7IY]MJILE[3WOZ6BHAEM&NGD?*<[8`"YGF9M<][X"5P2Z(J3 M^0R:MIG'IP`TS9Y4]"L1%>NDT]`2*#TWANH)VW;M0/'>W,HM5]`NS6<-?T<* MU\]S`5QRKHX#W=A/_]OU'P```/__`P!02P,$%``&``@````A`.\OZBLC$0`` MX68``!@```!X;"]W;W)KN__?[\=/+;>K??;%]N3D=G%Z[[?WFY>O-Z;]_U;\L3T_V MA]7+_>II^[*^.?UCO3_]VZ>__N7ZQW;W;?^X7A].J(>7_G5^OK][ M7#^O]F?;U_4+61ZVN^?5@?ZY^WJ^?]VM5_==H^>G\_'%Q?S\>;5Y.0T]7.T^ MTL?VX6%SMVZW=]^?UR^'T,EN_;0ZT/'O'S>O^]3;\]U'NGM>[;Y]?_WE;OO\ M2EU\V3QM#G]TG9Z>/-]=N:\OV]WJRQ/%_?MHNKI+?7?_@.Z?-W>[[7[[<#BC M[L[#@6+,E^>7Y]33I^O[#47@TWZR6S_7;G+R>GYI^LN0?_9K'_LB_\_ MV3]N?YC=YO[OFY_= MYX_-_>'QYG0R/YLM+B8C7IR]WU_V#[_-SB-8E>ADW'L9$)' MCYV\T7`:&])G;$CC\@U_.J3N:.DS^H]'9Z/IQ=P?[!OMYK$=?0X[P$5L2)\? M.D`Z_.X`Z7/0`5[&=O3YH0,\#V7L1D6[.JP^7>^V/T[H5*-"[5]7_L0=75%G M:3B$W/0#Y,_&!PT,W\EGW\O-*05!I=_3H/[MTV@TN3[_C0;B7?2YK?APCR9Y M^%'GNVTE4!)H"8P$5@)7@'-*0I\)&I0_(1.^%Y^)%,-M`CDU8Q%V\DA-6@F4 M!%H"(X&5P!6`A4WG8!EV?1Y(=?;.-Z=T]A5UGO)P;H//^+)/00.D!:*`:"`& MB`7B2L+BI(/^>)S>F*26C!:*`:"`&B`7B2L("I8M)&:B?H^>3LP4E9N`T[3OB20B$ M2ELF82F2T#OU20"B@&@@!H@%XDK"DD`7ES();\]3WID'&D@YAH&T0!00#<0` ML4!<25A4=,G]>%3>F4<5B!C#EZ)\O5-?/B`*B`9B@%@@KB0LT!%-DV6D?A#/ M:-@-',%=-SP'$?$Q/+X02?180*40:D4%D$3F&>"Z\!"E$U]MC>10$"UV, MTI'?1E2.9D0M(H5((S*(+"+'$(_/:XV/QQ>4"8LO(#ZNQR-9TMXK):8=`5*( M-"*#R")R#/&0O>XH0CY^CO:B0YSE$8D1+F5D]LKI"'T5XT2AET9D$%E$CB&> M#B]%BG2\,\*#<*'NTI'?CJ*6*30'HA:10J01&406D6.(Q^=%21&?+_=R=C;\ MBNR7WK+:`8EJB]54$QL6I6T1*40:D4%D$3F&>#:\121F<+FTS%XY&Z&O8E)7 MZ*41&406D6.(9\/KI@\/\'%06>4`CZ@X\@91BT@ATH@,(HO(,<3C$_+LG0&. M$FP<4=@2[_9`$+41C6DB+^9YL9Q6V2L57F-?)GN5?8FUGJ2_'^N)9$*K, MC_G1K-M(.#QN[K[=;CVH[O5.:%,W;/6.4:PE5"8G>F741J_QLML?'E^,Q(RO MLD.*16//)GOY;6;J1EQ&;79(W3C6#4^)$'+O#`Q4:_Z'!"_@:]P M%2*=4.[+))0;6D0NH:XAC\]KIH^?V$%AL1,[(C:D)W)U/8Y>>=^[38@W%&LX ME;PNNT&Q'(E+AD[VW+%)Z,V.;?(*'2\NQ4GHDKWKF*>,.AZ0,N\M+H8!^6M/ MG@4FIF.(!GEL?!D M>,E5C)_CIHR@V]BPBHB^N,B17.307-$E-U>_C8@FN90VE=`TY&@\$S."QFY, M:I.[L0G%;BX68BPZU@W/DM"'QV4)92/]B-*-D5S*)J%<\#8AFHF*7,*9%ON: M=UF:C!;O%+/EV*HN^30]6MX_;I]_;,K$LUYZ9+4 M]<+/P8BX()V(@=%DKS286D0*D49D$%E$CB&>BI\E2+WL%#-21/ZC&"'B^MMD MKYR-T!=9$E+HI1$91!:18XAG8Y`@]666(0=$WY".O(E>!6H1*40:D4%D$3F& M>'R#!.D$!6E$_AN*DHHIJ\E>*0LM(H5((S*(+"+'$`^YHCZ/VE*8H`*-R(^G M(AMBAFNR5\Y&Z*L8$PJ]-"*#R")R#/%L#!*>$Q2>$15'WB!J$2E$&I%!9!$Y MAGA\0G@>O;Z>H":-2%1;B)HF>^5JA[Z*G"GTTH@,(HO(,<2SX056(:/>7F9, M@APK]5)$Q9$WB%I$"I%&9!!91(XA'I^0B>_$AWIP$I`HJ5CM-MDKE[1OF)!" M+XW((+*('$,\9"^7/E[2(*Y820-B)0743@`I1!J10601.898?-.*-#MJNNXZ MXNHL(E[MJ5Q49J]4VA:10J01&406D6.(9\,+H0]7>QID4UGMB$C_I6`:1"TB MA4@C,H@L(L<0CT_H+3]='_'S_!2%6$2BUF)UTF2OE)X6D4*D$1E$%I%CB.=B MD#:;HC:+B-4Z>!6H12^%2",RB"PBQQ"/KR+$)DM_N^_0NS&FJ,0B$N46*$F M>^5RHQ)#+XW((+*('$,\'8.4V!256$3E1(ZH1:00:40&D47D&.+Q"27V]K5Y MBG(K(K[4F,J]FNR52QKEUKB?\Q1Z:40&D47D&.(A"[GE9[/C[IB;HA2+2(QP MN;60O7(Z0E_%.%'HI1$91!:18XBG8Y`ZFZ(ZBZ@X\@91BT@ATH@,(HO(,<3C M\QJIN#C[C4$:;(8:+")6[>!5H!:]%"*-R""RB!Q#/#ZO=GZ*!IL% MW51JL(A$N>4>0O;*Y48-AEX:D4%D$3F&6#KF@S18Y\TU6$3%AD&#J$6D$&E$ M!I%%Y!CB\0W28'/48!%Q#3:3^P39JR\I(H5((S*(+"+'$`_9*Z&?,L+G05.5 M(SPB,<+E&CM[Y72@/D,OC<@@LH@<0SP=@_39'/591,7LU2!J$2E$&I%!9!$Y MAGA\@_39'/591&*$RWV"[)5+V@N[A!1Z:40&D47D&.(A"WWVMB2=HPB+2(QB MN5;.7BF^%I%"I!$91!:18XB'/$B$S5&$1<1&"I%&9!!91(XA'I\0 M8>^4%)76/`HFMLJ8R;5R]LHE[1LFI-!+(S*(+"+'$`]9**VC5QES%&$1B0$N ME]'9*X7>(E*(-"*#R")R#/%L"%WVS@!`[34'"=4@:A$I1!J10601.898?`LA MM([?^^MZXB(L(E%NN<3.7GVY$2E$&I%!9!$YAG@Z!NFR!>JRB(K)JT'4(E*( M-"*#R")R#/'XA`A[>S@O4&A%)*[*^621J&5-T45>FE$!I%%Y!CB(0NA MY4>XWRD<^.3T`A581'QXS^4J.GOE7(2^BD&BT$LC,H@L(L<0S\4@4;9`4191 M<>0-HA:10J01&406D6.(QS=(@?DW0(BM[8CX$[+E7+VRB4-?5'#A!1Z:40& MD47D&.(A"P5V].5Z@>(L(C'`Y2(S>Z706T0*D49D$%E$CB&>C4%Z;8%Z+2(V MP*,2R[?"MNBE$&E$!I%%Y!CB\0EQ]L[\C0IL$9`8X'*AG+UR2?N&"2GTTH@, M(HO(,<1#%@KL_U`HJ,X6O3HK?@28RT5F]DJQMX@4(HW((+*('$,L'4LAV-X> M`9TW%V41E2,<48M((=*(#"*+R#'$XQ,*[/AR+U&=120F-+G`SEY]N1$I1!J1 M0601.89X.@8)MB4*MHA8N:,4*R8T]%*(-"*#R")R#/'XA#I[9SBC"%OV6JH\ M@^4".WOEDO8-$U+HI1$91!:18XB'/$B$+5&$153N;2-J$2E$&I%!9!$YAGA\ M@T38$D581.(:)7<)LE>J7XM((=*(#"*+R#'$0ZZ(L"/6&$N48!&)&4LNH;-7 MSD7HJSCO%7II1`:11>08XKD8),&6*,$B*HZ\0=0B4H@T(H/((G(,\?B$!/,7 MJ.7E,;=_+E&>123*+9?7V2N7.\JS/*[O6EZB_(BI/;40M(H5((S*(+"+'$(]/B*WCM>[[ZNF_73 MT_[D;OO=OS.;*O/INL?AA=ZWEQ?T1N_NL0^P^'=]=Q,>6,9DZ;9BI&4YO?+2 MA9(+EAE9ND,%RYPLW1LDP+(@RZ+:VY(LW7/WT.:2+-W;?:5E06UH'5PYM@6U MH25AQ;*D[-!BJF:A[-"ZHF:A[)`BKUDF9.F>Z8=CHS:TQUIILZ`VM.-8LU"N M::^N9J%#4+M:%?NFH6RC7]ZE.S4*[I M]Y**94&YII\.:A;*-6VZ5RQS:D.W@=0LU(;NEJA9*-=TXT#-0KFFG]QK%LHU M_3)=LU"NZ0?ANPYJ%VM"==S4+Y9KN6:M9*-=T_U;-0KFF.Y]J%LHU MW014L4RI#=VQ7K-0&[IYNV*94:[IMN>:A7)-%^V:A7)--]'6+)1KNOVT8IE2 M&WK\J6:A-O3@4,U"N:9G:&H6RC4]?5*S4*[I(8V:A7)-SRM4+!-J0\_1UBS4 MAIY`K5DHU_2@9LU"N:9''"N6*>6:'O>K62C7]*!7";4)H@`L ME.NPJ0X6RC4]+5_['LHU/3E>LU"NZ9GKBF5$V:'7^=4LE!UZM5W-0MFAE\)5 M+&.*E-Y?4[-0I.&=-3*>,45*;^"JM!E1&WI;;,U";>BEJC4+92?<("6_9T39 MH3=SUMI0=L*+F*`-C2IZOV.EC9\H:IP:5/TIS=4L4Y*K.:845S,\H@S3&X+Q MB.@E8E?^%6%HH5>"7?D7?J&%WJU%;6HYH==E49N:A?[0R.=ZYNG`*M]QZ\M; MXWX85_CGZ=5GTD]XL+=^)O'\O*\2_8&1U]77]3]6NZ^;E_W)T_J!Q-1%]V*R M7?@3)>$?A_@ZF"_;`_UI$5J-T!^LH#\ELZ97TE_X&XL?MMM#^H?_@OZ/TWSZ MGP````#__P,`4$L#!!0`!@`(````(0#K8/LFR@(``,X'```8````>&PO=V]R M:W-H965T&ULC%7;CILP$'VOU'^P_+X8R&V#0E;9KK:MU$I5 MU1;:2%7'-/!\2D2= MJ%36>4Q__WJ\N:7$6%ZGO%2UB.FK,/1N_?'#:J_TDRF$L`08:A/3PMHF8LPD MA:BX\50C:GB3*5UQ"X\Z9Z;1@J\5IIO2_#] M$DQYE M_:GV7X3,"POCGH$C-!:EKP_")-!1H/'"&3(EJH0"X$HJB4<#.L)?8AJ"L$QM M$=/)W)LM_$D`<+(5QCY*I*0DV1FKJK\MR#EB+9P;328>Y;S%P?EYF,9;#ITW>;?C"*28`;FO`7/7];08MQ@QKY@JSK?2$8 M6@]<;^WR;X^4.M#0;.`O>]!(':Q=KXY@I]ZWM8N$[B`/IS4?\[JS.X6*+A\8 MS!H+=!$8WYOAP#_O93'6O"R%X+%4%SGU@@MU<.;1RV2VQ(_N/W8P<:S11<9V M@O-VEF/9RW80/);J(J=V`MA$QWZ"\/8*/RYSK'((C1V]\VW!MAPI7[;DT$=J M2!#3P4?4;L]V155"Y^*3*$M#$K7#S1C"TNFC_=;>N)X/T/``#__P,`4$L#!!0`!@`(````(0`:@E`KKP0``/`1```8````>&PO M=V]R:W-H965T&ULG%C1CILX%'VOM/^`>$_`$!*(DE2%T>Q6 M:J6JVFV?"7$2-(`C3"8S?[_77`.VF'^.L/K^4A?5,:YZS M:FV3J6M;M,K8+J\.:_N_?Q\GH6WQ)JUV:<$JNK9?*;<_;_[ZM+JP^HD?*6TL MR%#QM7ULFM/2<7AVI&7*I^Q$*XCL65VF#7RM#PX_U33=M8/*PO%<=^Z4:5[9 MF&%9WY*#[?=Y1A]8=BYIU6"2FA9I`_SY,3_Q+EN9W9*N3.NG\VF2L?($*;9Y MD3>O;5+;*K/EUT/%ZG1;P+I?R"S-NMSMEU'Z,L]JQMF^F4(Z!XF.UQPYD0.9 M-JM=#BL0LELUW:_M+V29>('M;%:M0+]R>N'*9XL?V>7O.M]]RRL*:D.=1`6V MC#T)Z->=>`2#G='HQ[8"/VIK1_?IN6A^LLL_-#\<&RAW`"L2"UON7A\HST!1 M2#-%&ADK@`#\MA,'*>09%,PF)$0(;HH<0'9%T"%$(8-=3A'6; M%'VHX-O:=XS$()V19\P7OP$Q&(T1P;`LC2-(IW)\GYL`K^V9(D4XUV>.$=)V M=*MPHCS0)H8LMT\LP-!ZRL3ST)@8(5%;PPGQ0U>/)UH\=&=]6&,%3:VR$ETU MN[I=NI*)088LBSY]JT*,$$46Y8%&8*X3>+\>`JS+$IJR("3`UO9U5HD:G%]1 M9'$/(0$V"$7ZG#%"D)`_S(G-H@:O$1)'D[+QWU=(@'5"D=$8,4*0T&38)4A( M#0X#M8I%.A_1,A_O:`1(.`IMRO2H@U)/*-&$K-HN\;S MS;V6Z/'9?.@KG9CAT>^7BJ"-JIL\&A+C-I(8+!8QBZ5%?7?H/)V58!$4]D#HS[ M@ZBZ:H9?WTAO;-R1L>=C@ABKARZL%C<:UB];#C%R M+Q"S^(EXFX(*R'@4#-M8U^\N8R?HS*!,_](1&<+$$J,8A/I$G_PN$R=C%X_, M\TQBNIXR=D2BA\DP6J=UEY63-[S$J2TC_I$JY-G^/AM>[\= MI5L3<8?=(5F@Z6/!#(J)S""=839(I[,S_/Q&=F-?)Z[1QK&G.O>(G1J,KK(3 MYGNW,7EHV6IC$=?P[5B"I/.XIG,E6MP/PT%[7;\_:F6U450YXV> M86&)3()Q,O>'[:PS_"-S%Q=4XV@DKN$)L03AM2%PS:N6N)N+)#(>C`YOO'CC MQ;2D]8$FM"BXE;&SN%03>('JG^*%/X8+?WL[=OH`W+=/Z8%^3^M#7G&KH'L8 MZDX7,'6--W;\TK!3>S'ZTX!O&>LZ;Z(JVC_6\WF?P`` M`/__`P!02P,$%``&``@````A`,*&?VF=`P``M0L``!@```!X;"]W;W)KR79 M)`:L3N+(-DWWWV_9!CHQB,F\8%)UZJ1.E6+\51P(D0XPM&+E'J3L$M\7 MY8$T6'BL(RUX=HPW6,(CW_NBXP17.JBI_4D0S/T&T]8U#`D?P\%V.UJ2C)7' MAK32D'!28PGYBP/MQ(6M*6')G6=IDQ>]BWC>%N# M[G6%6S_TY$RPG?2`SC>)WFJ._=@'IO6RHJ!`E=WA9+=RGU%2+%Q_ MO=3U^4')2?3^.^+`3G]R6OU-6P+%AC:I!FP9>U70ETJ9(-B_B2YT`_[E3D5V M^%C+_]CI+T+W!PG=GH$@I2NI/C(B2B@HT'B3F6(J60T)P*_34+4SH"#X7:\G M6LG#R@WGWBP*0@1P9TN$+*BB=)WR*"1K?AH0.E,9DLF9!-8S">RND;'A.1;6 M<^QDZJ%I,/^-]T_/'+!>1,#?D0F`3%T!6"_!XY7/S\&P7K(/O0@%<1C]DL0W MK="=S;#$ZR5G)P>F!8HM.JQF#R5`K%H:PL:XWU+HI8IY5D$Z%-`"MN';.IHL M_3?8.N49LC$0:,TG9#J$I'<@LR$DNP.9#R'Y'4@TA!1W((LKQ(="7*L!FZI? MC<=54&"K"N&55A=J8R!Z)+4AM0V9;Q0'@`>CJ&YUO4_'8]$*;(FVFKX'I,X"`+/`#O&).7!WBQ?[UPK_\'``#__P,`4$L#!!0` M!@`(````(0"=@P'XC`(``&8&```9````>&PO=V]R:W-H965TV!G`$&5J;T]JY+F/,BAH4MY'NH,4OI3:*.UR: MBMG.`"_Z3:IA:1S/F>*RI8$A,^=PZ+*4`FZTV"EH72`QT'"'^=M:=O;(IL0Y M=(J;^UUW(;3JD&(K&^F>>E)*E,CNJE8;OFW0]V,RY>+(W2]>T2LIC+:Z=!'2 ML9#H:\]+MF3(M%X5$AWXLA,#94XW27:]H&R]ZNOS6\+>GOPFMM;[ST867V4+ M6&QLDV_`5NM[#[TK?`@WLU>[;_L&?#>D@)+O&O=#[[^`K&J'W9ZA(>\K*YYN MP`HL*-)$ZW=\,=7Z^,WA,<&92T'?<#F&1( M_+8?-.*Q&P_.*8XTYFJQ!P_K9#Y9L0NY3,OY M"Z4#Z-1DLEP,H)$ZCM'YZA[\?N[39!$A_OU1\?O&$H<( M-N[$\N7;;A9CU?>E/'@L%2(G+0KG.@R^`E/!)V@:2X3>^3.;XB@/T>$ZV:1^ MVE[&I]FFOV;8\`&/><IM3LN4)@-_Q#KOP```/__`P!02P,$%``&``@````A`%9<#`>6 M!```U1(``!@```!X;"]W;W)K/,?W]5!6)W`PKW8K2L_JJ^ MJNJOH3>?W[/4>&.E2'B^-9V9;1HLCWBM^>\_SY]6IB&J,(_#E.=L:WXP M87[>_?G'YLS+5W%DK#(`(1=;\UA5Q=JR1'1D62AFO&`Y_+/G9196\+,\6*(H M61C3HBRU7-M>6EF8Y&:-L"['8/#]/HG8$X].&%0#QDJ1)]4&@II%%ZV^'G)?A2PJ\WYUY&%VPZ4<'/DNBD@N^ MKV8`9]6)=CD'5F`!TFX3)\``RVZ4;+\U'YSUH^>;UFY#!?J5L+.0OAOBR,]? MRR3^.\D95!OZA!UXX?P57;_%:(+%5F?U,W7@1VG$;!^>TNHG/__%DL.Q@G8O M@!$26\EB039L2I"&G MU%^>2V1TQLA8+DSEL3;(8:Z)*&&\*6'0>6O.Y>1]KTV_CES[4.>40+!*YH,E M=I?8XH'.7ZCA.F@+P%XKYL^UH(V3S-?Q%ZV3D@A$E!.Y75ATINAM96N+Y]$\ MR0U;3L%%9Q6WL:C%7?93\-506,NY'HI5:F$8Y%%(K>X#4)/7`/:R3:DS= MH7!P2TND;D\;>6M$&DU0YF+E#!#11('4R9Z/F8NN0N!IACS5$@[HKS-)-LA; MX]D(1\]<],B$L_#&D.H*A=.G%*NK^"L2ZTR2"O+62#5BT4-*4POJU'(UN[^! MN\KA-":U4=>S1>'D:M)Q>R#)6^5T,74YN9HVC)\^6JF%:75"DO35P%GHXFX? MOO-TDKR%N+UFA%_7(I:X6G:<5X3EW9("P(#.VZ/J0'`T>O][]E M@U9J_/ID(Q@X(.'20&GC[4U&WEJT6DFD5\?Z$J%^4\]8>6!?6)H*(^(GO"!P MX16[M;:7%P]T%.GV^?JAOM2PVG_@4J$(#^Q[6!Z27!@IVP.F35NIK*\EZA\5 M+R!/N%K@%5PGT-,VV\;%CSWEU^8%'1GLAM?L/``#__P,`4$L#!!0` M!@`(````(0"JC\?9.`,``$T*```9````>&PO=V]R:W-H965TW/J> MTK3.:"EJEOBO3/EWJX\?EGLAGU3!F/8`H5:)7VC=Q$&@TH)55(U$PVIXDPM9 M40V/T*KT&KJ+R:=?L,W#"7S% M4RF4R/4(X`)[T%/-BV`1`-)JF7%0@&GW),L3?TWB>S+W@]72).@/9WO5^^^I M0NP_2YY]XS6#;$.=L`(;(9[0]6N&)@@.3J(?305^2"]C.=V5^J?8?V%\6V@H M]Q04H;`X>WU@*H6,`LPHFB)2*DHX`/QZ%ABG]R!'2]]*=TJ+Z:YV(.93%,D=[H)JNEE+L/:@W>*N&8O>0&("'SP*' M0-\U.B<^]"/0*$C@\RHBDV7P#*+3UN?>^L!OYT,ZCP!(.V9@NYX9G9$9LX)' MN;>&/DTT3#-V:3#ID[-)/PC%(/#KB8C(M,.W)[`^IE".+HBZ7A'':1=SX[.AKU+:VNQ/=.OULS%-;T;1J/YQ51BH,O16J"" M/Y03D?GHHAJ,26?6)EJ;Q4['`Q1[#S.FOWT;`V*3FV3^*U_9@( MNC>PS!NZ9=^IW/):>27+`3,TQ9?V<\`^:-%`]\!*%QK6N/E;P&<;@[T78E9S M(?3A`;HAZ#X$5_\```#__P,`4$L#!!0`!@`(````(0`.&PO=V]R:W-H965TVSVX> MOOXX'D;?B[HIJ]/"L,:F,2I.>;4M3R\+X\]OP9>Y,6K:[+3-#M6I6!@_B\;X M^OCK+P_O5?W:[(NB'8'"J5D8^[8]>Y-)D^^+8]:,JW-Q@E]V57W,6OA:OTR: M)C8INE.CEEY,KB"5]^B4>UV95[X5?YV+$XM%ZF+0];"^)M]>6Y0 M[9C?(G?,ZM>W\Y>\.IY!XKD\E.W/3M08'7,O?CE5=?9\@.O^84VS'+6[+T3^ M6.9UU52[=@QR$SY0>LWWD_L)*#T^;$NX`F;[J"YV"^/)\E+KSI@\/G0&_546 M[\W@\ZC95^]A76[3\E2`VW"?V!UXKJI7%AIO&8+D"SW:%KOL[=#^ M4;U'1?FR;^%VW\$5L0OSMC_]HLG!49`9V]TP\NH``X"_HV/)2@,; M=RI7,AV1"4>9:4U-EYW]2MY4Y,$1AWTU'M2ZRX2CB(<'X(J^*^+A^*EQS40> M''%CI\:G@7UQ6\W*S1QOZ^>R>H+!#Z(C.O6 M65@-[,,MHYOPDNPJW,_:[/&AKMY',&W`&9MSQB8ARV-B6-OQ M#A(=;'20#H!B%:/SS(@1J60::K!JWZ MH+Z@"%D3$A`2$A(1$A.2$+(A)!T2Q3)XWWS",A;=6887NN0$_$&R(L0G9$U( M0$A(2$1(3$A"R(:0=$@4,^"=]@DS6+1J!B=3>(H'Q3+3BJ4/0L?\G@S3YFK: MN@_"M("0L"<#(4M[XJ,^"(5B0I*>2*&9]F1L^AC428=$\16:C4_XRJ)57SD! M7_%4*T+\GL@AV^:]9F(?A$(!(6%/!D*6]K*-^B`4B@E)"-D0D@Z)8AET`XIE MO+48SZ!VVWV9ORXK*#&8E2Y,<0ZT$+RQ8"*JDYQ,'>FD(-);7Y!I'[,F)"!9 MH2#*;&K9JO]1']3;1H02$K,A)!UF*;9!OZG8=L$>:-S1'Q:M^L.),^5=F&G= MJ1>P$AFRV_!%!E^ZL+YK+8C;:FO2Q%@RY>&CZA;2W;%NQ;(F74REFEK]R+` M'"D3(I(R$2);R&C388R_2Y4$D539"(2#@56C6A@IYG0RJJ&L_QVN$J[7)%O/ M:$4ID#-'0_57"N8,RA+13#[%*'/_H:'BU%(FI#(1(J@@^9:SM/5*C%%2*T$D MA[01R/EH2"GF=#*JK:Q7_H2MO+6&;@^GGB5;L3&G^SK57KDK$:#4*<^Q96FL M,0I^^=B/`*-DF86(I%:$Z*I6C%%2*T$DM3:(KFJE&'6A;EF;/33X7[V"6'NM MES-'LIRU&7*%.;)V?(%L>?O6`DUAOKKFNSB_U`JI5G235BRB+*F54*W-35JI MHJ46-NO5_[OOO..'T\AZY\@>%H3>U:TL$21KRT?$6@_5(1$TM,?V1&9P,.;E)>(-1?,B.J0\YQ8`+#P=;0UR[2=^J M,TPM%_NS00/"-D+UIX.CKI_@=<&W5OG&T[&H7XI5<3@TH[QZ8]NF%IL[>]SO MZ3YU#9W&EVROEQ6$SFT/MAXN<,>#Q3;E3U/OB>\9ZT)3#Y::-&%YY\&JB_+0 M]6`]JM+W'<] M6)A1'7_FK2^-WY][T$S3^,#UH*4&/ND-A3WP<_92_);5+^6I&1V*'=QLLUL` MU'P7G7]I1:$]5RWL?G&PO=V]R:W-H965TWK99?_]L:N,#=7V%VXWIS&S30&V)#U5[ MVIA__$B^+4VC'XKV4-2X11OS"_7F]^W//ZVON'OKSP@-!BBT_<8\#\,EM*R^ M/*.FZ&?X@EIX<\1=4PSPL3M9_:5#Q8$.:FK+M6W?:HJJ-9E"V#VC@8_'JD0Q M+M\;U`Y,I$-U,<#\^W-UZ85:4SXCUQ3=V_OE6XF;"TB\5G4U?%%1TVC*,#^U MN"M>:_#]ZUY9*PN4MNM#!0Y(V(T.'3?F MBQ/FCF=:VS4-T)\5NO:3_XW^C*]I5QU^J5H$T88\D0R\8OQ&J/F!0##8TD8G M-`._=<8!'8OW>O@=7S-4G/*!_D-^P/GPY'SO(1^6 M"M6')^<'L^5B,?>7Q)T^,8N%F&8L+H9BN^[PU8!E`$'L+P595$ZX,@V1*J8P M)N^?<@=)(R(O1&5CPF0@+3T4W,?6]>VU]0%%4G).I',)B17CL9N)(W9U9"]AB0:DFI(IB'Y M%)&\0TMXWCLA4^]BQA%#P*A`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`J4XQ% M\Q`.?##`&E_`'?I2G-"O17>JVMZHT1&"9=-30<=NX>S#P!/UB@>X/=.'7 M$@1G('L&Y7/$>!`?R!>,O[]L_P8``/__`P!02P,$%``&``@````A`/_$T;7% M!P``>"(``!D```!X;"]W;W)K&ULK)I=;^(X%(;O M5]K_@'(_0`(4B$I'A7PG*ZU6L[O7*802%0A*TNG,O]_CV">.?5($H[TI[>/C M%^?-<7SL]/'KC]-Q\#TKJ[PXKPQS.#8&V7E;[/+SZ\KX^YOW96$,JCH][])C M<CI8C4'IZW.5P!6 M98R>'AN#_LFSCZKS^Z`Z%!]^F>^2_)R!VW"?V!UX*8HW%AKN&(+.(]+;:^[` MG^5@E^W3]V/]5_$19/GKH8;;/8,K8A=F[WXZ6;4%1T%F:,V8TK8XP@#@Y^"4 ML]0`1](?S>='OJL/*V/R,)S-QQ,3P@;!CSBJ=ADMI/6Z=-C67P,X'$!7UY=4O;P,6VFACG-;VN;Y9\E.60W M4WEF,BL#?(?\K6!F?G\RE\O'T7>835L1L^Z)42,V&,&F#I-U=.#JP-.!KX-` M!Z$.(AW$.D@Z8`3&M>Z!8?^'>TR&N8?7O48@[;0TJS`"NS@Z<'7@Z<#70:"# M4`>1#F(=)!V@6`7/*V+5!"9-_\,3\XKU6AGPR&KS"M8\U8HUC[&6K7T;0AQ" M7$(\0GQ"`D)"0B)"8D*2+E%L@DM5;+IN#XN&F0MJ'7],S1\>Q+SN!.GYU`:U M"46(2XA'B$](0$A(2$1(3$C2)8IEL`C=81F+;BS#"UUS,FD*A^:QLR'$(<0E MQ"/$)R0@)"0D(B0F).D2Q0Q8:^\P@T6K9G`"9G239:)FU*8-0@\=0EQ"/$)\ M0@)"0D(B0F)"DBY1_(&20O&'K7<3S>`1=6<6,1G5)4ZT+)II6=0&M5E$B$N( M1XA/2$!(2$A$2$Q(TB6*<:QB5IR[GD9-N.J00&`17OV&(H%D*E1)>\YKM=L`_)8T(X0PO115G.)J"&YV5;*ZG41N%ECJL$`5+M8X+M:,KH["C1Y$O46<0IE;[ M!S(*M4**(HFDUEQ;F6,9A%*)@E23635ZA\F\>`4]U%Z;'(%7B#84.1+)D5MC M;6?MRBC4\BCR)>IHF=IN(9!1J!52%%$44Y0H2/6/%;!=__BYPW`.O#[DV[=U M`:D'3[B>U6$"YPOBU(&7P8JM'$VETQMV1,>S$J_(031MS7W1&6*[5(D02958(!P,G%2K3_,$^S0RJJ&L M>+[#4%YK*X9R-%F@H60-$GVZ^2G0O#.UA%AE$PS'Y'4"A!=U0HQ2FI%B*16C.BJ5H)1-&\M?8?R2VM3HZ)N7`22 MZ:P]*#?81^:.(Y`E%PE7H*ERH$=\IUH^U0INT@JI5D2UXINT$D5+26Q(-S6Q M?\UWNBUJA%<&O!J4$U/OI-^E9<%?Q/+75:>L?,TVV?%8#;;%.WO):K'1MYB_`5XO;3AY M@*)+Y^;89COOOA9X:0S;S+X6"UJ:LDM3@_?,SWU\S:3ZE$"H-WYBPXL`^LW/ M4]#O[3"UX1B<=EC/;#@1[N$/-IR$]O"Y#<=\/7QAPXD7Y;`9L]E6JZ]E"BU] M8X)2&5KZ1@4[-)O5PU0--FHVJX%I"VS%P-N^EC6TK'M;-M#"BG^J!AM5FVU# M^UJFT-)W/;!G@)8^-=B]VFRO`&JC-E/@O?\E?4G;<[&]* M_I\#_(]:3)>7HH8W_LW,.&1P/#IFI]+[HJCQ#_8%[?^,//T'``#__P,` M4$L#!!0`!@`(````(0![@4N,?1```,Q>```9````>&PO=V]R:W-H965T$KGWYG+[XW#,&8[(OV29G__VV_/3Q:_;PW&W?[F] M+#Y=7UYL7^[V][N7;[>7__Y9_[2\O#B>-B_WFZ?]R_;V\O?M\?)O7_[ZE\\_ M]H=?CH_;[>F"/+P<;R\?3Z?7U=75\>YQ^[PY?MJ_;E^HY6%_>-ZGZZ*J^OYU?/F]W+9>=A=?B(C_W#P^YNV^SOOC]O7TZ=D\/V:7.B M\1\?=Z_'Z.WY[B/NGC>'7[Z__G2W?WXE%U]W3[O3[ZW3RXOGNY7[]K(_;+X^ M4=R_%=/-7?3=_@/??G<)N@_N^V/X^#_+XZ/^Q_FL+O_^^YE2]FF>?(S\'6__\6; MNGN/J/,5]-;M#/SS<'&_?=A\?SK]:__#;G??'D\TW3.*R`>VNO^]V1[O**/D MYE,Y\Y[N]D\T`/KOQ?/.EP9E9/-;^_?'[O[T>'LYF7^:+:XG!9E??-T>3WKG M75Y>W'T_GO;/_^V,BN"J#?:/?//2CO^,&N`@=Z>^'!DC#;P=(?T<-\";TH[\?&N!5-XUM532; MT^;+Y\/^QP5=:C11Q]>-OW"+%3F+Y=#EIB^0/ZH/*@SO9.V]W%Y2$#3U1RKJ M7[^4T^+SU:]4B'?!ID(;85%'"U]UWFTC@9)`2V`DL!*X`;BB)/29H*+\$S+A MO?A,Q!BJ"`:IX8FIHT7LTDB@)-`2&`FL!&X`6-AT#0[#SJ\#<9Z]\>TE77W] M/!?%E(=3=3;E39^"&D@#1`'10`P0"\0-"8N3!CV,\\Q"]U[H4J%/Z3-03DN1 M@O`&_,`^U(NU#;_'?[PF.D7`JJU#F6KS>^?' M/7<[K:BVN:RVL!\SZ5T*J[KHK6(R&T0*D49D$%E$CB&>7R$4SJ\V%!%%AT2U MR1N19)6RT7>,2*&51F00642.(9:-7OM+KVUB"^@]G)J55@=K1)J`BKITNN7YJ(4-U\J6<59UNC+)*NA+W'7 M89-5].68+YX%H5=\S1>S]K;S]+B[^Z7:>Y!]YC2AATO=(Z<294Q$*1,UHB:@ M$J$Q'FG,%#'E`$-8P?4 M1*MYKP84(AU1\F4B2ATM(A=1VY''-TJTE"A:(F(E/9&W?M$J/7]K(N(=Q=V- MBE8W;5$L"[%EZ-B>')N(WG1LHU7G>'$C+D(7VUO'/&6CU)A_H"W7B@[YU2BM M`A-Y(Q,ZTM4:R[2)J/TFH;W:5$1EN&C$)J)C>_)B(DI>;$2=EVD!R0@C;KWP M9&1$V?@E`P59&1"?1"G_HU6:_28@JOB8-A71M,M1.1,J5Z,;$_LD-S:BX.9Z M(6K1,3<\2Q3&4%*=M[!Z)V+7Z1!54@RV]GL+6;&R"8@F<5!O<*4%JWF;I4FY M@%("SR9^V)N>;;2*GF]$J;MHD"DOH45EXG[>O_[1CD0UW6])O4:-::IHE_%I MRBR(0O>]L^#WXBZEMIR*S%7TS-U_&'^0,Q%56">K.,H&D4*D$1E$%I%CB!7L M1.B]L]5OZX@7;4!<_4[$9E\GJSX;B!0BC<@@LH@<0SP;H]2A#TQC5&2;(*2+"`*.093(VH0*40: MD4%D$3F&>'Q>3`R>+YP_VYTJ&3[4F'1(S+:X0NID%1/4(%*(-"*#R")R#/%L M"`'US@J`2FG2(3;;@!JT4H@T(H/((G(,\?B\:AC,]COQ=1J#36F'Q)2*^]QZ MTENE*06DT$HC,H@L(L<0#UF(EG="1G$RZ1";4D`-6BE$&I%!9!$YAGA\0B*= M?P'WZBE.6C4)4HGVT*15I_)V,EG%C@TBA4@C,H@L(L<0R\942*6W9[NUYGHH M()(?,9@:48-((=*(#"*+R#'$XQ/BQ\_V&=\93U$5!<2O;/EZ4IVL8GH:1`J1 M1F00642.(9Z+47)MBD_"`F)S'517FOX&K10BC<@@LH@<0SR^C!";+/T+AV._ MT9NB$@M(3+>X%ZR359KN7L)%I-!*(S*(+"+'$$_'*"4V1246$.K^J=!`[RP: MO=!)BV(Y%5M@U?J4=YE3^<@D6<5D-H@4(HW((+*('$,\OT+[^*7EO-<%IJB+ M`A+E)F^ZDU5*!Z@GA58:D4%D$3F&>#J\8/FP5)IV\F8HE0(:Z@9$#2*%2",R MB"PBQQ"/3^@B/]UGKBZHF::]0$K72"&_]:Z359KNOF-$"JTT(H/((G(,\70( M&?7.&H!::=HA7%UFHR1):RV?*LR$Y*J"E;^)'P@S^50A6<5D-H@4(HW((+*( M'$,LOUZD?/QR:JVY,`M(K"#RT4&R2B%W6F=P'2JTTH@,(HO(,<1#'J5/9JA/ M`LJ4E%`&;Q?KK-_]4[&4,_'$N0I6HJ3DS7JR2OD-@F#PH`JM-"*#R")R#/'\ M"D%P]IW/#+5"0*+:Q"9?)ZN4CID]8:U(FX:ZR"%=]*9L*J3E9] M?A$I1!J10601.898?N="G9POAEM/7+D$),I-W@HFJY0.5"YHI1$91!:18XBG M8Y1RF:-R"2A3;J.4RSRK7$3FJF`ERDW>6R:KE%]4+FBE$1E$%I%CB.=7*)>W M]=L\BAY,D=Y$E"FI(0P>">9_>X_ M%,.B6*IY9R5*2MY?):N4W[YC1`JM-"*#R")R#/'\"D%PMAB>HU8(2%2;O/5* M5C'T!I%"I!$91!:18XAG0\B'=VH")<(<=OH:48-((=*(#"*+R#'$XQ-ZX/_8 MKU`KS#LDIEO>"2:K--U]QX@46FE$!I%%Y!ABZ5B,$C&M-=^B`\+%92&$P=N% MU%J#/!++@43AUD%E*FU4:I@T:N" MX48FMJ@J6/%:F\M;G6051]D@4H@T(H/((G(,\?P*H7#V1N9_GRW>_`I(5)N\ M,4E6*1N=+U9M@#1V-(@L(L<0S\8H<;/HQ4T<>150IMJ$8'AG9>M5P;#:A`2H M%IV5J#:AU^MD%4?9(%*(-"*#R")R#/'\"J%P_D:Z0!$1D"@WH37K9)72`>I# MH95&9!!91(XAG@ZA*]XI"M0."Y``-:(&D4*D$1E$%I%CB,6W%$+A_.EN/7$1 M$9"8;K'[U\FJGVY$"I%&9!!91(XAGHY1ZF;9/8X8?L<9T&!=K!$UB!0BC<@@ MLH@<0SP^H5O>+NTTH@,(HO(,<3SFY$G9TCA M)8J3@%BM%7.H-9`=3>H8TZ,0:40&D47D&.*Y&"5.EBA.`F++1V'Q"(OG=8GESS@M8RUX^Q2FJ`A+3+2Z0.EG%C@TBA4@C,H@L(L<0 M3X?02N^LIJB'EB!K:D0-(H5((S*(+"+'$(]/B!\_W>=OOT=+RXVW_WYV;2S'SYW.-PJ.=RNEIWIWJ*%M()*[\G M4Z*@948M[<="RYQ:VE]B0\N"6A99;TMJ:7^_"GUNJ*4]K4^VW%S36:3M^\+0 MXD\I;1]0B9;U@B*E._-,/-3B'X[D6BA2>E"`+>O%8K4FV88M=$-.?;*1+BA2 MN@_,]:%(Z0XJT[*D2.EF(M="D9(,S[64U-*J-)F#^9QRD/5&+?Z;CHRW.<5# M3_US+10//2_/M5`\].@86]:+@D:0SQO%0X]#L4^UH'CHX2"VK.?7JS5][XDM M]'TXC2`?*7T.?0V+?=;S"7G+S39]W4E]LJ.>4^W0-W`9;S/R1J\`8`N]]K7R MKUCE6L@;O6Z4:Z%*I!=U]\BUT,S1FP_8LI[.5FMZK1); MZ.WJE7^3.=="(Z"7>G,M-`)Z'3;70B.@-T.Q93VC.:6W\+"%WL"D46?G=$9S M2K(ATV="GT,_Y,FU4(W2CUHR+5/Z'/HY2*Z%/H=^')%KH1JEGQ7D6FBVZ0U[ M;%F7-ZMUMUF+ZY1^+[WROTW&/M6$QM;]>$+T64]*FKEL[5"+_^UISAN-C7Z' MF6NA2J1?,.9:J`[HUWRY%JH#^AUU_( M&?LU;?JY2JFHO-O\7O6!TUGBKYMOVW]L#M]V+\>+I^T#::;K]NR?0W<:>?>/ M4SAQX>O^1*>(DP*GLZGIU/@M'0M][5^-?-CO3_$?E*2K_ASZ+_\3````__\# M`%!+`P04``8`"````"$`M%4L=T`)```"+0``&0```'AL+W=O,\1) MJ`&=[M'>L@WV?ZA;71Z M[5:Z7V?/F_WK0_M??UI?;MNM_+C:/Z^VV3Y]:/]*\_8?C__\Q_UG=OB>OZ7I ML441]OE#^^UX?!]WN_GZ+=VM\D[VGN[IRDMVV*V.]-_#:S=_/Z2KY\)IM^V: MO=ZHNUMM]NTRPOAP28SLY66S3J?9^F.7[H]ED$.Z71VI_?G;YCWG:+OU)>%V MJ\/WC_4`_$L+<.Z;E[?CB3WD'HD.C9^_C5-\S6-*(7IF$,1:9UMJ0'T;VNW$:E!([+Z6?Q^ M;IZ/;P]M\[9S8_3N^C<4Y5N:'ZV-"-ENK3_R8[;[3VE4]*@.8E9!^M3Z\GI_ MU!G>]/H&W?.8B/XI:M)I^N=5FQ[P=&L/17]QQ5'G2[W5-O:D< MZ9=O.;SLEC35BL;2[W6WO*L3B!#9I!YH9R<0H;,H?-3LUNN#\5R,UT=5X_WA^RS16LXY4/^OA)/!&,L MHO%"4XI4+SV_6WEHR1%1OHHP#VWJ""TJ.2V7/QY-A#B(=Q#I(&J!+>M6B MT4S\?X@FP@C1>+@G#!HJ:@JQ!;M,=3#3@:4#6P=S'3@Z<'6PT(&G`U\'2QT$ M.@AU$.D@UD'2`(I"M.(I"IU^;O/L$=8/;5KR&K-GJ([\I+0Q[VJUGH!,@J4 M1GUZ,#>,;E2CI]JHGCU`9D`L(#:0.1`'B`MD`<0#X@-9`@F`A$`B(#&0I$D4 MP>B)?H5@PKH0C(=Y4I)^N;L5#Y8G(%,@,R`6$!O('(@#Q`6R`.(!\8$L@01` M0B`1D!A(TB2*%+1!4J00^P5SV"'[*W<,(I"J4DE(I>8R!!(`"8%$0&(@29,HPM'V5!'N_!-)6*OJE(16.![X M)R!3(#,@%A`;R!R(`\0%L@#B`?&!+($$0$(@$9`82-(DBA2T3;Y""F&M2E$2 M;:+<:1.E-F*]ID!F0"P@-I`Y$`>("V0!Q`/B`UD""8"$0"(@,9"D211UZ!!T MA3K"6E6G),V)`F0*9`;$`F(#F0-Q@+A`%D`\(#Z0)9``2`@D`A(#29I$D4)4 M/*[0HC!7Q:B0.E?Z/6VN2*MZLB":(;(0V8CFB!Q$+J(%(@^1CVB)*$`4(HH0 MQ8@2!:F*B2-KLYYP_C$CZE+:]*E0<[.&:(IHALA"9".:(W(0N8@6B#Q$/J(E MH@!1B"A"%"-*%*3*(\ZK5\A3'F_I[,/S8B*J@$*QLNA<[*4132MDTB-0GH?Z M6KEG)JTXO(7(1C1'Y"!R$2TJU&B])ZW.--675MS4):(`48@H0A0C2BI4-E45 M41QLFR*6-;N.J.P?WS;K[Y.,!IUFUHFYUZ?:7%6Q*X_'BK85:FH+:"I.PI0! M)CU`&]J:ZI(ZDU8\8!8B&]$(O#C^H[VA4: MT(FD$4LK:\W1T9'AFXY:Q<655MR(!<>2^>NQ%76UT0BM0[ZTXEA+CB4[%%3H M?(="=(PXO#JJ6H=B:<6-2#A6T2%U#1`']&:>G)CK],JLGNSE>5Y)B`JI2[1> MLJ(4+=)&%HFG%>K3E7I(#5S;2\?!3?$RX(O1O]4V71:&MBM4.1G#VSMM69FC MDW-1>URV&I7MZ75ZVH%I@:$]=CK;59^MJM"W/2V]EA@YJ!#W=#08:L0"CR5$B=]7J13;S+%`^+YJRO'7EUFK&5?"5A,9*. M-B-I-6$ M4>&H*B;*#$W%_MY>K2Q6*$*6B.:97(7-OK:(/(E7R_K4*]%`=G)660WH'%ZO MZ*:A;9,LC&5?Y#A'1X<=92-<1F<;L%9/(^B5?\^LPN$3W/Y9HY;"5#.\RDHX+=/382CKZC*3C$AT#M`K1*F(K&3YF),,GBJ,BCYAYBCQ_ M:V874535*J3.[(&V>WIB*_ETF59HV%P2<&/&5L9O-V88VE:=3FW,T,EAI[/M M<=G*_.W&#$-[['0VM,]656C-_N\M4U?*&%Z16'J4'[#6O[G6"7K MM^Q(WYX6>?M&WQJG]&:>/H!KMUZR[,C_H5MWZZ^7'_\+``#__P,`4$L#!!0` M!@`(````(0"%NQNK,P$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0! M**```0`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````"YO^<2*ES4!E3PX$)P[?8G*W!ILTY$:[?7NSKJL3?1+R$LZYOYQ[4LUW MNHT^P:'J3$VR)"41&-%)9;8U>5XMXAL2H>=&\K8S4),]()FSRXM*V%)T#AY= M9\%Y!1@%DL%2V)HTWMN24A0-:(Y)<)@@;CJGN0]7MZ66BW>^!9JGZ375X+GD MGM,#,+83D8Q(*2:D_7#M`)""0@L:C$>:)1G]]GIP&O\<&)0SIU9^;\-.8]QS MMA1'<7+O4$W&ON^3OAABA/P972\?GH958V4.70D@[-!/R]$O0Y4;!?)VSW9O MKHT0FXK^UBHIAG2E<,`]R"B\5Q[3G927XNY^M2`L3[-9G,[BK%CE:1G.5?Y: MT9-KG&<34(\!_DT\`=B0^^>?LR\```#__P,`4$L#!!0`!@`(````(0`OCE9Z MF@(``/P'```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!```````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````)Q5WT_;,!!^G[3_(,1B_I7EDA1P)P3BU:#3H>: MC8<."0D.,:;*%8"/^4)8YX-\T:AL^D]+4VGD#I%9H M%++I<^2S/*<>I*;DB3/R=>5GY9[&O02>B@WX8K,01W>&R^,D:MO&3 M-9@W]R9^)`TJ[@N-FM=D&-G9%VS.O3;#G>&O6K\U^`TXH0KD*6WL6M#:W/=I M?UP'6H7[@PR7V4_-8(-]CIHN+6\VQ]CL3`ZR.5BS_RS6!Z5?\:E*S0TMH-W/ M^/%2T/14-UZ?N>D7E0E%C8P#2,H8E^6R$\#]]MU=P0ES?'B4F$R\"&! MV6XWVKOD+\%%5MW`8B"TMIX0Q0?*3H:R$O?F46IVK6-]HJR5W"*!J.6$^W$\ M8.X"L-JK:N`\3:!B/P$J_1*MQO^*_0(``/__`P!02P$"+0`4``8`"````"$` MOQ`$``!H#@``&``` M``````````````!/#0``>&PO=V]R:W-H965T&UL4$L!`BT` M%``&``@````A`/;M\ET4`P``\@D``!D`````````````````E1$``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``Z^ M,:2E`@``U`<``!D`````````````````>1P``'AL+W=O+`(``"-*@``&0`````````` M``````!5'P``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!&.`XF_`@``5`<``!D` M````````````````U"L``'AL+W=O&PO M=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0!CXC_AJP0``-P1```8 M`````````````````(\U``!X;"]W;W)K&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A``.D#9-640`` MKP0!`!0`````````````````?CT``'AL+W-H87)E9%-T&UL4$L! M`BT`%``&``@````A`'XG,;JM"P``2&@```T`````````````````!H\``'AL M+W-T>6QEF@``>&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`$L&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.\OZBLC M$0``X68``!@`````````````````1[$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,*&?VF=`P``M0L``!@````````` M````````A&UL4$L!`BT`%``&``@````A`%9<#`>6!```U1(``!@` M````````````````&]$``'AL+W=O&UL4$L!`BT`%``&``@````A``YP],UE!@`` MA!D``!D`````````````````5MD``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'N!2XQ]$```S%X``!D````````` M````````(>T``'AL+W=O&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`$-6$<66````J@```!`````````````` M````A@T!`'AL+V-A;&-#:&%I;BYX;6Q02P4&`````"0`)`"E"0``2@X!```` ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9

Earnings (Loss) Per Share (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Earnings Loss Per Share [Line Items]

Basic EPS - Income (Loss) $ (1,380) $ (804)

Basic EPS - Shares (in shares) 15,892 16,469

Basic EPS - EPS (in dollars per share) $ (0.09)us-gaap_EarningsPerShareBasic $ (0.05)us-gaap_EarningsPerShareBasic

Dilutives:

Options/Warrants - Loss 0 0

Options/Warrants - Shares (in shares) 0 0

Options/Warrants - EPS (in dollars per share) $ 0 $ 0

Diluted EPS - Income (Loss) $ (1,380) $ (804)

Diluted EPS - Shares (in shares) 15,892 16,469

Diluted EPS - EPS (in dollars per share) $ (0.09)us-gaap_EarningsPerShareDiluted $ (0.05)us-gaap_EarningsPerShareDiluted

X

- Definition

The amount of diluted options earnings per share during the period.

+ References

No definition available.

+ Details

Name: prph_DilutiveSecuritiesOptionsEarningsPerShare

Namespace Prefix: prph_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the amount of loss attributable to dilutive warrants and options

+ References

No definition available.

+ Details

Name: prph_DilutiveSecuritiesOptionsEarningsPerShareValue

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents the number of shares attributable to dilutive warrants

+ References

No definition available.

+ Details

Name: prph_DilutiveSecuritiesOptionsEarningsShare

Namespace Prefix: prph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: prph_EarningsLossPerShareLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

ZIP 15 0001144204-15-030158-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-030158-xbrl.zip M4$L#!!0````(``V"K4;U.6KF9)X``.S/!0`1`!P`<')P:"TR,#$U,#,S,2YX M;6Q55`D``QFQ4U49L5-5=7@+``$$)0X```0Y`0``[%U[<^+&EO]_J_8[]'+O M)),JP`B,Q\8S.+$KVN337*WMER-U$!GA$2Z)=OLUG[W/:>[)20L&..` M>5A3F0E(_3KG_,ZK)4Y__,?CP"7W3$CN>Y\*5KE2(,RS?8=[O4^%7]JGI?T" M^CFG%3+EKGWV!$N;^"_!);MR<90#/N?"OT@ V=G#(H?"'?>CMTHX:=`>7 M4*G5K(+IX7+O:ZH'CE;V10]:5FH[>+L#_:/F>-?A<8=DX[T=?3-N^F3HAYIJ M:QT<'.RHNW%3R;,:PJ#6SF\7Y[=VGPUHB7LRH)Z=6@N?L?;)]ESZNU7KPZP> MND74P6%#P6R4[]0^!SM4V,)WV4Z7VD&)/0Y=ZM'`%Z-3^!X-9/NA%XA1FFV2 MV>6>?[]C;J)D:J6*51K+Q@Z%`/!-ZV?N8L?==$>'\>P^<".C.7NT^]GM\4Y& M!^[=,QED=]'W,JCQ*+=E=A]U"[M8Z2Z2V]D=X$96\V`HIK2'.QD=0EGJ43J, M^W2I["C)FAL9I#^Z,_#SVWD"U&$@9L`&[A9`A0GYB(K0D`KB-ZQ+E&(T@M&0 M?2I(/ABZB%]UK2]8]U,!5;P4:7'Y43H%L@,#:4MQ['L!>PS(+;,#,$#*2L`4 MVD[8YB8'.%]7K#OX#\:IMGVK>E?3G_62XA[,"W@P,M?BJ]S!ZUW.!%'+9BDR M(Y8?G_U<^%R!/_M[^]4/^Q]W)CM'4^U,S)5:P9`)[CN3*P"]%@'86_89%XT" MJEC1..-[T5`)7#`_-V#,9N]OV*S7#V-U-9.SN M2Q@+G6K+9VR,V+?$V*4CMIY`;'T3&5M_"6/K2T-L4UYY&V<"=-049.AR=&?1 MG-D4J"4X4U\N9^IW5FUS.5,O6;4E<`9L?C)BJ58V.&)10C8X@N^T/J/C:?.3RE9D_J;ZL!QP( MXOG,#0<6`AD_M[FAA3@1ISX53`[9^#9E4_#1T]S!39BF;8N0.4WGGHF`2^[UFIYS M%?29:+JN_X`[CW(SX874-9Y/GFK^+8Z]'LQ>+TP?X^78]X?X)(#?LS.EDO`A M1THV4J;S:@LQ,HZKA%ZMQR&PGNEGV>ZQ/QCZ'@RSP>"9GTR-N>X<'Q*+:B=Q-"$J[_JN+RGLMH-!LPW:(I2\ZE\V4(CDX## M%]_I"C:Z94'@,EQ_LR>8^O"F4:':?(LW6X:,2CVQ95R_J^YK-]1^\-M]/Y34 M:T_0UCZ.??85?=8,(>G-OIN^[X(VDP,3E@G:(^&;#-A$N_999.C M$#(';U:W=UQ_R=YQO53='T^^L`T^*_F^$WS0GY,8:S\P]Y[E"'N*L-F<61&^ MJB7K1:]]6:7J*SZ;R&W8)MNP-7M(,05CD'4,?.\V\.VO*20%,"UR0S,USDW4 MOLG=21@`2*0)-1W&SUF/NBW%*=7@C5O&6R6Y;,3@CWA@MF!+R02#5;E&_*0EOM6"GQ-I-6+O#G*LA M[MB]*8L]@_(\YLMXB);'?)L<\RWKF5AES_RT(_4CMAPLFP:6R:WNO<1O7E;^ M>[Z:<5V5A.NJW%U+?DU%_`SIZ9;/YL%G^C[)!+$K`D8%G@]EZ/,SQALI&8F#* M:178R#.I=_,L MCDX'UTO6EV!Q="DEB#RY>D4-H(^Y!JR%!B0%D6O`#`VXH'8?W)\8)06;6_ZY M<3^#C[F]WS*TYU9^I6C/;?LST8Y9<1@P<>MW@PZ>NI-)_-O<#3>EV*>LVWID M=HC5QJ^Z76XSD013FP3$T?9T=FS9,Y@4#M2O_MO, M[GN^Z_=&YT"U)UGZ-W4.ZW*(#MDY,,:9R$+DT>B"_N&+8Y?*#;DE88-GR0WLMFKA<^_]/*FCD>X7/ MU\*_[E/)R#GMR"(Y\^RR7D76!$\7<,SP:`X7GR`W_H!Z17VA",9?\"XI M?-<+#LG$<,?GK>9-H^,'?3U2Z;1Y<7;^>V-BJ$-U[_;L7RT]U>%X&7,LX9!T M@0$ER?^'E:CS1RB#!O$@NXRN!X(%=A^O"9!1@5"7]R!HQ(:\.U+KQ^5#.]_K MX;=+'Q2P3KZC@^'AWZQZY9`D!$)`9"0E$NR\,^ZMO@(O%LF7=NNW=NGL\J2% M'*F4Z]P[).O!*_S&U0?-K;V*9@"/6?&:G$%6K!E?S#D_9'S0#XE/^EDAIU:+ MH3./7.)K/)C'52N5W2)Y0)_[Y'C,C'<+))+ MZMDC\A/UV/@::F;,;M!,&$M=.V$25J`#`O(^\'L,CWDC\(_1\?UJM1()2L:7 MK,,?@")!N/='Z-FXIT`$^ZY1:K7^U M%"3"820YPQ[XW#"\22C.AUT#@G"85B<('1R&IWV72;L?4RN)##N2_1D"C-P1 M@8R6B0!99QBFPK80_(*P7>AS MNX^T0`CHN_>HLJY+'"[Q38$409'B1JK=&:%6XP(G-#M#][FG^*&M:)E<)Q:` MUZ$S=#3F:A8=BNM#RM-L)W]'T*$X(]0ED4:^G\#']\7O)2+C>X/(,>J4M*ME M2P$:QU.('G#71>//4S"PJHIV1`&NSD%:!O0K`UB%@M#XUUO0RE/V@HYTP`9D M+G2]5J52A#POO68G9*GUPJ2,@J`-CSWH[[8/`#1-@7;^4;T%* ML4>-=CY42'7IEXE5W*_M%^N[517@*(L0-UZ$-R\BB,&$S7#C2+=O+.,''^X,P$F@>\G0W,AD MEK<]P'@[H=0BL98"V:^,]"GD`"PZZY9TU6&WX+W5&^0I!8-<3R3\(.8.R@]. MQF\:G8[VGWKO4JD\V!,)-+NN_R#)>^4G]8_OY`^-K9?@\K':/#_[>3?>[`MHQV5/=@]!,O%?S373>:_R[I`<7=VG'UMF7'U%&U>%CXKX3W3>+.;IJMZ\N&N1O%?6'6)#:05S. M'<,)S1IBJ]PA4HOV[^>M2&9I=H-#1GY[P&^A^#VI2(<$*&V?'3?/HZ%!9H$_ M,`U_-:O>K0"%#]P)^I\*UH=WJ4U6_&QT`S?VGZ!B)W`RZ%T;:IX2,P/AV;1L MD.QJ[PH(25]/[P;FX M-U/<;1_BZ#X,L>D+1.ZJ2.NU"!]PQW'9DO5X=>3]9;DNF'JU,Y--_G7SY.3L\DOI1J^B M'F42:\>2ZE.>?-@[6'LHY$C/D?[7D6Z9[;1UAD*.]!SI?QWI^V_;IJ]-#-M5 M?Y:U5P1!ZMZJQ/QLRC;3H"U0W/'_/.&>Q_>L_[X3?*C&'^, M>/%QYV5%QB=+E*M"YGW?!=*D/M/IT@_80JJ3U_+JY$]K>'7P`[*8U)*%R=M8 M,E!7^92DV>UBT3>O1Y+2B4J16A\.B9:40D0GQD92,3:<2[,KD6\1H9T4Q0EQ MDQMT;9+@48\3Y"]-XNM4+>W*@Z&&@:X-N5\DUL$!_(N%5X]\*ARL*W?"!:B) M+Z0ILLZ(V()191LHF0*7)P6.S;W,HL:Z"*SJA@51T\7(\5`=X"K3]@B+ M!)I"GN_Y#^2"CDBUAD4[*["\]QPN-<,>B)!8^^KJ@6(2W(`[/X4>,]>QP"K. M.;DJ51LPFA)[8A%4+$A8Q%JC*%4)3*"FFJCJ3=317*ZZD>)G@IW`[&$D[2[$ M.Z;2N3K81(_GA5&E7UMC1)\&@F41-9_AM+Z47#O"W M&)6RQMK$':8:,2I4*LB0+'N("!+UA4O-E/'1.3$'61F,JJ M*1J1&$\5O?44LT#Y*)%\P,'6N.J$'3!70:AHHU@)-RID34G`=/%+`4(`Z$$\ M!J-UX0I,%KI*?4V1Z-2A`U;]^6O.5B(L+HRU-;%4+"P>(#`8JL7CA3:L]&>` M<"B+22U(!!:2'/-1\"1&$A_%2,Q9C$6DU(B0@-3AVT+E6*U,RK&K M+'_*A&.M86#.;)>@]3?3)VC^Q;<0E0KYRM;A6#U^'Y4S35H6NEA:ZY.TPAIM M73=<`T1).R6BJ#)RRAIU%=:4PN.J51%FE1V7%[K>,[TH=A\I"+&I[(,%3E@\ M@UQMH:-*_P8N(JW^JB/8$@_X\`Z,C\<`8!S,:L99'!JK26:ACTZ*9@`>::QO M7K0$9`U^2ZK/Q+#?]DA1A5NL0JW]$1Y9F7$BP!0\ZK6A-HZ]4#R,3/$LI M,1Q*H;%P>,(>&#^5I1W*/FMS/]8(K)<-?@S7"G:^"XJNQ(.^@GO408<6F+,9 M?%UG^P'EV6&1L>KHLN2Z/KFE^Q:1.1(J!-K4\:$'B>1BDO.IC$<="'`2PGK1T%\-\6!!/'1O1$Y# ML!9G9T5R?DW>)X:+&J>',;E//)*M]KP"E@KOBYB]_('>&RY"F!)0,%MHJ2`" MUQLKYC`&?<((\'L9L4NQGG5>P'137=1%U54LS7WE-6I[>+13T)=C5P&F$$QO MH,]%!!,X,E74HP@E3M$\9(^QCB)Y7(2,3FXWEYD8%VN7U%7B-ZN,&*J.JHEY M/IPX>V92\&62@MU>`G:0$:CD?,J"%$IN(<@4XV,>6I$?5]N;4CG;)$YN6\4>75!SI35F$%<,<1],'DQ`/@L,9%:B2,#4"SI`Q-]AQZ M$EQPG"S@,ESI1V?NI!43):IB`W2M6;)%MZK.[X"E14G\MAO1MW.VQ$D8VP)C MA'ZB7H@'RUD1#/L"CYQ+[/E8^JP_A3',%GL]/$QO"><6[1WL%ZN5#]/,:3KJ M]<>8#E4&CIKP+<.%C<;"!J*@(QX[3SS(KB!&MT%AEG#Z5+F:ILF)2$Q6WJE-+3KG>X(2N8AZN@> M.X*MHZU9=4N/)+O?>;YT@$"1A!L$:!R2Z%__YE%5*(`W14JDA`E[+))`5596 M5MZ5Z?/(IXBL?NIWR=U#_DJ:['VI=[_:M1-W*/5NB9^[@C6LF9$@%QKI0!AV M7XG6O3]1ZW;I`)K">HLTZ)4*CP:J?"/:^"19,M$G.EU=7R7$C8."4"C8`2^C MY^^/Z/FFDCJWBJ\4Y;&Z.E.2WK`GZ^DR(CA)4R?'T/X:5=E2;5WW2L&D0:\J ML"BD$/2;PSOD(41K2;K/.[:#W0.'\@@!!$37\%]6=+`3:4\$%JE]RD%J#["[ M881Q*QS>=C"22$J0IF/NO)IGA^H\CIR8;$](N>O;C]19+0L\2F+77ELE1,!> ME"%.R:>3G(Z+L,%3Z$:E-;OA0X#N7'2PPI!@$G(<$#58-0>MP,YBHNN)3XYS M@E0LQ_8=U!99LQR'UE%F(W?9!364&:]<'SG$C7@U(6?,)N?])(0J&`Y7C=]) M+JXZ*\+7\!>,5%JWKV:E>.(*U,YGHXW-;ZG];@"4E@QWJ9\A4(1#.M@JC\-Q M(3+]7K&*/[ZUKN=5/2PWL].1C@UO8+:;7A]L0&1H MR"=%"_,.)XPW1<1BT'$K$VGH8PHJ*?*5@4P%,'ZG`;^"S MY#"@MMU)SXMDY-QL'UF<+1L+F&%;P()H!M6=$I@(`$$Y#G)O!47\@)]("9"M MNP+O=S#6A%]C?B/,MV?E0IJ:M7+`"K:XSR^@C\-:'X&,T`?0=1H%:@WHB6"7 M@&1[`^%X'<_AC=!`]S'[)A*@V',`&'<(-3KEPY`:G=SYCU8O?(!E1Q45WYN$ M@RQ,6\1!5"4MZ6+DU-JDEII:7J6IMD=/WM-(3 M<-?K(EC$O#"?'%=4R78U?\KDP+*/;][B5UJAUQE_6A*\`CJJJ&:9&B!F>@)] MP)))D_+U$*;PE=0[5VK0[^\='X\F!Q'?*<(XUG(TTB#&ZJ`W*?"16L/=K;W[ M4PMIPU&JPU*9QW3?])CF=P2M"I6--\!9E<-EK(62!I+/(LEZ,>5O:>MU@JV+ M?AK=E#DS\#.O<^YX_7 M[+]\O*:Q5XA!+1:OV=^F>(W52JPO-D@(14)-(B%2UU;+SAM'E?VC^0G&OK<] MGW0]Y3>LH.3)^W\J!L[833/!+R/=-_>4$F-2W20WYNMR%):!+&/M>(AKQ\>' MUA7G2[_A>S=:?M3I[LGAQ&LWY":])[<_'T\#=R.74`BYA%4C5*7O'N1Y6+U: M;1KJ;*+V)GL=OY:W0C+O73>RZ?(C0KF&U*[]O>98"3`A&V'/^EVS(0T]\5'B M_CE]D""WP@%;)O"%H'[R@JXF<-)]C*Z8+)NWF'N+>>"1QWX0-F7M;B:12@"$V%#82 M&>4/C\")V"##??I3%/>D[[/+79A<'A?F4N:_Q!>;/?K>SWU(9#4('^2=&+"J M'-^.8\9PS-MM7M;,SD9N^Y&XST%0P>!XJZMPAP>PI4B`2(26(%PMSCQYOTO1 M.RA\0J@0(1^>O-1&))6Y6J]JI=^D-P/X`-Y&<%ECQ+P_Y3Q5UB<2NJ0FNI\% MM!0K1U\G35*\NS/*H$:T[YP&-<`GW-!)21N2_!X=C.+>"]/8'VJ:=>@>>JHN M&^05-WU5!"^1X34\=!IP[`4>)R^)!-V\]"R=+'0/,7\=`/#;3O%F`F!..C$Q MRA05>8EV*Q*3D*".U7;9"*=3N%H;Z0`34?-B1.^2<;5CW,YPY"X8=QO24M=ZLC=+_X3-JRK[!`6["&+[K2NCF&C2I%-993V4E*VQ4G8J^@Q%<]P= MYXJ^;4Q&H1ZW/">-R#]KWEZ>-@0NBO/C&R-Z,JVB MJ">SDT'_5+@0G6DLXYR@H_?",)Z.E[HX63SGII#C8]Z!NMZ\VBNZ>\4$I[P. M/?#3>!VZ^_&42QE\EQG#!&G2"R.@5S8I$#_D24'9HG/KQW%F>=MVC:ZUZ:8' MDT<&#TD(#FV8QAR858?RQI^I)=@/8-G%BBKZMBM`),I\_[Q47"TI5/:/:I7# M9E$:RGO/4BA.P;I6&`SI!PM4BT\#I6;03722Y?J6@TM+M.D2-_$"AV,R643$ MSCQT\N(%)D-J,F!VPI1JZXR>5>_[-+)M"P?X34&STC0[[E1G>7.X%E0S5GN5 M>>QVRGTTT.D@@+Z/>S#+XC&A7]SJ>4[%KG9<.6@>C]VH.7CP5*5[JEPK3;M7 ML]*[C#2!09O>DNQRO;LAQO_+*\YYLGB]'FJM^&F_ZV@AL`G60FDCC+<1%L+D M#,-A$5T?!!(J+7V\60<)`7A`GPB;//Y;Z,"R1Q M=;XHOZX0]Y?)VJ92A'DC:J7/J]OL'U:.JD?K4VX6VL!1>;8]M3KGKK99+--Y MH:NCQ!=!*W!;[CUJT?%=V%+UMN);IR?/I)]3OW"_K=TZKWWE@UN_, M,$Y99=:_0@_^_`,^PZZ^'6'\[.K9)BV>-!'DR/6Z4D8>1,6ZOKVPKNV(;G'B MW\H*SY'(:&66R\L3HPZ4Y);Y=TCUR/PXD>"K-?H>:9S=:\FT#5?<"S\<<+3( MI7N@:%K`>OZ&[RKTRD,8^>X#JA6Y:H'XO,RYL>C72%:V0TSM#D`<.)''X=T( M+7W,5$HI4S;#02Z[E&]9B804(AOK[`'X=]=?2J/VU:ST`D/]02#3T+2*FJ-N M\XR8V@[6*9RH/-C6I>>`8B#,<=3-9_,4CGC8KR*OZ^&!&1D@GYJ"14[)F>KX M0,7W0/91.+1]O"@$SU?XE.S207@WYMZT[_6]A-26&`8;V)Z[FP[@6YX3 M!W[H)=;5W8GE1FE77B>4KW/&-YP0O!"A*I_VVZ$[S![I3#I8<(9V%3O@@Q5+ M+R9_]R,('W9[X8/U;FH-6QS]3CB](/3#[M#$CBKM^IXNY`6[:T>2>@'XU2`$ M_3^/$80[#RS7_HGY_J9"H\SHH!0AH_0M7-:6JGM-V;=&]7EU>02C M=UY_X!,#XZ+*2&O,5K"BC9*+TKJ0M6M=G&/7-#%8"H((3CP[H;NE8``$CC>@ MFV0R.\V5)D&<#N24%HA/T0VC(1R?GN?C+=][$6&&&W.U<=.;D]#-!9M])JYY MVSCIH5FD[ZA*YCT%`'8P7_=2+O\[S[QT^RL*@<'&,2NVL*%V-Z=QDM:&3JZX MPUU`R,%'*9]\7S![!2]!>^)>)R[@?6FE);(ZI&X)R1,*4V:GEM/Q)+SLL5:+ M,2\+9E%EKAPODU:!(`ZDG_)0I0]SK?@8:^\2[^4L`M2K2+DCQSOY?S6UX1UL MQXY5L@V51@Y0^0(&:'7$@ZGWAA$C48T%E`V0Y2MYO_:S^G:XDG'%C0/CJ4I`+=M*07IEVTAT[ MC:DKA#Z:5-F(\L)IXC^%O&O\+N,X'E*Z,']]3W>V,*PQ8'%L9G-BT(CNJ,*[ M:*$9DPU$!">I+]4(6+D72;YK^\/8,[P_?%N0@PX9=V]4Y<5!]=P8?C&:)J-8 MKCDA+5CKML8-6]DFHI,"9S%>"!VJ8>^J?2OJ0)7Y0*'9'-`!N\Q6@:%Q7BP^ M]TS*4[8H!L0LTC&-A$NF]6I6>@4&O9.$5/;WT+AQ*Q4!;DLD^I0HBG'8J.VI MFX7:']8"#,)W`8/C"&%-N1:F!DZS''=1Q2[":!Q:Y?-G<;^ MQ@@F4YGZC<"F2_0";`RER(B@.*<$7%*>030)"=D!2C3,M$0E&F^B<:PBI]$& MF+P@7"['073"RG>8)B0A"44X)#^`AT.EIVYQ!/CI@=S1T#"BZ\Y^7$G3QF89 M])T6]-W/!WV)4`'UP&9>=Q;:6XSG<@[\^&H:;-B+Q.#5MUHS:.)JFE**PZPB47B8S]2G&K_UZEYM,GY)57A9[-:.YL#N[^3`B5.\1NZ1D6H_ MDHB4EBBJA9T.>IXYOMH?A!'*[00%>-=R/>P_A>862G=VNJ@NEJ;!)141&%P6 M<>.O1]Z0A9&HN#7[".5E](B,/Y!>+N879+8]=;2C.PV4MJ>-*\H>=`4`AY8D MSLO^U97V`/>O+).<9*QAZ`FK/(5N3N:ENU(F>45+R0*&CQI(R64)> M&,&IN2!6\8+MWA0C:)M4ELD*1E$9.;,C)/GX6D04G'F")G)0:B*CPAB>"X.N M5D<.375$X=YZ=PFL\KT%>\`1,MK8[,U7I:"\&2_#)SOV''2VRSWV:8^!`!E3F%NVMCO*4[ M9YD]\R9[W@FY9YUZ/L$X>261Z*`=S8Z#04CM5Y'5XXL4)$;.S?5#R)&(Q0OC MK#86=GNDW!GD.)%-`X4<<"]T$$4](W='$-Z`928J#2^_)M6\E8-DY+94E^W& M)D'38O2S>KG2\JJ&XBRNR[ M-DII?#C$6EBH$;33X6[;Q@7H+=-E$,SGS,)I=&-@D`EV*:WS)0K<8CFZK![$ MQ'>,OK'3JGP54]MI0.YCL?KD]LIAXWBT*`/.N.)Y#AJ'(_-4C*H6_O#U.X5S M(JS`O-(T==*&>/ MW9CY'B=*BX4E9.6BQG($LR=?[A#C]090XM%U5:CX19R;(_*84YQXN]GB9/=E MGIZ$508^((TR#I/6?@-4&F.MJ\+$;-<3JUO542< M(]X6)=$%#KG,C10`HQP\J*KHGJ!*A133#T(J_F"4SY.*<59/F3D$!3!BNHY` MY56E1IIIMF/9@8'B_YAJE,8`2*P[)QBJ'I6TC]]_ M>/7TL'Y[K75Y\?GKATO1@7'S2\>%?[LXO?L-'Z_^E#D%V!(J>AE@S_2_>PWC MY2/TQWRZNCD]N]D]N;J\;%W?`@08_+0',6#CZH^SF_/+JV\?+&SO#D//=-0H M5/D`M0%6I&#Z[>SB\V^X1_7!H_&[JWXW%FXY=)5(':&[?U^>J1W)(Y/"<)P/ M$Q$VK4^MD__]?'/U^]?3#]9_=>A_(R?QHP6+N[LX:5VJ^6";DK`O'_PF`=VO MPJ+(??7+3L-$M?)Z37&,L6-JFU98>^T+K#=^VD$"!Q(&*CT<6>T=*E+9DK^0 M1I5]/D/5ZC7@H=SHV_;3(HF?^;VNYM._42RKNK MZ[$@3L30HNG@Y.KRZD9/^O)T44J7[:";4KJ4U%%*EXV5+D\W37T*J3T1%8XCQ/H,TQE) MDDM0P/,NNN^YKB^>,0#Q,GNZ0B[XWTLLFKK-;\^JQ\B]=[5*XZCZ?N,W_-GI M>AV\"T1Q\TTSKPWQBVQPP/YYU[>=G&L3/'SK MY%&K6]\8)K1%V[=)6E2Y?9N_?25S*:FSI,Z2.DOJ++?OC6U?R5Q*ZMP$ZMP0 M`W^]B0^GLH)&/'J#_`WY5O*B%:WOHUD1)M+G>7V;?7VE[S(V!]F7AK=5_N MEL1>[G6YUR5C*XF])/:2V$MB?SO$7N[UV]GKDK&5Q+YUQ+XA/I?U)E64[K5- M6=XFE,_9`-_P"B]^;='FOY6X5+F[)>E-15,MJV3QQ4XIL;H);;*8+M`&GRPW3-LZ_P=O^A/HX"RY\"Z[1 MO7"QS:VFZRWU[;]LPN\&9)UB59KX>L7[(`YU93];:*YQOF`V"XEU_@':WO*ZSO MAM976`D!-3J]^:$3!HF:)8>Z?Q3&_D?E'[&(O,X_1O"5S8*#C4Q#FX@+`PJ) M7!']L@-XDS,2^C[4JM6?/EKTS*YO#\,T^=#Q'H7[<<=RA(\-;APOZ-)[^'E@ MNZ[\K,>/]%^NAL;\,\K^5#C^Y\]IO-NU[<&',]D]Y5I$U%[I3CPFG_S0^?'K M?_['?_Z'9?U3/7@5=>W`^]O&BTDG84!.0_J`75CBJ\YU)&(1)/Q5&GN!B.-3 M$3N11W>96H';=CP1Z\DL![`''VY$YY>=ZVKM._R#;8;OPFKC M>X/_WK$\%_;)=A+/_5X[W/FU0"=?6C>?+X!@85?@7RF_>)>LPGY6^(N*=8N[ M:NVLD.P^9F`L`,)'"\EG-_;^%KNV^V<:)WBH`Z&^3R*1.#UUT'ZP2\[ M^*#7&8XG]2U?"SP7!EWUR<,_B-*LL&.9M$;K]C0&\J^M&B'$AB^^GIXA*JI[ M30_8ZDLAZ:XGK#2P4]=#]RP<(%<$,?\E#R=\Z'B!'3B>[O8] M,"0A`FL0B0$<>O3N6C8',,&6^]8G!S5Z]6/MV MA$C2/$D1]X2%#L+8P\<^RX9W7\\`'0I%8' MCWNA&P,^7*`/>*IB;%_?=@53Q?@9U"!)+Q+"Z@/_Z<425=3_7>&I:0$1T*E1 M"/"`:.64'LR6#0M;H^;BDV33\;&=GB?N8=SP7D020VD4"X6O3@J8QIW:FZBX M;;Y&M59%26EE@VC0^_#53H!9776N]%[2\\,GJ%5'I5JU?K4JKT6\I`XQ0=&Z M%78%W3\5(#>0"*7)&O: M_E,X"2HY\).3I))W2TT!;'WDN;!7@Q0XM@TL5:H[%C!AKP\BP?*!\_KXB"OZ M^".R?9Q6P6,]]#Q@]C@_B#0EM.7V\P05&"3HHB:#(,%XD:00`9R=%QD3Z>Q9 MGY56`^+3_,4"#=X5(`M1G8P-X87#W*+Z0Z(9ULFRYZ$G>(F(61=QD@G7/L@J MB5HO1M3%-!?H-W^EN2=9I01``*&"LN#JA( M,0W?MZ,?@F0F#F^[@-;$B_$S@@'/)Z22NB(&4@2T`6Y@S_J@$^7WSTTCI3#E MMN(&0`M2J6!'PB.$R<[01!,L+V)14]@`A&O@*_P%(91A=G"P<`:V)[OERL MAPP)V`A(.M%%`$N'_P]-G,7.->'$5XGA#58CG])*T\?QY"="G MLWJ91+#_SEJSWJ?7+G31?&$[5%M8TZS\O`%B*,N]C MDUL`6^C;/X0E](D@+AT#?^`B36SAV)T.RN>(3%"4;7U4X4D@P+-"0N9[=MOS M,W='YG+`!_&H`;C$HR:\0WS90D-0VTR3L#`.E,@4!21=4&X:@@-%%*P#K3E^ MGU@D6Y=[UMDC*'DHV93;A,1W%-Y[Y*A!C:)M(_]N@]7,,A`PGD;2C`5Q$#Z@ M.R0V.7/8!A,)[!^4MA4KC058@;#H>W9YP.@P?<):$&[/0/-P#XRHH.LAYV5T MP:BPY5Y$3RS^+B)4I&3V"#C>N0P`920G%>V MM3U`8"(/-RZ'F$H.*V3;(U'PCK'M+VWJ>]*!8`'XEY:)4GSG?&0T?DL/:WJ' M*B!PR6D&2+'2P,-#H%T,7IP@?OHBZ86L'P+EDXH`Z[/1H64@`G^69T(23VS0 M0DP.AWC:L4&-HVVC+PI6T8.Y0_1M^8;N!?A@#=E4#G)JF_(NZ-/:%CYZ&$B: MDQL*-!<;]SQ1:JR8Z!_ZE'AV'CB(=:,13GQI'5>,==5*2SYS]3M M\O"P3%LI3>A.1'?`GM5"9=[7[A*'/&BN!^PD8AL"-L/$XZ@B\LHX_=LR)($G M]-&3*!78BG4"JL/NV=G_.YL6H;P=]D'%R$SX=*">DI/#WQ\,=8%Q6J])G,+S MX^.6LP)?5!=,5U'C@ M@`C' M,>S#^3J7G((8'*CG[%[/LA[<+AWWGMFK6"#ZJ=( MQ_#!MF`G?'\`M@="58''X7GU#7!V6K7GH`<7?H+?I*E'G^_?HR^?-`T9@XC` MVO(P@&O%/>%W=GVO(Z1=C7Z$&,A/`P&,U9/8(@4"E_8.A@2D(3!RQ$PP2Z./ M&.R?\(L#I`L2,E)*%AC$N\`K82?87!JHH6URJ*,50]_`]N6(>DYJK1WNY\C- M&D]O(,_8F%,*51)Y[127!V(R(GL$!#O:'X M)C`?'^CL5KJ\QCT72<7F& M31`,I2H:.CR&H\+&K,))@Q`7B]@FCIVIQVQ'H"8/W#'S&.;C>2JF"-KH%GJ? MQON3BMZF$[!X6H&+_SD#"PTL+]R!I\:QZM4-=4*]JCC6BSB^D%(L@U1>NY'P M36C5E1(1,-X`2J(/^J7GDK:FTA)DH*&/#E\=N3-"^B%&*>(X9PN;$2,VFH7MFUAC<@-4.%0_MI('+G@$6:13S(.\4 M:^"/4F"0A8Y)%?(]],>`I$H)1A(?O3!*=H&W]PO+%112T3C99KXY%V@,1_868<*:76N_.+\ZOW%2M4_`S-8SU- M(OJL(=N@G`[_9M>R'IPFTT&-'#LDIFOX+;33.I>KAB,#-P3VXH']X((FG(QD M=05C+6)VH6\U71R=7G9NKZ%^1W8.WL0`RZN_CB[.;^\^O;!0I,1!IZI=BA$X?T@ M`ZBE"I-@G$E$&W2!JM[\:986P7_B4+U91#+[DM7&(:#VUM7&?L#XO(@\VW^Q9N9KJQ2^[K.R8?N_^.KGK>WV/#4*5XB)Q9GF4>U@ MXRF@I/^2_M=%_X?'1QM/`2]'_QNB*[RH4^-;&/W`A,%!%#JJSLAKJHNY%=QR M"_3JYV:;*T3)XFRS7CW<>%(H#T)Y$-9^$/9K+Z8_;,%!V!#]X45]#>=>0!FN M5C<,W=+9L/I@ZX:1R,;AYY5:;O5*O;E,4+H\3N5Q*H_3F.-4/2Q=@1NORFQO M?L=;T7FWK"?.\\6OG[^CSG,;EL\8[&Y4ZH>E"Z8\A>4I?.%3^`K[LZY':2HT MTMK2X@>3ZA@4ZQUT:>`L+/@;J>0DP6(9A)WE`1*HGY0-4HC^-`JJ: MSY^\1ZZ@+[EILPH;B:6WZ(UM+A$S+_<;*;H54B%AKB!WX\4_3B+A>@G^M3BC M;)2,\LUUXLL1$/($))TIO6%>.;<_3XG9J.KJ%2[*3:4#NUX@RQ("0^QX5*;+ M]V6I]U05WI3*>-O(<^B]KJ#R MA+KK6K[-B"[[237$X:U<77HN!=_%"KU86$36Q9<59>(X1$DBW$Q,&-43D1JP MY4U6JQM8%'43PII?(BMJB0M"MHI+Y`*X@BOI!+9L]L$=:V"@GU6'P?Q/92GL M5[-2+(7=EBVF4"\Q^QT)%SO)<,^AA#H9V0^JQ4%7%I&&SVXX4%61D22-'C.Q MW9%E@$&_BKC]G=$X9\^Z&M.FB3C?K,*MK"_(>JV:LI',C0684,+IQJK$81JK M=57DHJC50XBE3.TN<`)/C'1!/`]#+K-W&J5=J^7V,>*M>+!9BO?\M)5ODAFX M%6J.I)MES4K/=>V`DBG M)$IE#2\L7CL(L0>$1^77%0VG5-\+NT]AR5XT9QQ3_M.!RXAQZ-VK9]MF*!YZVVP-Q>H;A<'W0YJKB'R@Z* M,#OXL<[I&V.G!P$FN_2%"97"SH"HK!B"H_IHA3U@VTW"72J>/*G?9"*;90[L(5E$H&*A[<)5]E4[3EUV^3[T4\0!\+NX MYPT&U,R#>QB*V&B:K;IOD*-0/`+PKH(46Q>:C\B^2NF`J^6+K#2HZH@IGU1J M8NWP8VQP6UWKGCDU3\+%]MG,S+H[/NA6ZM)(Y!*&"?[,BG4["FV7W8>D!6@@ M91U1ZK8V!*4^@@>T@0>XP5JJH#O3YPIW#`"5?FAHRK)!),(E=,>I\;N'':BQ M.QAL,J(*V156TQ:/`VZ_EFT[JC`52WALNU*K;FK+$F+7UZ[-GRK<"]-."HB7 MC:YCH`!8$';94MU:L*=`CWVHV'\&P`O[GE,QS6RLDDJS&KT&=/ML";S1[97; M=OD^C*]<`-AM3G9[D]6R4Q:7(W0Z0A;F.F:1Q0AIPX%54@_G3<>TZJ*N"Z[G M$JV$G0YZCLG1P4?3/)EI\]`RLK[GN<5^E^(EI>[0S-P@PH M`TA1U%BC2LU&OYU.RT3G"Q^W&0;@UAV&J]( MK#MV&I-$0/4?/259GVO9!A%#4;)7'FVIZD(,O$[^R0T&)C5LC@WAI?>8"WRC M!(I5*Q86R]J=-+F+][E\8A&DA;D6X@^B0+5&DTD7^#'0NB/=MUL=KIH2=AKI M8Z`;>5Y%IUX,8MCVKSJ7P-(NL=-ZBWIV/CG&O[^IH:M-XJ]O()R%=+6+86S7 M8LIZLY&L;T*VSY+>%-FDA3L.2#;N9]B2;8I)87,%:(H>NN>I=R]VA<=.C18* MF83,&T/_=;S(2?MQPJW"/-`K'32*2-M-QK2'D8))SH?Z,*J1;4ZC0%T>/8;< M?%<.%K*CW^@(+!X];-R`:JANKP!0DI)*;;IT7D,:J!Z\\"%.^[K7,L?YR,G4 MH1K[\`/U6).`@6"C%CNP#C0/A!<55P("XZ)##V%4T`3/#UDRXHI`A/[-21FT M:GH33`Y4V\'T`%."I>4$3)D080,&X<82&*.],_77H7V5'7D44K+^VOH)!$NW MZOTKQ7:4JA<%-:N,.7V$QI5RBJ'E\"3&&RB"YXH!"D;9[L?V@*G''Z40I('0 MP@H3*?0_XDL@9_^4[2Y'D&]L$G;@ME#1,_MRM(>%1MYMZIT`G]`=E8C,N-:: M"1I_C`[5(70$%]S@E')PLOE!31``&;7WS`#4%JZI%&4-@;%)7\0I,T9?Y*Q- M=\70>:B]DH[@4GP9,`=26OUH&_&@>Z&;>W_DP"GJ-;CD^./$KMBNV=X..(4* M^.((+K"(:)CU*0V#CZ8?0)NS]*5&9F;&5I`Z`="<1?CZ#;0WX^$_'\\JN#V\ MISLC/E!G1.;:@@0(I7?Y/EG[E$R&1][VZ`<@Y2#&-M@VB!3EX?`";E/J4@]M M>@09#TS6%LD#]@]6C`FT?0\5:HHTL53I@[61,EE3WTSJ4ZN3$."T1@(]D;E^J@>?T1:@YKYA!(?B;\%MSKQ@D`*` M:Q)S/JC'*Z> M&TZ.$4H!:0>SAN%-IHY#[#US@82,W>1J,KB9K<@H; MD:`5'V%_8[GAU,B49'Q4MU/M=X M\P$T)XSWH,!4DBYB(6!&:/8LA58R#;#%FLQQHL`6=X=G%2NS7W+]FRNLD2IE MU73-&]V:I:D1VWW=?9C;R&MG5)Q;$J:N4R2J;_\01J]G;"BJ`FM*95=MG#WK]1V5&?1,5VQBXLH-=I7LU*.*N!6`SVC]*-`5;\?M!RP[X&RF'#@>_A!1QQ(;^K9]WBT;`S]6K)U MHD`O,ION8$8"D'1$"MW?Z6#((*S7QPL?H(?*LX.DB^P&+5TX`ZP]9I1YGG!\!K3Q'T!+*`TZ7C?ES:%A,2P4%3&F M_&."$C54LKNFP]#(`WCHA8SR/DKI-+#3I`?RZF^B"'R0,7P.3#B*OWX;?R.XD@,DU`[9P(O*;C\LW)E>4A:XQ8;.WR5:9 M#Y0?S&=:91&$#TS/[#RC3W2]*Y"^QYB\PN.X'VT*"&$_#LEA:0]5VL$C"V63 M;1&J,`LD%SV4`ZD75`;*6J1L*5'7O=)Q29N3>@\_".7I<)G'80]4>=%1ZJ&9 MYKCR-L+/T46X5C^>T458A<19X\90.GM&;#8#2(Z@^XS1@1[@D4P:S/V1;EV, M*U?PD8A:6KO`DM06J\6&WOY)`6=Q4F9"=JND?;$J"). MPGK%$!U,AL@)I6/^GN@4K9U[PQ9C][Q*4QY#WG-OPUO">'VO]E2,;['C;J;3 MK>BENY6YHJW`_0TV!.-`)X"$)[OJ#C;55;=)LNQ5:2#CO7F*ONBT*PI[L_Z\ M:ZF+,B.DF'N6K8T8ZDD,H<<)T\B4'T^945'%T&ABBDXIOQ+81*'GJ+B*$OM8 MG,&WXQBT87Y%N\$N*#.6E&]UU=CTGH%)JQ_.5YKPF$]2B@"N8YOYY7SL;[3P M@;22,`&-489O/3V3['!3N>:S!@6VD25.BVC$)-TWBP;_&;$,X@) MQ<#MQ"X'_.6=`&)]HC_PPZ&0E@E[D.@20':EN1O9TBE(OA\K'*A4D3CS9N3* MU;#3(;N/0!>G>4HSY<"+\LE-67+"Z&SL6,Q2AI)>%*9=SJQ*8WVCYY-O.S]V M;YU>B.R?WR5VC0OIAZZ0'L\'WBZC$:]FI3!2$?##*[X"6MVK5JL%VQ&T&3Y@E5P=@A.&@H#/%20@=U\;DW6( M";#>@CM4X!N`I=WL&W*&VIS)1W%4.+1\]UQ>&K:[D1#9U7(3552&*[;>Q4)8 M7T,X:(WW>PQ8CA.(1Q$Y7DR:CRM+K*BSF$\L3/'*4THNY2"4'GJZ]B9S/U7% MJNS>"?K\U7J7NS7P(*1V2?B2!C&"OM(-;NP_@_OK8'22HO>+?'V&>!DK$]0! ML+M=S*9,S,RIC-E+4>/%<2H=V,@I1?$TP7YA&&R+M>(Y]=LQ]<"H:B>]]P?> MNH&1+V3>Z!GE3/$(BRO&1YNJ&&\2>W^-NK,B(TO1D<6$]&9UYZM`V+KT^E=PQQ>CU[85U;6-JBRE$Z?I`"_.R82X;MH=LV9CS7Z"N)M8?\&8:B8FS^W+]6<(O)=_BK0?J'$U>#(Q/ M:DQ=ZB=/^$FKI=2`$1@0+OUK3B.1BG8.2)E6K^(GVL=BJ!F&_D5Y%Q@+Y<32 M[()VOX\ZA$?M@=YBA$/\3X MVK3U$/3G&3+*""ES!]]&C%',FZ5TQ"7U*0 M&;HF+'];JB>4.L'J=()6 M(=YYH2-YUSJ/]?YP7>47B>OK%&&WQR3 M%,I#1QZYUCH4@T:I8YMQZXIEE$G(XAI95D)V:4V.*U/K9D1T8RD]J88-?`LF M7%]?:C-3(V36@\R*-D#0]^LK1J)=!ZUMF5AD1%HF#I*/ERR"/@K>IY32W5G8 MUN>2`*LUZR>%UU=NVS?V]L?.5*P5<:'B8=3U6="U+XV\+!U"B7AUUWC55=5J MAV-JFJT<*4='X[**YJMD4_2,D"(J,RL5XHJI)*/TN,UZR@QU8_0&4RP0KZW` M/7F&#D^=,D4U!&7K'VD<.`6K1,[#^^N'H+$59.`?Z)Q0(PK9%*E/:?!%K M<7BD7BE5*AY3O#T<4_E:ES;:8H$QAP08*3D4@+8K[NS'I]JRC5HI*5Z_+50E55TMUMBN[3M4=6/M1J?OF M8.@V5')#)B;CDT9E2^Y/=)^5,\\BS?FR.LCWQB:2X/`PIDQUIF0[50D&-.L) MLY)+,BLK1_4C7,[D)O7;K%^CRB%E515$`'RCKV[(&3=623["5+[]@'!1_98] MZW,O5"4>I@6J+"$IP4;?=,D?L_AA'["L[;6\GW\7@*[:5/(3PDAADK(1N M+_)QUK61J'`*?DH#E0^"A,,%?*EJ_!TECT58X1%'\SA1C:E1:&)7+Q"G,1E4 M>ZA30'`:CR-&#X)N!X9&L2L8$V@3J5K5-NEYA)=,!)0S]5#%1'J`8#8?O$S)!M=FV9KQ;"H2?W M&5<28Y3$6+S)-7&BBM`HE'!0)5$%`52=3%EP3#O1:&&THH[7` M*\#'AS<2-GDCN3ZU+H@-!SSQY87&5C#,0D)X#Q)XI$^\Q-!\)VRTQES682_. M#3:^4E9!(W_M)VQ+>,FDFX2V+`*;);S1]5.2("@Q0Z9S%?[+2`'$,%#'.!%D M=VWL,H$-J+":T(CT*=ZE4V,'5/MHLFVLFDACN5L5TQC(O$&`4;\I=TBZCCLR$C+9.3$$MY\M4(([DBVX?;S*K" M'K?Y6K(R@)<55H_-S,VVH$+@NO).+XR27=2]+'@4U+Q$%>6A:P%ZN[?98S47 M8RQR4R";%F\6P'(-)!VB4F2\\&1?5MG=]>TQUAN!>CNH[!><,)V1&)[IP+4C M]^VZO"XPC7,HX[+4EK%U^TFEEJ,SWLZPU4T][J?=NOW=^AKNT5N[U>-*OJX- M7]6DBP(G5!'&436U3U1!&2,!KF)1_A^_9!BHAD9)=AW"$LOM4@X3]I_9%@92 M?4%=L-FTICM,LLJ+60;&UUTB9+$:#5I6Z\;&#@98O"C.O'M&VN08-QL5C/&I M\8ZJ#(LV&QAYR*&Y22<9>"X6!E*NJ,#F=$-5#CO)VN!H4Y`%@[[]&N3*,9MQ M^K%!-G=]YQPJ[&5$Z3J`<;K)C!S48;]6/9=2N>#+XVAOW6G(C&(B<+]S%BFI<:3#IG@QL(L(OSXN5DL^S M./&AN>9OK*;(;!%$#)J`L?(IJMY/';X?G0YP&LX,:@L@]WNA?#2Q1FE6Y(JI M`)4/0!.V(Y2C!"1O MZ8X37S*^5E=HJ9,!SGBG+KEAMC]>`\54263E<,BIZ/VUB#JX!)SZ#CUS"7`O M++/]"4!Q>DC9KCRX.-Z-OFIZ*Z^:7M/)S]55NZ.F`W`T&1CB!_K0Z$9O7)@/ M.8<&(&$`^!!QVS-8UD,Q9=9WY/8-Q@\V` MTZ`P&W)9Z-PNP9I:MR?68>TH)XS-"U36KKPAF+OZ;0IB="PFTB5)$HLNZDH! M.1;"V,2-1@V^*8LWT:TWJMI-0\W:"^7KS-@G5V[ZEQVD&/2I*0Y]!L("BY)K MWN91C3ZNXB@+N0XEMI*I4[+L^V"]JU$%R\QGJA0&B01UM1,6!-J%+&.A-SK/ M[ZG6W[OZ^[P\'1ER!*],;T:-2##;2()R4P5E/V823'XA"!OH[`L`3[XBLBR5 M==I=U4K>/HII`Y7X]M0NR<7E%WFF#I1\P+EQ(TIY()=@G70AWM69"&A9-QE_+VU*`GP3^&T;;;>L$D2]DWI M$JVTB^5SQVL3F=;0S`FD4VTI(5G^KNTJ*K MQ:+@_!PBM5,KMLB49H4K7I/Y/Y&G/`=XKH)`.%);1NZ,^R*!VZ-9HX1?*`9_(VC'()(=AUB.H7HYB@(N5N MF&)34<(E<4\UHYVAT,FAL!MR#QY"H;*8@!S(7C)DG)MK:35>EI!A1Q3P#B\& M/G6L+`C-MCR/7>'ZYF38._CK^UEZ!5TQR5F.I!3PIA4W:K:%6)&-&*.\2!IO M@IK2\XQM7`9\C-Y"J]"(S:8DRP!)PE+?ESRXXP?GXMV1&(;'1:C'%F; M"FRTR+0LKL>MP\=.Y!$IR2*5QFU*J9)PMD+F[U+6$],3>VH,HR2AW%N89]P< MU`*[XSE(R>JB-%Y4DITDS$LSL@$U,S.ZDVUXZ>C8\U)R\!O]#R9\Z2Z?U-.T^44 M/DSG45=U*0I(_BUR#AGUI9D'R*X.&;=(/S@[[>G.Y8+U`_'.?YE9[>Q M\VNS6@>$58V[S/-,OR*8:W4)\WX>YN9TF.O']8.GPRPW*;[14=NO(CF1M^3F M1N_!=%`;^P='.5"GS?HT""3P[<^0!_5F`:1ILSX-PDE8F\7]F\?'2T/(")X?6S/8>VW_^'A_ MS`[..^TD%,S@V6!9-`_GF5:R\FM.0%KX$,U@U+5ZHS96=.3G6Q:J2J->A&WBK$^#<`+RFC,X=N/@J+DTA,3, M+[-;1@NC;Q;3KA[DZ6W"A$O#-0EI,_CXT='Q,F`]!5.SM/IF/<^65@/-)/S, MX-@`3&UY:`B;=ST[P/:KF+QX*MK)US!P%L79+%Y>K4X"<@8(JP1^$HIG2825 M`8_59CV^1X/XO.PEPDQWKYR?-.@E'(X)A MGEG#@*+3BUG5!S,8?:V1MT\+\RP.QX0E'\Q2P!>#([N9<0U:^D5P8@^\Q/:- MU^;'T`Q>WMP_."[HOC,G7P6XDQ`Y@\4#N`?[3P3W1D9WSV1P%T0KAZF%>TK5 M]N;G90?17P3D+O#`FQ6VO4:T^%]RZB./9PF?,\RXU3/=S/ M:VZCDRT#SB1TS>#VRX!#O_1"'W-!T4)*AO-C9X8=<-PHN"5&YUH&FDG(F:'_ MUZJ'M8,%P3'$)8B?)Z#J<)9@&#$89TW]=%`GX/%PENP8,3(7!55E8:>V?]7V MY?U9#BW\6]C1%WD'Y1:[O::^N$/S;/D[%H<;>WEMDP)VKST@^4U>)QWIO8>7 ME?MIWPHU)<99YY``"(W2^#E7V[P:SL$Y[,'L%F-C30H'=D*?TN+?<;YW&MN! M&[__\-H1_0PQ[M;EQ>>O'RY%!\;-+QT7_NWB].XW?+SZ4W9:.318//ZP,_I? MQII\^0!#A9^N;D[/;G9/KBXO6]>W`($#.VH/8L#&U1]G-^>75]\^6-@Y%8:> M&4-4J/(!:@.L2,'TV]G%Y]]PC^J#1^-W5_TN@?ET=7=W]>6#]5]DUU6MVN#1 MHI"IQ`2CQG*HFK>JEW7W[\LSM6=Y=%/W\ICR+"/"=['"UD<+5GIW<=*Z5$/# MGB5A7S[X34(-HFO'HC#K+SNUPY]R7)+NDO+90.X^&L'E"&IAO1NSFM'%3+M0 M/G8M6[1WC9]VD,R!D(%6ZR-+/Z-N,:IT7SOZF1[0MZK*O=WBO?T;J]^_G@+!.(X0 MG4^:5K/M?"^Y[J^6/,Y?KGE/7E?5[SZ"&][ MC%_^=>OT].+KY]T;AJ*I+(F-0TE]%">'!\<;3PHEI9>4_G1*K\G:QYM,"B6E MEY3^=$H_>ML\?6-TV`[];UV^(KS0]%+;//?*MI.AK7#CMH9CK7#-XX1OI5I_ M,9.JI-:26K=%52QIM:35!3EK[6USUHU1]Q;6^1=5]P[?LE:_" M-'6OI-:26A>BUMV-W\J24DM*+?GJ)BE[:_?M';UEG7X3EO>*F-)Z+=`7$Y\E MI9:46E)J2:DEI;XN2MT8)6_M'KTW':=?-EOX%=JFBR%@6ZW7TL]24GM)[26U ME]1>4ONKHO:G*ZQ3MGUCG)++WH1Z-7;)S#/=@#.-=?QQ_I89?W?Z\'+ M!EGGJ\R_KE>.7LZR*P]*>5`V$EGC#DJ99UD>D_*8S#HFC@HWX:"8^G76 M,L(:?4<-ZV]ZDXLGE?8:*08GG[KJJ&)_UR*B?IZ?[-AS6H%[ZOEI(MRG5@C; MV"[L&U78J4B5KVQ]+>IP&#B>[]E9!QMAM/6R@K0O(CL)97-G5P1AWPOX"_FT M%U"+G:P7MVJ[I=M#5KB3=\?GMEFR623\FOH)#2.[H5$?G@'.AS7)*M2Q<4)5 ML8HE'ATQH,FLN$>=RJB+=UEO;'/KC36,EX\VKM[81J>6-:HK#J=OW`I7G2^P M<0NLY\H3'8XZY7J1$-F2OP`[Z,79Y[/`%>YKP$.YT>5&;TO:2,G`-SG"MG$H MF'7RO]B1T\N0TJA5L@]+5BK;.!R49/!4,MA_VV10,O\WM=W;=NJ7=0AG&SUM,>&,B""6=Y#!T,(HA<@"7U%%2QTPN-E2Y/-TTW+"M^G&%*F0:6D/D'UCL?9,?[+,ZZ!`6\ MFNSP35C>"^9PK3[-_=E6/4;NO:M5&D?5]QN_X<].SQMT<66%VUUK5HZ.Z^5N ME]SK=7"OZE[UN&1>)3F_$G(^JNZ7U/Q61/%!9?]M-[;8A.65O&N%HKCYIIG7 MAOA%-CA@_VHN\&S"\C:I]MB+K&\,$]JB[=LD+:KQ`#=BWCT!OD;\N5LPO*VE!&M;GT;R8@V MESK+[=OJ[2N92TF=)766U%E29[E];VS[2N924N&&/CKC>!?#:BPW%MV MY+QH-X?-'M;HOWW3WL7*OR[TN&5M)["6QE\1>$OM;(_9RK]_.7I>, MK23VK2/V#?&YK#>IHG2O;W;WDEYRII^Q6[1=:;BB+;>*KFB9M29',3W&);UDMY$0P\ M?[/D37'TOG"QS:VFZRWU[;]LPN\&9)UB59KX>L7[(`YU93 M];:*YQOF`V"XEU_@ M':WO*ZSOAM976`D!-3K]N`^$:IP>]C%R1?3+#JQ.SDZ+_%"K5G_Z:-$SN[X] M#-/D0\=[%.[''*?/Z?Q M;M>V!Q]NG9YP4U]<=G%^:K'^?H:]R<3X`KA_<\7/7I+*&Y,%@MQXE2X5YZ=MOSO<03\4D:18!;D`%? M`>W\8=K1_'X6@VI@@[`X3Q/824DG\&?`Y#&(!CTY3B M#+Y1(FE,/^>U9N&8-:#@)`P'`LGS7EP0J<(?3UW\%/%(BS]XT<5G!V>- M^S]%(F_`_ALH6,?^3Y'^N/AZ;26+_P+<620,D@'@V>-`!+&81P#FH9ZA(S3V M"U!/GW\ET$YAIS,4B481QXM!>QV)@>VY\E>]YW$L$K4W4[E*GF`T85V#*A.B M)#P)XR3.R(Q&OV(Z#+KX([PE)_\L`OC>/PG[@S!`FA@AM^/I$N\PKVS.L;25 M8,,X8\^)C>/J5&P<'36?B@TXK6D_]9%MGHI!!*.3<@-_^P+_0`+KA[#>O^E[ M6"4L)1E>^S8=Z+._4F_0GT%`^25-46EV&Z"][]?WB_QD)1`^W\HG*'/'4Y0F M6GECO_8L*P=ZZX?!;0*6]+4=746W"4[QA^VG0IG?\V]G03?Z#B!\IR',Y>VC M)@UKR]D,,X%8"=R3-F/_1>#F5L^M-.F%D?>W<.?'LZF#4(9*;`)Z\?4<7175 MHN4[>>8G`3D)J0?/#>1%'*>+8/%P-H#U9@W^J36F`,BS+@W<).P=K1&XNTC8 M<1H-C0?GQ]KQ;,".ZXWZ4>TP@VO,A$O!-`%9M6IU/4"!C0\&OI.DMG_5]KTN ML]P4].FO`-?=@_!!I89G>O/CKU:=(?..#HX+)V)>&-8#_?>S_L`/AR@[U("& M1E.PL[)Y1M276G6&R#OMO=2-!?RRW_FF>`UA_4:]? MQ_IO!2S8_;>PHP4(=IK1CW`#%YH3\&SZ58.\.BJ=9M_3+FW":E=-FM/L^H5( MO85`[PZBISF$-B0M:Z:'J<8_KCD=2WV/$RCI+<8 M*=:FF.5SPYI-O&I@5T:&M1EZRTNO<\4D6)NAK:QON5YG81*-N'F]`/(T;6)6Z'J+6]F_"H>UCJ*T5 MN.@0\N(8ZRQ3*,[V+P#`2,1)EJTPOYNE;JH`Q00)=H\VZDT)[O(`+;8NV"S, M![L(XL3V?2+P,2E$<^W%]$0&125/`VL=BX,%F8>@7AUS".I3=(1U+ZX5!+31 M^NF+P/%35\07`06E9#A*18F'\PN>^O1\O0FK6A2>)9=U&0;=.Q'U,[ZWP%&; MGOBWY,)&(#K9HIP^`/_MO$%CO[GHZKN2(>Z\`5)J;&21C= M8,KZ7?A[+,X>'1''UU'H".'&457.PS_!@`FH12Y.Y MY&L+QG"%'&!!GC;=XJ`;6L6$^=6N<*5DEA]Z)-OJ]\";F8*VJ%"8G@=&[LN< MQ?9,2\RAE96!+P*.MLN*.(ZJ-?1,;;\1\&1$I(WRZD M_170-?.J6DU9;^L">@QF4$W2E@W8-&(#[-S]V9?=\IB:LHAUR;Y[V_,1RX!Y M(LMU*`_[M=G\O;9_>%0]6KTL+*YO(_"X&'_:GT.-/UZ3*K&QZ%N`^N;0^6O' M!\WCY\?>$AG,ZV%49!K5F?ED8^/A%:>>KP(K;V89I>S@)[/@`),Q)$ M6L^J9UPS;!3OM<]Z*>B7[\AY5/5D$_5[]>Q=VU'.J(\ZDPI MK&T.E1JVO<`TY@)WSD62$V6]:YQQY[`^8E_-`VE.MU!1ZKOP/`WD/P! MG]'[H=69]:QMQ@W%6B[<,A>88R^FRWO]7\646.Z$*Y^U_1D9A`>UP_S]JL*, MRP$T13-MSD@3;!X=5!:,Y+9ZL>%.C:3)W\RF-/0-R.+K7Y4 MJR\)IKS<2S>T^Q[8T`E?S%\>I;,2X)O5/$IG0+`:@*6+WV%(`Q!&"# M=8IEHH!I^B'==ET>OS/D1_TPSVJF3K\*6*>@]F"&:*E7GP"KOJTN?Y]2MV82 M+@]FW?(^+%2-&IES6:"F(6V&,&E6"Q>PYP?J@JK(7P)K70)7,V3)[E%U`JZR M69<';!J^9LB6W5KC\'A1R%3NW]+']&"69,E!5)AN.6BFX6B.:U0+0*.PAB8= MIM%Z00K8E&@-@_B3Z(2H1>-S=_:CB,\>@4>&D>L%=C2\2$0_QAHKF(`;DJ!2 M,RZ!YQGB!LARO["XM4'_\HB:1@(SQ!P&U!LESZG0S*;=:Q$5 MJG>.*PUE/1$5&$E58?N6"0 MEN4X^(D=14-@2>A4CD]AQCCQG*E^8?70"2:)1T/3%ZH/H#)F#C8^?7!P64EP<$>!D"R/]*(R]V.+?MZECT@.RJD224>5[D(C]-`+?5=$,7&>)3C_ M#&5CN@"=#=%Z%C2%O1_-4%%F".'%5_1-8(:"<%OWL,-=D0\$&CF`2V[0T?00 M.ED^!_N%ZBX+P;2.!4W;H.E!;?:O'1W75[>@L17/E]B))96DL=,_!<9IR%U2 MN9D*(W%YTFB\>W$K'."D>&M-YC057Z6@VA+8G7TG>PDX5K^$:JFK M7\'BXEDU&EUX.V952GV"$B1A6M>BINW0T[P1RZRJN)7+;\B*1.U*X)R&XQ6) MVPEP3M!Z3.>"J?PL@><9=Q4642XG0;6>14W;E.D94`LIF/,NRCPW7KQ05NV17-,*N;^P<'^^M=T#(7-W.+J%=GF-*UQJ(KF'ZX5[^`>=+/ MD174CP\*.<#3#OO"88(5G9/ZK"*O"P88%E_'"OA6?5:EUO5!O](C7I]5N75] MZUC!P9B_`-I4V(U.:'?A!/32<6H74^KIWD_L)4(F#G)"[HUPPFY`HRQG@]=G M%5MM%%H>K'D!FXBP59^#&7I(B?$5\@J7"%:^H!5Q@5E%?W=K^\WC=5BD M*Q8:L\KZ+N.%<(^#>VSQ%Z]<7"T!MA5:W5O MB1LP]6EE:J6,.YX!LS'_*H"=AN$9GI?=6G.5L*K-D#6%ET#N##&W6YN%VP(( MJX)Y&HYG2,3FPV7)9YCY[O3$K9_"H,8O*)P&S\F5,V8>I)3!Q&,>:#CWGBO<3\/?0>3"Z^K-%D!TSRVIQR3*+[%#LVZG'S=KQ<#' M$P!\EN5.V\D99;73MG&6!M%8YVH7+50UQ_;MS]`HCO2BNA:V>PGV." M?;G4JT8!]EF%%PX:1W/`7IA_14!/I)U9BD&SV$)N&:"OHJX=>'_3X8#S$H>^ MYW+%R,"]CD2,%5SQXU5''C#;UW&/^-2+'3^,TTC+K!ZLZ2.#?QX_6^=77NP]6#3_?>7T16U_%@W43]NV@ MPE]4K%L@K(ZU\S_=Y*-5&.[D\JQU\Z$=)CT>:?>\]>7B\M\?"D-]I-]N+_[? M&4_U,0-C`1`^6AW`P&[L_2UV;0K^?K"",!#J^R02B=/#[R+8RQW+]KUN\,L. MELH5$8&/T/\,X&_;4C2\;?SK:Y@(JV;]C]T??/RO6K/ZT3))S;(#U_J4QEX@ MXI@6W%[7TN_._K^[W8NOIV>XZ.I>TPL^6L^YL_B@UQGRUC(V#JJO?J4@GJ^Q M%+1U:;=A6&#X>]8[7OY1O5[]^"#TA]K'BF7\DL;&+U8864E/F+]C6,0.AL9# M[ROP&-&6<(%ENH+?\>V'V`H[]#?Q+/SP5=S;KEVQO-BR+5AXV@$V!`PLJL`G M]-[!RTB;+A84\]II`@#`:S9\<2^BV.MX,`?5TL6O>V%?A`,[Z7D.O=43MI_T MK$$4NJF3Q#"UG5AX.RGL=$0$;R8A@=/EXF76(&W['F#FFZ"G@+>'E@BZ=A<> M]0)Z-)+5N!BJK!X73C^`,P8J#@P4`G"[\/@N>7UA#2:NK^Y.3&Q9;I1V*U9@ MP[KA54P\&0'<]L.@:SUX\%V<#@;<5[)B@1H58ZJ%Y1"X`5XXB?O"$6GBX5UV M]?[>:R?OMW.0K]((MA7TCFAHM27#QM.#M&FR^G9'HP9B2Y]KE@Q-C@"BAW2 MZ#[548@P;\:WL,N7B/X4XD!ME;D] MM\-^._2U+(8#H)Z26(._/QA"CXFA7I/$`,]K688O:,J8/9#Q.D)JW3":$/B0 M]P$TL$%VT%YT22:$?P-@5M=/81.1T?KAW\#&D`P!T'L1(#-S?"\@)A$GJ8N1 M1]AS8(FI(XB6W)0M-,6Q'3+%B5KV0'Q8MLSSPM=R2YYS+;7#_=Q:P+$%\T@@9\+O5M/A'OO/>K!_S_IAXF)?E) M_)01<:GOO'7`=X42YG80V<.]=0[.XMSWP.QQ">MJ"_&`3)YVP_3 MI+<&8%>T4R!V.W:<(&6"K7:/##;!`*^I;"3V#SAR(6#'+Z+]I?@#[D]@B1AA M]>(>H%MS,$:[5$`,O2*3$GP@]ZQSJ0R"?!"X4=0JE7H/65](16K4*ECJITDC MH$5-YSDDYP_O,,@^&'401B2:8M$E54KQUXC+:<=6S[XG#B0RENL/K4X4]NFY M26*L5'M>S4I!(T]!+[:M4]!NJ9-?HV8-01/?!8)#/F)UE#_$(*A!&@W"&-6/ M&RR?)`('B0G^\$AN9=6HFE;<`YJR^L)F^N_P3SB#)&EC8H.JHVQ<&##$8+=I M'/$,I@&%(\;%V?!+.!M@MO3D;,`0S95*(4S@>('K46K:GG6'IT\`>UV3)6?9 M,:+=53@C@XB6C-`*Y`T#EK<`3T594W(<_-P5A!$R7#S@B7':CCW7LRG5*0U\ M5%Y9NR`O%2/PP8N1*U!<<\P95A_P;^*U5CN,P,C$XA"*Y!\\-^E]J%6K/WUD M?KSKVT.0)!\ZWJ-P/^Y8V*TM'MCHH*;W\/,`=1K^K,>/]%^NYJCFGU'V)TZ# MGXR2NBMVYHVD3<,QP;ZB&&GD_")L1`&S.(#>I[@`C]^R"S"S#Y((K&[M/*N; MSK/;M$\F&!Q,8Q>L;!LLM0\LD/50V^I-?'[Q\V*KRFT]?O+4'Y/4->L?!:#^ M4?E'C.#\0RXY6U9&7EHSP])89+Z8/(&>T!.OF8`V2=*C3$L#&VQ264#%Q4QK M^DLR4/B0"?M8,TS6$ML"=.T!J`!VQ"JF#4L#_1%^$0,9<@B%7@'B3<0*C.A`*E)E6=MMP0<(M:O..G+GHP?31-I""1-DD?"Y/( M+0`TM+6P+2I2QBS3,#H>?6/P+!'U>T!;2Z*.$-;JP_(<.X>1SZW6M8D25G9P M*E(N<+*544D;;9K`YGYLM"90%2P:G-UE\!FL"T*43V%1H`'1"NG].Z%,2QLC9J+3Y)-Q\=V>AZ8JBZY_26& MTB@6"E^=U&=38F^50B0G0UZ5`'Y&J_9%K??G5C1NA4WA(KPG*DDS%_,=JVZ\ M&1<#1B@"D5!P)":>`$:E=T^^L46<3M9)&F%W/A\L8'PP&\\+.GZ*S@(2.219 MTO:?PDE0R,-/3I)*WB4E9>+UD>=@:%&V\E7BW@(FY/7)MX\Q2'S$%7U;^D*D M'YQC.>Q6($<><"(IM.3V\P05&"3H)AS3C&&\2%*(`,[&BXR)=/:LSTJJ@_@P M?T&/HBLZ>%$:G089\R8+"<4_B298)_/>AY[@)2)F7<3)F$"#%7G8+,B.:2Z0 M[W^EN2=9I0)4?9#^63%,TF=>CJ#6Z[H8DE M.`Q(=1"SV"]%KD[B(A:H1VD,T!:I**"BKFPL5V`$23"*D\AV?BBG,>G%PO[D=UGM]P`Z?QOD:U&':9D'GKJF"M M>13AS/7M'P(#3(QI9H$Q'#XNT2N#8YT."C_VUZ/@Z-,=24KPH1X'G$[@V6W/ MSVSIS)[%!QU**NX2`YCP3L(!;9EQQ-[]"5@8!TID\EFA.M@97!GYOW#(5#!" M#VRZ[('I#T<4Q8:RR4DV8K8T>0%07+=M9(YM,,E8P`#&TTC:2,!KPP>TM6.3 M[85M,)Q$[*`HJZ"+'DP,6/0]V],#>0>%(=9W82CG`DRYH.NA8X'1!:/"EGN1 MSF%:[%TJY&8E]J-U;_NI8=N9FZV$$[)VOIEIBD,0(#VRQC&!'%&G##@)Z'R364PY$I-H`/5C]-R9O3B93IJD]K6_AHOI*H)!\'J`7HS)8'!V`1 M4TY-)+0C90^4.STJ'!M//,2:L2@/D72+5\QU50I+_C-UNSP\IJ8JC01]5>@J MW;-:J"G[VA9WR#WC>IC4QPHZ;(:)QS(0_&I6:N:_2>VPLJ5I9%F64YJ`L/H; MB7_.]"5IU($*R[XPE@A[\'A,!>+6"L8>/HITC%\4-S9P]L?@&*/ M4%4X-TI]`YR=5NTYZ!Z$G^`W:4?1Y_OWZ"@F34,ZN,%@!\9,"2<]X7=V?:\C MI-&*1GH,Y*>!$+KA%"L0E)H%0P+2$!@Y8B:8I45%#/9/^,4!T@TIBY*5++`V M=X%7E/COLG<[UQ"[02,!3+9'7OK M8):L"X="PO@'V$E].#@G1M)V/A.=Z7VXO-5LIO)R M5&C,I^,C,W*/.&%H\Q\B?DHZG?=;B2ZQ,M2^"8``:9X@-QXPWF$YY4` M3@=L5F@WWP06:*@W%#P#YH.Y@+?2GS3NN4AZ55!99D6,LJP[2&B2J=`L"DIT MQFCV@[/C`#`>ZXHV_D/1)$-K)&VJ(@T?U-:$F^E:H&7I4H[H[GL0BNEI#=.X M_A"C1U/!I<\*^I,\PR8(AE(5#1T>PU$Q25;AI$&(BT5L$\?.U&.V(U"3!^Z8 MN>/RP2(5L`)M=+M<.Z]3=7QE'B2\S&D9MSE?N[;]36@=D,+%Z!4';4MF=GM4 M'8&/OW2']_$6DXXO&8'7$'WI<9PS*LVX!MN>9,N+#+][UDGA&ZT\TJ-H!3-G M<8D[D9OEGKD>NN!AM2I?&6,?+IO8+!O(,T]N'E9E'R7G)5,70]_RO7NZ)^RF M0N4WQKTP2G8I[S*_7$&.?XV3+6-`+T5W8_+M"CQI^[/GQJUQ_?'>"VV6_*&< M1]ZGA1G.SBA3?^"W.#2'.R MWIU?G%_1;5=])\*8)A%]5N-LT*"&?[/_4P].DVG/>X[5$$,SC&OM62<=3IKS)@F\R-D1BZY,1\Q5P:7SK[HQ'P`;:'JUOI+(?'AR.S5`SO/NK$ZSNL=QS[EC6K$849/HF*4--%2P'H MC@*V81H#"N+W'[:5*;Z0([-U>?'YZX=+T8%Q1Y.!OEV/5)EXZ^'1U8#:`B!=%O9Q>??\,=J@\>C=]=];NQ;(L+6RB"O/OWY9G: MCSPJ24.+R0Z.")?6I];)_WZ^N?K]Z^D'Z[\Z]+\1NOYHP>+N+DY:EVH^V"2P M">6#WR2@^]@(C.YH_+)3;QJ('K_'Q:CW%"*1ES.V"0&UM[Y^0``>#S@``;:V M7!`9)/,RC("8>Q5(*8GB*42AM)Z2+N:E"WF5K90LK^D0K7_]4L_Y='5W=_4% M@*_2_ZS:X-&BU'ZI8FTLAI[&9M#**@FE))1Y"&6_))12_)3BY_6M7W*VNZOK ML6RM1,^2Z*F^#?R4]%$>G_+X;-'Q>;JJXI/O^8F88M$15IT8O^KKUNGIQ=?/NS<,6U/% MG)X?$XLSS:/:P<930$G_)?VOB_X/CX\VG@)>COXW1%=X4:?&MS#Z@8*4;(XVZQ7#S>>%,J#4!Z$M1^$_=J+Z0];9S*XU0>IS'' MJ7I8N@(W7I79WOR.MZ+SSN0K#>`K;IBV$;R7IX_GBU_/ZW5>$&T;9%@^8["[ M4:D?EBZ8\A26I_"%3^%QO3R%G)MWBE/\/*0&/%J%@:82E+++;$-_WQOCU5]L(^[WZH0E,NE5KFV*_"/U/-=55+P0&"@GI<`@Y$6=I('1*1Z4CY`]=+3**`2YOS) M>^1RYD:/K`Z6:J(WMJP2RNN\_/YFN.5)2"5_LR*7-U[\8TJ'BU?.)L]3.J6J MC'6%JQ]3C;:N%\CZ;\!).AZ5I7K)-M8XH/?,QI#\IMDLP>Q=3F_E"H!SS>TNED+%XABR`+FL MBA+'(;)@X6;\U2A3IYJ>9T6108+$W-2<*QG+ZH&X(&PJR9W0L=*HX&HPN@DZ M]]V`@7Y6?<+R/Y4UAU_-2K'F<%LVRJ$6U4;7%N%B/PSNG))0/Q;[0=62[\IJ MO?#9#0>J_*S17IG>LCNRWBHH)I'9QERVD[D:TVR&>.JL"IG,%65A3$W92.;& M`DPHX71C^=IF=AR&783N-TJ[5G[:RK>Z"]P*M7C1+>^X0M%O85^$`QO4&<>Z[MFP*B<W/-77"1["CW6'W6$=X\D6I+;JUGI-Y'I,$0$K*D4 MJDZ2,J%:.G!I[TZ.3L$42KB'0XM(+E^*C3N!T:AMVV?S#WC>:HND[14*I/5! MEZ.J<:CLH`BS@Q_KG+XQ=GH08++76)A0S>$,B,J*(3BJCU:)PW4ZV)>1M5X?CMP2A2@.:F;T3>7)Y_>S%?[%RGYN$AKM) M\F6*I).RK"#DN.L)0+>;A+M47'=2U[Q$MOP;V$.RB$#%0MN%RYFKIH*Z+.]] MZ*>(`^!W<<\;#*AK`G=B$['1^E:U.2`/FW@$X%T%*39@,Q^1#6S2`9SIN. MZ8E$Y>U=SR5:"3L==+F2HX./IGDRN=!UD%7MS[7P&N7EXZNPEAS^;7!XY#%9 M`SGR,&5F!S,J\@MPTRINI*.<5..ZR\J&%9'0;0[,XN7^<*7.=>LXK]+]1+2\ MVAF:A1E0!I"BJ+%&U8:-QB9S]/,&*+G4<;YX;RMG)E(`)V,OIH-'EKF/9;_D MBL2Z8ZJD"KY-_<@'Z26UG8T-XZ3WF(M4H@6+5 M\X+%LG8G3>Y%?#Y_$W2-M##7"/E!%*C6Z.;G`C\&6G>D^W;;XCR;Q"C*V,]* M8C^7,-6N3UV[6]2C\LV&?;X)V=1'NAYDQPLN,2]YGI]A2S9/)>V&&GE[Z,NF MCJ+8"!K[QUG(D1.R!0QET?$B)^W'"3X):@<+&2ON-&G5#QZ6*D?=39=3Q^@)(V.F@?IZ'D:J,Z@`KNM M]W4'6`Z*D4>F0T75X0?J_"0!`RE`_4I@'8%LFEU8"7#7BPX]A"$T$SP_9#&" M*P)Y\S>'_FG5]";HYZCC@IX.>C>+E@F8,B'"BOO"C24P1M-9:E9"^RK;FRBD M9%U_]1,(EFX@^E<:9CW#N85>S$D*-*YDZ@PMQ_+0.4_A+E=@"W,A>Z?8'LB* M^*.4�FB-A(B7D1WP)A-*?L@G?"/*-3<*^P!9J168CAG:NT[?L%1/VX1/Z M;A*16:):C*.EQ.A0?0M'<,%M%RG3(YL?9*H`R*CI8`:@-@=-#2)K4XJMPR). MS#"ZM6;-@RN&@I#O4T[!6,"<\/VL57P6/+D7NN7P1XXRHA*`2XX_3NS5ZYI- MMX!3J.@HCN`"BXB&6??$,/AH&LW:]J,O-3(SFZ^"U`F`YLRGUV_-O!EW^/EX M5L%-JSW=K^V!^K4QUQ8D0"B)R/?)-*:4)3SRMD<_`"D',3;GM75G[B$Q&AEE M!ZV2'D'&`Y.U1?*`74T58P+5V$/MD$R+%7ZH)JG3-;4S8^Z9^J(/9S62*#[ M2G=H=F0&`O8WCPP(#&Y@#(E4SBKS;N(1F>NG>O`9%6=J.1I&<"C^%MPSR@L& M*0"8QHP,.9SQKO(!X9":HWRP+BF1H%9AL4NB&'NJB(C]#7)8*0D4SY[$K#_* MX>JYX>08H120=C!K&-F?'5O,L*O)!1[B).QH0K&L/FDXF8OPY(W^++.S]0ENP20+I9%),MC(V<$(* ME/I^8`_Y2^(>'9_53ZF+GX2HP"*WAK_H;@-9#-D^W!I=[I.B!<7<*][Y%<;H(V]WGZ`-VR,6#=LE[[I?H"R];*$""M]%QST@
I=!*%C^VRI-Y?A3&]!XK&]NT?PF@LC4U757!96>*JA[39O7H$ M`,/OJQI`2SBDDHV>Q("^[B(DI#]=6LE"-KN-5`S[Z'!IZ#+J&0F[LK*L"3 M^,Y[SZ>+T]I=H^O\.P]^HQ"]Y?AA#)3%A`/?PP\ZZD;F4,^^QZ-E8_J#)5M@ M"HRDL$?.%>@;HB-2:#5/!T,F(GA]O"T$YJ4\.TBZR&[0@05G@-6*K//\D&UL M7`OU^/1],H/@.//2BB>W#QBB&'_:[H-EQ<)[X5FDZ& M&JVQQFL$5BKB\$'P_0!`M!AD&H*[>$*UFD8FK=Q" MN2@V0U$]ZL"AC156[$#.2>]2MH;$^2RQ0'WNF%N495_R.1B8`B9WCI31.S2;4A`'E``&NN*4LHS/1.3IN9IQ3 MS#'E)!P:%"DN!W)&/0-.9B1>&F:P9$U'C9SMJWL0A4GH_("GC>1MQ*/QU(V@ M@$OV>P8'K6$"("89`SX]NGV1<(QR8#L_@)90&G2\;LJ;0\-B:#0J8DRYO04E M*ZD+'YH.0R,7YJ$7,LK[**73P$X34-))"W!1B+,#%?;`D+8CT.*0]A#E7KSR$+99%N$*LR$ MRD70Y4#J!96%M18I6TK4=:]T7.+RI![2#T(Y,%WF<=C+5MZ2E7IHICFNO!WT M:_R6@-YE:02R.B MUN0NL-S$BU5,:$0;M\=MEMX2E-:KQ<9>/E%'9S)3=HZV:Z0],:J(D[!>,40' MDR%R0AEONR((Y)L@9":XRSR@XS.:L-F'A.[(<99(%&:]S3%(H MFQ%Y%'_N$'OM@PYLFRRY8AE9L#'%B2EI1@O<+,U"CBNMQAG,*I8>*+JB`-]V M([NOTS!,J2\%NG3X&2#H],F*84-V,`53ZLQJ%%CGQ$$0X7H]"Z&/Y%)*WLK. MP@F@G/&Y4LG1F"0Y5JZU-?;VQ\Y43`6^4'*;&E,(2E30R,LDO?)8JNRX55^: MJQV.N;*V[J%!4>TU)-#?X/\PW>[-ROMKZ;EA44FA[>Q^'V*H)S&$\1F\>*"B7LKI&%4,^S\3 M69P'=1]ZCDHN,@2=XP,;]3H>OZ*#1A=TEXI<5:HXC1EK`@U#/YPOZN4%!1&Y M74SF^53MK><@+V,QW*+'V_ID6$2<*+%CA0*47QYFK/&<1L)V17?B,L_0<,TW5 MB_()\5E"Z^AL'+7*TLQ!20[3+F?C&^D[GWS;^;%[Z_1"Y);\+G$W7$@_=(4, MI^7@)M:4OP2`OL%L07C90<;O_TI!><*HA8CN,7?>B`UBF/O!CES%1],XI5M8 M3H@WLEQU"1N?P]HE5)&0WBY#W:]FIZ"A9O5[C%1105"8^M=#";PUQ`.6N/]'@.6XP3B442. M%U.0V94U[-19S%]&2?%.>4KQRB"4X5^J*R#O"ZE:FMG%7@PHJ_4N=RWS04AE MC/`E'1@(^FH-Z/UG,$@/1BWB#9S$S+;/F+T4-5X< MIS(ZBIQ2%$\3[!?F6&R7$KE);*K4,Y?3,__`F^3(*A5$ M1V@@8Z*(QM2E?O*$G[1:2F2.P(!PZ5]STELJI3D@Y;5%%FY)\<)1&J(X-7*6%'$MR\@9UP3.'N^HLJ9]WX"$+=Z06A'W:' M.0K1#S%^]C(N>%=$4P4!9#7^0?!=):M9_7W08C`0-3@;F#<%') MDSWK=U!Z`>2T@ZHK7;JP'Z5:3!2)\HW+-[*/L(\6&N;OEXNJRP3.;]P&&'V#;4BPQR+5@(A]2O(:BR?OXV%)`MC:"NGQJJQE5D!2 MD*XO+[5Q];M1:J!R'(+\^^HF2:9;[X_1K5_9:7L[[GZ#K]A6\A#"2V*0L1*Z M&<3'69<3HEHC^"D-E#L<"8<+Q%)5\CN*G45801!'\SA.Q]0H-+&K%XC3F`RJ M/=0><)S&8R?`@Z";-Z%1'PK&!-I$JE:EP+(;2S!I/R37Q0\L54GG/PB3[$:4 MGIXN#=$UMA@7P\$].W6]Q(PA`B<-_50Q4.UT&`R$[1,S0[;9M66X+H1#3RD& M7'R+41)CO2/7Q(FJVZ)0PG9RHB[;JCJ,LD:73FZ@A=&*.EX'.#\P$X>B`KQ6 M@(\/;R1L2H?D^L>ZX#(<\,27EX5:P3"S\O&.$?!(GWB)H3I.V&B-N:SU69P; M;'QQJ8)*^]I/V);PDDFW=&Q99#2+]]'5+I(@*#%#IG/ET6M'[MNU>BXP.#.4,6GJ_-2Z_:2" MJ^C0L#-L=5./>UVV;G\'176/WMJM'E?RUX8YMX]"Y2=TX=91E4A/U'U=PZU= ML.0E6O.6K:\+4_BO6ME MC00V!Q%4$=$DJ[2OM0$N+*33)8-<$4LS=UO?/];+,O''`2)4.>3%7Y5(0=4$ M=%4X%$1`^+H2J=91\4)8VJ?&8JAD4)L!BPFNKXJ&*F76ZP]\6=>3NK+RCA5V M,Z(K(8&RN611<.IAX/)7^1?@8:0Y^`]/3G52J6E/C"5).#F#;U&`;N3UI0\T MSJZT8)"*'\M"'G8'XQPZ1Q[[^@!%'^Q95X'5&D1@F=:/I>>S>#(X\8O;.;@1 M#$3Z-S?*H!("&DS*%(%-1/CE>;%2,GN+$Q^::_[&H1X9YD'$H!80*[-2M9?H M<$)M.L!I.#+9%D#N]T*IZ;%&:59#@*D`BU<3P#7&*1_*6LGPXS?9:)9%2_6><\4ZE>6$,'Q,A M\;H>LG(XY%0J^%I$'5P"3GV'QED"W`N+DWX"4)P>4K8K#RZ.=Z.3+6]ELN4U MG?Q,S3QG M:U?FR.62GTU!C+9E(JU2DEB4JBH%Y%@(8Q,W&C7XIKP;3WE?5.N4AIJU%\K< MS=@G7XS_EQVDZ/>K*0Y]!L("2[EJWN91"10NDB/K9`TEMI*I4[+L^V"]JU&! MH,QL5@J#1()*;H0%@78A[SWHC<[S>RJE\J[^/B]/1X8V@79&[4BLQ2*6@,>?=P5%F39-JQK=?+"O3K2 M385)A%1$2G4-VQ$J/U^7.D[\PHF MX]+1]]:B),`_A=.VV7K#)DG8-Z5+M-(N5B<;KTUD6D,S)Y!.M:6$9/F[MG,H MM-(&=H<'4^9+F@E=K:Q%^4FHBG&AX/P<(K53C_C(E&:%Q*W)_)\[(O,YP',5 M!,*1VC)R9[P32T=R+'?1S8PD:S)-$*XAD]W@J&1UKO\1F_T/)(O2WGNC]44D M#W@F;\,H%Q/$7@U4'@[%!-6`=,,4^Y81+HE[JAF-+N].#H7=D#L7$`J5Q03D M0/:2(>/<7".0\;*$##NB@'=A]/2QLCB$[%U/8U>X?&368OK]++V"K@/D+$=2 M"GC3BALUVT*LR%Y/45XDC3=!3>EYQC8N`SY&;Z%5:$[<,8\1&\Q)%H--PI(? ME_PXX\?GHAV1V.8.Q46.K$T%-EID9)[+'>H(@A-Y1$JR!I"B'Y6CJP)6F;]+ M64],3^RI,8R2A/*78)YQ\>2P+]9J%&V2/2V9FE&EM>.GH MV/-2+Z0JT?R\OFZ@X7=94_8G3X*=__IS&NUW;'GRX MS6HF9KZ/:ZPA"?1T)QZ33SZ8V;_^YW_\YW]8UC_U6^@7(;?(25Z1!XI\3&Y$ MYY>=ZVKM._R##/\NK#:^-_CO'\XT!`&@,;C]]_*)W8"^UWZ_+B\]/6GC-28C1=I%W9!_5LS7FTB4_]T=7-Z=K-[V#A;5)8>"9W%XAR@>8#:`B!=%O9Q>??\,= MJ@\>C=]=];NQ;,NA2UA*KMW]^_),[4<>E53].R9'6D2XM#ZU3O[W\\W5[U]/ M/UC_U:'_C8C'CQ8L[N[BI'6IYH--2L*^?/";!!38YXY%,O"7G7KSIUEGFO^D MJ]BSB$0*OVU"0.VMKQ\0@,<##@#0>'U19-#-C@PCC5KE52"E)(JG$(5R=)1T M,2]=2%.AE"ROZ1"M?_U2S_ET=7=W]06`)].C:M4&CQ89Y%+%VE@,/8W-H*U3 M$DI)*/,0RGY)**7X*<7/ZUN_Y&QW5]=CV5J)GB714WT;^"GIHSP^Y?'9HN/S M=%7%)]_S$S'E.$*\F*)R8S_H4&R\!+4\+P;ZGNOZ8G-XR8;M_^*K_^\E%DW- M$,>O^KIU>GKQ]?/N#C M_PW1%5[4J?$MC'YP.R.J=/%2U#(W#EXEM]P"O?JYV>8*4;(XVZQ7#S>>%,J# M4!Z$M1^$_=J+Z0];B\\[D*PW@*W@Y',%[>?IX MOOCUO%[G!=&V08;E,P:[&Y7Z8>F"*4]A>0I?^!0>U\M3.)?2E-W@MD;>65\3 ME2VZS3[G!>;BQ6?]](W]\$7EM.1O.;?BJV#B[>;]*=>Q&SN_'M4.QQTZW M)$P3KX@WI\-T>'ST!)@PH'<17',X;P%$'4P'JEX]'`]4;KYEH9J(JL/I4.W7 M)J!J/JB4\_(S^BX7P-71#%P!V8T'*S?ALF!-1-;QS"V<0.Q3P3KQ[3B^ZGSC M=B57T0W*PC-N>BRN(\\1^L=8_AK7YD?F0:'0Q/>!B+Y3S89"68?]9@;Y4C"I MA0VB0>^#;E.)I4(+51.:1GF,YO?Z$?W]_>XAO)/7^L_#-$J$",[^2KUD>.D% M,-U))%PO^4(7&],8H;SMA1$-?RK:R=UP(%J/7EQ8?&WGU^O&P9=__CP*5`[< M:]FLF];V!W4JGH+A]<`ZI;(%;$]3UK68`.X(55&?;ZH4>F(/O,3V:<]C;(L6 MW0L`.SJG[C]835U5`WW>]3:,]5)3Z=A<\L77_O(@V7;1 M[5"]I4C_N!:]"*U*\$&I+H7J(]=264K4CF:[!4KR6':PG(8&%^KI151 MHU8\&)^&V2.R[.\5%28Z>QQXW(AI670U=W[]&F*?&*S(=(\%)8Q6\+KZKMGM M/>O>DK5N+]2>`W1015>+JHC?BQE//5`M/BJJ&8!JY[DI(S_6VO'QH77M MVUA]2M6&@N^.Y&ZN;).*/.$;-082;NM>1'97?$WQO%YU:+"KK$0MC.LYK<`] M]?PTH2;O"]8V.CB8>K)15M8.]@^.<\)R.>#6NL1IU'PX>XG-H^/Z&I8(2A>0 M9S)$`DK@,63$U*#R]UAT4O_2ZXAYUO/]4^KY.!T,H?Z\Z!.54LTPDYM/G/+3 M4/'V[U]`Q^FG??.U&R38,8S_"(1RK?KO##%S+&E;L&`_SHN%8U1-CC<#"U^P MZ#F(F*$YQOHHX+"*:W]-2Y][VP]1(SW`$.$]V&G02[UU\$P(&Z6)2) MBJ8MB(3".NN;L\7G:02L&K1"&./<>\2_%CW8A<4!>[]N+K0"8K[[@=,6$ND.P=A*#=MX1 MM!$QXD@K*_%%P.T>YMI-Q#%J4+D=A.^^VOUQ6]6<;674]H]JA\V9)0U7N-"Y M?`"&2C#%."OH7H?3=2]>[T$#EEN=8>X;TZ\0W"+%3M>C&-S#QO&3P!VK=TGM MBNU'X^56UDY@#L7WNV&1XJ&_M_VBVG"KRK"RQ7RBJQR.(=:CV=AH'AW4:\T9 M2N7LQ:T71R-R9H4X.IZ-HT;S:+]66SF.&+@O(NF%[H6N&WRE;/.,IT[UI9ST M/-$!3NND:`9?8<]D$9G(N/,2]N,K"W44"4?568R^GJU^;K!'':8Y?2#^*I*S M1]GF%5V95)IX\E*KWZ]C[TXXO2#TP^[P$M89Q,)<*2Q1=$!K3,0EH,(MSO=I M^,7^,XSHN(_!P90JM6,KP'C8>VQ'_EX8=7\&2[#Q,_[\,SZX M(Y]/0+WX98<;C@EWYU<:_.>1T>'[?_Z,0WD?\/\)BO\?4$L#!!0````(``V" MK48D^D2+00@``)9J```5`!P`<')P:"TR,#$U,#,S,5]C86PN>&UL550)``,9 ML5-5&;%3575X"P`!!"4.```$.0$``.5=6V_;.A)^7V#_@];G67&)'ZY=?G,0L>02HJ^&FC=7#8"(!'(J;\_K3QO7\5?FH$O_[]SW_Z\IE+$CVHA7S0.F@=?`KT#\?A#9F&1X>MC\%_6D-49),3II- M/?YY(-F!D/?-H\/#X^9B8&,V\N19TF^5<&CJ04VKFB:"?"/,#@;9 M&/KDN1ZLC-@&8*!A,7`%VD(E&(UU=)\1ID.D-P)(:CJM6MM&0)=RG>Y@`P#RZ.^Q.=&[!N?5VEY>I_1%FG!,UNF+B:;-6K&C=@!&]=#PF MFA(1%J7,Q-@U`L^8 M!,\)(+7QPBC]H,TD$E,G\.E,1)DG,EVAA,QZ$_(!&M2 MZT,36*(6O]'^_A`>MN8EZ9?YKW]K*V52V$PS(@9FGO?;^H"%:[8![SR5$N=, M)@-Z/$OQY6PSH+*5K"/YQ^;^4/A)FJDIR3J2< MXASZ!V$I6)AQE/>&L;586R?.T1R/"9VG/W4'$2#^`8-OD#C,,*O8KM!GMZ*8 MM2,?6.OP1X0HY!3Q6EC*#ML55K*HBUDX]H&%6PD30N/+YXFNY)@'NLD(I&N1 M%4]JIR=021-6BVYD3*[BJLUG18`_B MWY66]9E19,X.='&W9*J[&/?^;5W`+\H'K6:KDJFJQ=H[!HI,>S4Y]'"6Y`5^X7YH9Z0),[,7GX M/OI\,[?8C%(;XDDF.7I;#M M2L?:XQ!?P)!&U%;Y7(1WBDP7@SQ.F'T)1*5RZI0RBP;O%%E%!E1O'89;VHRJ MO%JQAC?0*2U[+HIV%;_4(RNP[\A MC?TG8(]P@V-&MI/L.DH\F#[U*,WW(>[&>MRAE)O1@TCP^)51G17?8[)7S?2X M=RDWH#^B\O4LKTCO,2C&T[OME1GE` MK"4\UPG)0/>8B!YAH.[@$7@*]KMEN9$>$%(01KFSJ'78'I.A[QYTAU^%B,UY M&\A'&H'J"19;F])RH=V@R&9!];9`N/UJ-;]FZE2K7L9Z0$Z-A%9@@,_<],#4 M38RGY.7!;BK,(^<36>KSEXC5!-7*;E+ M[%4:X_%6Z1TH0,?HEY`NL.8R8:YO5Q-8(;=+]%68XO$>Z&*144U7;J0'!&UA MU95S@\\5<6GW'.T9IAG[\JM4P@.V:VRC%!C@SI-GVY&ZY9$BC6?3[TA*AR^+0#O"BCR[?ER0 M:.P[NV]2[,'4>TT8K,_,M[K!XR[V[7O\6\RI&PCZ`JIW9%/R`B82(FK,L1"7 M';:WO&7-]'C-T69&.1;*$9%P1DSY'.N";[!7=[.N"O:6:E<'>+QV^4HHUPFF MR_6&;W>8>95X^1ZQ;0O!4<'>!H&K`]ROOFYEC9-I/SH\_TD-^X+'07QO(\#- M_.J;'S[QO_AX![7NSE?(_42,9^PNIOJOGE*]]OKUJ^;Y4O8GHCQG>S'M?WM; MF<]_5D__IAA._H7L`C+KB>\=G_7,+Z;TDP^=6]X&\]KOTBWS%]VJOBSEKF3O M0N$U3B@.B,]>I/82[^C2I-YC\\U9L0>1\XZ;;\YN\'@O`&N8V2GOBW:$[I%0 M^DDI2YC44>)!2&QFNN2^Q57#"=5[>MM+)@@[`HC-H6#!PM8U).IHV=^8J.,% MC[-$B7>N*"<\>H<"XZS8@\AYQP+C[`:/]QE7IT!'J51_Y:\[=/LFA8.L!P&P MF3UGJ(72:P:PRMP?>X=UE"OM)70T<0FWOS+A2M M">P:16OPG7N$XFKQ9?F_)ADW_`%02P,$%`````@`#8*M1F:N;&WX*P``IY(" M`!4`'`!P.2;[*V=I'P9S]&)/7;9WK-)I5(L MFH0LGJ%('5YLZZ3RW],@=:$D-"XD($";O.QX;0#LKS^0:'0W&K_^Z\=Y*0S"]( MN/N=GY\?5'^%IGGT2U[UOTT#OZA4)91K#VU!_V]_WFR? M_FJ_=[A_U/O\D8<+N:!-6"P>TQS@Y*#^XR=0U][>KUD:DTBGD/9R6#]``;9"\D;Q2Y"#Y#^A1@#5:N=7&QM6"P?P:/+L?W1Y(SB#:!#QFY\E,"7SVS3/'TCV-/(7A*H( MR1W&K)@M5"HSFO%9#(OFQG=`WV1FC[Z-5_/*ST[W_IS?P# M_PR_\N9/;SP4@)$!?+'S^>@@+XFK9WJB+M[Q4E=;%OO9?UG2+!:Y:NX=K8B[ M)/4':*L62D-A, M']HBK2GD];(VS#23'*U:FP: M)6L)C$W:EI>R9QA6L'S1)MZ)22)8EJFNQ6LN/5O;)]O1]@5($E)I;F+_%5'W M2AOO=-?TO2$^6^&GVYW>#R2+4K!PPVMX@07S?*6MU]\U`E`8;"+ZVR7B)LH# M/_X/XF?;(:7> M@#^2UR@O,C\I?OAC[%O%:NKUONP:%R@,9%OY99M$7`&4S(\'24@^_HU,N4RL MM?5ZO=VD@H4#X:*W'2ZNRBQ;^8#R%W&LN=<[W#5&N%`04CINQ]5>D)LH)MD5 M2/2:9OS78Z6E9]1!8O#EV$2!L-!QPRW+PG/FT_2VI^GX)8T1_:^T\)PFU8Z^BOOF]V5!T_&HJ/QU@M/1Z^WFAP0/."'WACKV_-P[<0!HM_L!MZ?9.F*C/T(5"?P"6^ ME-J=@(?L)^N6O/IQ_:8B00U&*Z]OTH*5BF)P2-C\$K'$-Q*Q4%LH4*_W>A.O M;]0^%88C,!UBW_R&U$:"#N;4[$9$H;6^#<<-VB\%%WD.R^?%"]W)!P5G*5AM MZ/4MVJ2M%@6&_$:""AWB;GX^HHG/\`]-VGOSXRH5NKCRLVP*1ME?_+CD+=92 M_;V^17.5PP42A).&9"1>T>&UJA/_\D<2$!`;5L`?I)BY!G@O&:>;U[<855)F M3HC$2%RC/6$TPSV!L:<@)H>@9C.O;S'*I$S(AN1&(AGM"7C(R,2/PF\?$[K3 M@Y?^OAB1K(8G?G$D>GM]BW$H9;ID`1D)?70U)R0^=*M`+(:CU+]L&Z*;"7MT M>952V*@5TX?8KU-$8>F<4#N)_VWC=?/.+$:I6KP\`B1F@B-=7QOA^^*=60R' MM'Q1*IG-Q#W:Z_LV\E^B'9+8^C-;>F<5H2*O]#P;"3#"DN^7\X$^IU2AO M,Z]V\,X;S`P@9J(GG4C*2A+>^=E/0D\W7:6YU*K/Z>:=.;`Q52:, M#X>0GMVGR6I!L?$U>BA]I$J@0)AC$.W-@R]J:2!EP",'6O!"<&A0\ MSRO>RSMW8..D1J$(#<*9-9_#YFEW"9L>[^2=6\P";,>8``P24;7FGVADG@AC M&FM-O7,'=L`"=>-OU082A!E[?H@PC&IA'OPH'"17_B0J_+@A.\^Z%W;VSIW8 M-;=@3Q(;PJ]01V+.6XC&GZU#7H/HAXGTAQ9^_<@4UV*SXE ML2%\6G../&?$S\ML*O7MW&SLG3NPQV[%%X(%X<>:7X15>$?!!/'.'=A6M^(' MP8+P8\T!TC2KDE")+5%7[WR7-]TX)(3"T^UG`;>J.*F4%[Q9+8K^QMM\R"TG MXU?4Q>OU6]AWTJ)A*;V\YE[O:.M%3>34M#IQQ1CLYODB)%6.D%E]P=I+3&.2 M=62_KFE,#.!#<5H"UIV5&*W".I5RCB4*74UIY1E!-3*(W MH#:Y+3"R!"O#GF]8P=B[QWY%.)S+?F"]!VI54#J6K[Z39F!MLN,'DRYB3[H3^*/,-X)0#H0UN]( MIPB>:SGP5VFU7:LO/7F,\I^7TTN2!*.QGXG**(NZ`F#KU93;[GKDL+F6-;\I M]5QF<05?05<`[$;-93EF9%EE@70MS=XPJVYM<4S3*]K=RN MG0NP-@7<6J,MS`7ALFW-8;60>I#`/CZOX!^)=\%X+X#K@`.RQ=LJH!I#JN]< M`IX=10]HKD8IZT(:<9R^T_*1.2_A1K:_!P_>M86Y!4!]IQ4Z\,5/NY`?`2`9 M=2'*9=2H$="2P29@?2<4'.'0C072!IFBE;'-,06$U&]Y$8WIX8B;DOHU9_LS M^#'A)\:(^@$,BX[?5B\0@S8YE/K.*B`D7:5IG=3S1A:9.'QZ\!X@LL6C6KJ( M$>'3=SR!ET^XBF!1+6*1)"5(+E,9`V!9/)&EBS9UQ/Q#"A;.4;[[62B10;;2 M#J"8S/$UZMYA`$$XL>;%J8K<7_I5%?DQ37;T:\UF?O):;W(NI\LV#_ZTNF"7 MXEJ"2T(:'*3WW0AW^B8>!XHUZMF5]@DQZ$8\N<:T@$PO:QZB/\CT M"6UL:]ZG;^-)G$X)J8[MW5=R"7U/:!^`ZL#I17,?"_:D$:@#.6QB+;/JSO]K MFEV5>9&.28;YK?#&`,ID0,&H>8&A02BREA=%Y]W]<$5:X9<<[0,0C;J#I5=[ M3/MLK@1X$,JLI4%II\RM%50C=Z*U\$B?O^D&-NIS`?B[X\V67N_4@;1?P5O` MV/5B2!!EZ_,;/;^G:`@".I"&JZYJ!`BB:7WNH&?XJ^2\9C0%(1W(DFVA M;0P*HN\67AOL,Y*6F>1G9*,EB.A`L:H6GQ$$":+L+5TDWNXVL][ISM4O0&$@ M^M_2S>&J%V[U3NV6&T#5N*GM3;D156_U/G`E5;MA,G;0N?"TOKZ83OQD>O$*BPSWQ)A";X!D,8.6/:D9GWH5,`@O^G(WZI)1MU$"Z]55 M1L)(P`36WNL?6K1RI'7/%Q_1MKTZD-2#)O`8+=H`YIU-,UX#@?!@[9A.)9[0 M3=MH!3#4RQ'^TW!$?U;.U#32O]NK,Y=B!`NS]:.OMSY']&X'$L<\VZT M`T@.Y,EN3';,=;TA.4*"M6R%.U">%`G-=E[/Z&W@FDG8E!PAP?X%E!?A7V'[ M7H6[.%RPF@,P![+I5`HZBM$@--F[(&(KE_3V^@YDW[4A4@$>PJRU@#J5^>9Z M<#5(Z*F'\&),\0N8W&@/T!Q(P&O+'`('*=IFK\0(B/I;$BGPM-8:8%DLA-Z5 M)288A"-KD?#KDMP`XDL_^WS^85OEWHPM$@--F^ M%G/S,CLPB:2NAI,;`,!;#+MWH5(%'T*N15?%[`@"R-HXG#`KG,OU7?`Z`M@= MM1AE<"$D6JP-2R9^-*]VO#B9(GEKO41O@+VCIJ4T.(13:YZ31Y(3T`_==U[3 M,^9I5;1-_%YR^P%4VW6Z6_(H`0MAT.JMF[-KU![\[#ZK+C8/*U\!F&95RC?7 M2!7V!M@6\]N[V:J2X!!.[=W*R4SFYQFMS`Y>O[>CNPP>'J1BNC6/"EKZ\K>< M#,OX-AKR7D")WM[9EQVUG M$8'U'#XE@&`$UEN@>D>6KHOR0":JQ5O.35IX8^_0WAVI"VFPF[;8#;W#GDGO M%O..+9$"D0\70VZ[]VIM+^/TT.AJ(Y7ZPJ-AE3`4@+:;L+:1_WAX:-0OU2K5 MM-+BIK(WY=9V(=66-.U&+DL'E1NX%TJ;[V]Y@_`D(T%4V7OP_AH0.'6=08EX;EV/53#;DK M(?.+LABE6?3WI1W/)W&]%Z!TXIKUEN2QX3AVI=2&O(,\+]4(JWL`.B?N6.]$ M5A.*8S=!K5P$7TO+(8G1&E`Y4!U=C2`4!O<*I^VZ',;CJ,[;H^E?:>5G(4GC M0FXM-W%S'L-S)$CW]0XUGHCA/)![2;>HGW=H]`I1_+9N>0VN3F,%5$[>W[U6 MW_'^)8Y>Z](TG-K!W$X`UHTC-G*L,.B4@&?Z/FY4!'YY64$WD-WNB1M9]:J0 MTH1F^@YM<[2XX;PPRX^S_HVZ6!;]4M"O1.8'$M=NHGT`J>VHGM2[PC;'!+"T M.1>0%^Q[&@XS,GTB15$O@Y)GGT7]8.FVG2'8@A0%:,XY"NK)4_IQ`RB]+N$' MF#C/[R1^(W?09B2XBD]R$-"![=-!;0W(MF"=W45O0&T[B<(;UELJ1JW)778' MW+8S1\VQNP[3O5NK49FJ*8!91_G[5;SN=G&+E4S72SYH,^U;=7-.>#-GKC656T^1=112CI04!Q)D^DZ?1G;UZ]U1:ND2P[ M/90+*UAO-@9,1MT#\I6F%&D0D]D$:"1ASRII;GC%M\&>`=\XLFS>9?_F9S]+ MP*;]EW?95=E&$:CJ4BS*\U`-@W@&?7J"\L`*8P`ZVXX7 M_N1'F5+!I\]EJDK;1?E:YD7O_/#+E_.6K&T.`:!L5WO21QH&3Y\GM`MG%_#K MD/ZI=S')HKC#RRX=&K[/:CFN-@PPAS5J>VX:HOT?%J-KZ43?& M*)H\IX)SERU'`G48K>HE[8#CD"7)K@Q0A'=K9_"L\N[&CF.;$T"T&^G92\L; M161X#U]%GW[@[H?#*.#<'B;1"^`Z<-RVU4N*1(E%6!%*[27>48&_?9"@+*(W MHD0INQ?`=,#7JYM2'E:$4GT.'.:DHH8&_?U-E/A@:?BQB+NV0P%(!SS,&@CM MI@"$96MI=[,[OO.;-*OJ12P3O'EV-*<7P+3M*FJ;P2"-#HE+ZW,4+9]X21+0 M'ZMF!;LA"&C;Z=,I@00!A&AO3'=.K'M'!N)3Q`R:E-EU>%=?UX MD!0D(WFQ+&B-4=-^1(!LV[W3B<.NR!&R];EYA`+"%X!NN`=)7OAQ7/E#L$L0 MN@WH'=J\XV<+5/.!(TSK.RJYE.\B2:HIMY!CD`1Q&9)\D%1E>&<%>!=7/8JI M5AT1(._&\2`AU^V0(V3KRRF1%_`V35Z?239>IN!VIWMS3("]&^<-.A..84?,AMZ(D9DX7K]_7ETVQ^1QN MRC+2W#LR>JP&SU06JHEE7_(P_!'RDA=U;VITM#)RFG!2E:3Z@7I,ILO(ATBX M]+%W/`"P7F.Z[6JUB<.Q MFAIS`84?N=6&WI'1XVSRR]&F@OE$-,5WK-I%!RK<6FC:^?G M?7Y@;+452&CQ&CG>3&;LC%BBF\YCIL^$WWX1*W79"B1S(-BOH-1UT8VG&5]' M&0F@<2ZG7J0Y".M`!%Y2SUP,QG.$-YY^$^6!3]-7OURFB>B0FUQO@.)`_+PM M'1Q(QI-Z<6%ZG=CIK4)QH"AU9W8V(>G+^)5EYYH,24;OWD["WQ)Z7R*]D;MY MP9CC(J/>#`\BUC%=[V>Q' M1H^K=#W%4)$ER:X,4'UIL7\`WMURVVQC`@A/,=@K6*D]Y?W([/$D,QG21_BA M%2%6XWFTEE/>CW;Q6`J#T&X*T)>[Z^KQHZ-=/*LB>G%Y6/5EZ&JZ&O+=S\)G M>(K`8%YI!U!,>M2,&LH,(/IR:4U>3W^197[R6A^FN)PNV\S.7%2XEN"24#K& M9>)QH%BC7CUI4YM!-WM>F-."ONS=_Y]>#<6Z9=%;GV*HZ M:^@[5D_WR/I!?3/,"A`C9'?<]>-97XX&7L@A&)!=E\J^T`A$MIK.R)RGC,\\2&M&GM82*I_(E)W\KZ4'Q M-_B/1!P>Z0'P=C9UE0L)87-CE3%%H'`)LI>]L"JVT*/,;`\0'4@8%;Q"4K0U\2!460O\UT=Y!DE(/DCX MG`[RO%RL"O5_!8N=W```WJ0/U>C:IX(0H==:Q)\GN]3W56X``&_4XR>]2*IP MI<[V.F"$;6MY!5MDVZVE=9NT"Y==:VD-J+($%*;^ESE*P\EQ]O9#3U^D:K0$J& M>1'=B;3X"V$@Q:&MG9#0R)5;EH<^TD1VQZF]/(YJ#QDN11>')=D] M`*8#YXYX[PUB+?+@(&SI\UW,SM[\*.DS805=EN>_*`M8G:._$UAJ,^KA]9.` MW+^1[.CT+DV*$>HQ[3"D=W1F\:ARZ_M].B-&:-9W\&.0O)$<&C]&KZ/B.?TM M)]\^`I+G#UD:$!+F,P3B"R:5!P*`MN^5;$-I2YP(D?H.C51'Y!_*+*"WC3V4 MQ?R8.SQP4Z;[X?U[`J!'T>1/)`XOIW-4S^E\B&J\?,`PHU'GY=8D\([.;=]3 MV>JVKRTK")ES^DZ\5$JH8GSA=9E%R2N('Z5A+==O"3SN:4*":!@%"SE*)'L0`&:Q)IUN"GD8$?*LI9XT3)$K M?Q(5?EQ/0/@FD>RMLDINRJ+,R-PVX=C=RF.!2FP?.%2DO2-4A'UKWB9AS1VL MY$Z=D)'?ET5>^$D(4[^V;;GN?,W/`I7:/OG8`PH9Q<] M$D:T@$P1>Z[#CB"_0\,"-E:U66=P;5M]$"C38NC-YL+&T@,RJ31F9VD5NF$9 MSK=R4;5#,/4]DGP\*',7W6Q;U0XRU326UZE0WQ%86@A[>\=&.K>]2@!"^ MK+E?Y['B&X"^B/TWLP,XS`G[`N0="XLI0D/8M'?U5NSG^?WP=Y]^78K[VD:< M&8[UDK7X8S[[:][CO9MMQO/ZQSO*>@>X[)EP9N*$(LG&F/VUTLCK&[WOTI2M MQ<"`*%??L<05JZZ*G6(:WFSI].VE(S1@01-?Z?%WT`N9;DL_WL_!*U?E+ MP#::KL?K`V+OXI9"#`EA0I\KJ(UE6ONTOGU,HJQJS:5-VP-`(3L69S6!'YD0 M^A+WFBE?UU$>I"7(DZS-4/3+*-/9.]NU;9PJ-H0DBX<>NWFO8;LY)!'-(\DO MDG`Y+[<1DQ(^&U2^8Y'/+:L&F8TSI8'"#I8:`[E_SC3YZ^IO5Q1)/@J2A,LM M_8HJW]_?/T^R=$(M"Y@0^><@'1]4NESZ-0?)GU/0]%_@1Q#_FA1^%.?/,&P) M(OZ+A3-CDSL)/X[Q MPRHR2D9>,0$>Y-YL&`X$#8M?@C0I8%9^JZM'?/V4D]=9H&OV]SB%=_/KIR*C MVP5W"X,?GYC>$WKE[Y_\US2KGO*`6A>)(H`WK M92K:F4:=`".;0D?I7R*0NH^\Q6B@%3?*;[5BL]7$P-7`GAS6(II.3`XWK$IW M9HG(2.U9*[-R7XQ(M@%#M.IS>@%O MT]LH@+F/&V>"'MY9SZ(36#-%4E@1>NS=FL,[1_Z#O%=_XGI2I08`?3E0/:># M0U(!)4*QO;JTG'/F'1A>[>\=VTRE,$8P"R3"KT;W3ATSRI_3FS()FSO!!BKT M8RO3&8"X<,N.,ENJ"!&JK$5TUY>6'Z3X]A'$)3V+_3U-P_=H&4]AVL#B[K#, M6`S3=W\1Y3$BY%IS6U7R#L83/\HHW"M8&UZY'U9V!Z]_N--?4AXJA++^]F/: M5RET2JH8?I*G<132:X9I3;WZUN'[X?V$S,+R5@+;X*>@-9B&EPG"J60N1;7I45-03DCD/H:+*(XG=!/ MC9A&;C^`:C'CKA.)$KCTQ7`-K7DJ:QU`&LM`<[.[:B8$/0%3'4Q,I\QM$;( M59K`-"IA)BU=_I=DF-)P(FWW['^0_-L'?"Q`\"CQLVFEA1]I0IVZH,JXFH0U M;BZ[QIX*:MZY?9YQ=;@7^YT!F;T;EV#,\7?R2`_OV.:])5W81J"X%LC]00JI ME72E'4!Q8&>HQ@H#`#]":Z$,I9\E\&KG#R2;'ZJ.`@F7"[>EYM)B0D9FW-K<.++H8_9:3"8>V]4XT7H[9>`"6V\9LYYT8/?S`3&T3 M:&1U1G*D=B>Q3W8I$9KQQN\`FK->C87#E&#CS8!B)`U.)TT2AT+970"? MWT#H@&G& M?W?8G''@.):P5VT[P!"\A4?$?RZS*`_K:Y^%E`EZ`EH'W&%MR),"YE@6WS49 MDBPC(45:G7!:1#*I=^?*S[+I,,UHOE[#'(6]41YD424(MFUH,Q:@M)@!CPQ>F)3WA\BH&.50!3(3AT* M/#%Z#K/=H<`3]@G,3;EWZE`@2.R&6Z*#RIWU/:PDH"RNR7M.&[=US>KS5U$0 MV5P<\4B@%=M[(.6EIQ-4QWP9O-A7OA[\:AE(W!@'-&%[L]2:]!9`'?-[,..F MJHD!@,SV7J=^IC0M'DID"U7]=#HC3R1H,Q`;_#N MUY?*K$O'O0E/;13OQ(5#JE+J9^S5VF#5=A2R+8M8%J1";T#B0#ZR,=8:&/4= M>.SZTG5^WP"0`Y$8XZ]:#=.U4X[R=K4XP4UY+%")`P'4%LQW1.S:64K$SFYF M5#?-;?6M"382J,.!8[(=)D`KO*X=UD3PJUN\`,^!//0.=')Q\4]T.A*"T9F' M:B`2<_9%GT&I,Q)C]-!QVTA,I2RU2`SGY/%.9:]>)$44;EA6=4U<$M:G@<:3 MLJABY_?##2_#E#V`(`76X%.!&I-.`"UQHS.\O*UIQ3B6E_[(7= M&B1VP!LE]\(QS`P>*--74ZX]^U!)_;/67O_<@5(RNM2_`LJQ*-?B;&A]H3S] M/*0)%5I@;W'[@6),N@4-6TP2T%R+?ZT**ES8F.V]LYX;UHV$_A$7``[+L6Q< M;82Y97[H9TYD->AS233\OHU/MV#QXO0!Z1VP(#BO!&O=$N)QK5AG=KJG7UQ._N&X6-2P^9:0(OID9'M]RY[^A^V`S0U1^Y7;SVZ/3(FI^L[;5'IX&K5,-.W4*OVK MV/L5+,?/-&LE(>%\IR*DC=T!3#@7 MLK55^>*!<'CF04:G("QN$:U[?=@7O3X\<2%A6XX,!P#6G[=*% MF#^GB!533:L7O_+FC>E]"E7^R2.!-S^/"C*[R/*!9%$:/I(@?:UIPO1 MH'`WJS=S9LQV=+(K?N+\?DAS,6[B]%VQPHTC_N$3>_6W.[XA\U6PCD]L9Z?PZ-AE3`4P$Y5P#D],6JEMZJ`4VEQ4]F;5.^M-!8N4KJ@/6?H6P6I].?T-/GB#9%$/[R(HHK7I;;MA.'#"_=;(BMUK:Z[>E4T%W1$D0123%;F? M4TDM27P"3#P.]&HQFVM[D\F<[ASS:E^324:"J-(,9RXUFP$.!X)YYAABSXA- M#3CF_[Z(J\%GZ6F7ZWX)\3W$<@-XIV;OV'"3?17=..9]_P[ZI/JX3Y[\F-P/ M02.@@V+Z$/MUWL)$D/TI-P!HSX&`\;;GA8IN7'/_@TIH:(]DI+#^T2B-X$?4Z8[`'<@UJI*E"S= M&%[7:AYM2CY(WN!KE68P^Y48;O0#J`Z$:TU1NP'4M4)&^&Q\\*>MW]Q97X#L M@"?!]&N[`I9?\4C#>3FF'%E)PCL_^TDJ4&E>\"Z_E.D.8!S8MG=C3ATO0IXU M]QT#/[T_=ET)8**H&5S((*`$!RQR4Z\K'S5"O3777S>STYB?WSOM.Y`UNA7? M<&0A`W("3,:7$KABM+=E[(CP)J M<,`'L(6)H:H2)!W'9I9P!Q496U]`60XX&LS/'QU:0J:4S9+K+$PW4>(G@4'3 M1?$!H+P_2O9+*^3(M+'FL&Q^2@=Y7@(B^)PV#FE*KDS,O@#9`1>)3OK$ZQ%' M$0CWUAR;W11C[%/AG;IP28[Y6:-#2\B4LG>B'0"!^;569;(^K['N;^),()5A M0!$[MQE6QX<0;P=5R,JF/ MC_CQ_&S2(!FFV;CZY$C8B)(C`'P']AF*9W)4H"',]K=_".VI'(_];'H_?(I> MDV@8!71_7$?E8#(^I'$4P`+3ZJ9U70&<.OP[O94XA[;9V.M;K%,6C$A84O?# M8#SQHXR$B[5[F:<@/*,F/8C7-UH^A'M^#5,\\JXH8G+G;%O[RFQ2R'!QXY$+2W]/LYR"I/)W<> MZF-Z0WX]H$/30D`5]/\%4$L#!!0````(``V"K4;RZ1H3S4<``.G=`P`5`!P` M<')P:"TR,#$U,#,S,5]L86(N>&UL550)``,9L5-5&;%3575X"P`!!"4.```$ M.0$``.U]>W/DN)'G_Q=QWP$WWG#,1)1F1M,S7O?8WHW2H]NUJV[I6C7V.28V M'!2)4F&:199)EJ3RQ7WWPX-O$"^2!4!>1_BAEC+!S,0O$Z]$XO?__K*+P1/, M/B>#T=]L,;H:E MB+/L&\+_30(?26>1+[PE7SC_#?G"K\I?WP0/,/X"$,J?/JV$"KWMM%4R?8.E MM"7G''`A7'5;))LQT- M[LN'G`Q+1=40%9\V_U<#WDK[2O^.J!G,TT,60B/=F56[,@4/)C+A,0]SDJ$= M)F<_W7_Q;Q4;P'R`,8(6)_BYXOVOW[/O]Y1:9MTN"+*PDA#_J-"JI/@F3/&` MO"_..@INLG1G;/-2E-38,.W.TD%5J1/5)X?AUX_ITS<11%BO\^_)#P1QWY]] M>UZ.ZK_"OZHE:0FP#AX:_VS!3$YN#5D*J85@ZB"(4CN$CX[I*\3HV]T4))L@ M?Z"B'_*SQR#8,Z3`N,BKW_0A4_[ZKWC\+R`1Z#(.\OQV?E"\H'<*/! M8PT\.O+W$41)0+H!E`A''TSF$#K:75#AQ]#^IXXT:]RL(KHP$B<1I91.&$7( MW_T(&VT[#H4*WHBGZMDE_EQ$/ODN#AX%7=NCL=JW??GZG5O_'1`"M[T[:,MV M]TH,>6K/K9>M5SB0*%RX1^O$E_OR"IV:$>*I9D0VD#SQ[T%K#SFZQ-2G1L0[ ME(=!_!<89._P;X8&?RFU$U3P,@MQP4@!H064V`]D"*P^A`VIR>V@@\%3'Q\= M>H<(Z8K)K>)"(C6WL.7.O1HK'9\7[Y^EY=_!XS`;5\/VK+=RQ)#GGAND.YV:4)W M+>^W`>ZCVT-!\B:(-/*)@I31Q:Q!KHEH"D&YV"[T`C!&T.+T(4;H]-'`]$*[ M@^R=P7@-7XH++,3GJ3AN->0GD-N:CDTCJ?YE7H[)W_Y<`"2-L\:L;EK4&@/&#&U;]^@Y[-''?XL*H(3. MBZIF09&"IF&\"B^;)NEA;3:?!JC9(--WEIGQ\@J<2&?\FZ/QU^-&LG&D[1"K MGA^M!7YTV_,C;P;4DUMH;*3Q:@">S[-F"S8>#-EANH/KX,5HWU#*Y2`^R'3@ M84VH`2;W=0-0HT]X`&IVB%-DZ8U0,C8?L"6/F8/@\FB@L**.8V_1B->Z(+/G M+]=!EN"5;'X',WK.I!&&Q2S6_40B/7=B6)*2M$1V4NA5]%7U0Q]+>IW@#DWZQ#,/T0$]1[M(8D7,4C0@K8[+N M&5(-N'M#-3&HJ+T*L^KNZ"-*MR_L0>HV>PP2]'=ZX_4R37(L5D3_<1'D*+_= MW&$4X%4>^]4A1PG,\RN8AQG:T\O4>*'(Z:03KD_\7>O`/K4=^[[1_MX"=+ZX M`/2;9*NG_57\Z_*[H/5AMB#$(>FC:=9EKZTQ%X-3I:"03]>&@Q"DPH M&_(Q*/#JZG9SNR>%L,BI'>M`69S39;1;,$1'D[X[,!X231HN?0B?.DB\5K6B M\F(8_?"<>K4V.7"4"IKPLV>J;=(,%%L($J8_H4D`I&FBO_[5F[>_R\%#Z6@+ M2K<+?L$<^RR-#F&!(U\&>($"[?9K1>G#DRT36M$$`_@0,PFW= M,M6'L#_0P%]9+X(%S'8H8>5.OB2_AB\!*;RT`$&>4W4S^`23`SE;('\MUQ)? M?>VXIHYV,.L4U#&,9/;FKS_E6*KKO$`[TM&2"6>?T/H,D9.T[[F8@(2CFF0! MRFCD3;`U4B6=I(K-J<\PAOIS%1F`+.8;!_F6)%/B_R/Y,T]!3,[@U/,10W[[ MV<6:>G$)MIB!9=:2'UJL_GJ/!ZI:S24V02R70FP.5[MI+@EN^ZCO?F(6)RDI M`NF'TB@HJ;].94<;VZD>,G0-)7"HH67/.^XR,JTNCG?8^+00(_;?/:VGH^TM M^DU8]QX#[?KXJU@Q_`@S#>DUN[\>YH_&-KW0%,5]KQP'89OWU[`92/$)LJC[ MA/+/EQF,4$%^DLTB95P.;J;)=."O9+6H`2%:`,90_L-7!YRJ9B?_Q4=?T\`B M?\5,$X@69X6[?8`RXN*W&;;X/LV#^'9SDR:/-^@)1DNZ.V0P8QS5G/W9Y#BM MN;E9W0RXS4#5$-D6(4V=T;;`LMQ@\]51Y[=%VK)%.HLMK,YD)W@$-\N=[`[V M(L$[+.F?@O@`;S?O4!(D(2(EGO(BHSO_I902U]?DM^[KNGKU`4WX`&4D#EVS M@A:OOTX]@]+I;$K;]%XC%/?==02$[?GG)W9`\PF&Z6."R`Q"?UC6X+7NESKZ M].%9\H`6D[\^Z$Q!F_ZFC_IBE'=G56=#E&3MGO,+!3PZP*J\F;>J#D,CA-$&FQL,06[?=8 MIF42_1'W0UR*I^]IN@W8+RFAJQE73Z)DI+BL6*D'^NN`7BAKM:"$$6ZY:A(C M0&NU--@>)CG;FB+)1S`R'/ZT6W!1#$Q3MX&*6#4G*%E]'Q?]T-9R`3`3[`Y4 M_C('KM5#CR;5^$]!ALA37ZND@!A#!2N9J=R<,6C#Q8&(MGX#YP;M?/>*&U3L MY8.!/CNKA\I;/D8Q0_?`HJUR\DYD"EYVIQ M.]B\T=&)W]U@7'3>U^(#):._;NJ+OG:W=K1QRV_N&(+6094,DS0X$8N[ZA@Z MB6-5*0E_W:&Z=;-ZE.5*\)6_&[N[=9KE6 M?.W>DJU[L%]Q>E6UP:3CA$\\:_>:`T"*WI<7$;H#F>A-^09.SA^2EUM7B(\9 M'H_7?;SG!CX&,5N5"QZ('Z2R^BP/+V._RRE%N;WB_`EXB5G;C^M(;7K:MYJN MTEV`N'OCG:>"*A('[R_5T@E>6OJ9$3CNX2%+\F\G#9G105"_00E'O3VM'@5$5#\@-L6,&7](6: M[[XZ596@^L;6^P.*2,D:N]VX['?CB?0L8.:@]TXZW\"C;%;8!R1VO`?XB!)2 M;(A<.&#"N)Y9G41/B'^OT-!]G0O!Z*!7YT(Z-%@O.YM_@B'$HCW$\",LRF?) M99,V*9NKTK,B+03%9W/0T"\`YEB`DL>+$6VL4EE+J006[KU'!V.":KH:`'-0 M$P:+(CT`;Y.YJ_W"I)142*&(]P#HNA*?>D96$%/,)2PUKWO?&\*LL+H,!UB; M%67@/D!1F?2"A\O;8@LSMC94#T=:W`[JR.CHQ!=4H5Q5UA.=(E'&^CYXR>NZ M9,P4Y2!C8R4X4ZI=R)C*$ILN%R-.5+-;^$;;V?B:-X:>9GO'46/NZC@LJ(#4 M<_/3#M%:8YY*8BJ@=RC7PK,7R!46DI)/-.5L_I1-&YXI*0J'^3(Y':W5OM8* M-EKA]5A9NONP.[`;0Q'(\-_^Y?O%]]]]3QGQCV^^/R?5IO,]>4CZ M"<9^3()G[VKWT4+'![4+P#F<2+.`IAS^G(U[D@'/DW%..,#Y-;#)1S17\+M! MP0.*4:'W?M4@M75@#LO,93$U5-XK&Y6Z]7U_8_NT2M!2!_*2GC8 MWR>_"XYD,U)_A[S/X&QOG)-Z'#2B+6\98JP"/CO` MZ`-]MJ6JB*(%>PF;"_#+M!B`$"$'-7UUG]\73QBC3-"KX\/VI((X3I_I*_!> M^(D2:P/>H@DTBP\N$LNV!BVUNP@Y[#]R*)2=>T./XJ=%ZHE[F&I0[5?%#8M[ M5U!`B'MD3P<_3F;_:NQ[`7LMO`QAW8/EJI;LW;U9K["N#W,O$4Y];[T-$E*A MF#P9=P4?BH]8=1/D*QMQZ1%J#:6>PL(L?="/5K4F+0#2Q`(TC9S8CW3.^R9I MS)2,4_+R(=$O?8C18_G@(-NJ_4&P5>O(U31A*W%!(\Q:KM>5FJ8H$K;I/7(C#8@-E$O3PY?- MBV=I^'F;QA$.CN3(HCAJ76H7,SFXB";1@+_5U1`#1@V619&AAT-!*X"M4W`7 MT.F1+_NZ9OJM;R__\X^W-U?7G^[I,[_@^G__M%K_Q8.]7C72^`ML>C"S.ZRD M"95+>0F((W4R@/2D'0JV:0(HS:*ZP;/*\P,\U5T"@S'#2/9_^?K;;[_]`>R# M##P1AM^!X%!LTPS]'4;@AV\7^*_DO[\#B&KW(_CNA\4Y^>_Y&Y!OL@:)5_;+*$KN`&A4@V/]-A=E#X4D,CO@XD8P(5%_BRQ0=*QJ^\R`X;I>"RD_U% MJ=P[E#[X^/*59LBSYU#K#`;Y(3MJ3=Z&B*T[S*#$W)9N2=29PLWM!V^9P`E\ M)!VI\@,SN7,F=U#@A7Y>@+>+[]Y\M_CM^;^6DS+WSB`&3A_\*M2X7-4;K>:] M6,6/6;T7U>K=@Q,9+8W8B4S>(F6K=D@9W%]+!@=5N$Y2V9T'FQ&ZL-`3]S0R"T6N0CBV_J<\!W*PR#^"PRR#T%QR+!X]^$61H<8TDJ3>H\)36K7 MQ2,FD^PP\+9'U1YH&EP`UB0@;8*J45"U6A8@]:?(]-Q6J14EA7L/!7D;OCE_ M.K8,I6T)N_NA,_C*P/,G39"!0?\"I- M.UZ,;M'^&F&T[D)O2#?-SA)N#-#6%H"VQ]X>82UZ%Q].8XO+(`[);DUY_?#C M8036W->A=2"BQOT5822U'UQG&'LTP0FA:!8^,AV[.)FA)[#.7EU&_02!U@F34V5 MLAU0-R0M2SY9WR@-#R0#B`;9$^J]2C9IMF.A_.$(PEH['-?9K8^TM@G9>67+ MO[I@29(6.,B'\2'"@Q^.]IB#;=!B]CR(8?ZU8W<8)$()IPU&G'[@\6.3J.PZ/PQHA']IHU&4:?90^/%`<41 MB]S5CZO=/DN?V*..PGF*(;]U1.KJQ64:E,04C/4_VJR*J8E-2!IU7A^4(WK. M'BP_X$43PM/T8]M;E&"4%U-RZXI,:;)[^+:D)9>`_=Q*!^H&!>@864%JT^]&-._ M7#2/AA[YE!$:!^X1F4+1GI^].V0)(AD+V/7?H1?RDWHV(6.R[E%2#?H@JXEI M^*[(/4*:NC_Z\-+M#*O)5V1S(:.[-I]0_OGB>`&3<+L+LL^*-;R:U44*E4J; M@2RIA@40'E"S>+-LU^VE@
@RYRB;I**N5J7HX;?U+B3 M=9+%I#%R3O.)'>N\3],H_Z@Q/94QV4_]DFG`93318ZF2>@$H/:TL[M$@JNX2 M+O-(LS\L3LP"E-%K3A?'^L<_(IAA4VR/-UC26#&4ZC9@?\*FJQDW><@#&#_02'MMZXN54#K2&[;B#IJ:>8H2V`>K-T#NJ&X5( M->]#!X!=)7CMG5,'>J->U\JXW(%Q4`=9<&0,"T!9P!N/1F:-?A'B3=4ITQ)_ M28WC[A$Y>W"KKMXL2_74Y[>>&JRKEZBH=3\7I'PAKV;W(*%S9BV7`UHZ3_XP M!&@_87H$.D_L3O+$2Y,6_',IX?Q`WZD\2*^<7=/7ZEB2!,:Q.)W@7-=Y@7:D M5`B[:5BN7/&/B3Q;4NF#K.(49 MTB:XPF5:)F4_P3J?4>X$,@Z[\)?*SF_MUL2M!%4?`#]=#=<05X.H`VY=!$V] MO](=4NK75^IT745NNED;#NZLZ.LW?%NE/X5J7A)JFO#"0V;7=BG0UK4CC8$M M?QMD%&8M%F-]#K)((QF]1V>_Q&I/3FY^3O[N5Q[YH&FYHJ)BNUH\\BNOI,.( MY/;`)*B9D?83%C_) MVU=-RY?;0Y1V%]6#LG*'Q&3GI>E[YP.+PLJ=U:'*Q!/Z>?VZ6&'>*3V,_ZKIRH.DEGMY4%JNGPF5;D]/%EAQ^^=4#%!:'F^&9.7&&TSD74^+K=P=;Q0FGM#/-VB'R%L/ M9?'D(UFE!\EQ^8BA);U!:\1M%P_:.O%EOREC_<[Y$92LH.;U!3EF_=9!TYA. ML_@@$MD84JR&6S3VGS=JR<>]8D3^YLW"E[,D]XC/L!DM][5R"ZU#Y::_A1&C M['%O5JX#%AWL===;7R]H=]AI5&?HT#G8\.K*R5=@H'_W8$R06I;?YQ*:U2(& M4**'@2Z=?0STY.0PP/[N$P:&+,MA0&S66:M6WZ`$K@JXD^6KBUE<5Z]N2Z]5 MP9HP`,KA>H*HT16*4M:"?K`7(E;)$YZ.IMEQ&?V"5S_TM%`2*8;)K0<,@=1\ MW>:2#+3HO'C?UNEPEY"9;M-P1;Y2@74!O MOSJ`0&[NF`?3+0"A!"4I8+2.2P2=1GRK50QDR.%*%ZAA8Q?S/R7(`/$PB_.L!W6)6+(/DLF[ITR:QCNB=E'Q+X MSX#\'5`"MR#6$'6C$-4F:H?ZOP]7<><[K%AT!S/RB^`1GLM"LI3-?:6BKA;J M*D4+T'"X+EWHORH%S+Q0Q&G)J`%'49:+$GJ)Y5)1S<506FA(XNC#Y&[*0_%2 M#Q>&:NC*VE".7_+3D_TN2Y]07C[,UU/$/?QEL!DL9"7%C,6[,NQR=.N-X,M# M1AZ07R;11ZPZ^X?$`70;L'^[1E[7_*/CL)T+-R0T=!IX7P%SL:N%>'D?9"#-V(.245FRLGYKW/4NS'3U]EB])ZK4ER@! M41K'09:#/58P)_Q?N7R4S?<+%;LI< MUAG8I:B:!NVV%Z!NG2V^6NTO0._%PT7WK:]3N3K[1!+GL?3 MKLN47B*!";E"L@X>XJ%-34T^VV60E7H,!<62A=9"[3"!GRF;ZXM`NMW3*RUL MTC?SE9"_?8C1(RL1*'GC1,'DM'@\IX&RR'K#X<$#)C-JXWKK3@M:LFKQ,ER= M`O+R=TB4;)[`7EP-509\#QX9F5$C$"FNWJJZ07R7!$MM#5KX-+ M>!Q57QV6?[CZ*LV,J(D]NF&N[(KAXJO*?I@05-^GT2:#QWM8%#&M8J-9P4C- M9S>L:NC1!TO)`AH>_\H5Z79/)Q"9]KS>K&1N)!4-%*N9&V]J M&YCTE^ZR1M!95J]@TFOP(7XKU,XR?X`=,LY5M#IDTXN)ZEKZ& M`Q>#*N;6-&L!R(V_50)("X`U`5@;KC=6)^A*(I3[4=XGNX?8 M3-%?8"";7^JQ>^1H':T,78SQ`L+LJV])U<,0^(W/7L4C3M^?1'#SP9/66Y2- M=Z06MT=^U-;)T(THJ]=>)%,.]_Z_^NQ$'-CT?4B`-!]YLWORE"X-&'-P) M-M"0OX?*TMXIC3^5](T[C;^0.J['W`!3^=;<$+%3H`F/Z'N`\J=0O]#<,NC, M_*CY_*[ED6)R-7NB(#C,*+)]9UQ/U,*5RGA@QW?N>X3-;S MDV!W>8@BM#VJ<-`(]?8'=@V\0`CWT2?I_2OY=^1)PG4T@ M>GQ72FTYVTXDL_#=YH;2^31*P^K=!#0-D\_:_XK$2R&]:PR($Q.'4.!\[J-E M?0429IX!-8EIK4^0Z=;'](E&G=]BGG/Y.&76A@O,:.LGR4-L(8DV`*H6P&\7 M@#3BQ1@X4=]/Y)YQDE,M8>5#0=E2#O:8V`OW,0/L@$N-0>LIW&QY>#SDQ?E; M;(>W([ULJ`E/G&Q0.Q,?8PV`\[?$Q;Y]Z[>+:6F;40]C[I5V_:M@#N9Z:CH" MJWH.I@+JJ?UKB7\=D3^=+_<9BB<,;)JM>NB%,AM,<].#7X,!*9S#W:4U/L'BO'!4QO-VLD@@]H>@0Q(IC!0&]_;OE`KFYXRI" M1\JD-Y3.U[I:MN=N9ZL-[Q`U?T;%EFY"DP.++=JOT^ND0!JG!,8MN4>:4M?! M\X62&!0I8.0>++8G=J<2HB9]:3%K88O@YG8/R5L;R>/M9H-"F"FO"4JY[.!>U6JI`:8'%#ZUG5QQUFU$%)Y`;"8P1^8$3@RX]I`<$;01VY\9*_ M99(G&$D%C$XG^0\GEGPM>^=$6_Q/,#K05$NR3[1GC@;25O)VSNGG3Q$?\M3+,(-Q&4;ZIEZ3&(R?MC="H3DOH).7N=T)LZ7\+0UIF>*.+:A-"Z MC"):*SV(/U7&HL4E*E/E]#&W(%XE!<0=5S2O?XIB\)06[0;K2;IS=<_KQD#= M6EF(I&X/E`V"JD7G+_9:LD/0M/.1R]"W3^P(0R#W0R66.&9&7EQ M"K)9WIZ\Z<-6IZW@%S`;M2,=JFR$,#&U4=BWD3]A<&S8$,3!:3'#2B"\29/' M-\`H_?DK1.%^;L;PCJVMWBYE@%$#1@YTE_UV'&><*FE/%><']6HX=<_A=;$TI=Y9?5!2^9#>8EC- M9[EFF5H/R5E7/4KH+I0G*Z.3)#E")RJZ4+&?=UXL_G4QURT<9@0XFZ\]Y$6& MP@)&>@=\`GH';SX,R\TGT%=TWAWV24W//_Z@M/N4J?VA"+U26I^%] M&;G)=4G@01=+C-J=(DHL:C'CZ/#`+@87UT_X?];X>ZI<(Q&'_2PCH>Q'/@J^H#++M+I`*<(4IX(2WA\0)'PG%B`(V_.C)5]H8$EMPE'/8&4 M8=W0%)N,[2B\6.Z+K=P=_M3;MXIS^8% M+VAWV'T\D/'V=M/*!5X>BFV:D=)/[]*,`"W`VMP^P>S-;SZD2;$58F%2DY:? MXYND/?<2'FL-L.;`[09T4L.;)FG!Q*I10%H%;WX#6+L.-UG_^UA#[^G#DY@C M8>9(-[36!C9'3LT1-.8@-2A198Z4F*/8(O+0;(Y>P(ZV[_KX9H:HT7V5<:Z0 M,2$2KI(GB/LB^X0>M\4Z_2F'UR\AS/.[+`TAC/)21G6AM1$-V8UZ8S3E[A&7 M;0#:"%BG`#<#6#N@:@A4H/>BG)HUM1?V]-8*9',HOMY"D&.-RNJ.54T,E.`H M!D$1O`#X0HZC<,3*FE*1242IHRHM14Z^AUF!9Z^DU#6>Q^,X5*#D0/Z5L@+0 MI"C1`\3AD;38*C?Y%,0'=K07Q''Z3"*$ZP`Y.IATPN+$2#+ERODVR.`=1N,V MR/'_%]61$>D#[JNWF]OG!"]#MFC_1QA'%\=*[G5:-4';RU<)6ZGW"(:CT#VUQ`K=38NN M#AF> MSE?YF>+B\T>J/^$U$)P:HT2->!&=A!H:."=MXU4$I%>H[908I*UNKWY=$AI MR=!.`3L'R@?@45!'*TP@D]UZ=V*/CND[*_%P&>U0$,8N->"8(LR>ZE_ON M4!PR6.WH2LZL1[3ELDR0MKZR,D(+4#9332>JANA9"6NJ/C)Q_&2B-=4WNJH[ MJK)DAG1)%:8Q,+>844?$NL#+LJA]`V&99;A'V5,XQX:D?(5L^1QDY>6=_/90 MY$601#ATL?,>63;>_-^RG\EW`GL-;G:'M`ES`1Y30G?F+(#YAT&'#]'T19(4J\-BP:TD*TH86G(&'VAAX MND$O@7^)DG+Q,_O[91W#7"?"M]?ID\9I+X3UM ML'X%(UR5O\"ZODE=.,4()_[6ZQGA)/8:'N$NY"/<137"70R-<$TB4CFS;#[X M2F.4L?TFS1`^UIE+FO9[%5%.Y;.S13D]AYUZ9C\A_EZ1/8/HDLSNXG@P:)WF M,PY.WV>UTO#)HV:H`H.AJIZ,LZ^!^G.NC]#_:;BQY^"GMUP9M=LE<$#0C>YY MBZYZMSA@EDLKRT7,=;IJ<):_R)]:EBVBN8N)9JO,>$1;Y*V);R"?=E M^A]Z/5-6D:5.N2/#/D:R3=CG\%0,TK>YWZ79!B*R*8BIUFD1Q*]T(NNK55_Q MO%;JTG,OW67^['!&VQ6KM<->G=2S4$3S72U/_^Z9L#Z5IU]@E=Y;^6\J\IY MNW>+ZAP<)LDKGC3_T]86Y]E3C:TY_P8#\^]J^@T>ZU&IS%CHW!*K$ZR8)*]] M:FX8GV>=LH\*SI.K"WZ`Q3:-6(HKD:C.?6T28C^1E.*,'OC2>Q_Y]0O^&\K) M.W(TMXS^5IGB=;KON:AF>!*[":H@LF^!YF.M5/Q6BG[U/9J2P;X(6I\L,T#9 M/3$?$LW^:?;A1:#(8A]TM]X[X-Q^HP=!$0!BH_@*8WQ=\$S)$&=/)^`K4L&U#U5F]P+/&3=96^9 M6$Y:VJ`G2&ZKYS`\%.3G(@MH#E`4',M5G!]CK(:?#@R6VD[Z"LXY>F?P3[CS MR8".!WFZ'+20I\-_\O672+[_24P]S>W9UIWM%B\HNIT^Y M+/`\XA_&&J_B$$K"R^#%S6.WF'+5O7@&I7B9($;@U>^^\':^C# M/59:U50B3*UR:=VR:FXCX22]B-NTZIYUZZ.Y]V%M#'(O*IL!T.(L*MS"Z!!C M89K%8KXF_BZ;!TF8[,]D9!IP5(95]P<7YS4[8\I#SSFZ M"TBI+\5+SWTRRT\]&B5ZMDWE!QK-Y78.2C$PNL!4H<+F)?YL MGV9!`?\C14GQ)]PIAPPJ']"0H_>U-#H$_YBN6:' MV$,6J5^_00DJX`UZ@M$*NWORB/"T99GGL,@OCA^"7]+L,@[R7/'0AG%+UA%H MKBM?<[9JX2PF38"F#<`:<5[*?F+']B$[J5>]@7$CY,=@IWZ;8U1KOL%9H+,Y MI$D-9=P4H&T!TIA';WA,Z'A#J*M[W>+K,\469IR`JOF`E,O^.S-2';B+_81Z M*-PZ74&.T\54"ZMOXJB1Q3V$HPLKQ_MIY/1T5<"=]`5,!:,?^VIM3;3WU@@3 MH%P>P$RO@[0VV02]8Q%LLA*4'^$S_9,4=)H-V`>?KF;ZE1"K4T%RQ>N943AZ M9^&!S@,,K3,Y(;[T M^7T)+YQ>)HY'F;T/+J]"Q2FA1:F@++)X&TV&/4XSF,C<;-KU4YO=.@D=J1)ZW" M(-^2NGV;.'T&09ZG(0I(`O`S*K8LN??`ZOGAA M-IF[HLWMU>[J_B,LKE_"^$#ZXWV:1L\HYA#?V:3387>P@:JEE7+[AI6K^++F M!16S!R.92<_Q&Z*FW683D>3YNGLY\D8F/M4<"^5AG.9XS']_0-'08PSC+.P^5@B\C5LZ MR5S-9KI-7MQNR!"7+Y/H'F9/*(3Y?1K+"K')F!PDVT@TX-?B.:VV1[*4,J7/$90WJ@LN<;[[.4OGJ[&7PO=I#*.OJ[,O;10?\* MV)]/B^V"M*U"MHZP>_IGMQXX54Z;CC8`TKYG"1%J,8N#O:6=/%ZS![ASC56, MA,=^!H=$?OYAAI(65,3*M8PM8(]3HWPT/?_1/=J5..(R-O1`9'$Q!F/ MXCX$V6?8$DVV+I,PV5^BR33@3G<8,9UJU>258W@QW3)3ATZSB#*[BMB]4Z@A MQ2T^-/%D<:X%$^RH,99H&>U0@HB3DK(6:M]0X*?TD( MO_)@!:,G/_DUNUF>,OHT\6!C2H(7X:Q)!!:KYW$0=V>A'@@X2A>G;#U9!P[4 M*$45UN?&\ELF:$)?)U:^VF<@+ZR&H42T)6SYJ&\(%`.G>F)$V#[`(TY$JC%< MI@GVK`-VKMLZ.%S`34I.OPG=.GB!^?4+'F/2+$))D!UIRN]';!G,B:T44[]D MFBD/`4_T54<'B:>RH>`PD@T[+)(WGP3--\$#_6@U3-'/+D#GPRP/?0&ZWP;5 MQST8T^R:EHZ-I=D0,UL1O/@04D[NI,/'Q!8\U':HPZ*6(?<"3YWEV^="#D;&@_F" MCBHQ_M.I,D?8S64\/&IDCNC(6LY"OB0R.XTDO@A;5BP.9K2Q&`\V0]U@L.@' M.$FDL%AA/\@2/)W+[V!6U'.$ M:JH1DYYL[$R`+ZJL-S,MFF??ZL!J:QQS^C&*306Z^#Z&%<'>C8RG3 MB/&1XW0^0O*ZZ(R1E=.=?)34FLB:ZU3)WYG>*@=)5V.^IC[HR8N<*4UO40WP M4E=Q/#.F=7FNZBL%.MF%ANTXCPLJ/;5GT@O`"DRUFO%[2XSO$CL: M]4I%+![@1U)Y=`A!'E46E?>#&D5N:X3BK\.\0.%E>DB*[*BL#BJ@MXX@D=S< M:J*DZP/(FU*:T@[HHT?#^C8+C@4%7";1#?Y$_!^'#.41"LF>AQ)$2DX'1<94 MNO"UMTC9>;)K1WE`F\DC>&EV$E^=RJ"'YID-WT@*KTIHG55?)0-8&-: MLS^\C=*9&_S*5MC@5U8A:FX(T'S"3EL+4+7F=C/#4_6MS@O&HYZ;-4R%_(0` MSW_J7?FIZY<]8FX]JR.T",U%=\C:=!*:@Z"31- M`=H6:#7FLK#?3,J3.G^P43$B$ZUT`V`0;JM;0=@P-!<@;(&7G(#$AX@>A0": MCB6C7H`THP4#@_T^1B%-%://K=*2(`?\J9X(SJL&3G&ESN`^W8^\'/P[<]9Y M9@"])GV>!O2UGV$P["UQ7LV4P)4I/)T>#/K%A#F"Q"DF3!2JTQCRN>I$1GI` M(F&P.^3+)!<>+5*0U>>+GIR>*/N@,XQH=L#,F%!N$RB8W&-#MG$@Q(<_>PA: MG:($BO-=A4ZN\O(I0#&![CIMO?.]3>,(9CD]%Y;,)XQ;G:LPS-Z[M[<-:U@OMYP$@82S/W33%LSVFK))4ERU'Y M>"";T;<;]@++;9.BHG)9PW:L.ZRIGL)DGK(!P%H@2UO6!F@U8L53-6?Y4Q5G MGJI\<\A.X)E'&19VRF[SZC6E4=[8CSP37-%QYJ0DO@CH__RQ] ME4BTX#)MQ>X*S%A'43XZ:%H`91.`]QOV[I8+?YE'VY+\FS\'61:0EX3.Z%+4 MY:G"9)T^P?):;LXV_'X;,A>BA0-"[+!Y5_?U MD5`&$M^#Q^!-Q]'^9V->,GE*XEW(:&DV;2+B;^20J#@0/$RG\IX$$8F2Z\X< MI"IM4$XP`*QZLE841.QE5Q)T]O214->9",;^.6X&XO_10'FQ6Z@YY/.ZZT8G!VXFQ>(93>H MJ^+A"8+N"/Z:3A$4@[86J.QYQ3(I4,0M`]BST3!BI91V^P-;@]UNN%.0XW`# MBNOS)_VJ=>\\K0VY]VA:Q.T-"%_N\EM`5-^GK,')M5]^#'9065U`S>J)AW2T MT83Y`A`NC\H.Z':4'F9%O31A"_(,_Z?8PC-,!(^.MQKE..KL M*^J`R')U!+*/?+MI[XD0`8NC1I$U37XWE1(T]!JLET#XP.VFLP\(&*NRD)KU MJ@FZG3=8.\&LYRR.\%%$"\`'\5V`HE5R&>P17IXI2W8H^.R/[0H]^/<4*WI` M&'"(`R6+1\4ZM#J'&]+U>\8>S#[!`L\F8%1->I7X$C%8!Y90>03"2Z"F#R.!)Z)984J7NKH4@IKX9B("7Z=*!\@G55LJW-KW1,>;\YPEM$OA[P@,_I\ MG0JF6U38AR"'$=GT@TE.=_T^D=5UC@IX#[,G%,([VKN?8)@^LG>81(GU]C[M M8.9^I+`X, MW+9:V&JP>ONX?"?QC0?AQY8S\\LTFY[L9)^+;,"]B]-GG3<$Y&PN=[6&M)!N M9M'=8,KAZQZ6L&,D6U>*7K&:C4EDNG M^9S;>?Q\5I/-W=?3+@2GQ,BBK39F4#_21 MWY*?0V+%?3OV'ZK8[VEX.Z4+2V?R)_%?F^4U]Q@&:/"N4Z?:8)O,01G,CI1\ M/&(A)+[\'NS0KT-\E;>>\Q0R8U](R!I MS^/>!R@AP^]M'<+AO,7DQC317B_W5X'TU_J6-UR>E%#M$8_6I%]HS$1_\1H$Y_ MN!F$W+0'4/DO90<8?0BRSY!.'].\D+V)JL=N_9E43:WT)V:$'=3\@#;@\+;E M>!4K78((?Z=`.5T9D1*SQ19F((CC])ED[3JMN3M>.W(L&]+%'U^WCC[,UZE^ MIVL+$!3M=F#BO`:>H>/V7]@J?S8@,;,&55.SL+DDW@XS1`A6>-W1TM,+^6+,F394>^ MNJS(DV9#GK@6%FE;Y?4GL0Z7+S24)>0^#LSC(_/F/GH6+\A607[*K&KC#_@2 M/\PM8QA'Z@^\_JSJZ;;J9U6CVCA>I1W.ZT6:D662"]F+,'?!L;KM%/[M@#+8 M.:U>)I%.0H9)(]8CA9&&?817S/1"(F.OTS$6+!]C0>?3?B5E3-*Y.N&FR5`1 M*@Z9#],"$ZUR1:;AUE3(]#+N>A8Z+Z6*?G)IN*O;@I^TJFWOTOX:=:A2_CR MEL_@;-M]%)C'/^:=9'L6*]ZA)$C"$R[?C3_@2^PPMXQA#*D_\/J7[]-MU5^^ M;VKCO(;E^T@OTHPLDUSHM428DT665Q=13AI)_)V-3+,.=Z`P%$!>>_PX3=QP M%2^(R'@5U2O"S6H5]8]/)='!K!GKLIS&*F&!)=,?>'"\?$2HG`4%<5VK3 M6A)*'N^P-B&"N4[$TFW`_@Q>5S-N M;MLP@H835*P>10N'*EJ=N!MAE)NWCP"HQ;E%E>);ECV2[7H/T-H?W0?DY4:8 M.G.[(O)@^TE'<"ID*_'\G&$0&#FW=IAB27U6EK MD[JLRCA*>/TB\I8?[!&Z`Z#K]8H?&'"?7'V MBN0-2N#MYC*#$2KD+^N*Z>W>")?(W4=$^1XHH25K&$;MP1-C6O;OW//5,[[% MP!YN870@R8]UD9/+0Y;AG]:DJ('6DD&["?O!7U\[+@B5K`1O-3->8#-V/*4F M#0"_)M:&?UHG2,22,N\:K64(K8DKV5.=(T M4(+7+\1J]J@$LT;=:0^U`_*0"O%91#(X2$8IV4.Z.%[&09[7VTMMZN4+DBTC M9VK?.M;GL@N74$$86CN=/>@3+@^0/RLJ^DYQ`DAXYB]BT:_278!D*].9VO?3 M7S3L8N@OC.^U>(PN+D9YC!DH;!;G*6=K9%FQ*N!.7F*2)W90;&=`8F'51?`S M7?A1.@^`*#8W7R-&;FL'$/D4/'\("IBA(-9"29?>'5!Z<@NQL@"8$M2D"_`^ M2W-'1>%,E2"2[ZJ_>X3S(M$SUX)[C\$=WON22P!/ M2$D*;4GL%^15>E3"[QF%1Z@?Q(X0]A+@.,`]GJ*@'"^,WZ=II(7['H,[W/95)!FQ1IFNROX4*SQUQ0[G0)Z!RD%PW+SY]B8 M[@R'WAT@E`M`:+W9@91:GS_"5II^P@GV\C&#-)62M"SOL>%@6[>5-_19ZP(&&PV_,RR3GGKVE!`P5/,A:4 M/=#!@J;Y[8T;-ZA`CS2'AN1@'W+%L#%,;GW4$$C=QTU#!AB=-P.&S.S]\4)M MA-;/Z7J;'O(@B=;/,'Z"IEET M!@W8':1,-.,RII]34#$#Q@W:N7>WFKEWI]YOF:PH!L1WP.NL0F.`=L;LD>B< MQZ'>X>XN($PFN)2Z"6=.I:&=U*TJ_E'PL^U8(Y0EH_"K<2U=J(JW;_DSU352M!9EJN'YP: M!(5@'<\A8@(8[W"W;(-R0_%/07P82K@54MJ%Y:"L7,GCDJC<*:9D+A&J)?0P M3'/V*%JET)XJ]$2:<(U6,6HZD%5!9@)N29V7&YCGU8;X[8;N@!/?$#ZG*.>Q MBV6%_(.EQ0A]Z^!5M"4Y$'J$+"NX(2G?,+BE5K]^V2-63U#J+C-^ MP/+>[HR6&;S0""ZXJZ6@U3RX.((V7?D)P+X!FH^X=]U3FJKGYWF1AI]!ROZ] MQY3D#FAE""_\?':/ZNZ]G\:=ID00TB/;-(Y@EC>K'E'6L9K%LI=+I>?\MD7] MZU^]>?N[:EWK1T*R;G]T$:7;&>[.97G>RX MO?K`SB:C1BCA#J.2P_[9CE#VX;-D\FAPC2+W6VF:7<`=[.C8?THUA-T^3H^= MT^I<40]!PF&Y(H),=JXF0DW<)!CD'N!"LQ>Z51$TNV#BVK]5>OD[.29$U/;7 M^X,R#Z[T6Y3@.Q_.$?3%3W<['-/89+]5^QNDA^(LW9P56WB&">#1@S6]&$/< M:EX%('O#Y)\AV4J`T1)W6_`(/QZ(,+<;NG2X/11Y$2012A[Q*@*%RR2Z0O$! M4TM&T;$-6A]D1VO.750I&P)E2X`U11:IM+$&WBTTJS+IASS0=RS28&]X'9#:MR28INW26]_6GCRI\=L M^3!04R,.7#4?.4&I.,%MPI^L.#TV'*F>X,![WVB-1[FHTIKLO&XA",M*6+L@ M^PR+\J!QDV;\B8SK+5HC''?/(LU![/CF6&N(D@1^-:L?]\&ZVAA<_6HQN@_W MNAVE=9E+V$N.5Q/E1(C-A5M"+J-?#JQ\BNER0J=%/]836KKK+BC*Q@96%:!I MSSVH)X)`:]IMBH`IVT-T"X(>CK26[8I-(BF/Y:TBN?R"'1=*W]DX\F3_4*<[ MNOLMVGWANFBV_/!V^1QD$3O!S=^EV0:B@CS$16;Z]8%NODK8RW&R8X[3?]N3 M4M[SVE.W*G@G=>.A3-THZ:K4#?KM19G!D2]`Z_ML>=I(0.NW4!G<1W9KL-6K MDWTRS)H&@AR&7S^F3]]$$+$8@'_HNS[^U5^ORJ5:ZS4Y[DB^Y;%J%FN.IB$] MEZ]3DG\#(C=\' MC8[EIVS:YF@-PVV2QNGC\0:%Y,$,^3)&QF%Y>U8F.[[\"#34HR7U9P*B[ MH;O1J.@#+#_3!X]&G_&_\;_P#V2Z217\_U!+`P04````"``-@JU&'E$VMP\Q M```-!@,`%0`<`'!R<&@M,C`Q-3`S,S%?<')E+GAM;%54"0`#&;%351FQ4U5U M>`L``00E#@``!#D!``#E?5F3XSB2YON:[7^(S7G.0Z$XRZIF3'%51T]D*BQ" MU35C:VLTI@A)Z*1(-8_(4(_M?Q\'J5LX25!P:EXJ50H`PN>?XW(XW'_]M_=I M>/)&DI3&T6\?.I^^?#@AT3`.:#3^[<,?@X>/5Q]._NU?__?_^O7_?/QX\CN) M2.)G)#CY/C^Y\S-_D/C#'^FR_DGG4^?3U0G[T/WXU9]_//W2.3_YOYW37\X[ MOW2O_M_)?_6^_O^3^]?!R<>3GS]_?@J@A:QHX=,PGIY\_,A^)Z31C^]^2DZ@ M8U'ZVX=)ELU^^?R9E7__GH2?XF3\^?3+E^[G9<$/9YOK[^7/P5BJ;TE[2H_Q0/_:P0E;)?)\(2 M[/\^+HM]9%]][)Q^['8^O:?!!Y#!R:/T2A.ID6O/YRP=O]X M>=SJ_BR)9Q/H2>A_+XCXS`I]EK?S&;I9LZ./H&93,O#?26K2KZUJ%KIQ&T^G M-&-(4X!Z&P/6:`Q#@)IU2]J,%6F]D;1H_S'Z:TRC[&_P,4^(F>A$;5CHX+V? M1``Y?8K3])DDKQ/?K'/\^A8Z]II/IWXR[X]>Z3BB(SKT0:F'PS@O*'J.0\I( M6OYKTF73EJUH:Q20*"5,PU)H.&"S\8T?LBGM=4)(9JBTZM8.QL#`_QXV(?]E MN\W.%>:]UVBLH6%IWE=9*P=3D#N2^31L0$-6#1\:RH"\9[D?-H9HU?Y!9IYG M4(HHFY`,.F6$R;AI"W!@YQJE_I#M9M+>:$2&3'RO63S\,8G#`/:S]__(8=-3 MG:B*/V!W8U6]^Y)&FIU(*XQRG=8.TND*_.O/33\U@_!S:V? M3A["^*==:C9:M0"BGXS]B/ZSX!HFNIL\I1%)C7HL;.)@VS;[&[5#[F4:V+UL M='^6D!04IV#G"7J[A0-F*@+J%BR1L-^H:X,J#&7PPV$\W/JMD)GHXD0E-/:- M)_N!WO>4&2>S94/0-1(6S7O:=;W3M81TN[J02F$R3,GPTSA^^QP0^AEZ?\8^ M,!AG'[]T%@;#?X&O5GW9Z$)Q/./T75;@PK]]Z'PX`8@C MDB0D>"HE)(10]+\08SU&1W[ZO6@U3S^.?7]6TDK"+%U^L\OOXFMO-3??AGZ: M+E:;WCM-.20KZWA7':=>TZX+7&?`QK(GD$F?"&JZJ*YY13L[&J@X5/Z%D+"!U`LPH"61'O M'"%A6Q2(25OVGT_2.6*2>M#]@$%X"/VQ@*6M,MY%^VC:`\#GZ0(Q3TO0SR2A M,6SS@CM8+!2C:JNL=]D^WH1`^/Q=MH"_!YH._?`_B9\\P#>JA6VGM'?57@XY M4/@L7K6&Q5(M]7G<*.]=MYW)'3!\+J\1E5_(F+(3B"957U.M\ M:1^%0B""P_X7]/S=`O[$#Q^C@+S_.YE+"=PIZW4Z;660AT1`H0N#C2Z%MWF2 M;"T-\GV-J+C7.6T?D5(P`BY=F&7,AN,##4ER"S#&<2(?C%LE/926-:VAN(]# M0!YFV\L@\9GW\NM\^CT.!;1ME?'=TK5S<&G%XQSY`;^,D?9F!6U;RNTR.=KKSYMPA*8)8N M`]](\CU.R9.[021[<^!@4,E\,;\K]-!W!N-:$CA5)"R-W1!'I+^:*.T MUL)9LVVO>^YN>:W8=[U%N&[C7M?I'99=AD4+NA4A'- MB4!4Q3OKN!K?NUW2&;;".MZ94^N=EICY@TP.Z6C&CN&330>C:K\W&N-*7,D[ M_^)J9&WZ:Z^=S.%_;OR4IOW1\P:_2V?N.Y(.$SI;N'AS'G-JC,Y&?]<[=WK1 MHDDX?XPW+YC&Y@D+OM[??+:UWGQR4F"8RU1*KZ)WCF+6-]()`V26W&KKD6IG M2OHC!;3W:4:G;-,HF4.V"WKG3J]T:@UZ#A)+_K08"&6/E)C9`/YA+U+>_)!M M_-4#VZB^=X["I[H2_?H`+3GE8M`*=@:,H.VYOB*(JGCG3N^1:G$OQ63)O1<# MW<^PU2=)-G\._?+A$"CZK/"UU*9?MPGO'(6YI9(Z&&&TY%6,03U@JSLL?(P8 MF!>:_KB%WM.,?9(:Y86UO',4%OAJZX$"EB5O9`R\/TYG/DV*I]G)'4UG<>J' M_=%3'(V?Z!L)>FE*3+8*59KSSIUZ.==;/:KBM>0*C4&%'D`"?_/#'+;0#S3R MHR%ECHH@NL*Q8X%>HC-:];V+]JXI^@`M.55CT(H7`ONJG+R083R.*$.D/XLH MZWKG*'PO*FF#'CA;_MD85*$70"\RFH*<;N/49#E1U/0NVFMRT(%FR\,;@Q*\ M3NAL!F!A3_T7/PK"!6Y]7=!KP+MP^DJCEDH8(+3E+XY!,V[CZ8Q$:;G9)B$+ ML6,X36BVX%VT]UK"!*(M?W0^BS99M"28!WZVT77XC/S<$E,01?!R2C;.UOAZ8-N5=M-?* M60FK0&\LV#X/_S!`&=?=@6?31J3,E:WH.4[I9F@WV2%)H[IW<>WL$+CLGBCP M'K^@=XGB4*4=XGBX,4A8)LI4=?Q MQ,PS>S0JC(VW6\2[=/Z@GB?W?7;V.HTG[)V%6?%)$OY.7-B[1&$%58XN!0(\ M\>YJ6+J+^SX=7^2M@MXEB@.F@!B!_7H?P1%YR_`]PGK9K9\D<]@N%]=YQBYS M._6]2QR'RWTF!28F;5!'Y!BS."*E+V1(`#),;=](MHCEHGYLP*WF7>*XR];E M78GEF/QAENZ``%''$Q**>9$@,.C1'M.WNN\+8^1+,[\$*>KLGQ.EE7S MKE!8D`R&K0++,;F&E%)1CE3O"L?MK-D0+7IMRUW#_=A\HOYW&M),[\DMI[1W MA+Y2;_V9^S';[^"6>[@G>%PI0A8DQ^P.%`.29'"8"9Y"3X MZB<_2+;T.]0B6EC-NT)APC"F6P[HF)PABOW^AGS4?`MJ>%J]#CP<2/V-.BC"33._(]^Q9'0Q.R%8UX5RA, M&Y650`>>0#F,;5W0O.L;"DE<2\F]A+B6=XWBB&Q&OPJ/@.]6VK7V,XMJ.02) M*GG7*)PRS/A6P!$X:K3RU=1&A&OE;>-.4>\:A:5$099X1.]A$?#:3FM7$-`2 MR+-/@\?HUI]1V&ELX):=Q925O6LD]I4*W&NB$VA#*Q\_O;`T]1$)EJ$%X6R: M3_/B?<\=&=$AE4WNZLK>-0IS3"5MT$0GT(96&N$&"?'3/)EKS?K[A;UK%-:8 M2FP+T`C8U;>_79?L1F3,%`?9!LYHX^9=HS#`5&)7@$;`KK&A#=59'0XB1DRK MJGK7[3;.B$$)Z#>VP.W2CS-@;N$7>Q3AN#$MC'^%>+4""6@V M`3!1##P5$8(9UPBE_8"2;8V=9 M#C?V?$5<2A(LWBE'X_7;#>73:^U&`"H.IVD%&*>_PO;B M_X33,DFH'VIQO5D>Q('BQX$6QUL50"XH[E4K(&I$;LTR`LJ*IPB+A)'E^S+VAKN,P?`[B>![YM0XBR,0F,"D4JD= M$(G3+:F:+@Z]U4"Z-898X%UHRJC8$HC%Z5ZU!I*J]&:"F&`U5)D1+>W[GD2T8QYET;!`WUGG]3KA+@2"`;%16=- M)5`!M!51T?&LL)/+^F9^0Z+A9.HG/Q2G"%55D))3DV+5(X0>+EL1%I&QOP2J M/#VHJH*44%Q_Z[&IJPD\C+:B-SK5A%<_).DB]W!Q5_A-8TL@K@2207%KJL<@ MGWT5.EOA'=TN__4)*`F"?S)Y824.73J=4`2*R5YB03=+9B0>+0 MAZ_%>_OR'+P/7>UH:=(.R`^%F?+P!,OOHO5;`#DXM0Y5(*TBZYMX;065M,O[?9K1*8MY\Y`SR\9B MLPL?(_E-LZH>8'9J_*E$$8=E/9RV`DC:Y?8VCLNK]3>RN@^7LRJN`3A16''J M\JE":"LV9`,>0]NP5W')5QX."M\0DS9`%B@\Q.JR;8[95@Q)I]OPWD\_"30< M0+;*`7[WGF$5SN8<$+9"/[HUQ2UB`+#4XU/F$;4@(O&C<7G^N)FORSS[<_9= M(8RU1**`77I\\Z=J-Y`F?@[80&'^XZB(P-;7F!!LQ9]TJI+WTUD8SPDI`K7U M"S#*P[VP#L@%Q1N,YCCGZYA"(+5#66)0E*_^W^/D-D^S>$H2D6%`7!@DX=00 M6'4I$B&Q%<#2*:=,N_NC+8C*1458!^2"PJXG8HS/KP*.K4"5=L\.#W#"6?96 M?D+8+^EU+E`X=BD$S]GYB[`(.')L?1O\C/4HVBL(J%!X6IDS)(`B(,BQF6P` M?]4<19RB@`R%)U0%DD1@!#0=.&6*:,J+\T1SRMLK"?!0O("L,.4)L`@>.[EP M4$O)\-,X?OL<$%IN/.##[GX#OO*>R-@/[V'SEY'0`"XMIE^B@P*2V=&Z4`.PI/MATR M)(QM]EO`6;O>/W[UW^DTGVH\:]LH!_A1F*7V*!'9&_?Z+N"N90\4::3'W68Y MKW.)PE:ER]U^WP7<.39][*\!3Y*XEZHJ@!2%[Y>I@Y\'W)V>(/2#$>0:20=N:+]=,)2RL"_[`=]YL?,IR][-9/ MDCF(3)E$5J<^B`V%LU@5-3``*-`+8SM-L$KK\GM.`^;7Y%(['NX>;Q\CUIN@ M-V425&C#7GD0#D8[G#;[`D`"MEN93Y;!_".B!BSOE`:18'06T^:8"T?`<"MS MQ-[EY`&D=>-'/V2+^&8Q$`)&KPLM3O=Q",@TMAAA('/O^>HS2=@7_IAT9.-6 M4@V$Y/2D6VL`*W$)R&]ED/+BR<':XUD5OII7W.M<87Q5I46V&(^`Y%9&*5_X MNF_DPUVDX82MZ#=0]_)_9*[<6@V`X#">OK44P02A0#6,K6`85&/U8`%P;CQE M6$3)E%HV915!4*W=I>L@$ZB`L3$-@PH\)V3FTV5@U-4K&!:#:CD()'J@41M$ MUMKMO#8\@488&^G<9SQX`7)`L,Q.<<<>D,=%."OUC""M!T)R'Q"XH@YH`!,$ M>FVG$2^>3N.H>$#P["?]Y#5C+U0+R]0R>:CT6*"L#2+#>/FL>3K0A"?0"`O9 M4[$\%I,=$[@5O,M.:T^%,D0"JMOU(%`8Q_"/E(SR\(F.9*->H[9W]:6U6T)M M>`)5J./N=>AT.;R1AZ:9<@2W MP.+F)2EP-&MZIPYSF+/5H0@&JDIXO%40NNS>5JHK6<%\R0&$)WMQLY[BIVZ7 M.1D%VV0).X\GRV]3+N*GITYMED+)[Q.TW^UC2'.[4LXGC32W^X5!$"@>IJG' MF`K#,22*@5U5/LU#ME&X(]#O(2UX@,\A*0B)V$UHDM%_%M\+=U-R"[25GP"A MHW@L)U('H77:(OHCRK';O*WB]!3%@STS?=$&=D2I>#6/:9J;T5W6`,F@R+%=D^I-,):RR6"@>9`4 M87'G&T@E%'-*@T101(HRHU<(Q%(VF'UJ#VUJ&B1^E/K#(DQ>;S0B0V:8*^!. MXA!`I>6S/?>IF??[]"W.B$9Z9GE%K[N3OJ*.#6W_IZ0IF@7%H4M(9D*UX+:' MC1H5'ON3A7-SB6Z5OU05!DM:#\3C_G)62IWB3"T&A<>252,PWC8Z95PL;GD0 M!XZ`>&K.^&1+4!V#06QC,Z>3)6^[+(@!Q8M@"4?*+>PFDF,PBBUC-JK2)&\4 M`_#N+\@KS,/[&(XB\;%N<-N=Z)Q=MTDFQ*3(R=OLO=L4Q8(-+NMHY_KZ4AZJ M9+L4P$%Q3\`3,F?[RNN\VYS`$B[@VR]J+M:E``X*T[L!%[N==YNB5\#%'4W@ MY!PGJ1XI@N(`$(6A6Y,=*0JWZ7)U:7J@Z=`/V:>;.,H5^17T:@-\%";KJB1* M0#E.A&M,:J<6J9UM_"A,,K5)W0?E.+^M+JEWB[[THN"/B#T'8(]\-_U`#6G6 M;`]DA,)L795X(YB.$]R*PM-,"[MV&4A?;P,JJ0)(4=A@-`E5(G&Q98BWW_0",_&E(_5#%?M2D0$`I+E@5UJ"<"QUEG+**R!S7'-URV),(XB$Z]9WH8N@KP-%1:;'0!' MD:_6/&]#%UO>AJY>WH:N.&]#VU+'5HK]W\67MZ&K&_N_*\[;T+(4L=5R;G3Q MY6V0<;??=YQY7Y=YIE=)KT0.Z)+2@,]]O$B#Q4P)!6?ZU_T>"P\UTO*`T7WZ M!9GXM=C:Q((S&VS9YV+7O.XU>[_[+7XKYH4KYDNAN,LT:`-DX3Z?@IPH(;,F M"&TEE3T0V[U\G*=9YQI^^+HBV?M-@"3<&ZOL<2T"Z#@I;1VJ"Z<+]J=.;Y;0 ML,90UVH5Y.4^-FLS"J'`W,(\N-7"474O6_6X3PC!<6;<0T2EZEXZM>X(1;_/ MT'ZW<6:ZOR7*TJ9I M7,D):H!,6NG-)85S%%EO.0C5=VVB.E[7;0H2+=JTF=[$=!391'04.75+'_''*"#O)!C$12"BY617_E[1 MA$6^'B@@VDH6;/F5U-(((]FH\PL"*O?F)],K(`$*6PE[&^1&?O'#*>I=(H@, M)9"WBIE-!+;2Z]KEYI5D64BVS)AR.X6P`J!T[Q$L(T&=[$8RM'KMT) M=_`S'DSB//6C8/"3A&^D5.8G&I'^Z!;Z1!43L'8#(`443[VE)''F94.`.++D MJME^B/,D(R2JP;>J"1`("N_.&HSK03RF]+=/-*/C@B$6ES)715'E%0>AM'*! M%F.QE=S6Z?J\"T^Y//,K>)=N[P+5;.FQNXG&5JI:M_NOX@`1K'&J;Q7X-4`F M*+R[98P)-F`R0+8RTEH^\>[-4T^2_$^J*H#4_:G7U'JDQ&,KZ=]R MIF*P+5@'[ETG&'F($V;R9&D#^["Z=R^^QE$V$3);HTFOBR"=M)))#ONU,=M* M-MO(COLQ>B,I%'ZAXTDVB/](R?W[D*3I-@/?"ZUTY=3RHKWJ%%)-#8`T<:D^U+RO1)=WG" MTD.3A,9!B>F/"+KZ.B-#.J+#E;E:NE\Q:PH$A/$AE(8.5<4J4(8#YR`T4X8B M?5Y=->`W`D+!Z-=260%D*`74MSWGX*T_HYD?EJH/Y0E9[N99F?A3`H"M/$]*K)\N_ M!72X?T=64?<:$H9`-UN9<;&RB);G6H,,K-9_"^C`:)!O5C?EPA#HIH64D;9. MBS7&XQW;702W;)4(0ZZJ-?$S(-AV6J`:D8,@89"QM;G5D]]"0+]#P0P.PN56 MN,%5>?N'@`BG-U4NEV2>)`0J:6Q&1SGG;0/>2P3]1T1%F;`/^?-`1#N-L@>5 MCT!1<5CT2XE]);"?"$J;'\.Z,@:N+80O!$HFQ!G/_Q9@N^3`0*:WQCD`$H-/<%B^M2T39=4<,[Z[9N.Z,%2*T^>35\?">'*NB"GUET6&X(3*$&[')!O0S]-^Z,_?38+9OUR^[W8DY<+ M\^J/Z>*O:49I=O,<)79$4$14-2N9!MN?3(NW2:*.ZQ/QJ4X M3]REXZ?U+-7P$TF71C!8*DH'6YB.A/[HLCJ`M9U&`34H`8&.`S=6.5*6UO?[ M]QE-BM)2MJW]`$BQ=;XP34A`H$>.[82;/LQW-!W&.8"(=D:#<,W7J>Q=M<]P M8XI.P&W+0D[6O-6#!7!$*%L!TUX4K,?`(>[ZE;\-/+7.'^7`PA$H<9U8FB#G MSYN"!K@_%A3\NOO]%@/D/2-1L#;][7$P2^(9VZ/#CZ6?AO&T_.G'"#Z2@?]. MTCN2^31,!]!2#G#^]?#C:=49-GF$<0KR[WU/L\0?RNSGDEK>^4X(A7IOT5:B M*AYDBI^:;9>#3J!X#ZR4$V=&YV,1Y&9MU=R]0K9P;50&%.57\,X1'-GY+/&G M1AD,04*3EO.J#-0@J@)"01$@6$:9+LF;B`3A/EM%,^`A:4:'MVR/FT#0HGY*JHW+(:X*(G/K9 MU.%<"YK`-=_MH7ECA5IMX#7V3^O-_CD"DXC.,JM`(+A':M70O%OTE.ENFI(L M[<\(.QY%XZ^T>V[OCE/\RU*+EZH>=!)%1.(*DN5=@&JA=6LC$_FXP[9BRM): MEO?N_>_A(M"?-->VK!*`=;\"ZS'"H5(#FEN;F"F/BD3<\FH`V/V2J$&)"9&; MR([![K5.5,O4G,U3XDR4RCH@%O?>@%K4\;=#"F!N[6""H?M['(P2,C?.U*&J MYYV>N;^(J,"E`3B4EBW)VJ.T=.G4!>CN'0`K+[#Z"(_!,K:6GQJ2 MK72[LW`H)K@R'I7.C4 M:@KU&+R9-Y$I_9CW"X,@4#@[FE*G5H!-?&[O=02S_=?DW_WD1RZ^G>&4`C@H M_)%%@N9,USP`*.]=OB:W>1#0B=A5G%<,`#DUDE1BA(,`Y=5)>7U'R.JR1Y0M M55(:X*&V5`A7-24FMQR."3/I:9&UBL70OT01=6Q>J*?,N M#;[%;\7L<`5U.O(9T:0-$(7[H[^<)R&Q)@C=^N*:DMW+QWF:=:[AAZ\KI=4'\THD.2*'V$);5`-BB,B)4H%=SNJ=`*-*%=;^@+E/?O9)AG M](T8:0*_%L@&A7W2MB;(T`HTP;77,4^!V;+)OG^@D0_KIA^J**_:%$@&A574 M@A[4$X%`.1P;Z9IW2;]HLP" MOY`#>_M65168N=CR]ABEF1^&A75KRD*`5=8448/>Z25JHY`%19%#%^@)CGRO M:VR]*"J4?87A,1J&>4#2QZB?34ARFR=,S$_4_TY#V`NK%<6T11!76]ZA*36E M&G:!JN#(N*H/[BF.QBS^^MKCN;ZR[+<)(D-]?+"I+B+T`H4QMC3N9J`[?/CH M9;;/Q^BO,8VRO\''/"'N_<77/0,N@.)>\,92C*2#N`?G^)"R&%NOPPD)\M*$ ML"JM%7&Z9MO>V5F%N-26(FOR.B9R0%=7`BA(HEM;X81_7%3!Q^..GI+AIW'\ M]CD@M%0)^+"K"?"55YQZ2^.8X,:04\H[P_'20$7'-HE"('@*`2"G&V2^@#D;&VZ_+;ES-[*W?9[$ M*6Q+8.=&APKW%DY1P.?T/DN?%U'?W?IUVWK9E\SB!-;GS0VD^II27`M$X_1Z M2H=6;1C'$!?G$4X6(QK1C#S1-Q(\`A71F,)R708QO9E_]?\>)T5Z5F42#J.6 M0(1.CYK5-BRUP+KU0S^(OJQA?_.G1".]AW%K($H4`4LK:4`E91)+X1CB3A>V MF#W(JB5&4@M$X_02M#:K?"51(D811D>\-Q^0X22*PW@\?Z)#$J7B;82BAG?5 M:<,$H,NO%EK'?NP-6K>>)%XO>A5!J$[OS>MM)'2P'84W?)$NDF63)L%=GM!H M7&9K+--.?R,_BS])M4"K`9`8"ING#J\"C3#`:L3JPI\)K>M":!/11.O:1MZ,3!X-=`9/*(&;^HG%4G(LG<0C`TAL_E2:V-6P)1(@@(I::9/Z> ML1)82\X+NSZPAU>:/PD=3UC0&#C;^F/R+6=&]?ZHM*;U\RR%@Q0[-:E4QJ@= MD*'[=WB5%:8"5$N>$.[597#LU04[NG_!9HYX+#D4B'\&6L.@P?2.O9)@GE+TJZQ<=37>1%>9RT1[1K!7O M_`J%54F+/,[NL0I:2[X&=2:"JAI00*G,?%$;9(#B8J$QQC=0VO(\<$'U4BZU MQSF(`J69S/H0+X':\C=PO\[KGWT6HK1R:%RT!<)$$9*I@M;4Q'Q,;@F"T]`" M[]ZAR/P(*6H)1(GBEK*&^E1";,MKP?WL(Y"<^>D"!(,BJ%<-59`BL^6_X/K) MM>3^TN%S:ZO7F%>7**\QKU"X@,K%9G:->25V_&R5U;X79338VW^6WBHD>``9 MPF9BEI=<]4=[UJ%BQ+E[T83NNOP$@1@9)AS>9L'HLC(DY?IE4/ MA.H^B%JE%5\#UC$\8M]!IURHN>6]JPZ*U5F#,\$16XP*90:T#2/BQLRDF)TE M=0`JB@56P@-O8E8BPIG1S+[SW=67EIVK=#&Y351F*1(,>\G<'_WI)XD?9?WD MA5EV]>S>JJH@).S>4@6-_%E7#]U1/.#FFO-%QOQ>\/>\?-IB>B6B;A%DBMW! M2J(QM4`W\!;\T%;RVQ@J12EAH5W3.*0!2^JWVO7`6%JD^X"_NHE.RBX\5_W1 MBCG*K>&=[3RN<7$.4D8/W2H(749Q92V5J.*HLP$$C_V\X=B?;I^6R"C8)DO8 M>3R6X\;B?;I]6B*4_#Y!^]UV:Y.U/"/*3BGBPB`(%%&'U&-,A>$8G@*]PBDY M?2%O)&)!+V1K\TY)$`&*X&`B<@14\D`%L=Z,9!4>2X9:#'S_GK`S4Q+STV-Q2H$$<$1U,F)T#X"M]S-Q MYH=."5PE9+Q_G[&CG$YF!F$=[PS'`PHS(M67Y/=D%', MPH*R<@/_G?GRP@0'H&GD)_-"@M]B^&N4`:BP4/Y29LI+K49^%2AJX6F^<8'8 M"M6)809:B&`Q)L6IT!4UO#,<'O-5-$4`QE:83@Q'Q*WGP1)VM\J!&%"<_\TX MY4`0,-E"B-?G**X0#"0K^#6F`,+CV\RMM>V%Z>XEO$-TA3TBN'@\6]V_M,UIS1(!,5=C#'!0BQN(UW@>*ITT<5U\:*_@=[!8,F)>E9D MR+V/W+IQ<&P-,E9W"X-$4%BH1%R)F.7CL.0G73(+74HRM]P:A('>#WM\T<5Z MHR%CE@_#ENLS%F:KN3A<='$9KK08Y4`X'D_F=1R-=!`+3@&%2G_W"W/QE'GN M%'R]$)BW4IJ1Q9.\,M_Z"QG&XZAH191+YE`_#53A,IAI:=MAI'),F0AJ;R#. M<%G>*F\@SL0!E8R-;4CVAO7V#V->->_B_(OS0[/I'>,Y"@N(6JQZ5XOG8L=4Q,%TJH4]NCA' M:>79P[M5H();]/T'ZWC^$^K[8M\1R7;4(XQE08CN$N M#T[H;'%X3N(W"MN1F_D?L+EXC%9O&GO#C+X5$>%YOL<:B[N='P"!HS5_G`N= M=&QB/Z+83!4-8.]H\G_?D>@QT-:R%2BAYO%0`(HK"S-L:W2Z8RL74GCF&NVL?>&P[C',8RC&1"WQ2F=)WJ M(#04?DNF-.LJBPAQ[9MGU'//8_0&,H\3*@T))ZT'8D)A6FQ*,?:@UKZR1JT1 MRW'P[,\KSQJ+NB`N%-:CIJ>,+;BV+KX;2:'*Q9#D9!T%ET4O%^9]TZP.@D!A MHJG'NSEB6X&_<.XHBM?KNP*4)VW0;P0$B.(4U-14(<==.Y88HA6EWD:_L3LM M[^(2Q1.H@]QDU);3\81$$TB#;>K2)J]:#7\`Q(["MFCEJK42]F.*Q@8;PJ5# M]/`?.4W(EG&K%P4ZYD/]1D"`F&T\E=2!KW"F,JD=B0W1P@I0AX0$14@ZCLE4 M5ZOT6P$1HK#X'$"M3(5B*\(;ALFJGG@;6QE!T"C,2LUKGPTYV0HEAW;#]D`C M/QHVN&$S_`$0^_'XQE7"WEQT.;=KZV.:YLQ'JS_:B":CN:)RZX*X4)C#;)*O M7DJH?P6O5! M:"B,$C;4@@M-H`_F_N%((F0<2BM0V!2:T0JQ9<#8@K!2 M)X_?-[NR?IU?]NMY`WI_M-@0^N'ZX;Y.LFL;[0/_UZY&<"T`ZUCU`U"5FU!^ M$+;]4]X%CJ1A%G6`/XTT(SA+T0/<3S>O^73J)_/^Z)6.(SJB0V:2+UVO8.U] M!FD-F?NB@]EGOQ^8V3JLW8:'(RJT!AF" MX6@$]-`#\M?/K-,LZETAX?\&4$L#!!0````(``V"K4:(M,H==0T```",```1 M`!P`<')P:"TR,#$U,#,S,2YXH/]!YP,.[0?'\::[W>0V+?*ZE[MD'23>HD!1%(Q$V\1* MI$I*2=S#_?>;H21;MD5:DKU9]LY?=F6),WR&#SD<4ASEW8_/4>@]4JF8X,>= M_MY^QZ/<%P'CX^/.Q^%E]VW'^_&'K[]Z]Y=NUWM/.94DH8'W,/7.24*&DOB? M5"'O]??Z>V\]O#CHWI!I]]5^_[7W2__5T>O^T<';7[U_G]S\Q[NX'WI=[^GI M:2\`#8G6L.>+R.MVL1[E3VA$O(3(,4T^D(BJF/CTN#-)DOBHUT.Y6(IX0A0- MR8.6[&$]^P<'?<`>THCRY%+(Z)R.2!HFQYW?4Q*R$:-!QP-CN3J*93RIJU!+ M+!1^.M@3<@Q%]ON]GV^N[S7>0G7(^*>%TL\/,BS*'_3P\0-45!3'IT$R$R@7 M?MW+'LZ*AA:]/U^#XK)29BG,N$H(]^<@5D#G)O8/#P][^FE1-%7=,2'QK/"( MJ`==-'^`#?===[_?G37=D2]2GLCIHHV*^GMC\=C+'Z+8P9)8*B5T1)-<_K2B MOH"R:AEX4%&JDFJ1[%F%-9PP7U7+Z$1M5*@D3V$'$/"G6A%)7,G\FM%\H%P)=XWCO"N0`G`\Y) M_\8[<HY`A\EE:V).A,\H!RJ@0LE M0A9@_STE(?K`^PFEB6I7FK,T4>F6-7J[2RW3NN-N,NUL" M,T$RH0D#C'6)7!2RLWK0AE7OEX4J?MVQW)CE69NKP6@08]P)L&Q#U2!@9_>[ M>NS.=7MBY,VU[WAMS^M@=)\(_]-$A`&L'RY^3V%6JT-OI9R=Y=<-64:2RY7\ M[:\'AW_WLJIVE&\TE,^(FER&XJGN2)Z7MU/\ILU`1N6>UKYCU<;J0(X)9W_H MBB$$/4T5XU3E%)H>VOGZ'L-:IOQ0J%12^%%6XQ&(C$?6Q[4Q39-W"=BX/E[DLJ_5F>G=S82M"KSALI:4+:C MR3XX<*\4F^Z*_U,PGOP$E]"JQ4@Q/+43]&IUV!1Z/`91A:=U>;FR'4$V@BZ( MY-"7U;50ZI;*^PDIR*E\8B?F8)F80H?W#6KYU@,]GE:T(V7S:*]-U%P$_QZ$X*S&G;TM@U0RIRN+V8G\DVC8&7' M7>M)L4R:Y;F=K97M$.,$N6-JBT[TG":$A8V\:"%BYW.#71+OF[R*'$'82M+.]\I.2@N^O;RJ'>_;V">K(KZ=J)7Y5RM;-0WWT';TM]Y5JZ+8 M_-A.X\K>3GG';)V,EJ1 MN1N3&VVX5CO16F7M=*YL%5DW8W=T;KX27?"MM@)VXE:V@"QKT9U#W9"LA7%7 MHYR=NI5-G_74_3^.-_P'\S#NZ,C3"0Y'>';\N*-8%(>8&*'O320='7W)V#TL%]1F<"\URO`=[S>%@T# M1IH:MDBBFV;!.&QJ%HC0T%V+8``TM6AIS&S7KFR\E=,JX% MF=!ERD_*0Z^*M;O]5]Z"_]ZR">>LW`3&WL1F(0JX%B.KL MKYK5%P)8[^NZ-5K3MPP5ZTHK!7LT3%1QISM7URR.U?0 M"L5R2EX=#(4,7FQ<_W*V7BT`A9"^:@%A-?-/3S:-%BP-KS-&LUR++4 MICQ5IY@V0R+XA]9@[,FY[6=>K@!'5>PK(,>]$AOI8@$PD#EZH9&#U0Z8'@CM.:1#'4&BZIT MBYZ$H7C"E:URK;O7Q[R!T0$41!KJ7*7K\>Q)2=4?ADCO3E]=# M--AV)D0V]!_I;`0X8Y4-G,T%+Y)]0^0GJF>R8F2[XX.:P378?`G-2NM?\E:A,_4>DTCD#JD`9\%^S"(2#:T8>6`B+ M#0Q7")^>C*$)L)@S-M4%6GO9<,VX#MQ?/KZHFF?-X`P&F3_OXLY2M@Y&X]QJ M3P9P:;VW'FN]X&CP$+)QMLYW+.Q=`[2I>>0RZS'DJ#B3?R7Q`HINZ$LLN`C+C/TB!@DZE#P)<0F5Q!%(=B2NFL M$SJWLC#C(971?''U/]%2 M56:9_.M*OJ5S6QA&B`:3;J%]^X>'WSLS'RX#LN"&F&#?*=QE0*:C*TQ2/Q%2 M.6>`$5E=2RZ9\@D&:ONG@CNT)J\+M+&=_3^+G?U6=I[3$85))(")^"./"0OP MF[.X6P_+;@W57691&'U(T=C#"H%UP'8>^`#C1N@-+9*E"PMYQ\:39"@^*GKQ M[$-_N)7"IS10>9W;6Z=NW@PM()N"9&3Q-I4^)I/>ILD=Q8ZP3/W@.\$@*5\-?"E6^TE;;6M2;!WTN`\18=Q MJRW,-'V$>4+>Q]3'C_C,1K0#HZX5ZF8M\!,)4[K&=K'C;+MM.B]R2[)]V"VA;-^@S-=Q[ M*)C`X,U8*TTD1:]FFMH_?X/6-M0:B]Y0F%Z#^9O[5\Y*Z M>(9G3*'1VDGHNRMC^\O-!Y_/,FM3XD0QFX5@_J$N118U()KV>!3+SAHY$]BO M(#(AGP@53\`VSGQWEB65J$P69,->#<5ERH/REW3F_5JY/)G6-,`8P<^^Q>;< M%N\JMO5&.'3@IQJ5Z21[\6(4OP%S1J2<@L?$J0@<9LPR*/CJ&"9YY4L6K[Z5 M,)OX&7U>.]@F'V_Z,J]+G=("LH%9#G73-?",FZAAB@D:]]2'"!Y?8^8Q4Z&N M4*6#>I?]9U-+VC9(_M<9OOB*M"[038E?"LCT/==,G6,U';4A:H)QW2,)<1IU MYVB1"9AYAI04(M)SFOU_Q?-,N5G^DXW#N'WOP`^O!)#">V980F=:VY7V(;05B=0\R-?3O55@MD_(U5<56 M$K"8OA&,/X\_'[-LY89`.']KSK9=\7TZ;]%U!+`0(>`Q0````(``V"K4;U M.6KF9)X``.S/!0`1`!@```````$```"D@0````!P`Q0````(``V"K48D^D2+ M00@``)9J```5`!@```````$```"D@:^>``!P`L``00E#@``!#D!``!02P$"'@,4````"``-@JU&9JYL M;?@K``"GD@(`%0`8```````!````I($_IP``<')P:"TR,#$U,#,S,5]D968N M>&UL550%``,9L5-5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`#8*M1O+I M&A/-1P``Z=T#`!4`&````````0```*2!AM,``'!R<&@M,C`Q-3`S,S%?;&%B M+GAM;%54!0`#&;%3575X"P`!!"4.```$.0$``%!+`0(>`Q0````(``V"K48> M43:W#S$```T&`P`5`!@```````$```"D@:(;`0!P`L``00E#@``!#D!``!02P$"'@,4````"``-@JU& MB+3*'74-````C```$0`8```````!````I($`30$`<')P:"TR,#$U,#,S,2YX M`L``00E#@``!#D!``!02P4&``````8`!@`:`@``P%H! #```` ` end XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9

Transactions Affecting Stockholders' Equity
3 Months Ended

Mar. 31, 2015

Stockholders Equity Note [Abstract]

Transactions Affecting Stock Holders Equity [Text Block]

Note 3 – Transactions Affecting Stockholders’ Equity

Stockholder Rights Plan

On September 8, 1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a “Right” and collectively, the “Rights”) payable to the stockholders of record on September 25, 1998, thereby creating a Stockholder Rights Plan (the “Rights Agreement”). The Plan was subsequently amended effective each of (i) May 23, 2008, (ii) August 18, 2009 and (iii) June 18, 2014. The Rights Agreement, as amended and restated, provides that each Right entitles the stockholder of record to purchase from the Company that number of common shares having a combined market value equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding common shares, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the ownership of 15% or more of the outstanding common shares. The Rights Agreement allows for an exemption for Ted Karkus, the Company’s Chairman and Chief Executive Officer, to acquire up to 20% of our Common Stock without our Board of Directors declaring a dividend distribution. The dividend has the effect of giving the stockholder a 50% discount on the share’s current market value for exercising such right. In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is June 18, 2024.

2012 Equity Line of Credit

On November 21, 2012, we entered into the equity line of credit agreement (such arrangement, the “2012 Equity Line”) with Dutchess Opportunity Fund II, LP (“Dutchess”) whereby Dutchess committed to purchase, subject to certain restrictions and conditions, up to 2,500,000 shares of our Common Stock, over a period of 36 months from the first trading day following the effectiveness of the registration statement registering the resale of shares purchased by Dutchess pursuant to the 2012 Equity Line. On November 26, 2012, we filed a registration statement with Securities and Exchange Commission (“SEC”) to register for sale for up to 2,500,000 shares of our Common Stock and the registration statement was deemed effective by the SEC on December 12, 2012. We amended this registration statement effective May 29, 2014 to withdraw and remove from registration all unissued and unsold shares. We also agreed with Dutchess to terminate the 2012 Equity Line as of May 28, 2014.

During the period January 1, 2014 through May 23, 2014, we sold an aggregate of 698,207 shares of Common Stock to Dutchess under and pursuant to the 2012 Equity Line and we derived net proceeds of $1.2 million. The sales of the shares under the 2012 Equity Line were deemed to be exempt from registration under the Securities Act of 1933, as amended in reliance upon Section 4(2) (or Regulation D promulgated thereunder).

2014 Equity Line of Credit

The Company and Dutchess executed a new equity line of credit agreement (such arrangement, the “2014 Equity Line”) dated May 28, 2014 whereby Dutchess committed to purchase, subject to certain restrictions and conditions, up to 3,000,000 shares of the Company’s Common Stock, over a period of 36 months from the effectiveness of the registration statement registering the resale of shares purchased by Dutchess pursuant to the 2014 Equity Line. On May 29, 2014, we filed a registration statement with the SEC to register for sale up to 3,000,000 shares of our Common Stock and the registration statement was declared effective by the SEC on June 4, 2014.

We may in our discretion draw on the facility from time to time, as and when we determine appropriate in accordance with the terms and conditions of the 2014 Equity Line. The maximum number of shares that the Company is entitled to put to Dutchess in any one draw down notice shall not exceed shares with a purchase price of $500,000, calculated in accordance with the 2014 Equity Line. We may deliver a notice for a subsequent put from time to time, following the one day pricing period for the prior put.

The purchase price shall be set at ninety-five percent (95%) of the VWAP of the Company’s Common Stock during the one trading day immediately following our put notice. The Company has the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales for a specific put, Dutchess must remit such excess proceeds to the Company; however, in the event Dutchess receives less than a five percent (5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on the applicable closing date so Dutchess’s return will equal five percent (5%).

There are put restrictions applied on days between the draw down notice date and the closing date with respect to that particular put. During such time, the Company shall not be entitled to deliver another draw down notice. In addition, Dutchess will not be obligated to purchase shares if Dutchess’s total number of shares beneficially held at that time would exceed 4.99% of the number of shares of our Common Stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, we are not permitted to draw on the facility unless there is an effective registration statement to cover the resale of the shares.

During the period June 13, 2014 through December 31, 2014, we sold an aggregate of 2,561,520 shares of our Common Stock to Dutchess under and pursuant to the 2014 Equity Line and we derived net proceeds of $3.7 million. The sales of the shares under the 2014 Equity Line were deemed to be exempt from registration under the Securities Act of 1933, as amended in reliance upon Section 4(2) (or Regulation D promulgated thereunder). At March 31, 2015, we have 438,480 shares of our Common Stock available for sale, at our discretion, under the terms of the 2014 Equity Line and covered pursuant to a registration statement.

The 1997 Option Plan

On December 2, 1997, our Board of Directors approved a Stock Option Plan (the “1997 Plan”), which was amended in 2005, the 1997 Plan provided for the granting of up to 4.5 million shares of Common Stock. Under the 1997 Plan, we were permitted to grant options to employees, officers or directors of the Company at variable percentages of the market value of stock at the date of grant. No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998. No options were granted under this Plan for the three months ended March 31, 2015 or 2014.

We are precluded from issuing any additional options or grants in the future under the 1997 Plan pursuant to the terms of the plan document. Options previously granted continue to be available for exercise at any time prior to such options’ respective expiration dates, but in no event later than ten years from the date granted. At March 31, 2015, there were 26,500 options outstanding under the 1997 Plan with an expiration date of December 2015.

The 2010 Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by shareholders on April 24, 2011 and further amended and approved by shareholders on May 6, 2013 (the “2010 Plan”). The 2010 Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Plan is equal to 1.6 million shares plus up to 900,000 shares that are authorized for issuance but unissued under the 1997 Plan for an aggregate of 2.5 million shares. The 1997 Plan expired on December 2, 2007 and no additional awards may be made. As of March 31, 2015, 1,481,750 of the options issued under the 1997 Plan prior to December 2007 expired unexercised or were terminated. As a consequence, these shares are deemed and remain unissued which up to a maximum of 900,000 shares became available for issuance under the 2010 Plan and the remaining 581,750 options are deemed cancelled. No options were granted under the 2010 Plan for the three months ended March 31, 2015 or 2014. At March 31, 2015, there were 19,659 shares of Common Stock that may be issued pursuant to the terms of the 2010 Equity Compensation Plan.

There were no stock options exercised for the three months ended March 31, 2015 or 2014.

The 2010 Directors’ Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Directors’ Equity Compensation Plan which was subsequently amended and approved by shareholders on May 6, 2013. A primary purpose of the 2010 Directors’ Equity Compensation Plan is to provide us with the ability to pay all or a portion of the fees of directors in restricted stock instead of cash. The 2010 Directors’ Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Directors’ Equity Compensation Plan is equal to 425,000. For the three months ended March 31, 2015 or 2014, no shares were granted to directors. At March 31, 2015, there were 147,808 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors’ Equity Compensation Plan.

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\V8S4Q-65B.5\Y-SAC7S1F9F%?.3EC9%\X,F8S M-F8V8C%C,#'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=OF%T:6]N7V%N9%]"=7-I;F5S M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E1R86YS86-T:6]N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN M8V]M95]487AE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O5]O9E]3:6=N M:69I8V%N=%]!8V-O=6YT,SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O&5S7T1E=&%I;'-?5&5X='5A;#PO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O6QE#I!8W1I M=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0 M&UL/CPA M6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G M92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S9C-3$U96(Y7SDW.&-?-&9F85\Y.6-D7S@R9C,V9C9B,6,P-PT* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V8S4Q-65B.5\Y-SAC7S1F M9F%?.3EC9%\X,F8S-F8V8C%C,#'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L'0^36%R(#,Q+`T* M"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^,C`Q-3QS<&%N/CPO'0^43$\ M2!296=I2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P M,#@V.#(W.#QS<&%N/CPO'0^+2TQ,BTS,3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^4%)02#QS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\V8S4Q-65B.5\Y-SAC7S1F9F%?.3EC9%\X,F8S M-F8V8C%C,#<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F,U,35E M8CE?.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2`H3F]T M92`R*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E2`H3F]T92`R*3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D M(#4P+#`P,"PP,#`[(&ES2!S=&]C:RP@870@8V]S="`Y+#(S,BPX,3<@3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\V8S4Q-65B.5\Y-SAC7S1F9F%?.3EC9%\X M,F8S-F8V8C%C,#<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F,U M,35E8CE?.3'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A&-E<'0@4VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V8S4Q-65B.5\Y-SAC7S1F9F%?.3EC M9%\X,F8S-F8V8C%C,#<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-F,U,35E8CE?.3'0O:'1M;#L@8VAA M2`H=7-E M9"!I;BD@;W!EF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,SQS M<&%N/CPO3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA2!O<&5R M871I;F<@86-T:79I=&EE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\V8S4Q-65B.5\Y-SAC7S1F9F%?.3EC9%\X,F8S-F8V8C%C,#<- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F,U,35E8CE?.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UEF4M861J=7-T M.B!N;VYE.R!F;VYT+7-TF%T:6]N(&%N9"!"=7-I;F5SF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE2!B=7-I M;F5S2!P2!A;F0@;&]C86P@6QE.FYO6QE.FYO2!A;F0@;W5R('!R M:6YC:7!A;"!P6QE.FYOF5N9V5S+"!P2!L;WIE;F=E2!Z:6YC(&=L=6-O;F%T92!F M;W)M=6QA=&EO;BP@*&DI($-O;&0M145:13QS=7`@6QE.FYO6QE.FYO6QE/3-$9F]N="US='EL93IN;W)M86P^)B,Q-S0[/"]S M=7`^($-O;&0@4F5M961Y($]R86P@4W!R87D@:7,@82!L:7%U:60@9F]R;2!O M9B!O=7(@>FEN8R!G;'5C;VYA=&4@9F]R;75L871I;VX@=&AA="!I65D(&EN('1H92!M;W5T:"X@0V]L9"U%15I%/'-U<"!S='EL93TS1&9O;G0M M2!1=6EC:TUE M;'1S/'-U<"!S='EL93TS1&9O;G0M6QE/3-$9F]N="US='EL M93IN;W)M86P^)B,R,3`[/"]S=7`^/"]F;VYT/B!#;VQD(%)E;65D>2!I2!PF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M65A65A'0@;W1H97)W:7-E M(')E<75I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\V8S4Q-65B.5\Y-SAC7S1F9F%?.3EC9%\X,F8S-F8V8C%C,#<-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F,U,35E8CE?.3'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^ M/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F M;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2!A8V-E<'1E9"!I;B!T:&4@56YI M=&5D(%-T871E2!M86YA9V5M96YT('=I=&AO=70@875D:70@86YD('-H;W5L9"!B92!R96%D M(&EN(&-O;FIU;F-T:6]N('=I=&@@;W5R(&-O;G-O;&ED871E9"!F:6YA;F-I M86P@65A2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!O9B!T:&4@8V]N2!B92!A8VAI979E9"!O M=F5R('1H92!C;W5R65A#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2!A;F0@ M2!M86YA9V5M96YT(&%N9"!M87)K971I M;F<@<')O9W)A;7,@=&\@;W!T:6UI>F4@8V]N6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`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`^($-O;&0@4F5M961Y(&QO>F5N9V5S+"!W92!M M87)K970@86YD(&1I6QE.FYO6QE.FYO M#QS=7`@6QE.FYO6QE/3-$9F]N="US='EL M93IN;W)M86P^)B,Q-S0[/"]S=7`^('!R;V1U8W1S(&-A2X@4V%L97,@86QL;W=A;F-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@8F]L9"!I=&%L:6,@,3!P="!4:6UE2!L M:7%U:60@:6YV97-T;65N=',@=VET:"!A(&UA='5R:71Y(&]F('1H2!M87)K970@ M9G5N9',N(%1H92!C87)R>6EN9R!A;6]U;G0@87!P6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE7IE9"!T;R!D971E&-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P:6X@,6EN.R!724142#H@-3`E.R!"3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/DUA6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C(P,30\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/E)A=R!M871E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z M(&)O=&@G/C@Q-CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/E=O6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-, M14%2.B!B;W1H)SXR,#<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2 M.F)O=&@[0TQ%05(Z(&)O=&@G/D9I;FES:&5D(&=O;V1S/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-, M14%2.B!B;W1H)SXR+#`W-CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/C,L,C6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M>#L@1D].5#H@,3!P="!4:6UE2UN:6YE('EE87)S.R!M M86-H:6YE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!R97%U:7)E M;65N=',@87-S;V-I871E9"!W:71H('1H92!D979E;&]P;65N="!O9B!/5$,@ M86YD(&]T:&5R('!E6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE M2`\6QE/3-$9F]N="US='EL93IN;W)M86P^(#PO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P>#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I;G-U'1E;F0@8W)E9&ET('1O(&]U2P@:6X@=&AA="!O M=7(@8W5S=&]M97)S(&UA>2!B92!S:6UI;&%R;'D@869F96-T960@8GD@8VAA M;F=E2!O2!O9B!A;6]U;G1S(&1U92!T;R!U6UE;G0@<&%T=&5R;G,L(&)A;&%N8V4@9'5E M('5S(&%N9"!O=&AEF4M861J=7-T.B!N;VYE.R!F;VYT M+7-TF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T&EM871E;'D@/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2X@02!S:6=N:69I8V%N="!P;W)T:6]N(&]F(&]U M2!P2!R96QA=&5D('1O(&1O;65S M=&EC(&UA6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D]. M5#H@,3!P="!4:6UE3X\6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6EN9R!A;6]U M;G0@;V8@=&AE(&%S2!W:&EC:"!T:&4@8V%R2!C;VUP971I=&EO;CL@86YD(&=E;F5R86P@96-O;F]M:6,@86YD(&)U MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE2!T2!O8G-E M2!T;R!D979E;&]P M(&ET6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE2!O9B!T:&5S92!I;G-T6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG7IE(&AI2!O9B!T:&4@F4M861J=7-T.B!N;VYE.R!F;VYT+7-T&-E961E9"!T:&5I2!B92!R971U'!I2`F(S@R,C`[3W9E2!M96%N2!O9B!A;B!E>&-H86YG92X@5V4@9&\@;F]T(&AA=F4@86YY M('-I9VYI9FEC86YT('!R;V1U8W0@97AC:&%N9V4@:&ES=&]R>2X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UEF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4 M:6UE3Y!2P@=VAI8V@@87)E(')E<&]R=&5D(&%S(&$@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P M="!4:6UE3Y!9'9E2!A'!E;G-E+"`H:6DI(&-O;W!E'!E;G-E2X@26YC;'5D960@:6X@<')E<&%I9"!E>'!E;G-E M6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P M="!4:6UE3X\6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'!E;G-E(&]V97(@=&AE(')E<75I6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@ M,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D]. M5#H@,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T MF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T2!O9B!0 M4TD@4&%R96YT+"!A;F0@4&AU2!!9W)E96UE;G0@*'1H92`F(S@R,C`[3$Q# M($%G6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M#L@1D].5#H@8F]L9"`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4 M:6UE3Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@87)E(&-H87)G960@ M=&\@;W!E#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N M;VYE.R!F;VYT+7-TF4M861J=7-T.B!N M;VYE.R!F;VYT+7-TF4@=&AE(&%S"!A M"!C;VYS M97%U96YC97,@;V8@979E;G1S('1H870@:&%V92!B965N(')E8V]G;FEZ960@ M:6X@;W5R(&9I;F%N8VEA;"!S=&%T96UE;G1S(&]R('1A>"!R971U"!L87<@ M;W(@6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`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`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4 M:6UE"!L;W-S97,L('=E M(&AA=F4@2P@ M=V4@:&%V92!N;W0@F4M861J=7-T.B!N;VYE.R!F;VYT M+7-T#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ M(#!P>#L@1D].5#H@,3!P="!4:6UE2!O9B!R979E;G5E(&%N9"!C87-H(&9L;W=S M(')E;&%T:6YG('1O(&-U2!A9&]P=&EO;BXF(S$V,#L@5&AI M65A65A2!A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N M;VYE.R!F;VYT+7-TFEN9R!T:&4@8V]M<&5NF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@ M,3!P="!4:6UE3Y);B!!=6=U28C.#(Q-SMS($%B:6QI='D@=&\@0V]N=&EN=64@87,@ M82!';VEN9R!#;VYC97)N)B,X,C(Q.RXF(S$V,#M4:&4@86UE;F1M96YT2=S(&UA M;F%G96UE;G0@2=S(&%B:6QI='D@=&\@8V]N=&EN=64@87,@ M82!G;VEN9R!C;VYC97)N('=I=&AI;B!O;F4@>65A2!A<'!L:6-A=&EO;B!I6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4 M:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE'!E M8W0@=&AE(&%D;W!T:6]N(&]F('1H:7,@9W5I9&%N8V4@=VEL;"!H879E(&$@ M;6%T97)I86P@:6UP86-T(&]N(&]U3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V8S4Q-65B M.5\Y-SAC7S1F9F%?.3EC9%\X,F8S-F8V8C%C,#<-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO-F,U,35E8CE?.3'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T3PO8CX\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UEF4M861J=7-T.B!N;VYE M.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6%B;&4@=&\@=&AE('-T;V-K:&]L9&5R M2!T:&%T(&YU;6)E&5R8VES92!P2!A('-I;6EL87)L>2!C;VYS=&ET=71E9"!P87)T>2!T;R!M86ME M(&$@=&5N9&5R(&]R(&5X8VAA;F=E(&]F9F5R(')E6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG&5R8VES:6YG('-U8V@@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T2!,:6YE)B,X,C(Q.RD@=VET:"!$=71C:&5S2!&=6YD($E)+"!,4"`H)B,X,C(P.T1U=&-H97-S)B,X,C(Q.RD@ M=VAE2!$=71C:&5S6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!,:6YE(&%S(&]F($UA>2`R."P@,C`Q-"X\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2`R,RP@,C`Q-"P@=V4@2!, M:6YE(&%N9"8C,38P.W=E(&1E2!, M:6YE('=E6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M2!L:6YE(&]F(&-R961I="!A9W)E96UE;G0@*'-U M8V@@87)R86YG96UE;G0L('1H92`F(S@R,C`[,C`Q-"!%<75I='D@3&EN928C M.#(R,3LI(&1A=&5D($UA>2`R."P@,C`Q-"!W:&5R96)Y($1U=&-H97-S(&-O M;6UI='1E9"!T;R!P=7)C:&%S92P@28C.#(Q M-SMS($-O;6UO;B!3=&]C:RP@;W9E2!,:6YE+B!/;B!- M87D@,CDL(#(P,30L('=E(&9I;&5D(&$@6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T2!I;B!O M=7(@9&ES8W)E=&EO;B!D2!F2!I2!,:6YE+B!792!M87D@9&5L:79E#L@1D].5#H@,3!P="!4:6UE28C.#(Q-SMS($-O;6UO;B!3=&]C:R!D=7)I;F<@=&AE(&]N M92!T28C,38P.VEM;65D:6%T96QY(&9O;&QO=VEN9R!O=7(@ M<'5T(&YO=&EC92X@5&AE($-O;7!A;GD@:&%S('1H92!R:6=H="!T;R!W:71H M9')A=R!A;&P@;W(@86YY('!O6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F;VYT+7-T&-H86YG92!!8W0@;V8@,3DS-"P@87,@86UE;F1E9"X@26X@861D M:71I;VXL('=E(&%R92!N;W0@<&5R;6ET=&5D('1O(&1R87<@;VX@=&AE(&9A M8VEL:71Y('5N;&5SF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D]. M5#H@,3!P="!4:6UE3X\8CX\:3XF(S$V,#L\+VD^/"]B/CPO9&EV/B`\9&EV('-T M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE65E6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@ M,3!P="!4:6UE3Y792!A2!T:6UE M('!R:6]R('1O('-U8V@@;W!T:6]N'!I M65A'!IF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2!S:&%R96AO;&1E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D]. M5#H@,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T2`U+"`R,#$P+"!O=7(@2`V+"`R,#$S+B!!('!R:6UA2!# M;VUP96YS871I;VX@4&QA;B!I2!#;VUP96YS871I M;VX@4&QA;B!P2!B92!I2!#;VUP96YS871I;VX@4&QA;BX\+V1I=CX@/"]D:78^/'1A8FQE M(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^ M/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0@0FQO8VM=/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T'!I6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&EM871E;'D@)#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGFEN M9R!T:&5S92!T87@@8F5N969I=',@:6X@=&AE(&9U='5R92XF(S$V,#L\+V1I M=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2!3971T;&5M96YT M($%G2P@3F%N8WD@2F%N92!' M;V1F2!38VEE;F-E(&%N9"!$97-I9VXL($EN8RX@ M*'1O9V5T:&5R('1H92`F(S@R,C`[1V]D9G)E>7,F(S@R,C$[*2!F;W(@:6YJ M=6YC=&EV92!R96QI968@6QE.FYO6QE.FYO"`P<'@@,"XU:6X[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T2!*86YE($=O9&9R97DL(&5N M=&5R960@:6YT;R!A(%-E='1L96UE;G0@06=R965M96YT(&%N9"!-=71U86P@ M1V5N97)A;"!296QE87-E("AT:&4@)B,X,C(P.T=O9&9R97D@4V5T=&QE;65N M="!!9W)E96UE;G0F(S@R,C$[*2P@<'5R6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A6UE;G0@:6X@=&AE(&%M;W5N="!O9B`D,3`P+#`P,"!W:6QL(&%C M8W)U92!I;G1E6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!3 M971T;&5M96YT($%G6QE.FYO2!A6UE;G1S+CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M>#L@1D].5#H@,3!P="!4:6UE'0@9FEV92!Y96%RF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T M.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL M93TS1"=-05)'24XZ(#!I;B`P:6X@,&EN(#`N-6EN.R!724142#H@-C`E.R!" M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^ M(#QT6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-R4^(#QD:78^,C`Q-3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I M=CXQ+#`R-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[ M($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,C`P/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)W=I9'1H.C$P M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE MF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T'!L;VET(&-E2!F;W(@=7-E(&EN(&$@<')O9'5C="!C M;VUB:6YI;F<@;VYE(&]R(&UOF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T2`D/&9O;G0@6UE;G0@=&\@4%-)(%!A2!L:6-E;G-E+CPO9&EV/B`\9&EV('-T M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T2X@ M5VAI;&4@2P@;W5R(%!H M=7-I;VX@<')O9'5C="!D979E;&]P;65N="!I;FET:6%T:79E2!PF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2P@8G)E86-H(&]F('1H92!0:'5S:6]N(&IO:6YT M('9E;G1U2!S=&%G92!A;F0@ M870@=&AI3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\V8S4Q-65B.5\Y-SAC7S1F9F%?.3EC9%\X M,F8S-F8V8C%C,#<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F,U M,35E8CE?.3'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE M2!T:&4@=V5I9VAT960M879EF4@=&AE('1R96%S=7)Y('-T;V-K(&UE=&AO9"!W:&EC M:"!P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE M#L@1D]. M5#H@,3!P="!4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;B6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P:6X@,"XS:6X[(%=)1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0W)2!C;VQS<&%N/3-$,CX@/&1I=CY%4%,\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0V)3X@/&1I=CXH,2PS.#`I/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`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`C8V-E969F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#8E/B`\9&EV/B@X,#0I/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`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`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#8E/B`\9&EV/C$U+#@Y,CPO9&EV/B`\+W1D/B`\=&0@"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T M871E2!M86YA M9V5M96YT('=I=&AO=70@875D:70@86YD('-H;W5L9"!B92!R96%D(&EN(&-O M;FIU;F-T:6]N('=I=&@@;W5R(&-O;G-O;&ED871E9"!F:6YA;F-I86P@65A2!F;W(@ M82!F86ER('!R97-E;G1A=&EO;B!O9B!T:&4@8V]N2!B92!A8VAI979E9"!O=F5R('1H M92!C;W5R65A&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^ M/'1D/CPO=&0^/"]T2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I M;CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2!O9B!T:&4@0G5S:6YEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M2!A;F0@2!M86YA9V5M96YT M(&%N9"!M87)K971I;F<@<')O9W)A;7,@=&\@;W!T:6UI>F4@8V]N2!497AT M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M&%M<&QE2!A('5N:69O2!B87-I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE6QE.FYO6QE/3-$9F]N="US='EL93IN;W)M86P^)B,Q-S0[ M/"]S=7`^($-O;&0@4F5M961Y($]R86P@4W!R87DN(%=E(&%L6QE/3-$ M9F]N="US='EL93IN;W)M86P^)B,Q-S0[/"]S=7`^($-O;&0@4F5M961Y($]R M86P@4W!R87D@86YD(%%U:6-K365L=',\6QE/3-$9F]N="US='EL M93IN;W)M86P^)B,Q-S0[/"]S=7`^('!R;V1U8W1S+"!A;F0@3W)G86YI>#QS M=7`@6QE.FYO2P@=V4@;6]N:71O2!C=7-T;VUE2!O=&AE2!497AT($)L;V-K73PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'@[($9/3E0Z(&)O;&0@:71A;&EC(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!- M05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE2!O9B!T:&5S92!I;G9E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\ M='(^/'1D/CPO=&0^/"]T2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T2!I MF5D('1O(&1E=&5R;6EN92!C M;W-T(&%N9"!T:&4@;6%R:V5T('9A;'5E(&%N9"!A<'!R;W!R:6%T92!V86QU M871I;VX@861J=7-T;65N=',@87)E(&5S=&%B;&ES:&5D+B!!="!-87)C:"`S M,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L(#(P,30L('1H92!F:6YA;F-I86P@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2X@/&9O;G0@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/C(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXW.3@\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/C(P-SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H M)SXT,3@\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXR M+#(U-#PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78@"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/C(L,#6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.T-,14%2.B!B;W1H)SXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/C,L,CDR/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)W=I9'1H.C$P,"4[ M('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D M9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!497AT($)L M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T'!E;G-E(&ES(&-O;7!U=&5D(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@ M9F]L;&]W:6YG(')A;F=E65A'1U'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2!O=7(@86)I;&ET>2!T;R!M86EN=&%I;B!O=7(@ M;6%N=69A8W1UF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2!O9B!UF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!- M05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE2!F961EF4M861J=7-T M.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2!A;F0@9V5N97)A;&QY M('=E(&1O(&YO="!R97%U:7)E(&-O;&QA=&5R86PN($]U2!L87)G92!N871I;VYA;"!C M:&%I;BP@2!A;F0@;&]C86P@2!I;7!A8W0@ M;W5R(&]V97)A;&P@97AP;W-U2!I;7!A8W0@=&AE('1I;6EN9R!A;F0@8V]L;&5C=&%B:6QI='D@;V8@86UO M=6YT6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE2!P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE2P@8GD@=VAI M8V@@=&AE(&-A&-E961S M('1H96ER(')E2!M86YA9V5M96YT('1O(&)E(&-O;6UE M;G-UFEN9R!D:7-C;W5N=&5D(&9O6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ M(#!P>#L@1D].5#H@,3!P="!4:6UE2!A;F0@8V]M<&%R86)I;&ET>2!I;B!F86ER('9A;'5E(&UE87-U MF5S('1H92!I;G!U=',@=7-E9"!T;R!M96%S=7)E(&9A:7(@=F%L M=64N(%1H97-E('1I97)S(&EN8VQU9&4Z($QE=F5L(#$L(&1E9FEN960@87,@ M;V)S97)V86)L92!I;G!U=',@#L@1D].5#H@ M,3!P="!4:6UE3X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6%B;&4@87)E(')E9FQE8W1E9"!I;B!T:&4@0V]N9&5N6EN9R!V86QU M92!W:&EC:"!A<'!R;WAI;6%T97,@9F%I2!497AT($)L;V-K73PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@ M,3!P="!4:6UE3Y386QEF4@ M:&ES=&]R:6-A;"!R971U6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P M="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE2!A2!F86QL&-E961E9"!D M97-I9VYA=&5D(&5X<&ER871I;VX@9&%T97,@86YD("AI:6DI('=E('=I;&P@ M86-C97!T(')E='5R;G,@:6X@=&AE(&5V96YT('1H870@=V4@9&ES8V]N=&EN M=64@82!P2!F2!T;R!O=7(@ M2!OF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2P@86-C M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^ M/"]T#L@1D].5#H@,3!P M="!4:6UE3X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@ M,3!P="!4:6UE3Y!9'9E2!A'!E;G-E+"`H:6DI(&-O;W!E'!E;G-E2X@26YC;'5D960@:6X@<')E<&%I9"!E>'!E M;G-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@ M1D].5#H@,3!P="!4:6UE6UE;G1S('1O(&5M<&QO>65E'!E M;G-E(&EN('1H92!F:6YA;F-I86P@2!C;VEN8VED97,@=VET:"!T:&4@=F5S=&EN9R!P97)I;V0N/"]D:78^ M(#QD:78@F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE65E65E&5R8VES86)L92!D=7)I;F<@82!P97)I;V0@9&5T97)M:6YE9"!B M>2!U6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2P@9F]R('-H87)E+6)A'!E;G-E(&9O6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!- M05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M>#L@1D].5#H@,3!P="!4:6UEFEN9RP@9F]R('=O2!P871E;G1E9"!4 M4$TF(S$U,SL@=&5C:&YO;&]G>2`H)B,X,C(P.U10328C.#(R,3LI+B8C,38P M.U1H92!*;VEN="!696YT=7)E+"!O9B!W:&EC:"!W92!O=VX@82`U,"4@;65M M8F5R6QE/3-$)W=I9'1H.C$P M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!4 M97AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I M=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(&)O;&0@ M,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA M>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^ M/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@ M1D].5#H@,3!P="!4:6UE2!A<'!R;V%C:"!W:&EC:"!R97%U:7)E"!C;VYS97%U96YC97,L('=E(&=E;F5R86QL>2!C;VYS:61E"!AF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE"!P;W-I=&EO;B!F;W(@2!P97)C96YT(&QI M:V5L>2!O9B!B96EN9R!R96%L:7IE9"!U<&]N('5L=&EM871E('-E='1L96UE M;G0N($%N>2!I;G1E2X\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE"!A2!F;W(@=6YR96-O9VYI>F5D('1A>"!B96YE9FET&5D.R<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@ M1D].5#H@,3!P="!4:6UEF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE2!U6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@1D]. M5#H@,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UEF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T2!I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\V8S4Q-65B.5\Y-SAC7S1F9F%?.3EC9%\X,F8S-F8V8C%C,#<-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F,U,35E8CE?.3'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!- M05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@ M,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C(P,34\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B0\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.T-,14%2.B!B;W1H)SXW.3@\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2 M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\ M='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C(P-SPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXT,3@\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXR+#(U-#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C(L,#6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXD M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C,L,CDR/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE65A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@ M/&1I=CXQ+#$R-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ+#`R-3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T M:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,BPX M,3D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,RPP,3D\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P:6X@,"XS:6X[(%=) M1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0W)2!C;VQS<&%N/3-$ M,CX@/&1I=CY%4%,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V M)3X@/&1I=CXH,2PS.#`I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V)3X@ M/&1I=CXQ-2PX.3(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8E/B`\9&EV/B@X M,#0I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`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`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U M<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D M/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8E/B`\9&EV/C$U+#@Y,CPO M9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-) M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4 M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2P@ M3F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L,C7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$P,"PP,#`\'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M,SD@>65A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2P@4&QA;G0@86YD($5Q=6EP;65N M="P@57-E9G5L($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA65A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1U'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L2`R."P@,C`Q-#QB'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES92!O9B!T:&4@4FEG:'0@86YD('1H92!A8W%U:7)E3QS<&%N/CPO6UE;G0@3W!T:6]N($5X<&ER M871I;VX@5&5R;7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&EM=6T@3G5M8F5R($]F M($-O;6UO;B!3=&]C:R!!=71H;W)I>F5D($9O'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!,:6YE(&]F($-R961I="!;365M8F5R73PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!,:6YE($]F($-R961I=#PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^,S8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!-971H;V0@26YV97-T;65N="P@3W=N97)S M:&EP(%!E6UE M;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!;3&EN92!)=&5M6UE;G0@07=A M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!;3&EN92!)=&5M6UE;G0@07=A M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!;3&EN92!)=&5M6UE M;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!;365M8F5R73PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^1FES8V%L(#(P,C`@=&AR;W5G:"!&:7-C86P@ M,C`S,SQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^1FES8V%L(#(P,3@@=&AR;W5G:"!&:7-C86P@ M,C`S,SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6UE M;G1S(&9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6%L=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'1U86PI("A54T0@)"D\8G(^26X@36EL;&EO;G,L(&5X8V5P="!3 M:&%R92!D871A+"!U;FQE'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61I;F<@1V]O9'=I;&PI/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'1U86PI/&)R/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V8S4Q-65B.5\Y-SAC M7S1F9F%?.3EC9%\X,F8S-F8V8C%C,#<-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-F,U,35E8CE?.3&UL#0I#;VYT96YT+51R86YS9F5R+45N M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O M:'1M;#L@8VAA&UL;G,Z;STS1")U M XML 18 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9

Summary of Significant Accounting Policies
3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2014. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of operating results that may be achieved over the course of the full year.

Seasonality of the Business

Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

Use of Estimates

The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Our primary product, Cold-EEZE^Ò Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE^® Cold Remedy QuickMelts^® and a Cold-EEZE^® Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Cold Remedy Oral Spray and QuickMelts^® products, and Organix^® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

Cash Equivalents

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.

Inventory Valuation

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At March 31, 2015 and December 31, 2014, the financial statements include adjustments to reduce inventory for excess or obsolete inventory of $505,000 and $797,000, respectively. The components of inventory are as follows (in thousands):

March 31,

December 31,

2015

2014

Raw materials

$

816

$

798

Work in process

207

418

Finished goods

2,254

2,076

$

3,277

$

3,292

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures – five years.

Concentration of Risks

Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.

Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.

We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2015, our cash balance was $5.0 million and our bank balance was $5.3 million. Of the total bank balance, $582,000 was covered by federal depository insurance and $4.7 million was uninsured at March 31, 2015.

Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at March 31, 2015 and December 31, 2014.

Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately 93% and 95% of total revenues for each of the three months ended March 31, 2015 and 2014, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three months ended March 31, 2015 and 2014, our net sales were principally related to domestic markets.

Long-lived Assets

We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.

Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Fair Value of Financial Instruments

Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments.

Revenue Recognition

Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

As of March 31, 2015 and December 31, 2014, we included a provision for sales allowances of $55,000 and $129,000, respectively, which are reported as a reduction to sales and account receivables. Additionally, accrued advertising and other allowances as of March 31, 2015 included (i) $1.5 million for estimated future sales returns and (ii) $1.6 million for cooperative incentive promotion costs. As of December 31, 2014, accrued advertising and other allowances included (i) $1.5 million for estimated future sales returns and (ii) $2.1 million for cooperative incentive promotion costs.

Advertising and Incentive Promotions

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2015 and 2014 were $3.1 million and $3.4 million, respectively. Included in prepaid expenses and other current assets was $172,000 and $885,000 at March 31, 2015 and December 31, 2014, respectively, relating to prepaid advertising and promotion expenses.

Shipping and Handling

Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.

Stock Based Compensation

We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.

Stock and stock options for the purchase of our common stock, $0.0005 par value, (“Common Stock”) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 3). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended March 31, 2015 and 2014, we charged to operations $34,000 and $64,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.

Variable Interest Entity

On March 22, 2010, we, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM™ technology (“TPM”). The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010 (see Note 6).

Research and Development

Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended March 31, 2015 and 2014 were $208,000 and $278,000, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.

Income Taxes

We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 4).

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.

As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits.

Recently Issued Accounting Standards

In May 2014, the FASB issued new accounting guidance ASU No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. There is no option for early adoption. This ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016. On April 29, 2015 the FASB issued an exposure draft to extend the effective date of ASU 2014-09 until December 15, 2017. We are currently assessing the impact of this update, and believe that its adoption will not have a material impact on our consolidated financial statements.

In June 2014, the FASB issued new accounting guidance ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this update require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. Companies should apply existing guidance in ASC 718, “Compensation - Stock Compensation”, as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in this update will be effective as of January 1, 2016. Earlier adoption is permitted. We may apply the amendments in this update either: (1) prospectively to all awards granted or modified after the effective date; or (2) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If a retrospective transition is adopted, the cumulative effect of applying this update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. In addition, if a retrospective transition is adopted, we may use hindsight in measuring and recognizing the compensation cost. We are currently assessing the impact of this update, and believe that its adoption on January 1, 2016 will not have a material impact on our consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The amendments in this update state that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our consolidated financial statements.

In February 2015, the FASB issued guidance that changes the evaluation criteria for consolidation and related disclosure requirements. This guidance introduces evaluation criteria specific to limited partnerships and other similar entities, as well as amends the criteria for evaluating variable interest entities with which the reporting entity is involved and certain investment funds. The guidance will become effective for us at the beginning of our first quarter of Fiscal 2017. We do not expect the adoption of this guidance will have a material impact on our consolidated financial statements.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

ASSETS

Cash and cash equivalents (Note 2) $ 5,021 $ 2,926

Accounts receivable, net 3,468us-gaap_AccountsReceivableNetCurrent 5,836us-gaap_AccountsReceivableNetCurrent

Inventory (Note 2) 3,277us-gaap_InventoryNet 3,292us-gaap_InventoryNet

Prepaid expenses and other current assets 670 1,404

Total current assets 12,436us-gaap_AssetsCurrent 13,458us-gaap_AssetsCurrent

Property, plant and equipment, net of accumulated depreciation of $4,424 and $4,341, respectively (Note 2) 2,558us-gaap_PropertyPlantAndEquipmentNet 2,599us-gaap_PropertyPlantAndEquipmentNet

Total assets 14,994us-gaap_Assets 16,057us-gaap_Assets

LIABILITIES:

Accounts payable 1,231us-gaap_AccountsPayableCurrent 667us-gaap_AccountsPayableCurrent

Accrued advertising and other allowances 3,232us-gaap_AccruedMarketingCostsCurrent 3,685us-gaap_AccruedMarketingCostsCurrent

Other current liabilities 1,061us-gaap_OtherLiabilitiesCurrent 889us-gaap_OtherLiabilitiesCurrent

Total current liabilities 5,524us-gaap_LiabilitiesCurrent 5,241us-gaap_LiabilitiesCurrent

Other long term obligations (Note 5) 100 100

Commitments and contingencies (Note 5)

STOCKHOLDERS' EQUITY:

Common Stock, $.0005 par value; authorized 50,000,000; issued: 25,125,113 shares (Note 3) 13us-gaap_CommonStockValue 13us-gaap_CommonStockValue

Additional paid-in-capital 54,698 54,664

Accumulated deficit (14,599) (13,219)

Treasury stock, at cost 9,232,817 shares (30,742)us-gaap_TreasuryStockValue (30,742)us-gaap_TreasuryStockValue

Total stockholders' equity 9,370us-gaap_StockholdersEquity 10,716us-gaap_StockholdersEquity

Total liabilities and stockholders' equity $ 14,994 $ 16,057

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

No definition available.

+ Details

Name: us-gaap_AccruedMarketingCostsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 20 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Cash flows from operating activities:

Net loss $ (1,380)us-gaap_NetIncomeLoss $ (804)us-gaap_NetIncomeLoss

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

Depreciation and amortization 83us-gaap_Depreciation 64us-gaap_Depreciation

Share-based compensation expense 34 64

Gain on sale of equipment (5) 0

Changes in operating assets and liabilities:

Accounts receivable 2,368 2,463

Inventory 15us-gaap_IncreaseDecreaseInInventories 309us-gaap_IncreaseDecreaseInInventories

Accounts payable 564 (19)

Accrued advertising and other allowances (453) 35

Other operating assets and liabilities, net 906 839

Net cash provided by operating activities 2,132 2,951

Cash flows from investing activities:

Capital expenditures (42) (17)

Proceeds from the sale of equipment 5 0

Net cash used in investing activities (37) (17)

Cash flows from financing activities:

Proceeds from issuance of common stock 0 947

Net cash provided by financing activities 0 947

Net increase in cash and cash equivalents 2,095 3,881

Cash and cash equivalents at beginning of period 2,926 1,638

Cash and cash equivalents at end of period $ 5,021 $ 5,519

X

- Definition

Net change during the period in the amount of Accrued advertising and other allowances at the period end.

+ References

No definition available.

+ Details

Name: prph_IncreaseDecreaseInAccruedMarketingCosts

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities less other operating liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets and liabilities, other noncurrent assets and liabilities, or a combination of other current and noncurrent assets and liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 21 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies (Details) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Commitments And Contingencies [Line Items]

2015 $ 869

2016 1,125

2017 1,025

2018 0

2019 0

Total 3,019

Employment Contracts [Member]

Commitments And Contingencies [Line Items]

2015 769

2016 1,025

2017 1,025

2018 0

2019 0

Total 2,819

Godfrey Settlement Agreement [Member]

Commitments And Contingencies [Line Items]

2015 100

2016 100

2017 0

2018 0

2019 0

Total $ 200

X

- Details

Name: prph_CommitmentsAndContingenciesLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of contractual obligation maturing after the fifth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueAfterFifthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the fifth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInFifthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the fourth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInFourthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the next fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the second fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInSecondYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the third fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInThirdYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: prph_EstimatedFutureObligationAxis=prph_GodfreySettlementAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: prph_EstimatedFutureObligationAxis=us-gaap_EmploymentContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9

Investment in a Joint Venture (Details Textual) (USD $)
In Millions, except Share data, unless otherwise specified
12 Months Ended 1 Months Ended

Dec. 31, 2014

Mar. 31, 2010

Schedule of Investments [Line Items]

Asset Impairment Charges $ 3.6us-gaap_AssetImpairmentCharges

PSI Technology License [Member]

Schedule of Investments [Line Items]

Intangible Assets, Net (Excluding Goodwill) 3.6

PSI Parent [Member]

Schedule of Investments [Line Items]

Stock Issued During Period, Shares, New Issues 1,440,000

Stock Issued During Period, Value, New Issues 2.6

Payments To Fund Joint Venture Investments $ 1.0

X

- Definition

The cash outflow associated with the funding of joint venture investments.

+ References

No definition available.

+ Details

Name: prph_PaymentsToFundJointVentureInvestments

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2420-110228

+ Details

Name: us-gaap_AssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ScheduleOfInvestmentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=prph_PsiParentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=prph_PsiTechnologyLicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 24 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9

Organization and Business
3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 – Organization and Business

ProPhase Labs, Inc. (“we”, “us” or the “Company”), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along with supplement, personal care and cosmeceutical products.

Our primary business is the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE^Ò Cold Remedy and our principal product is Cold-EEZE^Ò Cold Remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration of the common cold. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute non-lozenge forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE^® Cold Remedy QuickMelts^® and (ii) Cold-EEZE^® Cold Remedy Oral Spray. Cold-EEZE^® Cold Remedy Oral Spray is a liquid form of our zinc gluconate formulation that is sprayed in the mouth. Cold-EEZE^® Cold Remedy QuickMelts^® are fast dissolving tablets that are taken orally. Cold-EEZE^Ò Cold Remedy is an established product in the health care and cold remedy market. For the three months ended March 31, 2015 and 2014, we operated in one reporting segment and our revenues have come principally from our OTC cold remedy products.

We use a December 31 year-end for financial reporting purposes. References herein to Fiscal 2015 shall mean the fiscal year ended December 31, 2015 and references to other “Fiscal” years shall mean the year, which ended on December 31 of the year indicated. The term “we”, “us” or the “Company” as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)
In Thousands, except Share data, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

Accumulated depreciation (in dollars) $ 4,424 $ 4,341

Common Stock, par value (in dollars per share) $ 0.0005 $ 0.0005

Common Stock, shares authorized 50,000,000us-gaap_CommonStockSharesAuthorized 50,000,000us-gaap_CommonStockSharesAuthorized

Common Stock, shares issued 25,125,113us-gaap_CommonStockSharesIssued 25,125,113us-gaap_CommonStockSharesIssued

Treasury stock, shares (in shares) 9,232,817us-gaap_TreasuryStockShares 9,232,817us-gaap_TreasuryStockShares

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 26 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9

Earnings (Loss) Per Share (Tables)
3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block]

A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):

Three Months Ended

Three Months Ended

March 31, 2015

March 31, 2014

Loss

Shares

EPS

Loss

Shares

EPS

Basic earnings (loss) per share

$

(1,380)

15,892

$

(0.09)

$

(804)

16,469

$

(0.05)

Dilutives:

Options

-

-

-

-

-

-

Diluted income (loss) per share

$

(1,380)

15,892

$

(0.09)

$

(804)

16,469

$

(0.05)

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9

Document And Entity Information
3 Months Ended

Mar. 31, 2015

May 13, 2015

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q1

Entity Registrant Name ProPhase Labs, Inc.

Entity Central Index Key 0000868278

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol PRPH

Entity Common Stock, Shares Outstanding 15,892,296dei_EntityCommonStockSharesOutstanding

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 28 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9

Summary of Significant Accounting Policies (Details) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

Inventory [Line Items]

Raw materials $ 816us-gaap_InventoryRawMaterials $ 798us-gaap_InventoryRawMaterials

Work in process 207us-gaap_InventoryWorkInProcess 418us-gaap_InventoryWorkInProcess

Finished goods 2,254us-gaap_InventoryFinishedGoods 2,076us-gaap_InventoryFinishedGoods

Inventory, Net $ 3,277us-gaap_InventoryNet $ 3,292us-gaap_InventoryNet

X

- Definition

Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InventoryLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 29 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Statements of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Net sales (Note 2) $ 5,860us-gaap_SalesRevenueNet $ 6,171us-gaap_SalesRevenueNet

Cost of sales (Note 2) 2,198us-gaap_CostOfGoodsAndServicesSold 2,191us-gaap_CostOfGoodsAndServicesSold

Gross profit 3,662us-gaap_GrossProfit 3,980us-gaap_GrossProfit

Operating expenses:

Sales and marketing 2,812us-gaap_SellingAndMarketingExpense 2,997us-gaap_SellingAndMarketingExpense

Administration 2,021us-gaap_GeneralAndAdministrativeExpense 1,507us-gaap_GeneralAndAdministrativeExpense

Research and development 208us-gaap_ResearchAndDevelopmentExpense 278us-gaap_ResearchAndDevelopmentExpense

Total operating expense 5,041us-gaap_OperatingExpenses 4,782us-gaap_OperatingExpenses

Loss from operations (1,379)us-gaap_OperatingIncomeLoss (802)us-gaap_OperatingIncomeLoss

Interest expense, net (1)us-gaap_InterestExpense (2)us-gaap_InterestExpense

Loss before income tax (1,380) (804)

Income tax (Note 4) 0us-gaap_IncomeTaxExpenseBenefit 0us-gaap_IncomeTaxExpenseBenefit

Net loss $ (1,380)us-gaap_NetIncomeLoss $ (804)us-gaap_NetIncomeLoss

Basic and diluted loss per share:

Net loss $ (0.09) $ (0.05)

Weighted average common shares outstanding:

Basic and diluted 15,892 16,469

X

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a),(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35710027&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.

+ References

No definition available.

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total amount of expenses directly related to the marketing or selling of products or services.

+ References

No definition available.

+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 30 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9

Investment in a Joint Venture
3 Months Ended

Mar. 31, 2015

Investments in and Advances to Affiliates, Schedule of Investments [Abstract]

Investments in and Advances to Affiliates, Schedule of Investments [Text Block]

Note 6 – Investment in a Joint Venture

On March 22, 2010, we, PSI Parent, PSI and the Joint Venture entered into the LLC Agreement of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM.

In connection with the LLC Agreement, PSI Parent granted to us, pursuant to the terms of a License Agreement, dated March 22, 2010 (the “Original License Agreement”), (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit OTC drugs and certain other products that embody certain of PSI Parent’s TPM-related patents and related know-how (collectively, the “PSI Technology”) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug.

Pursuant to the Original License Agreement, we issued 1,440,000 shares of our Common Stock having an aggregate value of approximately $2.6 million to PSI Parent (such shares, the “PSI Shares”) and made a one-time payment to PSI Parent of $1.0 million in March 2010. We recorded an intangible asset valued at $3.6 million in March 2010 for the acquisition of the PSI Technology license.

As previously announced in September 2014, we are implementing a series of new product development and pre-commercialization initiatives principally in the dietary supplement category. While several of our product development initiatives have advanced, including those specific to the dietary supplement category, our Phusion product development initiatives have not progressed to management’s satisfaction. At this time, management believes that any products embodying the licensed technology to be developed by Phusion will not be available until Fiscal 2016 or 2017 at the earliest, and may be more limited than previously forecasted and may encompass fewer products or have limited retail distribution.

During the third quarter of Fiscal 2014, our evaluation of the Company’s progress in its new product development pipeline and delays in Phusion product development caused management to reassess projections (including income projections) relied upon in December 2013. Accordingly, management performed an impairment analysis for the period ended September 30, 2014 for the licensed technology. As a consequence of our impairment assessment, we determined that a full impairment occurred of the intangible asset, licensed technology. As a consequence, we charged to operations a $3.6 million impairment charge during the third quarter of Fiscal 2014.

On October 17, 2014, we initiated a demand for arbitration with the American Arbitration Association, case number 01-14-0001-7373. This demand for arbitration pertains to our Phusion joint venture and the matter is against Phosphagenics, Inc. and Phosphagenics LTD (collectively known as the “Phosphagenics Entities”). We have raised certain claims based upon the alleged Phosphagenics Entities’ breach of a certain amended and restated licenses agreement for the exploitation of certain intellectual property and, separately, breach of the Phusion joint venture operating agreement as between the Company and the Phosphagenics Entities. The Phosphagenics Entities have made counter claims of breaches against the Company and Phusion. This matter is at its preliminary stage and at this time, no prediction as to the outcome of this action can be made.

X

- Details

Name: us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 6

-Subparagraph (SX 210.12-14)

-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611322-123010

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 14

-Article 12

+ Details

Name: us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies
3 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Note 5 – Commitments and Contingencies

Godfrey Settlement Agreement

In November 2004, we commenced an action against John C. Godfrey, Nancy Jane Godfrey, and Godfrey Science and Design, Inc. (together the “Godfreys”) for injunctive relief regarding the ownership of the Cold-EEZE^® trademark. The Godfreys subsequently asserted against us counterclaims and sought monetary damages and injunctive and declaratory relief relative to the Cold-EEZE^® trademark and other intellectual property.

On December 20, 2012, we and the Godfreys, including the Estate of Nancy Jane Godfrey, entered into a Settlement Agreement and Mutual General Release (the “Godfrey Settlement Agreement”), pursuant to which we resolved all disputes, including claims asserted by us and counterclaims asserted against us in the action. Pursuant to the terms of the Godfrey Settlement Agreement, we paid the Godfreys $2.1 million in December 2012 and we agreed to make four additional annual payments of $100,000 due in December of each of the next four years. Each annual payment in the amount of $100,000 will accrue interest at the per annum rate of 3.25%. The second annual installment of $100,000 plus accrued interest of $10,000 was paid in December 2014. Under the Godfrey Settlement Agreement, the Godfreys assigned, transferred and conveyed to us all of their right, title, and interest in U.S. Trademark Registration No. 1,838,542 for the trademark Cold-EEZE^®, among other intellectual property associated with such trademark. At each of March 31, 2015 and December 31, 2014, other current liabilities and other long term obligations include $100,000 and $100,000, respectively, for the two remaining annual installment payments.

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2015, as follows (in thousands):

Fiscal Year

Employment
Contracts

Godfrey
Settlement
Agreement

Total

2015

769

100

869

2016

1,025

100

1,125

2017

1,025

-

1,025

2018

-

-

-

2019

-

-

-

Total

$

2,819

$

200

$

3,019

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies (Details Textual) (USD $)
1 Months Ended 12 Months Ended

Dec. 20, 2012

Dec. 31, 2014

Dec. 31, 2012

Mar. 31, 2015

Commitments And Contingencies [Line Items]

Payments for Legal Settlements $ 2,100,000us-gaap_PaymentsForLegalSettlements

Settlement benefit (Note 3) 10,000prph_SettlementBenefit

Additional Royalties and Commissions, Accrual Interest Percentage 3.25%

Additional Royalties and Commissions Payable, Installment Amount 100,000 100,000

Additional Annual Installment Includes In Other Current Liability 100,000

Additional Annual Installment Includes In Other Long Term Obligation $ 100,000

X

- Definition

It defines the portion of additional annual installment includes in other current Liability.

+ References

No definition available.

+ Details

Name: prph_AdditionalAnnualInstallmentIncludesInOtherCurrentLiability

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

It defines the portion of additional annual installment includes In other long term obligation.

+ References

No definition available.

+ Details

Name: prph_AdditionalAnnualInstallmentIncludesInOtherLongTermObligation

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Represents the interest rate percentage computed on royalty installment amount due.

+ References

No definition available.

+ Details

Name: prph_AdditionalRoyaltiesAndCommissionsAccrualInterestPercentage

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents additional royalties and commissions installment amount.

+ References

No definition available.

+ Details

Name: prph_AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: prph_CommitmentsAndContingenciesLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the amount of realized benefit as a consequence of a reduction of the previously recorded accrued royalties and commission obligation.

+ References

No definition available.

+ Details

Name: prph_SettlementBenefit

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for the settlement of litigation or for other legal issues during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_PaymentsForLegalSettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 33 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9

Summary of Significant Accounting Policies (Details Textual) (USD $)
3 Months Ended 12 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Accounting Policies [Line Items]

Inventory Adjustments $ 505,000us-gaap_InventoryAdjustments $ 797,000us-gaap_InventoryAdjustments

Cash and Cash Equivalents, At Carrying Value 5,021,000 5,519,000 2,926,000 1,638,000

Cash, FDIC Insured Amount 582,000us-gaap_CashFDICInsuredAmount

Cash, Uninsured Amount 4,700,000us-gaap_CashUninsuredAmount

Due from Banks 5,300,000us-gaap_DueFromBanks

Provision of Sales Allowance 55,000us-gaap_SalesAllowancesGoods 129,000us-gaap_SalesAllowancesGoods

Marketing and Advertising Expense 3,100,000us-gaap_MarketingAndAdvertisingExpense 3,400,000us-gaap_MarketingAndAdvertisingExpense

Prepaid expenses and other current assets 670,000 1,404,000

Research and development 208,000us-gaap_ResearchAndDevelopmentExpense 278,000us-gaap_ResearchAndDevelopmentExpense

Common Stock, par value (in dollars per share) $ 0.0005 $ 0.0005

Share-based Compensation 34,000us-gaap_ShareBasedCompensation 64,000us-gaap_ShareBasedCompensation

Estimated Future Sales Return [Member]

Accounting Policies [Line Items]

Accrued Liabilities 1,500,000 1,500,000

Cooperative Incentive [Member]

Accounting Policies [Line Items]

Accrued Liabilities 1,600,000 2,100,000

Sales Revenue, Goods, Net [Member]

Accounting Policies [Line Items]

Concentration Risk, Percentage 93.00% 95.00%

Building and Building Improvements [Member] | Maximum [Member]

Accounting Policies [Line Items]

Property, Plant and Equipment, Useful Life 39 years

Building and Building Improvements [Member] | Minimum [Member]

Accounting Policies [Line Items]

Property, Plant and Equipment, Useful Life 10 years

Machinery and Equipment [Member] | Maximum [Member]

Accounting Policies [Line Items]

Property, Plant and Equipment, Useful Life 7 years

Machinery and Equipment [Member] | Minimum [Member]

Accounting Policies [Line Items]

Property, Plant and Equipment, Useful Life 3 years

Computer Software, Intangible Asset [Member]

Accounting Policies [Line Items]

Property, Plant and Equipment, Useful Life 3 years

Furniture and Fixtures [Member]

Accounting Policies [Line Items]

Property, Plant and Equipment, Useful Life 5 years

Advertising and Incentive Promotion Costs [Member]

Accounting Policies [Line Items]

Prepaid expenses and other current assets $ 172,000 $ 885,000

X

- Details

Name: prph_AccountingPoliciesLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph a

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 5

-Article 9

+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.

+ References

No definition available.

+ Details

Name: us-gaap_CashFDICInsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.

+ References

No definition available.

+ Details

Name: us-gaap_CashUninsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

A bank's noninterest bearing demand deposits in other banks (such as correspondents).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.1)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 9

+ Details

Name: us-gaap_DueFromBanks

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Certain changes made in the current period to the value and amount of inventory reported.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph b

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

+ Details

Name: us-gaap_InventoryAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total expense recognized in the period for promotion, public relations, and brand or product advertising.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_MarketingAndAdvertisingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate selling price reductions recognized during an accounting period including, but not limited to, the sale of defective or nonconforming goods, a strategy to increase sales (generally over the short-term), move slow-moving items, develop distribution channels, or reward valuable customers. Allowances are a deduction from gross revenue in arriving at net revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesAllowancesGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: prph_AccruedAdvertisingAndOtherAllowancesAxis=prph_CooperativeIncentiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: prph_AccruedAdvertisingAndOtherAllowancesAxis=prph_EstimatedFutureSalesReturnMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: prph_OtherOperatingCostAndExpenseGeneralComponentAxis=prph_AdvertisingAndIncentivePromotionCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9

Summary of Significant Accounting Policies (Tables)
3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Schedule of Inventory, Current [Table Text Block]

The components of inventory are as follows (in thousands):

March 31,

December 31,

2015

2014

Raw materials

$

816

$

798

Work in process

207

418

Finished goods

2,254

2,076

$

3,277

$

3,292

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9

Earnings (Loss) Per Share
3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Note 7 – Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of our Common Stock outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that shared in the earnings of the entity. Diluted earnings per share also utilize the treasury stock method which prescribes a theoretical buy-back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Options and warrants outstanding to acquire shares of our Common Stock at March 31, 2015 and 2014 were 1,739,500 and 1,637,500, respectively.

For the three months ended March 31, 2015 and 2014 dilutive earnings per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the three months ended March 31, 2015 and 2014, there were 358,411 and 586,215 Common Stock Equivalents, respectively, which were in the money, that were excluded from the earnings per share computation.

A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):

Three Months Ended

Three Months Ended

March 31, 2015

March 31, 2014

Loss

Shares

EPS

Loss

Shares

EPS

Basic earnings (loss) per share

$

(1,380)

15,892

$

(0.09)

$

(804)

16,469

$

(0.05)

Dilutives:

Options

-

-

-

-

-

-

Diluted income (loss) per share

$

(1,380)

15,892

$

(0.09)

$

(804)

16,469

$

(0.05)

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9

Summary of Significant Accounting Policies (Policies)
3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Policy Text Block]

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2014. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of operating results that may be achieved over the course of the full year.

Nature Of Operations [Policy Text Block]

Seasonality of the Business

Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Our primary product, Cold-EEZE^Ò Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE^® Cold Remedy QuickMelts^® and a Cold-EEZE^® Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Cold Remedy Oral Spray and QuickMelts^® products, and Organix^® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.

Inventory, Policy [Policy Text Block]

Inventory Valuation

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At March 31, 2015 and December 31, 2014, the financial statements include adjustments to reduce inventory for excess or obsolete inventory of $505,000 and $797,000, respectively. The components of inventory are as follows (in thousands):

March 31,

December 31,

2015

2014

Raw materials

$

816

$

798

Work in process

207

418

Finished goods

2,254

2,076

$

3,277

$

3,292

Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures – five years.

Concentration Risk Disclosure [Policy Text Block]

Concentration of Risks

Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.

Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.

We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2015, our cash balance was $5.0 million and our bank balance was $5.3 million. Of the total bank balance, $582,000 was covered by federal depository insurance and $4.7 million was uninsured at March 31, 2015.

Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at March 31, 2015 and December 31, 2014.

Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately 93% and 95% of total revenues for each of the three months ended March 31, 2015 and 2014, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three months ended March 31, 2015 and 2014, our net sales were principally related to domestic markets.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-lived Assets

We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.

Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

As of March 31, 2015 and December 31, 2014, we included a provision for sales allowances of $55,000 and $129,000, respectively, which are reported as a reduction to sales and account receivables. Additionally, accrued advertising and other allowances as of March 31, 2015 included (i) $1.5 million for estimated future sales returns and (ii) $1.6 million for cooperative incentive promotion costs. As of December 31, 2014, accrued advertising and other allowances included (i) $1.5 million for estimated future sales returns and (ii) $2.1 million for cooperative incentive promotion costs.

Advertising and Incentive Promotions [Policy Text Block]

Advertising and Incentive Promotions

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2015 and 2014 were $3.1 million and $3.4 million, respectively. Included in prepaid expenses and other current assets was $172,000 and $885,000 at March 31, 2015 and December 31, 2014, respectively, relating to prepaid advertising and promotion expenses.

Shipping and Handling Cost, Policy [Policy Text Block]

Shipping and Handling

Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.

Compensation Related Costs, Policy [Policy Text Block]

Stock Based Compensation

We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.

Stock and stock options for the purchase of our common stock, $0.0005 par value, (“Common Stock”) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 3). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended March 31, 2015 and 2014, we charged to operations $34,000 and $64,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.

Consolidation, Variable Interest Entity, Policy [Policy Text Block]

Variable Interest Entity

On March 22, 2010, we, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM™ technology (“TPM”). The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010 (see Note 6).

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended March 31, 2015 and 2014 were $208,000 and $278,000, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.

Income Tax, Policy [Policy Text Block]

Income Taxes

We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 4).

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.

As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Standards

In May 2014, the FASB issued new accounting guidance ASU No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. There is no option for early adoption. This ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016. On April 29, 2015 the FASB issued an exposure draft to extend the effective date of ASU 2014-09 until December 15, 2017. We are currently assessing the impact of this update, and believe that its adoption will not have a material impact on our consolidated financial statements.

In June 2014, the FASB issued new accounting guidance ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this update require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. Companies should apply existing guidance in ASC 718, “Compensation - Stock Compensation”, as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in this update will be effective as of January 1, 2016. Earlier adoption is permitted. We may apply the amendments in this update either: (1) prospectively to all awards granted or modified after the effective date; or (2) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If a retrospective transition is adopted, the cumulative effect of applying this update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. In addition, if a retrospective transition is adopted, we may use hindsight in measuring and recognizing the compensation cost. We are currently assessing the impact of this update, and believe that its adoption on January 1, 2016 will not have a material impact on our consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The amendments in this update state that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our consolidated financial statements.

In February 2015, the FASB issued guidance that changes the evaluation criteria for consolidation and related disclosure requirements. This guidance introduces evaluation criteria specific to limited partnerships and other similar entities, as well as amends the criteria for evaluating variable interest entities with which the reporting entity is involved and certain investment funds. The guidance will become effective for us at the beginning of our first quarter of Fiscal 2017. We do not expect the adoption of this guidance will have a material impact on our consolidated financial statements.

X

- Definition

Disclosure of accounting policy for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

No definition available.

+ Details

Name: prph_NatureOfOperationsPolicyTextBlock

Namespace Prefix: prph_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=32704220&loc=d3e8275-108329

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 20

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6387522&loc=d3e8384-108330

+ Details

Name: us-gaap_AdvertisingCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f(1))

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_CompensationRelatedCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for credit risk.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61082-112788

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61044-112788

+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 5A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6759159-111685

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=28200181&loc=d3e5728-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 2AA

-Subparagraph a

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6759068-111685

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 2A

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6225816-111685

+ Details

Name: us-gaap_ConsolidationVariableInterestEntityPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section CC

-Subsection 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 05

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6390181&loc=d3e202-110218

+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.

+ References

No definition available.

+ Details

Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 45

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6408196&loc=d3e61069-111654

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Handling Costs

-URI http://asc.fasb.org/extlink&oid=6514758

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 45

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=21915142&loc=d3e60635-111653

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 45

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6408413&loc=d3e221937-122793

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Shipping Costs

-URI http://asc.fasb.org/extlink&oid=6525344

+ Details

Name: us-gaap_ShippingAndHandlingCostPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies (Tables)
3 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Schedule Of Future Contingency Obligation [Table Text Block]

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2015, as follows (in thousands):

Fiscal Year

Employment
Contracts

Godfrey
Settlement
Agreement

Total

2015

769

100

869

2016

1,025

100

1,125

2017

1,025

-

1,025

2018

-

-

-

2019

-

-

-

Total

$

2,819

$

200

$

3,019

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-K (SK)

-Number 229

-Section 303

-Paragraph a

-Subparagraph 5

+ Details

Name: us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes (Details Textual) (USD $)
In Millions, unless otherwise specified
12 Months Ended

Dec. 31, 2014

Domestic Tax Authority [Member]

Income Taxes [Line Items]

Deferred Tax Assets, Operating Loss Carryforwards, Domestic $ 38.6

Operating Loss Carry forwards Expiration Dates Description Fiscal 2020 through Fiscal 2033

State and Local Jurisdiction [Member]

Income Taxes [Line Items]

Operating Loss Carry forwards Expiration Dates Description Fiscal 2018 through Fiscal 2033

Deferred Tax Assets, Operating Loss Carryforwards, State and Local $ 20.1

X

- Details

Name: prph_IncomeTaxesLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The expiration date of each operating loss carryforward included in total operating loss carryforward, or the applicable range of such expiration dates.

+ References

No definition available.

+ Details

Name: prph_OperatingLossCarryForwardsExpirationDatesDescription

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 25

-Paragraph 20

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314

+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 25

-Paragraph 20

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314

+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9

Earnings (Loss) Per Share (Details Textual)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Earnings Loss Per Share [Line Items]

Class of Warrant or Right, Outstanding 1,739,500 1,637,500

Common Stock Equivalents [Member]

Earnings Loss Per Share [Line Items]

Weighted Average Number Diluted Shares Outstanding Adjustment 358,411 586,215

X

- Details

Name: prph_EarningsLossPerShareLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=prph_CommonStockEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Statement of Stockholders' Equity (USD $)
In Thousands, except Share data

Total

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings (Deficit) [Member]

Treasury Stock [Member]

Balance at Dec. 31, 2014 $ 10,716us-gaap_StockholdersEquity $ 13 $ 54,664 $ (13,219) $ (30,742)

Balance (in shares) at Dec. 31, 2014 15,892,296

Net income (loss) (1,380)us-gaap_NetIncomeLoss 0 0 (1,380) 0

Share-based compensation expense (Note 3) 34 0 34 0 0

Balance at Mar. 31, 2015 $ 9,370us-gaap_StockholdersEquity $ 13 $ 54,698 $ (14,599) $ (30,742)

Balance (in shares) at Mar. 31, 2015 15,892,296

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11178-113907

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 41 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes
3 Months Ended

Mar. 31, 2015

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Note 4 – Income Taxes

As of December 31, 2014, we have net operating loss carry-forwards of approximately $38.6 million for federal purposes that will expire beginning in Fiscal 2020 through Fiscal 2033. Additionally, there are net operating loss carry-forwards of approximately $20.1 million for state purposes that will expire beginning in Fiscal 2018 through Fiscal 2033. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock are assured, a valuation allowance equaling the total deferred tax asset is being provided. Management believes that this allowance is required due to the uncertainty of realizing these tax benefits in the future.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 60 159 1 false 29 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.prophaselabs.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.prophaselabs.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Sheet http://www.prophaselabs.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets [Parenthetical] false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.prophaselabs.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations false false R5.htm 105 - Statement - Condensed Consolidated Statement of Stockholders' Equity Sheet http://www.prophaselabs.com/role/CondensedConsolidatedStatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity false false R6.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.prophaselabs.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows false false R7.htm 107 - Disclosure - Organization and Business Sheet http://www.prophaselabs.com/role/OrganizationAndBusiness Organization and Business false false R8.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.prophaselabs.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R9.htm 109 - Disclosure - Transactions Affecting Stockholders' Equity Sheet http://www.prophaselabs.com/role/TransactionsAffectingStockholdersEquity Transactions Affecting Stockholders' Equity false false R10.htm 110 - Disclosure - Income Taxes Sheet http://www.prophaselabs.com/role/IncomeTaxes Income Taxes false false R11.htm 111 - Disclosure - Commitments and Contingencies Sheet http://www.prophaselabs.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R12.htm 112 - Disclosure - Investment in a Joint Venture Sheet http://www.prophaselabs.com/role/InvestmentInJointVenture Investment in a Joint Venture false false R13.htm 113 - Disclosure - Earnings (Loss) Per Share Sheet http://www.prophaselabs.com/role/EarningsLossPerShare Earnings (Loss) Per Share false false R14.htm 114 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R15.htm 115 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) false false R16.htm 116 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.prophaselabs.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) false false R17.htm 117 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.prophaselabs.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) false false R18.htm 118 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) false false R19.htm 119 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) false false R20.htm 120 - Disclosure - Transactions Affecting Stockholders' Equity (Details Textual) Sheet http://www.prophaselabs.com/role/TransactionsAffectingStockholdersEquityDetailsTextual Transactions Affecting Stockholders' Equity (Details Textual) false false R21.htm 121 - Disclosure - Income Taxes (Details Textual) Sheet http://www.prophaselabs.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) false false R22.htm 122 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.prophaselabs.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R23.htm 123 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.prophaselabs.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) false false R24.htm 124 - Disclosure - Investment in a Joint Venture (Details Textual) Sheet http://www.prophaselabs.com/role/InvestmentInJointVentureDetailsTextual Investment in a Joint Venture (Details Textual) false false R25.htm 125 - Disclosure - Earnings (Loss) Per Share (Details) Sheet http://www.prophaselabs.com/role/EarningsLossPerShareDetails Earnings (Loss) Per Share (Details) false false R26.htm 126 - Disclosure - Earnings (Loss) Per Share (Details Textual) Sheet http://www.prophaselabs.com/role/EarningsLossPerShareDetailsTextual Earnings (Loss) Per Share (Details Textual) false false All Reports Book All Reports Element us-gaap_PrepaidExpenseAndOtherAssetsCurrent had a mix of decimals attribute values: -3 0. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '120 - Disclosure - Transactions Affecting Stockholders' Equity (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '123 - Disclosure - Commitments and Contingencies (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2014' Process Flow-Through: Removing column 'Dec. 31, 2013' Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Process Flow-Through: 104 - Statement - Condensed Consolidated Statements of Operations Process Flow-Through: 106 - Statement - Condensed Consolidated Statements of Cash Flows prph-20150331.xml prph-20150331.xsd prph-20150331_cal.xml prph-20150331_def.xml prph-20150331_lab.xml prph-20150331_pre.xml true true XML 43 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9

Transactions Affecting Stockholders' Equity (Details Textual) (USD $)
3 Months Ended 1 Months Ended 7 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Nov. 21, 2012

May 28, 2014

Dec. 31, 2014

Stockholders' Equity [Line Items]

Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement 15.00%

Common Stock, Shares, Issued 25,125,113us-gaap_CommonStockSharesIssued 25,125,113us-gaap_CommonStockSharesIssued

Proceeds From Issuance Of Common Stock $ 0 $ 947,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 45

Cash Less Exercise Of Right Terms In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company

Share Based Compensation Arrangement By Share Based Payment Option Expiration Terms No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998

Percentage Of Discount On Exercise Of Right 50.00%

2012 Equity Line of Credit [Member]

Stockholders' Equity [Line Items]

Maximum Number Of Common Stock Authorized For Issuance Over 36 Months 2,500,000

2014 Equity Line of Credit [Member]

Stockholders' Equity [Line Items]

Maximum Number Of Common Stock Authorized For Issuance Over 36 Months 3,000,000

Investor Right To Use Excess Proceeds, Maximum Percentage 5.00%

Share Purchase Put Restrictions Maximum Percentage Of Ownership Held By Investor To Purchase Shares In Equity Line Of Credit 4.99%

Common Stock, Capital Shares Reserved for Future Issuance 438,480 3,000,000

Equity Line, Purchase Price Percentage 95.00%

Common Stock, Shares, Issued 2,561,520

Proceeds From Issuance Of Common Stock 3,700,000

Agreement Term 36 months

Purchase Price Value 500,000

Common Stock, Capital Shares Reserved For Future Issuance 438,480 3,000,000

Ted Karkus [Member]

Stockholders' Equity [Line Items]

Equity Method Investment, Ownership Percentage 20.00%

Plan 1997 [Member]

Stockholders' Equity [Line Items]

Options outstanding - Shares 26,500

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Common Stock Shares Unissued 2,500,000

Available for grant, Shares (in shares) 900,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 1,481,750

Plan 2010 [Member]

Stockholders' Equity [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 1,600,000

Share Based Compensation Arrangement By Share Based Payment Award, Options, Deemed Cancelled 581,750

Available for grant, Shares (in shares) 19,659

Directors Plan 2010 [Member]

Stockholders' Equity [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 425,000

Available for grant, Shares (in shares) 147,808

Amended Option Plan 1997 [Member]

Stockholders' Equity [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 4,500,000

Common Stock [Member] | Dutchess [Member] | 2012 Equity Line of Credit [Member]

Stockholders' Equity [Line Items]

Stock Issued During Period Shares Under Specific Agreement 698,207

Stock Issued During Period Value Specific Agreement $ 1,200,000

X

- Definition

This element represent the agreement term.

+ References

No definition available.

+ Details

Name: prph_AgreementTerm

Namespace Prefix: prph_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of cash less exercise of rights terms.

+ References

No definition available.

+ Details

Name: prph_CashLessExerciseOfRightTerms

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

It represents the lowest daily volume weighted average price of our Common Stock during the five consecutive trading day period.

+ References

No definition available.

+ Details

Name: prph_EquityLinePurchasePricePercentage

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity method investment ownership percentage required for rights exercisable under right agreement.

+ References

No definition available.

+ Details

Name: prph_EquityMethodInvestmentOwnershipPercentageRequiredForRightsExercisableUnderRightAgreement

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations before deduction of valuation allowance.

+ References

No definition available.

+ Details

Name: prph_InvestorRightToUseExcessProceedsMaximumPercentage

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Maximum number of common stock authorized for issuance over thirty six months.

+ References

No definition available.

+ Details

Name: prph_MaximumNumberOfCommonStockAuthorizedForIssuanceOver36Months

Namespace Prefix: prph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represent percentage of discount on the current market price for exercise of right.

+ References

No definition available.

+ Details

Name: prph_PercentageOfDiscountOnExerciseOfRight

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the purchase price value.

+ References

No definition available.

+ Details

Name: prph_PurchasePriceValue

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Share-based compensation arrangement by share-based payment award, options, deemed cancelled.

+ References

No definition available.

+ Details

Name: prph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedCancelled

Namespace Prefix: prph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Share based compensation arrangement by share based payment award options grants in period common stock shares unissued.

+ References

No definition available.

+ Details

Name: prph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodCommonStockSharesUnissued

Namespace Prefix: prph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Description of stock option plan expiration terms.

+ References

No definition available.

+ Details

Name: prph_ShareBasedCompensationArrangementByShareBasedPaymentOptionExpirationTerms

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Share purchase put restrictions maximum percentage of ownership held by investor to purchase shares in equity line of credit.

+ References

No definition available.

+ Details

Name: prph_SharePurchasePutRestrictionsMaximumPercentageOfOwnershipHeldByInvestorToPurchaseSharesInEquityLineOfCredit

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: prph_StockholdersEquityLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares under specific agreements.

+ References

No definition available.

+ Details

Name: prph_StockIssuedDuringPeriodSharesUnderSpecificAgreement

Namespace Prefix: prph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

It defines the aggregate value of stock issued during a period .

+ References

No definition available.

+ Details

Name: prph_StockIssuedDuringPeriodValueSpecificAgreement

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_PlanNameAxis=prph_AmendedOptionPlan1997Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=prph_DirectorsPlan2010Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=prph_Plan1997Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=prph_Plan2010Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=prph_TwoThousandFourteenEquityLineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=prph_TwoThousandTwelveEquityLineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Earnings (Loss) Per Share (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Earnings Loss Per Share [Line Items]
Basic EPS - Income (Loss)	$ (1,380)	$ (804)
Basic EPS - Shares (in shares)	15,892	16,469
Basic EPS - EPS (in dollars per share)	$ (0.09)us-gaap_EarningsPerShareBasic	$ (0.05)us-gaap_EarningsPerShareBasic
Dilutives:
Options/Warrants - Loss	0	0
Options/Warrants - Shares (in shares)	0	0
Options/Warrants - EPS (in dollars per share)	$ 0	$ 0
Diluted EPS - Income (Loss)	$ (1,380)	$ (804)
Diluted EPS - Shares (in shares)	15,892	16,469
Diluted EPS - EPS (in dollars per share)	$ (0.09)us-gaap_EarningsPerShareDiluted	$ (0.05)us-gaap_EarningsPerShareDiluted

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
ASSETS
Cash and cash equivalents (Note 2)	$ 5,021	$ 2,926
Accounts receivable, net	3,468us-gaap_AccountsReceivableNetCurrent	5,836us-gaap_AccountsReceivableNetCurrent
Inventory (Note 2)	3,277us-gaap_InventoryNet	3,292us-gaap_InventoryNet
Prepaid expenses and other current assets	670	1,404
Total current assets	12,436us-gaap_AssetsCurrent	13,458us-gaap_AssetsCurrent
Property, plant and equipment, net of accumulated depreciation of $4,424 and $4,341, respectively (Note 2)	2,558us-gaap_PropertyPlantAndEquipmentNet	2,599us-gaap_PropertyPlantAndEquipmentNet
Total assets	14,994us-gaap_Assets	16,057us-gaap_Assets
LIABILITIES:
Accounts payable	1,231us-gaap_AccountsPayableCurrent	667us-gaap_AccountsPayableCurrent
Accrued advertising and other allowances	3,232us-gaap_AccruedMarketingCostsCurrent	3,685us-gaap_AccruedMarketingCostsCurrent
Other current liabilities	1,061us-gaap_OtherLiabilitiesCurrent	889us-gaap_OtherLiabilitiesCurrent
Total current liabilities	5,524us-gaap_LiabilitiesCurrent	5,241us-gaap_LiabilitiesCurrent
Other long term obligations (Note 5)	100	100
Commitments and contingencies (Note 5)
STOCKHOLDERS' EQUITY:
Common Stock, $.0005 par value; authorized 50,000,000; issued: 25,125,113 shares (Note 3)	13us-gaap_CommonStockValue	13us-gaap_CommonStockValue
Additional paid-in-capital	54,698	54,664
Accumulated deficit	(14,599)	(13,219)
Treasury stock, at cost 9,232,817 shares	(30,742)us-gaap_TreasuryStockValue	(30,742)us-gaap_TreasuryStockValue
Total stockholders' equity	9,370us-gaap_StockholdersEquity	10,716us-gaap_StockholdersEquity
Total liabilities and stockholders' equity	$ 14,994	$ 16,057

Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	$ (1,380)us-gaap_NetIncomeLoss	$ (804)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	83us-gaap_Depreciation	64us-gaap_Depreciation
Share-based compensation expense	34	64
Gain on sale of equipment	(5)	0
Changes in operating assets and liabilities:
Accounts receivable	2,368	2,463
Inventory	15us-gaap_IncreaseDecreaseInInventories	309us-gaap_IncreaseDecreaseInInventories
Accounts payable	564	(19)
Accrued advertising and other allowances	(453)	35
Other operating assets and liabilities, net	906	839
Net cash provided by operating activities	2,132	2,951
Cash flows from investing activities:
Capital expenditures	(42)	(17)
Proceeds from the sale of equipment	5	0
Net cash used in investing activities	(37)	(17)
Cash flows from financing activities:
Proceeds from issuance of common stock	0	947
Net cash provided by financing activities	0	947
Net increase in cash and cash equivalents	2,095	3,881
Cash and cash equivalents at beginning of period	2,926	1,638
Cash and cash equivalents at end of period	$ 5,021	$ 5,519

Commitments and Contingencies (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015
Commitments And Contingencies [Line Items]
2015	$ 869
2016	1,125
2017	1,025
2018	0
2019	0
Total	3,019
Employment Contracts [Member]
Commitments And Contingencies [Line Items]
2015	769
2016	1,025
2017	1,025
2018	0
2019	0
Total	2,819
Godfrey Settlement Agreement [Member]
Commitments And Contingencies [Line Items]
2015	100
2016	100
2017	0
2018	0
2019	0
Total	$ 200

Investment in a Joint Venture (Details Textual) (USD $) In Millions, except Share data, unless otherwise specified	12 Months Ended	1 Months Ended
	Dec. 31, 2014	Mar. 31, 2010
Schedule of Investments [Line Items]
Asset Impairment Charges	$ 3.6us-gaap_AssetImpairmentCharges
PSI Technology License [Member]
Schedule of Investments [Line Items]
Intangible Assets, Net (Excluding Goodwill)		3.6
PSI Parent [Member]
Schedule of Investments [Line Items]
Stock Issued During Period, Shares, New Issues		1,440,000
Stock Issued During Period, Value, New Issues		2.6
Payments To Fund Joint Venture Investments		$ 1.0

Condensed Consolidated Balance Sheets [Parenthetical] (USD $) In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Accumulated depreciation (in dollars)	$ 4,424	$ 4,341
Common Stock, par value (in dollars per share)	$ 0.0005	$ 0.0005
Common Stock, shares authorized	50,000,000us-gaap_CommonStockSharesAuthorized	50,000,000us-gaap_CommonStockSharesAuthorized
Common Stock, shares issued	25,125,113us-gaap_CommonStockSharesIssued	25,125,113us-gaap_CommonStockSharesIssued
Treasury stock, shares (in shares)	9,232,817us-gaap_TreasuryStockShares	9,232,817us-gaap_TreasuryStockShares

Document And Entity Information	3 Months Ended
Document And Entity Information	Mar. 31, 2015	May 13, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	ProPhase Labs, Inc.
Entity Central Index Key	0000868278
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	PRPH
Entity Common Stock, Shares Outstanding		15,892,296dei_EntityCommonStockSharesOutstanding

Summary of Significant Accounting Policies (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 816us-gaap_InventoryRawMaterials	$ 798us-gaap_InventoryRawMaterials
Work in process	207us-gaap_InventoryWorkInProcess	418us-gaap_InventoryWorkInProcess
Finished goods	2,254us-gaap_InventoryFinishedGoods	2,076us-gaap_InventoryFinishedGoods
Inventory, Net	$ 3,277us-gaap_InventoryNet	$ 3,292us-gaap_InventoryNet

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	12 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Dec. 20, 2012	Dec. 31, 2014	Dec. 31, 2012	Mar. 31, 2015
Commitments And Contingencies [Line Items]
Payments for Legal Settlements			$ 2,100,000us-gaap_PaymentsForLegalSettlements
Settlement benefit (Note 3)		10,000prph_SettlementBenefit
Additional Royalties and Commissions, Accrual Interest Percentage		3.25%
Additional Royalties and Commissions Payable, Installment Amount	100,000	100,000
Additional Annual Installment Includes In Other Current Liability				100,000
Additional Annual Installment Includes In Other Long Term Obligation		$ 100,000

Income Taxes (Details Textual) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2014
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ 38.6
Operating Loss Carry forwards Expiration Dates Description	Fiscal 2020 through Fiscal 2033
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating Loss Carry forwards Expiration Dates Description	Fiscal 2018 through Fiscal 2033
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$ 20.1

Earnings (Loss) Per Share (Details Textual)	3 Months Ended
Earnings (Loss) Per Share (Details Textual)	Mar. 31, 2015	Mar. 31, 2014
Earnings Loss Per Share [Line Items]
Class of Warrant or Right, Outstanding	1,739,500	1,637,500
Common Stock Equivalents [Member]
Earnings Loss Per Share [Line Items]
Weighted Average Number Diluted Shares Outstanding Adjustment	358,411	586,215

Condensed Consolidated Statement of Stockholders' Equity (USD $) In Thousands, except Share data	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings (Deficit) [Member]	Treasury Stock [Member]
Balance at Dec. 31, 2014	$ 10,716us-gaap_StockholdersEquity	$ 13	$ 54,664	$ (13,219)	$ (30,742)
Balance (in shares) at Dec. 31, 2014		15,892,296
Net income (loss)	(1,380)us-gaap_NetIncomeLoss	0	0	(1,380)	0
Share-based compensation expense (Note 3)	34	0	34	0	0
Balance at Mar. 31, 2015	$ 9,370us-gaap_StockholdersEquity	$ 13	$ 54,698	$ (14,599)	$ (30,742)
Balance (in shares) at Mar. 31, 2015		15,892,296

Transactions Affecting Stockholders' Equity (Details Textual) (USD $)	3 Months Ended		1 Months Ended		7 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Nov. 21, 2012	May 28, 2014	Dec. 31, 2014
Stockholders' Equity [Line Items]
Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement	15.00%
Common Stock, Shares, Issued	25,125,113us-gaap_CommonStockSharesIssued				25,125,113us-gaap_CommonStockSharesIssued
Proceeds From Issuance Of Common Stock	$ 0	$ 947,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 45
Cash Less Exercise Of Right Terms	In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company
Share Based Compensation Arrangement By Share Based Payment Option Expiration Terms	No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998
Percentage Of Discount On Exercise Of Right	50.00%
2012 Equity Line of Credit [Member]
Stockholders' Equity [Line Items]
Maximum Number Of Common Stock Authorized For Issuance Over 36 Months			2,500,000
2014 Equity Line of Credit [Member]
Stockholders' Equity [Line Items]
Maximum Number Of Common Stock Authorized For Issuance Over 36 Months				3,000,000
Investor Right To Use Excess Proceeds, Maximum Percentage	5.00%
Share Purchase Put Restrictions Maximum Percentage Of Ownership Held By Investor To Purchase Shares In Equity Line Of Credit	4.99%
Common Stock, Capital Shares Reserved for Future Issuance	438,480			3,000,000
Equity Line, Purchase Price Percentage	95.00%
Common Stock, Shares, Issued					2,561,520
Proceeds From Issuance Of Common Stock					3,700,000
Agreement Term				36 months
Purchase Price Value	500,000
Common Stock, Capital Shares Reserved For Future Issuance	438,480			3,000,000
Ted Karkus [Member]
Stockholders' Equity [Line Items]
Equity Method Investment, Ownership Percentage	20.00%
Plan 1997 [Member]
Stockholders' Equity [Line Items]
Options outstanding - Shares	26,500
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Common Stock Shares Unissued	2,500,000
Available for grant, Shares (in shares)	900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	1,481,750
Plan 2010 [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,600,000
Share Based Compensation Arrangement By Share Based Payment Award, Options, Deemed Cancelled	581,750
Available for grant, Shares (in shares)	19,659
Directors Plan 2010 [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	425,000
Available for grant, Shares (in shares)	147,808
Amended Option Plan 1997 [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	4,500,000
Common Stock [Member] \| Dutchess [Member] \| 2012 Equity Line of Credit [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period Shares Under Specific Agreement	698,207
Stock Issued During Period Value Specific Agreement	$ 1,200,000